US20230014730A1 - Phosphodiesterase inhibitors and use - Google Patents
Phosphodiesterase inhibitors and use Download PDFInfo
- Publication number
- US20230014730A1 US20230014730A1 US17/641,633 US202017641633A US2023014730A1 US 20230014730 A1 US20230014730 A1 US 20230014730A1 US 202017641633 A US202017641633 A US 202017641633A US 2023014730 A1 US2023014730 A1 US 2023014730A1
- Authority
- US
- United States
- Prior art keywords
- compound
- alkyl
- methyl
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 271
- 238000000034 method Methods 0.000 claims abstract description 85
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 claims abstract description 52
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 claims abstract description 52
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 133
- 150000002367 halogens Chemical class 0.000 claims description 133
- 150000003839 salts Chemical class 0.000 claims description 128
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 127
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 107
- 125000000623 heterocyclic group Chemical group 0.000 claims description 100
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 98
- 239000012453 solvate Substances 0.000 claims description 97
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 87
- 239000000651 prodrug Substances 0.000 claims description 87
- 229940002612 prodrug Drugs 0.000 claims description 87
- 125000001424 substituent group Chemical group 0.000 claims description 76
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 58
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 50
- 229910052739 hydrogen Inorganic materials 0.000 claims description 49
- 239000001257 hydrogen Substances 0.000 claims description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 47
- 150000002431 hydrogen Chemical class 0.000 claims description 43
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 42
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 42
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims description 41
- 125000001188 haloalkyl group Chemical group 0.000 claims description 41
- 229910052757 nitrogen Inorganic materials 0.000 claims description 36
- -1 —OR3 Chemical group 0.000 claims description 32
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 28
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 28
- 229910052805 deuterium Inorganic materials 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 27
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 claims description 11
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000033558 biomineral tissue development Effects 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 210000004872 soft tissue Anatomy 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000033173 Generalized arterial calcification of infancy Diseases 0.000 claims 1
- 229910006074 SO2NH2 Inorganic materials 0.000 claims 1
- 208000004900 arterial calcification of infancy Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 claims 1
- 125000000565 sulfonamide group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 248
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 158
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 126
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 111
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
- 239000000047 product Substances 0.000 description 88
- 238000005160 1H NMR spectroscopy Methods 0.000 description 83
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 78
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 59
- 235000019439 ethyl acetate Nutrition 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 38
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 35
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- 239000003112 inhibitor Substances 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 30
- 125000004432 carbon atom Chemical group C* 0.000 description 29
- 239000000243 solution Substances 0.000 description 28
- 239000012044 organic layer Substances 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 26
- 239000010410 layer Substances 0.000 description 26
- 239000007787 solid Substances 0.000 description 26
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 23
- 239000002244 precipitate Substances 0.000 description 23
- 239000000543 intermediate Substances 0.000 description 22
- 238000002953 preparative HPLC Methods 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 239000007832 Na2SO4 Substances 0.000 description 20
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 229910052938 sodium sulfate Inorganic materials 0.000 description 20
- XRILCFTWUCUKJR-INFSMZHSSA-N 2'-3'-cGAMP Chemical compound C([C@H]([C@H]1O)O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H]2N1C=NC2=C1NC(N)=NC2=O XRILCFTWUCUKJR-INFSMZHSSA-N 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 16
- 229940127007 Compound 39 Drugs 0.000 description 16
- 125000005842 heteroatom Chemical group 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 238000000132 electrospray ionisation Methods 0.000 description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 15
- NCRURRDBVYGVNJ-UHFFFAOYSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)NC(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)NC(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O)OC NCRURRDBVYGVNJ-UHFFFAOYSA-N 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 14
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 14
- 239000001301 oxygen Chemical group 0.000 description 14
- 239000011593 sulfur Chemical group 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- MSMNIOSWGDZDGM-SNVBAGLBSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3[C@H](C)C1=CC=C(C=N1)S(=O)(=O)N Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3[C@H](C)C1=CC=C(C=N1)S(=O)(=O)N MSMNIOSWGDZDGM-SNVBAGLBSA-N 0.000 description 11
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 10
- 125000004076 pyridyl group Chemical group 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 230000007062 hydrolysis Effects 0.000 description 9
- 238000006460 hydrolysis reaction Methods 0.000 description 9
- 125000000714 pyrimidinyl group Chemical group 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- POWBKABTEIGGSF-UHFFFAOYSA-N COC=1C=CC=2C3=C(N=NC=2C=1)NC(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O Chemical compound COC=1C=CC=2C3=C(N=NC=2C=1)NC(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O POWBKABTEIGGSF-UHFFFAOYSA-N 0.000 description 8
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- RWOAVOYBVRQNIZ-BFHYXJOUSA-N p-nitrophenyl thymidine 5'-monophosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)[C@@H](O)C1 RWOAVOYBVRQNIZ-BFHYXJOUSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 8
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 7
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 7
- XKTGUEXZJLQHPG-UHFFFAOYSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)N=CN3CC1=CC=C(C=N1)S(=O)(=O)N)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)N=CN3CC1=CC=C(C=N1)S(=O)(=O)N)OC XKTGUEXZJLQHPG-UHFFFAOYSA-N 0.000 description 7
- JJRPBWGQXRBMCK-UHFFFAOYSA-N COC=1C=NC=2C3=C(C=NC=2C=1)N=CN3CC1=CC=C(C=C1)S(=O)(=O)N Chemical compound COC=1C=NC=2C3=C(C=NC=2C=1)N=CN3CC1=CC=C(C=C1)S(=O)(=O)N JJRPBWGQXRBMCK-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- NNKXNYWUYFSMQM-UHFFFAOYSA-N S(=O)(=O)(NCC1=CC=C(C=C1)N1C=NC=2C=NC=3C=C(N=CC=3C=21)OC)N Chemical compound S(=O)(=O)(NCC1=CC=C(C=C1)N1C=NC=2C=NC=3C=C(N=CC=3C=21)OC)N NNKXNYWUYFSMQM-UHFFFAOYSA-N 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 6
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- KJJXIVWRJCFDSE-UHFFFAOYSA-N C(#N)C1=CC=2C3=C(C=NC=2C=C1OC)NC(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O Chemical compound C(#N)C1=CC=2C3=C(C=NC=2C=C1OC)NC(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O KJJXIVWRJCFDSE-UHFFFAOYSA-N 0.000 description 6
- VBQYVAXVQCUREK-UHFFFAOYSA-N COC1=CC=2C3=C(C=NC=2C=C1)N=CN3CC1=CC=C(C=C1)S(=O)(=O)N Chemical compound COC1=CC=2C3=C(C=NC=2C=C1)N=CN3CC1=CC=C(C=C1)S(=O)(=O)N VBQYVAXVQCUREK-UHFFFAOYSA-N 0.000 description 6
- AQDJMAKUXDXNEA-UHFFFAOYSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)N=C(N3CC1=CC=C(C=C1)S(=O)(=O)N)C)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)N=C(N3CC1=CC=C(C=C1)S(=O)(=O)N)C)OC AQDJMAKUXDXNEA-UHFFFAOYSA-N 0.000 description 6
- WMWDJSASAHCDKI-UHFFFAOYSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)N=CN3CC1CCN(CC1)S(=O)(=O)N)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)N=CN3CC1CCN(CC1)S(=O)(=O)N)OC WMWDJSASAHCDKI-UHFFFAOYSA-N 0.000 description 6
- QXGVMGKDVXPJRU-UHFFFAOYSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)N=CN3CC=1C=C(C=CC=1)S(=O)(=O)N)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)N=CN3CC=1C=C(C=CC=1)S(=O)(=O)N)OC QXGVMGKDVXPJRU-UHFFFAOYSA-N 0.000 description 6
- NZNBLOGZNJRIMC-UHFFFAOYSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)N=CN3CC=1C=CC(=NC=1)S(=O)(=O)N)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)N=CN3CC=1C=CC(=NC=1)S(=O)(=O)N)OC NZNBLOGZNJRIMC-UHFFFAOYSA-N 0.000 description 6
- YNXXYKQHJCPIAD-LBPRGKRZSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)N=CN3[C@@H](C)C1=CC=C(C=C1)S(=O)(=O)N)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)N=CN3[C@@H](C)C1=CC=C(C=C1)S(=O)(=O)N)OC YNXXYKQHJCPIAD-LBPRGKRZSA-N 0.000 description 6
- YNXXYKQHJCPIAD-GFCCVEGCSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)N=CN3[C@H](C)C1=CC=C(C=C1)S(=O)(=O)N)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)N=CN3[C@H](C)C1=CC=C(C=C1)S(=O)(=O)N)OC YNXXYKQHJCPIAD-GFCCVEGCSA-N 0.000 description 6
- RUTFOXJHCCWNHD-UHFFFAOYSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)NC(N3CC1=CC(=C(C=C1)S(=O)(=O)N)F)=O)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)NC(N3CC1=CC(=C(C=C1)S(=O)(=O)N)F)=O)OC RUTFOXJHCCWNHD-UHFFFAOYSA-N 0.000 description 6
- BLICZIPWWYBMDT-UHFFFAOYSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)NC(N3CC1=CC=C(C=N1)S(=O)(=O)N)=O)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)NC(N3CC1=CC=C(C=N1)S(=O)(=O)N)=O)OC BLICZIPWWYBMDT-UHFFFAOYSA-N 0.000 description 6
- DYZFNWFGWXFGKA-UHFFFAOYSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)NC(N3CC=1C=C(C=CC=1)S(=O)(=O)N)=O)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)NC(N3CC=1C=C(C=CC=1)S(=O)(=O)N)=O)OC DYZFNWFGWXFGKA-UHFFFAOYSA-N 0.000 description 6
- XABRYWAJOAMLFM-NSHDSACASA-N COC=1C(=CC=2C3=C(C=NC=2C=1)NC(N3[C@@H](C)C1=CC=C(C=C1)S(=O)(=O)N)=O)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)NC(N3[C@@H](C)C1=CC=C(C=C1)S(=O)(=O)N)=O)OC XABRYWAJOAMLFM-NSHDSACASA-N 0.000 description 6
- XABRYWAJOAMLFM-LLVKDONJSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)NC(N3[C@H](C)C1=CC=C(C=C1)S(=O)(=O)N)=O)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)NC(N3[C@H](C)C1=CC=C(C=C1)S(=O)(=O)N)=O)OC XABRYWAJOAMLFM-LLVKDONJSA-N 0.000 description 6
- MZBKBCXZYDGSFU-UHFFFAOYSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)OC(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)OC(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O)OC MZBKBCXZYDGSFU-UHFFFAOYSA-N 0.000 description 6
- TXNPZPJVVFVNGF-UHFFFAOYSA-N COC=1C(=CC=2C=3N(C=NC=2C=1)N=CC=3CC1=CC=C(C=C1)S(=O)(=O)N)OC Chemical compound COC=1C(=CC=2C=3N(C=NC=2C=1)N=CC=3CC1=CC=C(C=C1)S(=O)(=O)N)OC TXNPZPJVVFVNGF-UHFFFAOYSA-N 0.000 description 6
- VOEDTMQQUALBFP-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2C=1)NC(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O Chemical compound COC=1C=CC=2C3=C(C=NC=2C=1)NC(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O VOEDTMQQUALBFP-UHFFFAOYSA-N 0.000 description 6
- VDIMDEGDHQQZHR-LLVKDONJSA-N COC=1C=CC=2C3=C(C=NC=2C=1)NC(N3[C@H](C)C1=CC=C(C=C1)S(=O)(=O)N)=O Chemical compound COC=1C=CC=2C3=C(C=NC=2C=1)NC(N3[C@H](C)C1=CC=C(C=C1)S(=O)(=O)N)=O VDIMDEGDHQQZHR-LLVKDONJSA-N 0.000 description 6
- ZFIXBUKGPVMYHG-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)C=NN3CC1=CC=C(C=C1)S(=O)(=O)N Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)C=NN3CC1=CC=C(C=C1)S(=O)(=O)N ZFIXBUKGPVMYHG-UHFFFAOYSA-N 0.000 description 6
- JKNBNQBHGFTLLU-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=C(N3CC1=CC=C(C=C1)S(=O)(=O)N)C Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=C(N3CC1=CC=C(C=C1)S(=O)(=O)N)C JKNBNQBHGFTLLU-UHFFFAOYSA-N 0.000 description 6
- IKQMGMMJVPCWJE-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3C1=CC=C2CCN(CC2=C1)S(=O)(=O)N Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3C1=CC=C2CCN(CC2=C1)S(=O)(=O)N IKQMGMMJVPCWJE-UHFFFAOYSA-N 0.000 description 6
- HVBNSNAATCAFED-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1=CC=C(C=C1)B(O)O Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1=CC=C(C=C1)B(O)O HVBNSNAATCAFED-UHFFFAOYSA-N 0.000 description 6
- FPMCZSTXOYJLRH-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1=CC=C(C=N1)S(=O)(=O)N Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1=CC=C(C=N1)S(=O)(=O)N FPMCZSTXOYJLRH-UHFFFAOYSA-N 0.000 description 6
- DYQPBSJEXQLWPD-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1CN(C1)S(=O)(=O)N Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1CN(C1)S(=O)(=O)N DYQPBSJEXQLWPD-UHFFFAOYSA-N 0.000 description 6
- SQTWJVDHDFLQII-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC=1C=CC(=NC=1)S(=O)(=O)N Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC=1C=CC(=NC=1)S(=O)(=O)N SQTWJVDHDFLQII-UHFFFAOYSA-N 0.000 description 6
- QMYJPMICDBBVFH-LLVKDONJSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3[C@H](C)C1=CC=C(C=C1)S(=O)(=O)N Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3[C@H](C)C1=CC=C(C=C1)S(=O)(=O)N QMYJPMICDBBVFH-LLVKDONJSA-N 0.000 description 6
- QVDAYYKULIUILO-UHFFFAOYSA-N COC=1N=CC=2C3=C(C=NC=2C=1)N=CN3CC1=CC=C(C=C1)S(=O)(=O)N Chemical compound COC=1N=CC=2C3=C(C=NC=2C=1)N=CN3CC1=CC=C(C=C1)S(=O)(=O)N QVDAYYKULIUILO-UHFFFAOYSA-N 0.000 description 6
- OEFHSVKLYNDGIZ-UHFFFAOYSA-N COC=1N=CC=2C3=C(C=NC=2C=1)NC(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O Chemical compound COC=1N=CC=2C3=C(C=NC=2C=1)NC(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O OEFHSVKLYNDGIZ-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- AGRPRXJTRCYOOP-UHFFFAOYSA-N FC=1C=C(C(=O)N)C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F Chemical compound FC=1C=C(C(=O)N)C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F AGRPRXJTRCYOOP-UHFFFAOYSA-N 0.000 description 6
- MSALFVJHCRACJQ-UHFFFAOYSA-N FC=1C=C(C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)B(O)O Chemical compound FC=1C=C(C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)B(O)O MSALFVJHCRACJQ-UHFFFAOYSA-N 0.000 description 6
- DLKHFKVOVFYVJW-UHFFFAOYSA-N FC=1C=C(C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)S(=O)(=O)N Chemical compound FC=1C=C(C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)S(=O)(=O)N DLKHFKVOVFYVJW-UHFFFAOYSA-N 0.000 description 6
- BWWDXHDCYTWMDU-UHFFFAOYSA-N FC=1C=C(CN2C(=NC=3C=NC=4N=C(C=CC=4C=32)OC)CC(=O)OC)C=CC=1S(N)(=O)=O Chemical compound FC=1C=C(CN2C(=NC=3C=NC=4N=C(C=CC=4C=32)OC)CC(=O)OC)C=CC=1S(N)(=O)=O BWWDXHDCYTWMDU-UHFFFAOYSA-N 0.000 description 6
- IBRLYDNACAVUON-UHFFFAOYSA-N N1CC(C1)C=1N(C2=C(C=NC=3N=C(C=CC2=3)OC)N=1)CC1=CC(=C(C=C1)S(=O)(=O)N)F Chemical compound N1CC(C1)C=1N(C2=C(C=NC=3N=C(C=CC2=3)OC)N=1)CC1=CC(=C(C=C1)S(=O)(=O)N)F IBRLYDNACAVUON-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 229940127573 compound 38 Drugs 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 210000001853 liver microsome Anatomy 0.000 description 6
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000010189 synthetic method Methods 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 5
- PLJYXFNFQDCFNE-UHFFFAOYSA-N BrC=1C=C(C=CC=1CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC)S(=O)(=O)N Chemical compound BrC=1C=C(C=CC=1CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC)S(=O)(=O)N PLJYXFNFQDCFNE-UHFFFAOYSA-N 0.000 description 5
- VZZVDILQIYVELC-UHFFFAOYSA-N C(#N)C1=NC(=CC=C1S(=O)(=O)N)CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC Chemical compound C(#N)C1=NC(=CC=C1S(=O)(=O)N)CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC VZZVDILQIYVELC-UHFFFAOYSA-N 0.000 description 5
- YXFMADRCROTKDL-UHFFFAOYSA-N C(#N)C=1C=C(C=CC=1CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC)S(=O)(=O)N Chemical compound C(#N)C=1C=C(C=CC=1CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC)S(=O)(=O)N YXFMADRCROTKDL-UHFFFAOYSA-N 0.000 description 5
- JNVJIMUAIYABQC-UHFFFAOYSA-N C(#N)CC=1N(C2=C(C=NC=3N=C(C=CC2=3)OC)N=1)CC1=CC(=C(C=C1)S(=O)(=O)N)F Chemical compound C(#N)CC=1N(C2=C(C=NC=3N=C(C=CC2=3)OC)N=1)CC1=CC(=C(C=C1)S(=O)(=O)N)F JNVJIMUAIYABQC-UHFFFAOYSA-N 0.000 description 5
- BJJCBUIGKDNOAG-UHFFFAOYSA-M C(C)(=O)[N-]S(=O)(=O)C1=CC(=C(C(=C1)F)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F.[Na+] Chemical compound C(C)(=O)[N-]S(=O)(=O)C1=CC(=C(C(=C1)F)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F.[Na+] BJJCBUIGKDNOAG-UHFFFAOYSA-M 0.000 description 5
- WENDMSWXRJDSFJ-UHFFFAOYSA-N CN(C)CC=1N(C2=C(C(=NC=3N=C(C=CC2=3)OC)C)N=1)CC1=CC(=C(C=C1F)S(=O)(=O)N)F Chemical compound CN(C)CC=1N(C2=C(C(=NC=3N=C(C=CC2=3)OC)C)N=1)CC1=CC(=C(C=C1F)S(=O)(=O)N)F WENDMSWXRJDSFJ-UHFFFAOYSA-N 0.000 description 5
- PBEGQHDSXCGCLT-UHFFFAOYSA-N COC1=C(C=CC(=C1)CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC)S(=O)(=O)N Chemical compound COC1=C(C=CC(=C1)CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC)S(=O)(=O)N PBEGQHDSXCGCLT-UHFFFAOYSA-N 0.000 description 5
- ALXPUJRXTVNAGY-UHFFFAOYSA-N COC1=NC2=NC=C3C(=C2C=C1)N(C(=O)N3CCO)CC4=C(C=C(C=C4F)S(=O)(=O)N)F Chemical compound COC1=NC2=NC=C3C(=C2C=C1)N(C(=O)N3CCO)CC4=C(C=C(C=C4F)S(=O)(=O)N)F ALXPUJRXTVNAGY-UHFFFAOYSA-N 0.000 description 5
- HELYWZVSKLLXBB-UHFFFAOYSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)N(C(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O)C)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)N(C(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O)C)OC HELYWZVSKLLXBB-UHFFFAOYSA-N 0.000 description 5
- LRANCVMOMVHAJN-UHFFFAOYSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)N=NN3CC1=CC=C(C=C1)S(=O)(=O)N)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)N=NN3CC1=CC=C(C=C1)S(=O)(=O)N)OC LRANCVMOMVHAJN-UHFFFAOYSA-N 0.000 description 5
- WABQZXLDFMIZFF-UHFFFAOYSA-N COC=1C(=CC=2C3=C(C=NC=2C=1)NC(N3CC=1C=CC(=NC=1)S(=O)(=O)N)=O)OC Chemical compound COC=1C(=CC=2C3=C(C=NC=2C=1)NC(N3CC=1C=CC(=NC=1)S(=O)(=O)N)=O)OC WABQZXLDFMIZFF-UHFFFAOYSA-N 0.000 description 5
- RQCISCDMJOESKY-UHFFFAOYSA-N COC=1C(=CC=2C=3N(C=NC=2C=1)N=CC=3C(=O)N1CCN(CC1)S(=O)(=O)N)OC Chemical compound COC=1C(=CC=2C=3N(C=NC=2C=1)N=CC=3C(=O)N1CCN(CC1)S(=O)(=O)N)OC RQCISCDMJOESKY-UHFFFAOYSA-N 0.000 description 5
- SKZMONQQIASOKW-UHFFFAOYSA-N COC=1C=CC=2C3=C(C(=NC=2N=1)C)N=C(N3CC1=CC=C(C=N1)S(=O)(=O)N)C Chemical compound COC=1C=CC=2C3=C(C(=NC=2N=1)C)N=C(N3CC1=CC=C(C=N1)S(=O)(=O)N)C SKZMONQQIASOKW-UHFFFAOYSA-N 0.000 description 5
- RRSNUSLCDHTZJU-UHFFFAOYSA-N COC=1C=CC=2C3=C(C(=NC=2N=1)C)N=C(N3CC1=NC=C(C=N1)S(=O)(=O)N)C Chemical compound COC=1C=CC=2C3=C(C(=NC=2N=1)C)N=C(N3CC1=NC=C(C=N1)S(=O)(=O)N)C RRSNUSLCDHTZJU-UHFFFAOYSA-N 0.000 description 5
- IMYAZTSDEZTVEV-UHFFFAOYSA-N COC=1C=CC=2C3=C(C(=NC=2N=1)C)N=CN3CC1=CC=C(C=N1)S(=O)(=O)N Chemical compound COC=1C=CC=2C3=C(C(=NC=2N=1)C)N=CN3CC1=CC=C(C=N1)S(=O)(=O)N IMYAZTSDEZTVEV-UHFFFAOYSA-N 0.000 description 5
- DLUKICBJVUMXJF-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)C=CN3CC1=CC=C(C=C1)S(=O)(=O)N Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)C=CN3CC1=CC=C(C=C1)S(=O)(=O)N DLUKICBJVUMXJF-UHFFFAOYSA-N 0.000 description 5
- IBXHKRBCXHRNFR-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=C(N3CC1=CC=C(C=C1)S(=O)(=O)N)C(F)(F)F Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=C(N3CC1=CC=C(C=C1)S(=O)(=O)N)C(F)(F)F IBXHKRBCXHRNFR-UHFFFAOYSA-N 0.000 description 5
- HSBXSBSLKNEXGC-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=C(N3CC1=CC=C(C=N1)S(=O)(=O)N)C Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=C(N3CC1=CC=C(C=N1)S(=O)(=O)N)C HSBXSBSLKNEXGC-UHFFFAOYSA-N 0.000 description 5
- OBELEESUCRXPMK-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=C(N3CC1=CC=C(C=N1)S(=O)(=O)N)C1CCOCC1 Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=C(N3CC1=CC=C(C=N1)S(=O)(=O)N)C1CCOCC1 OBELEESUCRXPMK-UHFFFAOYSA-N 0.000 description 5
- JXGPSFQKHUOLSB-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=C(N3CC1=CC=C(C=N1)S(=O)(=O)NC(C)=O)C Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=C(N3CC1=CC=C(C=N1)S(=O)(=O)NC(C)=O)C JXGPSFQKHUOLSB-UHFFFAOYSA-N 0.000 description 5
- ONERJHJYGZWDPC-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=C(N3CC=1C=CC(=NC=1)S(=O)(=O)N)C Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=C(N3CC=1C=CC(=NC=1)S(=O)(=O)N)C ONERJHJYGZWDPC-UHFFFAOYSA-N 0.000 description 5
- SAQKXPNZFSEDKH-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1=C(C=C(C=C1)S(=O)(=O)N)C(F)(F)F Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1=C(C=C(C=C1)S(=O)(=O)N)C(F)(F)F SAQKXPNZFSEDKH-UHFFFAOYSA-N 0.000 description 5
- ZUKKSMZPADJRBZ-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1=CC(=C(C=C1)S(=O)(=O)N)C(F)(F)F Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1=CC(=C(C=C1)S(=O)(=O)N)C(F)(F)F ZUKKSMZPADJRBZ-UHFFFAOYSA-N 0.000 description 5
- UJYRQVYXZJNTTD-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1=CC=C(C=C1)S(=O)(=O)N Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1=CC=C(C=C1)S(=O)(=O)N UJYRQVYXZJNTTD-UHFFFAOYSA-N 0.000 description 5
- XUXOCPDPISPWTJ-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=NN3CC1=CC=C(C=N1)S(=O)(=O)N Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=NN3CC1=CC=C(C=N1)S(=O)(=O)N XUXOCPDPISPWTJ-UHFFFAOYSA-N 0.000 description 5
- NTQSHNDYHOFSPU-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)NC(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)NC(N3CC1=CC=C(C=C1)S(=O)(=O)N)=O NTQSHNDYHOFSPU-UHFFFAOYSA-N 0.000 description 5
- VKVCPVWWZRKEFY-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)NC(N3CC1=CC=C(C=N1)S(=O)(=O)N)=O Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)NC(N3CC1=CC=C(C=N1)S(=O)(=O)N)=O VKVCPVWWZRKEFY-UHFFFAOYSA-N 0.000 description 5
- DDVBWHARLGPKHZ-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)NC(N3CC=1C=CC(=NC=1)S(=O)(=O)N)=O Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)NC(N3CC=1C=CC(=NC=1)S(=O)(=O)N)=O DDVBWHARLGPKHZ-UHFFFAOYSA-N 0.000 description 5
- NPOIAKVNNZHYFC-SNVBAGLBSA-N COC=1C=CC=2C3=C(C=NC=2N=1)NC(N3[C@H](C)C1=CC=C(C=C1)S(=O)(=O)N)=O Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)NC(N3[C@H](C)C1=CC=C(C=C1)S(=O)(=O)N)=O NPOIAKVNNZHYFC-SNVBAGLBSA-N 0.000 description 5
- HYVYIXXDGAIHEH-UHFFFAOYSA-N COC=1N(C2=C(C=NC=3N=C(C=CC2=3)OC)N=1)CC1=CC(=C(C=C1)S(=O)(=O)N)F Chemical compound COC=1N(C2=C(C=NC=3N=C(C=CC2=3)OC)N=1)CC1=CC(=C(C=C1)S(=O)(=O)N)F HYVYIXXDGAIHEH-UHFFFAOYSA-N 0.000 description 5
- QSUAQWRTPITNPU-UHFFFAOYSA-N ClCC=1N(C2=C(C=NC=3N=C(C=CC2=3)OC)N=1)CC1=CC(=C(C=C1)S(=O)(=O)N)F Chemical compound ClCC=1N(C2=C(C=NC=3N=C(C=CC2=3)OC)N=1)CC1=CC(=C(C=C1)S(=O)(=O)N)F QSUAQWRTPITNPU-UHFFFAOYSA-N 0.000 description 5
- OLAAAWRVKHPDAQ-UHFFFAOYSA-N FC1=C(C(=CC(=C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)S(=O)(=O)N Chemical compound FC1=C(C(=CC(=C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)S(=O)(=O)N OLAAAWRVKHPDAQ-UHFFFAOYSA-N 0.000 description 5
- JLRRYLMBGCDUQQ-UHFFFAOYSA-N FC1=C(C=C(C(=C1)CN1C(=NC=2C(=NC=3N=C(C=CC=3C=21)OC)C)C)F)S(=O)(=O)N Chemical compound FC1=C(C=C(C(=C1)CN1C(=NC=2C(=NC=3N=C(C=CC=3C=21)OC)C)C)F)S(=O)(=O)N JLRRYLMBGCDUQQ-UHFFFAOYSA-N 0.000 description 5
- YMAYTLZUJSERBW-UHFFFAOYSA-N FC1=C(C=C(C(=C1)CN1C(=NC=2C(=NC=3N=C(C=CC=3C=21)OC)C)CCOC)F)S(=O)(=O)N Chemical compound FC1=C(C=C(C(=C1)CN1C(=NC=2C(=NC=3N=C(C=CC=3C=21)OC)C)CCOC)F)S(=O)(=O)N YMAYTLZUJSERBW-UHFFFAOYSA-N 0.000 description 5
- ZMKOBGBKTLGVRL-UHFFFAOYSA-N FC1=C(C=C(C(=C1)CN1C(=NC=2C(=NC=3N=C(C=CC=3C=21)OC)C)CO)F)S(=O)(=O)N Chemical compound FC1=C(C=C(C(=C1)CN1C(=NC=2C(=NC=3N=C(C=CC=3C=21)OC)C)CO)F)S(=O)(=O)N ZMKOBGBKTLGVRL-UHFFFAOYSA-N 0.000 description 5
- DCLCNXIYBIWOCU-UHFFFAOYSA-N FC1=C(C=CC(=C1)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)C)S(=O)(=O)NC(C)=O Chemical compound FC1=C(C=CC(=C1)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)C)S(=O)(=O)NC(C)=O DCLCNXIYBIWOCU-UHFFFAOYSA-N 0.000 description 5
- HYTRICJYXBKMKV-UHFFFAOYSA-N FC1=C(C=CC(=C1)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)C1CN(C1)S(=O)(=O)C)S(=O)(=O)N Chemical compound FC1=C(C=CC(=C1)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)C1CN(C1)S(=O)(=O)C)S(=O)(=O)N HYTRICJYXBKMKV-UHFFFAOYSA-N 0.000 description 5
- DPXFQNRMXWANRG-UHFFFAOYSA-N FC1=C(C=CC(=C1)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)CN1CCOCC1)S(=O)(=O)N Chemical compound FC1=C(C=CC(=C1)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)CN1CCOCC1)S(=O)(=O)N DPXFQNRMXWANRG-UHFFFAOYSA-N 0.000 description 5
- CDNHHSBSPTVERT-UHFFFAOYSA-N FC1=C(C=CC(=C1)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)CS(=O)(=O)C)S(=O)(=O)N Chemical compound FC1=C(C=CC(=C1)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)CS(=O)(=O)C)S(=O)(=O)N CDNHHSBSPTVERT-UHFFFAOYSA-N 0.000 description 5
- BEUQOJQWMITOQS-UHFFFAOYSA-N FC1=C(C=CC(=C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)P(O)(O)=O Chemical compound FC1=C(C=CC(=C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)P(O)(O)=O BEUQOJQWMITOQS-UHFFFAOYSA-N 0.000 description 5
- WJKUDRDYYFMIOI-UHFFFAOYSA-N FC1=C(C=CC(=C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)S(=O)(=O)N Chemical compound FC1=C(C=CC(=C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)S(=O)(=O)N WJKUDRDYYFMIOI-UHFFFAOYSA-N 0.000 description 5
- MZXFZAXLYVSNBE-UHFFFAOYSA-N FC1=C(C=CC(=C1)CN1C=NC=2C(=NC=3N=C(C=CC=3C=21)OC)C)S(=O)(=O)N Chemical compound FC1=C(C=CC(=C1)CN1C=NC=2C(=NC=3N=C(C=CC=3C=21)OC)C)S(=O)(=O)N MZXFZAXLYVSNBE-UHFFFAOYSA-N 0.000 description 5
- YXWZPTNKKLHEDZ-UHFFFAOYSA-N FC1=C(C=CC(=C1)CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC)S(=O)(=O)N Chemical compound FC1=C(C=CC(=C1)CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC)S(=O)(=O)N YXWZPTNKKLHEDZ-UHFFFAOYSA-N 0.000 description 5
- DOEQGJAIIDJRBZ-UHFFFAOYSA-N FC1=C(C=CC(=C1)CN1N=CC=2N=NC=3C=C(C=CC=3C=21)OC)S(=O)(=O)N Chemical compound FC1=C(C=CC(=C1)CN1N=CC=2N=NC=3C=C(C=CC=3C=21)OC)S(=O)(=O)N DOEQGJAIIDJRBZ-UHFFFAOYSA-N 0.000 description 5
- GTENTSJURYUDSB-UHFFFAOYSA-N FC1=C(C=CC(=C1)CN1N=NC=2C=NC=3N=C(C=CC=3C=21)OC)S(=O)(=O)N Chemical compound FC1=C(C=CC(=C1)CN1N=NC=2C=NC=3N=C(C=CC=3C=21)OC)S(=O)(=O)N GTENTSJURYUDSB-UHFFFAOYSA-N 0.000 description 5
- NUCUYECICFXDMA-UHFFFAOYSA-N FC1=C(C=CC(=C1F)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)S(=O)(=O)N Chemical compound FC1=C(C=CC(=C1F)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)S(=O)(=O)N NUCUYECICFXDMA-UHFFFAOYSA-N 0.000 description 5
- REORUGQAEYCUCW-UHFFFAOYSA-N FC=1C=C(C(=O)NO)C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F Chemical compound FC=1C=C(C(=O)NO)C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F REORUGQAEYCUCW-UHFFFAOYSA-N 0.000 description 5
- FSIOAXISJJQFOK-UHFFFAOYSA-N FC=1C=C(C(=O)O)C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F Chemical compound FC=1C=C(C(=O)O)C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F FSIOAXISJJQFOK-UHFFFAOYSA-N 0.000 description 5
- BVDGGEGSGORGDQ-UHFFFAOYSA-N FC=1C=C(C=C(C=1CN1C(NC=2C(=NC=3N=C(C=CC=3C=21)OC)C)=O)F)S(=O)(=O)N Chemical compound FC=1C=C(C=C(C=1CN1C(NC=2C(=NC=3N=C(C=CC=3C=21)OC)C)=O)F)S(=O)(=O)N BVDGGEGSGORGDQ-UHFFFAOYSA-N 0.000 description 5
- VFEGNLOPTJHCIK-UHFFFAOYSA-N FC=1C=C(C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)P(O)(O)=O Chemical compound FC=1C=C(C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)P(O)(O)=O VFEGNLOPTJHCIK-UHFFFAOYSA-N 0.000 description 5
- TVXYCLZHOWHPDP-UHFFFAOYSA-N FC=1C=C(C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)S(=O)(=O)NC Chemical compound FC=1C=C(C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)S(=O)(=O)NC TVXYCLZHOWHPDP-UHFFFAOYSA-N 0.000 description 5
- NDKNLIGUEOGNSU-UHFFFAOYSA-M FC=1C=C(C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)S(=O)(=O)[N-]C(CC)=O.[Na+] Chemical compound FC=1C=C(C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)S(=O)(=O)[N-]C(CC)=O.[Na+] NDKNLIGUEOGNSU-UHFFFAOYSA-M 0.000 description 5
- KCCDQHDBRSVMSU-UHFFFAOYSA-N FC=1C=C(C=CC=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)S(=O)(=O)N Chemical compound FC=1C=C(C=CC=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)S(=O)(=O)N KCCDQHDBRSVMSU-UHFFFAOYSA-N 0.000 description 5
- OMXPIHAROXVTPK-UHFFFAOYSA-N FC=1C=C(C=CC=1CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC)S(=O)(=O)N Chemical compound FC=1C=C(C=CC=1CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC)S(=O)(=O)N OMXPIHAROXVTPK-UHFFFAOYSA-N 0.000 description 5
- HAONPZKVTGUSHQ-UHFFFAOYSA-N FC=1C=C(CN2C(=NC=3C=NC=4N=C(C=CC=4C=32)OC)CC(=O)N)C=CC=1S(N)(=O)=O Chemical compound FC=1C=C(CN2C(=NC=3C=NC=4N=C(C=CC=4C=32)OC)CC(=O)N)C=CC=1S(N)(=O)=O HAONPZKVTGUSHQ-UHFFFAOYSA-N 0.000 description 5
- 102100026720 Interferon beta Human genes 0.000 description 5
- 108090000467 Interferon-beta Proteins 0.000 description 5
- FUSUOZNOLUNLHM-UHFFFAOYSA-N S(=O)(=O)(NC1=CC=C(C=C1)CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC)N Chemical compound S(=O)(=O)(NC1=CC=C(C=C1)CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC)N FUSUOZNOLUNLHM-UHFFFAOYSA-N 0.000 description 5
- WFKHNJZFRUVUNG-UHFFFAOYSA-N S(=O)(=O)(NCC1=CC=C(C=C1)C1=NN=C2N1C1=CC(=C(C=C1N=C2)OC)OC)N Chemical compound S(=O)(=O)(NCC1=CC=C(C=C1)C1=NN=C2N1C1=CC(=C(C=C1N=C2)OC)OC)N WFKHNJZFRUVUNG-UHFFFAOYSA-N 0.000 description 5
- MCYHADNAXMWMLW-UHFFFAOYSA-N S(N)(OC1CC(C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)(=O)=O Chemical compound S(N)(OC1CC(C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)(=O)=O MCYHADNAXMWMLW-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- OSCVZXXDNXKECT-UHFFFAOYSA-M sodium butanoyl-[3,5-difluoro-4-[(7-methoxy-2-oxo-3H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl]phenyl]sulfonylazanide Chemical compound CCCC([N-]S(C1=CC(F)=C(CN(C(C(C=C2)=C(N=C3)N=C2OC)=C3N2)C2=O)C(F)=C1)(=O)=O)=O.[Na+] OSCVZXXDNXKECT-UHFFFAOYSA-M 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 4
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- WNEHUIPHOBAKLO-UHFFFAOYSA-N BrC1=CC(=C(CN2C(NC=3C=NC=4N=C(C=CC=4C=32)OC)=O)C(=C1)F)F Chemical compound BrC1=CC(=C(CN2C(NC=3C=NC=4N=C(C=CC=4C=32)OC)=O)C(=C1)F)F WNEHUIPHOBAKLO-UHFFFAOYSA-N 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- LPSIKUDVUQJCKB-UHFFFAOYSA-N CN1C2=CN=C3C(=C2N(C1=O)CC4=C(C=C(C=C4F)S(=O)(=O)N)F)C=CC(=N3)OC Chemical compound CN1C2=CN=C3C(=C2N(C1=O)CC4=C(C=C(C=C4F)S(=O)(=O)N)F)C=CC(=N3)OC LPSIKUDVUQJCKB-UHFFFAOYSA-N 0.000 description 4
- HQZYWHVRTCOSDC-UHFFFAOYSA-N COC1=NC2=NC=C3C(=C2C=C1)N(C(=O)N3CC(F)(F)F)CC4=C(C=C(C=C4F)S(=O)(=O)N)F Chemical compound COC1=NC2=NC=C3C(=C2C=C1)N(C(=O)N3CC(F)(F)F)CC4=C(C=C(C=C4F)S(=O)(=O)N)F HQZYWHVRTCOSDC-UHFFFAOYSA-N 0.000 description 4
- HDFBMYXHECKWBL-UHFFFAOYSA-N COC1=NC2=NC=C3C(=C2C=C1)N(C(=O)N3CCCO)CC4=C(C=C(C=C4F)S(=O)(=O)N)F Chemical compound COC1=NC2=NC=C3C(=C2C=C1)N(C(=O)N3CCCO)CC4=C(C=C(C=C4F)S(=O)(=O)N)F HDFBMYXHECKWBL-UHFFFAOYSA-N 0.000 description 4
- VEQBIFWVCUDFOV-UHFFFAOYSA-N COC=1C=CC=2C3=C(C(=NC=2N=1)C)N=C(N3CC1=CC=C(C=N1)P(O)(O)=O)C Chemical compound COC=1C=CC=2C3=C(C(=NC=2N=1)C)N=C(N3CC1=CC=C(C=N1)P(O)(O)=O)C VEQBIFWVCUDFOV-UHFFFAOYSA-N 0.000 description 4
- YBVBUWGHFCLJJE-UHFFFAOYSA-N COC=1C=CC=2C3=C(C(=NC=2N=1)C)N=NN3CC1=CC=C(C=N1)S(=O)(=O)N Chemical compound COC=1C=CC=2C3=C(C(=NC=2N=1)C)N=NN3CC1=CC=C(C=N1)S(=O)(=O)N YBVBUWGHFCLJJE-UHFFFAOYSA-N 0.000 description 4
- VRAQQTOJBCBKOT-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)C=NN3CC1=CC=C(C=N1)S(=O)(=O)N Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)C=NN3CC1=CC=C(C=N1)S(=O)(=O)N VRAQQTOJBCBKOT-UHFFFAOYSA-N 0.000 description 4
- VLQAPJGDRYAROM-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1=CC(=C(C=C1)S(=O)(=O)N)OC(F)(F)F Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1=CC(=C(C=C1)S(=O)(=O)N)OC(F)(F)F VLQAPJGDRYAROM-UHFFFAOYSA-N 0.000 description 4
- YROKNELCHWZAMK-UHFFFAOYSA-N COCCN1C2=CN=C3C(=C2N(C1=O)CC4=C(C=C(C=C4F)S(=O)(=O)N)F)C=CC(=N3)OC Chemical compound COCCN1C2=CN=C3C(=C2N(C1=O)CC4=C(C=C(C=C4F)S(=O)(=O)N)F)C=CC(=N3)OC YROKNELCHWZAMK-UHFFFAOYSA-N 0.000 description 4
- KSWJUIMIKPFAKS-UHFFFAOYSA-N ClC1=C(C(=NC2=NC(=CC=C12)OC)C)[N+](=O)[O-] Chemical compound ClC1=C(C(=NC2=NC(=CC=C12)OC)C)[N+](=O)[O-] KSWJUIMIKPFAKS-UHFFFAOYSA-N 0.000 description 4
- VNXFSJCSADPFEH-UHFFFAOYSA-N ClC=1C=C(C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)S(=O)(=O)N Chemical compound ClC=1C=C(C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)S(=O)(=O)N VNXFSJCSADPFEH-UHFFFAOYSA-N 0.000 description 4
- HNUOWCWGEBRAQU-UHFFFAOYSA-N FC1=C(C=C(C(=C1F)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)S(=O)(=O)N Chemical compound FC1=C(C=C(C(=C1F)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)S(=O)(=O)N HNUOWCWGEBRAQU-UHFFFAOYSA-N 0.000 description 4
- CLCZBZZDZDBXIH-UHFFFAOYSA-N FC1=C(C=CC(=C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)P(OC)(O)=O Chemical compound FC1=C(C=CC(=C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)P(OC)(O)=O CLCZBZZDZDBXIH-UHFFFAOYSA-N 0.000 description 4
- CXESGRSEOCRZKS-UHFFFAOYSA-N FC1=C(C=CC(=C1)CN1N=C2C(C=NC=3N=C(C=CC2=3)OC)=C1)S(=O)(=O)N Chemical compound FC1=C(C=CC(=C1)CN1N=C2C(C=NC=3N=C(C=CC2=3)OC)=C1)S(=O)(=O)N CXESGRSEOCRZKS-UHFFFAOYSA-N 0.000 description 4
- FANDZJVVUSADJN-UHFFFAOYSA-N FC1=C(C=CC(=C1)CN1N=CC=2C=NC=3N=C(C=CC=3C=21)OC)S(=O)(=O)N Chemical compound FC1=C(C=CC(=C1)CN1N=CC=2C=NC=3N=C(C=CC=3C=21)OC)S(=O)(=O)N FANDZJVVUSADJN-UHFFFAOYSA-N 0.000 description 4
- LKOPPZIDWPETRH-UHFFFAOYSA-N FC=1C=C(C=C(C=1CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)C)F)S(=O)(=O)N Chemical compound FC=1C=C(C=C(C=1CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)C)F)S(=O)(=O)N LKOPPZIDWPETRH-UHFFFAOYSA-N 0.000 description 4
- FYEKZZOFVRWAMD-UHFFFAOYSA-N FC=1C=C(C=C(C=1CN1C(N(C=2C=NC=3N=C(C=CC=3C=21)OC)C1COC1)=O)F)S(=O)(=O)N Chemical compound FC=1C=C(C=C(C=1CN1C(N(C=2C=NC=3N=C(C=CC=3C=21)OC)C1COC1)=O)F)S(=O)(=O)N FYEKZZOFVRWAMD-UHFFFAOYSA-N 0.000 description 4
- ZOSRKOOZGKLOSN-UHFFFAOYSA-N FC=1C=C(C=C(C=1CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC)F)S(=O)(=O)N Chemical compound FC=1C=C(C=C(C=1CN1C=NC=2C=NC=3N=C(C=CC=3C=21)OC)F)S(=O)(=O)N ZOSRKOOZGKLOSN-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 150000001412 amines Chemical group 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- SIACJRVYIPXFKS-UHFFFAOYSA-N (4-sulfamoylphenyl)methylazanium;chloride Chemical compound Cl.NCC1=CC=C(S(N)(=O)=O)C=C1 SIACJRVYIPXFKS-UHFFFAOYSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- PWKJBECFMAPCME-UHFFFAOYSA-N 2h-triazolo[4,5-c]quinoline Chemical compound C1=NC2=CC=CC=C2C2=C1N=NN2 PWKJBECFMAPCME-UHFFFAOYSA-N 0.000 description 3
- HMLOMVBFQJAMCN-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinoline-3-carbonitrile Chemical compound C1=C(C#N)C(Cl)=C2C=C(OC)C(OC)=CC2=N1 HMLOMVBFQJAMCN-UHFFFAOYSA-N 0.000 description 3
- BMXJFKLSEGBBSJ-UHFFFAOYSA-N 5-bromo-2-(bromomethyl)pyrimidine Chemical compound BrCC1=NC=C(Br)C=N1 BMXJFKLSEGBBSJ-UHFFFAOYSA-N 0.000 description 3
- DEUALFRBMNMGDS-UHFFFAOYSA-N 6-methoxypyridin-2-amine Chemical compound COC1=CC=CC(N)=N1 DEUALFRBMNMGDS-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- TXEYJHKQIDBGLP-UHFFFAOYSA-N COC=1C=C2C(=C(C=NC2=CC=1OC)C(=O)O)NCC1=CC=C(C=C1)S(N)(=O)=O Chemical compound COC=1C=C2C(=C(C=NC2=CC=1OC)C(=O)O)NCC1=CC=C(C=C1)S(N)(=O)=O TXEYJHKQIDBGLP-UHFFFAOYSA-N 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- PZQLPTNPRQSRGP-UHFFFAOYSA-N ClC1=C(C=NC2=NC(=CC=C12)OC)C(=O)OCC Chemical compound ClC1=C(C=NC2=NC(=CC=C12)OC)C(=O)OCC PZQLPTNPRQSRGP-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LLIQBKAQUSZZGH-UHFFFAOYSA-N FC=1C=C(C(=O)OC)C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F Chemical compound FC=1C=C(C(=O)OC)C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F LLIQBKAQUSZZGH-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000036515 potency Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- WAJJIVIBRLOHEU-UHFFFAOYSA-N (4-bromo-2,6-difluorophenyl)methanamine Chemical compound NCC1=C(F)C=C(Br)C=C1F WAJJIVIBRLOHEU-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- DEVUYWTZRXOMSI-UHFFFAOYSA-N (sulfamoylamino)benzene Chemical compound NS(=O)(=O)NC1=CC=CC=C1 DEVUYWTZRXOMSI-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 2
- PXGDYVQYFSCAPZ-UHFFFAOYSA-N 4-(aminomethyl)piperidine-1-sulfonamide Chemical compound NCC1CCN(S(N)(=O)=O)CC1 PXGDYVQYFSCAPZ-UHFFFAOYSA-N 0.000 description 2
- QNJHTLTUBNXLFS-UHFFFAOYSA-N 4-(bromomethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(CBr)C=C1 QNJHTLTUBNXLFS-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YIGSCEUQIQKFPL-ZCFIWIBFSA-N 4-[(1r)-1-aminoethyl]benzenesulfonamide Chemical compound C[C@@H](N)C1=CC=C(S(N)(=O)=O)C=C1 YIGSCEUQIQKFPL-ZCFIWIBFSA-N 0.000 description 2
- AHFGKYBAYSEBPR-UHFFFAOYSA-N 4-bromo-2-(trifluoromethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Br)C=C1C(F)(F)F AHFGKYBAYSEBPR-UHFFFAOYSA-N 0.000 description 2
- PVNJEWZCQLRQLP-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinolin-3-amine Chemical compound C1=C(N)C(Cl)=C2C=C(OC)C(OC)=CC2=N1 PVNJEWZCQLRQLP-UHFFFAOYSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-M 4-nitrophenolate Chemical compound [O-]C1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-M 0.000 description 2
- UPJKSWLLCONYMW-UHFFFAOYSA-N 5'-Adenosine monophosphate Natural products COc1cc(O)c(C(=O)C)c(OC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)c1 UPJKSWLLCONYMW-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- OHWLFVXAHDKHKE-UHFFFAOYSA-N BrC1=CC(=C(C(=C1)F)CN1C(N(C=2C=NC=3N=C(C=CC=3C=21)OC)C(=O)OC(C)(C)C)=O)F Chemical compound BrC1=CC(=C(C(=C1)F)CN1C(N(C=2C=NC=3N=C(C=CC=3C=21)OC)C(=O)OC(C)(C)C)=O)F OHWLFVXAHDKHKE-UHFFFAOYSA-N 0.000 description 2
- ICOSABXZMJVOFC-UHFFFAOYSA-N BrC1=CC=C(CN2C=NC=3C=NC=4N=C(C=CC=4C=32)OC)C=C1 Chemical compound BrC1=CC=C(CN2C=NC=3C=NC=4N=C(C=CC=4C=32)OC)C=C1 ICOSABXZMJVOFC-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- YWUBLPSZHCLMOQ-UHFFFAOYSA-N C(#N)C=1C=NC2=CC(=C(C=C2C=1NCC1=CC=C(C=C1)S(=O)(=O)N)OC)OC Chemical compound C(#N)C=1C=NC2=CC(=C(C=C2C=1NCC1=CC=C(C=C1)S(=O)(=O)N)OC)OC YWUBLPSZHCLMOQ-UHFFFAOYSA-N 0.000 description 2
- OPWMWJVHVPYJJT-UHFFFAOYSA-N COC(C=C1N=CC(NN)=NC1=C1)=C1OC Chemical compound COC(C=C1N=CC(NN)=NC1=C1)=C1OC OPWMWJVHVPYJJT-UHFFFAOYSA-N 0.000 description 2
- OQJSWPGQPVOVLM-UHFFFAOYSA-N COC1=NC2=NC=C3C(=C2C=C1)N(C(=N3)C4CC4)CC5=NC=C(C=C5)S(=O)(=O)N Chemical compound COC1=NC2=NC=C3C(=C2C=C1)N(C(=N3)C4CC4)CC5=NC=C(C=C5)S(=O)(=O)N OQJSWPGQPVOVLM-UHFFFAOYSA-N 0.000 description 2
- MVPCOPJUHUUSQB-UHFFFAOYSA-N COC=1C(=CC=2C=3N(C=NC=2C=1)N=CC=3C(=O)OCC)OC Chemical compound COC=1C(=CC=2C=3N(C=NC=2C=1)N=CC=3C(=O)OCC)OC MVPCOPJUHUUSQB-UHFFFAOYSA-N 0.000 description 2
- AMCFCPVFZVGBEM-UHFFFAOYSA-N COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1=CC=C(N)C=C1 Chemical compound COC=1C=CC=2C3=C(C=NC=2N=1)N=CN3CC1=CC=C(N)C=C1 AMCFCPVFZVGBEM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- QXQBDENGDLEWCZ-UHFFFAOYSA-N ClC1=C(C=NC2=CC(=CN=C12)OC)[N+](=O)[O-] Chemical compound ClC1=C(C=NC2=CC(=CN=C12)OC)[N+](=O)[O-] QXQBDENGDLEWCZ-UHFFFAOYSA-N 0.000 description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- PNRLKLXZHMPXEU-UHFFFAOYSA-N FC1=C(C=C(C(=C1)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)C)F)P(O)(O)=O Chemical compound FC1=C(C=C(C(=C1)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)C)F)P(O)(O)=O PNRLKLXZHMPXEU-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 2
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 101710141452 Major surface glycoprotein G Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- FNFSFONYUSAHEX-UHFFFAOYSA-N NC=1C=NC2=NC(=CC=C2C=1NCC1=CC(=C(C=C1)S(=O)(=O)N)F)OC Chemical compound NC=1C=NC2=NC(=CC=C2C=1NCC1=CC(=C(C=C1)S(=O)(=O)N)F)OC FNFSFONYUSAHEX-UHFFFAOYSA-N 0.000 description 2
- TYRWQSLKCWUGLR-UHFFFAOYSA-N NC=1C=NC2=NC(=CC=C2C=1NCC1=CC=C(C=C1)S(=O)(=O)N)OC Chemical compound NC=1C=NC2=NC(=CC=C2C=1NCC1=CC=C(C=C1)S(=O)(=O)N)OC TYRWQSLKCWUGLR-UHFFFAOYSA-N 0.000 description 2
- OPZGYCUBWNPLFA-UHFFFAOYSA-N NC=1C=NC2=NC(=CC=C2C=1NCC1=CC=C(C=N1)S(=O)(=O)N)OC Chemical compound NC=1C=NC2=NC(=CC=C2C=1NCC1=CC=C(C=N1)S(=O)(=O)N)OC OPZGYCUBWNPLFA-UHFFFAOYSA-N 0.000 description 2
- LUYZIUCNMCKLEH-UHFFFAOYSA-N NCC1=CC(=C(C(=C1)F)S(=O)(=O)N)F Chemical compound NCC1=CC(=C(C(=C1)F)S(=O)(=O)N)F LUYZIUCNMCKLEH-UHFFFAOYSA-N 0.000 description 2
- PQTCMCRIXLZZGZ-UHFFFAOYSA-N NCC1CN(C1)S(N)(=O)=O Chemical compound NCC1CN(C1)S(N)(=O)=O PQTCMCRIXLZZGZ-UHFFFAOYSA-N 0.000 description 2
- 229910019213 POCl3 Inorganic materials 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 108010016672 Syk Kinase Proteins 0.000 description 2
- 102000000551 Syk Kinase Human genes 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 2
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000018678 bone mineralization Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 108010042209 insulin receptor tyrosine kinase Proteins 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- QSRRZKPKHJHIRB-UHFFFAOYSA-N methyl 4-[(2,5-dichloro-4-methylthiophen-3-yl)sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=C(Cl)SC(Cl)=C1C QSRRZKPKHJHIRB-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- DWXLVZSMXXCSMJ-UHFFFAOYSA-N piperazine-1-sulfonamide Chemical compound NS(=O)(=O)N1CCNCC1 DWXLVZSMXXCSMJ-UHFFFAOYSA-N 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 230000001696 purinergic effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- NKFLEFWUYAUDJV-UHFFFAOYSA-N pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CN=C1 NKFLEFWUYAUDJV-UHFFFAOYSA-N 0.000 description 2
- NIRIGNIPEFMZHT-UHFFFAOYSA-N pyrimidine-5-sulfonamide Chemical compound NS(=O)(=O)C1=CN=CN=C1 NIRIGNIPEFMZHT-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- HZDNNJABYXNPPV-UHFFFAOYSA-N (2-chloro-2-oxoethyl) acetate Chemical compound CC(=O)OCC(Cl)=O HZDNNJABYXNPPV-UHFFFAOYSA-N 0.000 description 1
- PNVPNXKRAUBJGW-UHFFFAOYSA-N (2-chloroacetyl) 2-chloroacetate Chemical compound ClCC(=O)OC(=O)CCl PNVPNXKRAUBJGW-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- XRNVSPDQTPVECU-UHFFFAOYSA-N (4-bromophenyl)methanamine Chemical compound NCC1=CC=C(Br)C=C1 XRNVSPDQTPVECU-UHFFFAOYSA-N 0.000 description 1
- OLTVRSUIOUTBRQ-UHFFFAOYSA-N (4-nitrophenyl) sulfamate Chemical compound NS(=O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 OLTVRSUIOUTBRQ-UHFFFAOYSA-N 0.000 description 1
- AKSXQPCIAOIJGP-UHFFFAOYSA-N (4-sulfamoylphenyl)boronic acid Chemical compound NS(=O)(=O)C1=CC=C(B(O)O)C=C1 AKSXQPCIAOIJGP-UHFFFAOYSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- RBQHMOOKZFLRBA-QDEBKDIKSA-N (NE)-N-[(4-bromo-2,6-difluorophenyl)methylidene]hydroxylamine Chemical compound BrC1=CC(=C(C(=C1)F)\C=N\O)F RBQHMOOKZFLRBA-QDEBKDIKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- DICWFQIPICOIBQ-UHFFFAOYSA-N 1-[(4-amino-2,6-difluorophenyl)methyl]-7-methoxy-3H-imidazo[4,5-c][1,8]naphthyridin-2-one Chemical compound COC(C=C1)=NC(N=C2)=C1C(N1CC(C(F)=CC(N)=C3)=C3F)=C2NC1=O DICWFQIPICOIBQ-UHFFFAOYSA-N 0.000 description 1
- VDYQIIAPAHGPRM-UHFFFAOYSA-N 1-[(5-benzylsulfanylpyrimidin-2-yl)methyl]-7-methoxy-2,4-dimethylimidazo[4,5-c][1,8]naphthyridine Chemical compound CC1=NC(C(C)=NC2=C3C=CC(OC)=N2)=C3N1CC(N=C1)=NC=C1SCC1=CC=CC=C1 VDYQIIAPAHGPRM-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- ZRIKJXDEJYMBEJ-UHFFFAOYSA-N 1-fluoro-4-methoxy-2-nitrobenzene Chemical compound COC1=CC=C(F)C([N+]([O-])=O)=C1 ZRIKJXDEJYMBEJ-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- ITIRVXDSMXFTPW-UHFFFAOYSA-N 1H-imidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C(NC=N3)C3=CN=C21 ITIRVXDSMXFTPW-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- RFBONBFMRTWGGB-UHFFFAOYSA-N 2-(4-bromophenyl)acetaldehyde Chemical compound BrC1=CC=C(CC=O)C=C1 RFBONBFMRTWGGB-UHFFFAOYSA-N 0.000 description 1
- MFHFWRBXPQDZSA-UHFFFAOYSA-N 2-(4-bromophenyl)acetonitrile Chemical compound BrC1=CC=C(CC#N)C=C1 MFHFWRBXPQDZSA-UHFFFAOYSA-N 0.000 description 1
- HIFGQHGWMTZMOH-UHFFFAOYSA-N 2-(trifluoromethoxy)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1OC(F)(F)F HIFGQHGWMTZMOH-UHFFFAOYSA-N 0.000 description 1
- RFYIUZCGZXPAMZ-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-1h-imidazole Chemical compound C1=CC(Br)=CC=C1CC1=NC=CN1 RFYIUZCGZXPAMZ-UHFFFAOYSA-N 0.000 description 1
- MRAYNLYCQPAZJN-BQYQJAHWSA-N 2-[(e)-2-ethoxyethenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CCO\C=C\B1OC(C)(C)C(C)(C)O1 MRAYNLYCQPAZJN-BQYQJAHWSA-N 0.000 description 1
- KJGOYBHXJBMXIL-UHFFFAOYSA-N 2-chloro-6,7-dimethoxyquinoxaline Chemical compound C1=C(Cl)N=C2C=C(OC)C(OC)=CC2=N1 KJGOYBHXJBMXIL-UHFFFAOYSA-N 0.000 description 1
- IZSFWGSSJFDFLR-UHFFFAOYSA-N 2-fluoro-4-[[7-methoxy-2-(methylsulfanylmethyl)imidazo[4,5-c][1,8]naphthyridin-1-yl]methyl]benzenesulfonamide Chemical compound COC(C=C1)=NC(N=C2)=C1C1=C2N=C(CSC)N1CC(C=C1)=CC(F)=C1S(N)(=O)=O IZSFWGSSJFDFLR-UHFFFAOYSA-N 0.000 description 1
- WFLBWYLZCQOPCA-UHFFFAOYSA-N 2-fluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1F WFLBWYLZCQOPCA-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 1
- IEEHKTFVUIVORU-UHFFFAOYSA-N 2-methylpropanedioyl dichloride Chemical compound ClC(=O)C(C)C(Cl)=O IEEHKTFVUIVORU-UHFFFAOYSA-N 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- HNENXADRSCEPIJ-UHFFFAOYSA-N 3-(aminomethyl)benzenesulfonamide Chemical compound NCC1=CC=CC(S(N)(=O)=O)=C1 HNENXADRSCEPIJ-UHFFFAOYSA-N 0.000 description 1
- SWROXHQUCQZFFC-UHFFFAOYSA-N 3-bromo-7-methoxy-1,8-naphthyridin-4-amine Chemical compound COC1=CC=C(C(N)=C(C=N2)Br)C2=N1 SWROXHQUCQZFFC-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- BBWMYJKKAKAERM-UHFFFAOYSA-N 4-(aminomethyl)-2-fluorobenzenesulfonamide Chemical compound NCC1=CC=C(S(N)(=O)=O)C(F)=C1 BBWMYJKKAKAERM-UHFFFAOYSA-N 0.000 description 1
- HNCRVPPYRDOKFL-UHFFFAOYSA-N 4-(aminomethyl)-3,5-difluorobenzenesulfonamide Chemical compound NCc1c(F)cc(cc1F)S(N)(=O)=O HNCRVPPYRDOKFL-UHFFFAOYSA-N 0.000 description 1
- MEDZIOXQDCBAHD-UHFFFAOYSA-N 4-(bromomethyl)-2-fluorobenzenesulfonamide Chemical compound NS(=O)(=O)c1ccc(CBr)cc1F MEDZIOXQDCBAHD-UHFFFAOYSA-N 0.000 description 1
- YIGSCEUQIQKFPL-LURJTMIESA-N 4-[(1s)-1-aminoethyl]benzenesulfonamide Chemical compound C[C@H](N)C1=CC=C(S(N)(=O)=O)C=C1 YIGSCEUQIQKFPL-LURJTMIESA-N 0.000 description 1
- UFLJELDEANZBFA-UHFFFAOYSA-N 4-[[(3-amino-7-methoxy-2-methyl-1,8-naphthyridin-4-yl)amino]methyl]-2,5-difluorobenzenesulfonamide Chemical compound CC1=NC2=NC(OC)=CC=C2C(NCC(C(F)=C2)=CC(F)=C2S(N)(=O)=O)=C1N UFLJELDEANZBFA-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- SSEAJHBQTBTYMI-UHFFFAOYSA-N 4-bromo-2,3-difluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Br)C(F)=C1F SSEAJHBQTBTYMI-UHFFFAOYSA-N 0.000 description 1
- BFQSQUAVMNHOEF-UHFFFAOYSA-N 4-bromo-2,6-difluoroaniline Chemical compound NC1=C(F)C=C(Br)C=C1F BFQSQUAVMNHOEF-UHFFFAOYSA-N 0.000 description 1
- CZGVAISJIQNQEJ-UHFFFAOYSA-N 4-bromo-2,6-difluorobenzaldehyde Chemical compound FC1=CC(Br)=CC(F)=C1C=O CZGVAISJIQNQEJ-UHFFFAOYSA-N 0.000 description 1
- XSCXKUIQRGHUQJ-UHFFFAOYSA-N 4-bromo-2,6-difluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=C(F)C=C(Br)C=C1F XSCXKUIQRGHUQJ-UHFFFAOYSA-N 0.000 description 1
- BULOZZLPZKWYCR-UHFFFAOYSA-N 4-bromo-2-(trifluoromethoxy)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Br)C=C1OC(F)(F)F BULOZZLPZKWYCR-UHFFFAOYSA-N 0.000 description 1
- YFXYEMZYOMNQLD-UHFFFAOYSA-N 4-bromo-2-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC(Br)=CC=C1S(Cl)(=O)=O YFXYEMZYOMNQLD-UHFFFAOYSA-N 0.000 description 1
- AKMOQOUJQRDNSP-UHFFFAOYSA-N 4-bromo-3,5-difluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC(F)=C(Br)C(F)=C1 AKMOQOUJQRDNSP-UHFFFAOYSA-N 0.000 description 1
- GQUUOLHRLZCAIO-UHFFFAOYSA-N 4-bromo-3-(trifluoromethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Br)C(C(F)(F)F)=C1 GQUUOLHRLZCAIO-UHFFFAOYSA-N 0.000 description 1
- FJYMQJYFQAGVFY-UHFFFAOYSA-N 4-chloro-6,7-dimethoxy-3-nitroquinoline Chemical compound C1=C([N+]([O-])=O)C(Cl)=C2C=C(OC)C(OC)=CC2=N1 FJYMQJYFQAGVFY-UHFFFAOYSA-N 0.000 description 1
- CBSKRPSEOOEJLL-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinoline-3-carbaldehyde Chemical compound C1=C(C=O)C(Cl)=C2C=C(OC)C(OC)=CC2=N1 CBSKRPSEOOEJLL-UHFFFAOYSA-N 0.000 description 1
- YNPIJOVOGOLRNP-UHFFFAOYSA-N 4-cyano-2,6-difluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=C(F)C=C(C#N)C=C1F YNPIJOVOGOLRNP-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- SKBSXDAOGNSTNE-UHFFFAOYSA-N 5-(aminomethyl)pyridine-2-sulfonamide Chemical compound NCC1=CC=C(S(N)(=O)=O)N=C1 SKBSXDAOGNSTNE-UHFFFAOYSA-N 0.000 description 1
- HGGXVMDSBYMMLM-UHFFFAOYSA-N 5-chloro-2-methoxy-1,8-naphthyridine Chemical compound ClC1=C2C=CC(=NC2=NC=C1)OC HGGXVMDSBYMMLM-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- CTQPCFFQBYXOAJ-UHFFFAOYSA-N 5-methoxypyridin-3-amine Chemical compound COC1=CN=CC(N)=C1 CTQPCFFQBYXOAJ-UHFFFAOYSA-N 0.000 description 1
- VZJDHPYFCBLKGI-UHFFFAOYSA-N 6,7-dimethoxy-4-oxo-1h-quinoline-3-carbonitrile Chemical compound N1C=C(C#N)C(=O)C2=C1C=C(OC)C(OC)=C2 VZJDHPYFCBLKGI-UHFFFAOYSA-N 0.000 description 1
- AIYWJDMRKDTSKP-UHFFFAOYSA-N 6-acetylpyridine-3-sulfonamide Chemical compound O=S(=O)(N)C1=CN=C(C(=O)C)C=C1 AIYWJDMRKDTSKP-UHFFFAOYSA-N 0.000 description 1
- ZDFRONWVKDXVNE-UHFFFAOYSA-N 6-cyanopyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CC=C(C#N)N=C1 ZDFRONWVKDXVNE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- FSPNJEFIRMQPLC-UHFFFAOYSA-N 7-amino-3,4-dihydro-1h-isoquinoline-2-sulfonamide Chemical compound C1CN(S(N)(=O)=O)CC2=CC(N)=CC=C21 FSPNJEFIRMQPLC-UHFFFAOYSA-N 0.000 description 1
- MXGRPTSQFXCJGW-UHFFFAOYSA-N 7-methoxy-1,8-naphthyridin-4-amine Chemical compound COC1=NC2=NC=CC(=C2C=C1)N MXGRPTSQFXCJGW-UHFFFAOYSA-N 0.000 description 1
- CKJGCCCRTSEZRX-UHFFFAOYSA-N 7-methoxy-1H-pyrazolo[4,3-c][1,8]naphthyridine Chemical compound COC(C=C1)=NC2=C1C(NN=C1)=C1C=N2 CKJGCCCRTSEZRX-UHFFFAOYSA-N 0.000 description 1
- GRQMDWMPZBOMGJ-UHFFFAOYSA-N 7-methoxy-1H-pyrrolo[3,2-c][1,8]naphthyridine Chemical compound COC(C=C1)=NC2=C1C(NC=C1)=C1C=N2 GRQMDWMPZBOMGJ-UHFFFAOYSA-N 0.000 description 1
- BZFOTLPKYUUHPG-UHFFFAOYSA-N 7-methoxy-2-methyl-1,8-naphthyridine-3,4-diamine Chemical compound CC1=NC2=NC(OC)=CC=C2C(N)=C1N BZFOTLPKYUUHPG-UHFFFAOYSA-N 0.000 description 1
- YRDDFOQVNBKNBJ-UHFFFAOYSA-N 7-methoxy-2-methyl-3-nitro-1,8-naphthyridin-4-amine Chemical compound CC1=NC2=NC(OC)=CC=C2C(N)=C1[N+]([O-])=O YRDDFOQVNBKNBJ-UHFFFAOYSA-N 0.000 description 1
- YKQQLHBXLKNJLJ-UHFFFAOYSA-N 7-methoxy-4-[(4-sulfamoylphenyl)methylamino]-1,8-naphthyridine-3-carboxylic acid Chemical compound COC1=CC=C(C(NCC(C=C2)=CC=C2S(N)(=O)=O)=C(C=N2)C(O)=O)C2=N1 YKQQLHBXLKNJLJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- YTRWYKIONSOWGQ-UHFFFAOYSA-N 8-bromo-7-methoxy-1h-1,6-naphthyridin-4-one Chemical compound N1C=CC(=O)C=2C1=C(Br)C(OC)=NC=2 YTRWYKIONSOWGQ-UHFFFAOYSA-N 0.000 description 1
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 1
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo[3.3.1]nonane Substances C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 101150051188 Adora2a gene Proteins 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 108091005625 BRD4 Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 1
- LJRRDIHSMJJKSU-UHFFFAOYSA-N BrC1=C(C=C(C=C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F Chemical compound BrC1=C(C=C(C=C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F LJRRDIHSMJJKSU-UHFFFAOYSA-N 0.000 description 1
- LGQSNIQBIXRBEB-UHFFFAOYSA-N BrC1=CC(=C(C(=C1)F)CN1C(N(C=2C=NC=3N=C(C=CC=3C=21)OC)C)=O)F Chemical compound BrC1=CC(=C(C(=C1)F)CN1C(N(C=2C=NC=3N=C(C=CC=3C=21)OC)C)=O)F LGQSNIQBIXRBEB-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 1
- 108091005575 Bromodomain-containing proteins Proteins 0.000 description 1
- 102000001805 Bromodomains Human genes 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- CRQAQPXUBUSWCH-UHFFFAOYSA-N C(C)(=O)OCC(=O)NC=1C(=NC2=NC(=CC=C2C=1NCC1=C(C=C(C(=C1)F)S(N)(=O)=O)F)OC)C Chemical compound C(C)(=O)OCC(=O)NC=1C(=NC2=NC(=CC=C2C=1NCC1=C(C=C(C(=C1)F)S(N)(=O)=O)F)OC)C CRQAQPXUBUSWCH-UHFFFAOYSA-N 0.000 description 1
- YSKKHRMTTUVJND-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1=CC(=C(C(=C1)F)CN1C(N(C=2C=NC=3N=C(C=CC=3C=21)OC)C(=O)OC(C)(C)C)=O)F Chemical compound C(C)(C)(C)OC(=O)NC1=CC(=C(C(=C1)F)CN1C(N(C=2C=NC=3N=C(C=CC=3C=21)OC)C(=O)OC(C)(C)C)=O)F YSKKHRMTTUVJND-UHFFFAOYSA-N 0.000 description 1
- WFIHBVBBYIGHDI-UHFFFAOYSA-N C(C)(C)(C)OC(NCC1=CC=C(C=C1)C=NNC1=NC2=CC(=C(C=C2N=C1)OC)OC)=O Chemical compound C(C)(C)(C)OC(NCC1=CC=C(C=C1)C=NNC1=NC2=CC(=C(C=C2N=C1)OC)OC)=O WFIHBVBBYIGHDI-UHFFFAOYSA-N 0.000 description 1
- NVYGADOGUJOWCA-RIYZIHGNSA-N C(C)(C)(C)S(=O)\N=C(/C)\C1=CC=C(C=N1)S(=O)(=O)N Chemical compound C(C)(C)(C)S(=O)\N=C(/C)\C1=CC=C(C=N1)S(=O)(=O)N NVYGADOGUJOWCA-RIYZIHGNSA-N 0.000 description 1
- RARBZDDGHJZRHC-UHFFFAOYSA-N C(C)OP(=O)(OCC)C1=C(C=C(C=C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F Chemical compound C(C)OP(=O)(OCC)C1=C(C=C(C=C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F RARBZDDGHJZRHC-UHFFFAOYSA-N 0.000 description 1
- OUSCNMMITNIIJL-UHFFFAOYSA-N C(C1=CC=CC=C1)SC1=CC(=C(C(=C1)F)CN1C(N(C=2C=NC=3N=C(C=CC=3C=21)OC)C)=O)F Chemical compound C(C1=CC=CC=C1)SC1=CC(=C(C(=C1)F)CN1C(N(C=2C=NC=3N=C(C=CC=3C=21)OC)C)=O)F OUSCNMMITNIIJL-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- HATPEDXSNDYHNV-UHFFFAOYSA-N CC1=C2C(=C3C=CC(=NC3=N1)OC)N(C(=N2)C)CC4=NC=C(C=N4)Br Chemical compound CC1=C2C(=C3C=CC(=NC3=N1)OC)N(C(=N2)C)CC4=NC=C(C=N4)Br HATPEDXSNDYHNV-UHFFFAOYSA-N 0.000 description 1
- FMMMCYJARQYIRF-UHFFFAOYSA-N CC1=C2C(=C3C=CC(=NC3=N1)OC)N=C(N2)C Chemical compound CC1=C2C(=C3C=CC(=NC3=N1)OC)N=C(N2)C FMMMCYJARQYIRF-UHFFFAOYSA-N 0.000 description 1
- CSOJQKSZZXFKNI-UHFFFAOYSA-N CC1=NC(C=NC(C=C2OC)=C3C=C2OC)=C3N1CC(CC1)CN1S(N)(=O)=O Chemical compound CC1=NC(C=NC(C=C2OC)=C3C=C2OC)=C3N1CC(CC1)CN1S(N)(=O)=O CSOJQKSZZXFKNI-UHFFFAOYSA-N 0.000 description 1
- BORGFLCXXNGJRA-UHFFFAOYSA-N CC1=NC2=CN=C3C(=C2N1CC4=CC(=C(C=C4)S(=O)(=O)N)F)C=CC(=N3)OC Chemical compound CC1=NC2=CN=C3C(=C2N1CC4=CC(=C(C=C4)S(=O)(=O)N)F)C=CC(=N3)OC BORGFLCXXNGJRA-UHFFFAOYSA-N 0.000 description 1
- UZMSYVMKAIOQCF-UHFFFAOYSA-N CC1=NN(CC(C=C2)=CC=C2S(N)(=O)=O)C2=C1C=NC(C=C1OC)=C2C=C1OC Chemical compound CC1=NN(CC(C=C2)=CC=C2S(N)(=O)=O)C2=C1C=NC(C=C1OC)=C2C=C1OC UZMSYVMKAIOQCF-UHFFFAOYSA-N 0.000 description 1
- UHEARIFIDDKYII-VOTSOKGWSA-N CCO/C=C/C1=CN=C2C(=C1N)C=CC(=N2)OC Chemical compound CCO/C=C/C1=CN=C2C(=C1N)C=CC(=N2)OC UHEARIFIDDKYII-VOTSOKGWSA-N 0.000 description 1
- 125000006414 CCl Chemical group ClC* 0.000 description 1
- RTNPEYPZSZEEII-UHFFFAOYSA-N CN(C(C=NC(C=C1OC)=C2C=C1OC)=C2N1CC(C2)CN2S(N)(=O)=O)C1=O Chemical compound CN(C(C=NC(C=C1OC)=C2C=C1OC)=C2N1CC(C2)CN2S(N)(=O)=O)C1=O RTNPEYPZSZEEII-UHFFFAOYSA-N 0.000 description 1
- GILJLOKMSFIZAU-UHFFFAOYSA-N CN(C(C=NC(C=C1OC)=C2C=C1OC)=C2N1CC(CC2)CCN2S(N)(=O)=O)C1=O Chemical compound CN(C(C=NC(C=C1OC)=C2C=C1OC)=C2N1CC(CC2)CCN2S(N)(=O)=O)C1=O GILJLOKMSFIZAU-UHFFFAOYSA-N 0.000 description 1
- OWOLMHMFZIVDDZ-UHFFFAOYSA-N COC(C(OC)=C1)=CC2=C1N=CC(N1)=C2N(CC(CC2)CN2S(N)(=O)=O)C1=O Chemical compound COC(C(OC)=C1)=CC2=C1N=CC(N1)=C2N(CC(CC2)CN2S(N)(=O)=O)C1=O OWOLMHMFZIVDDZ-UHFFFAOYSA-N 0.000 description 1
- RZWFLIGXLSOSHF-UHFFFAOYSA-N COC(C(OC)=C1)=CC2=C1N=CC1=C2N(CC(C2)CN2S(N)(=O)=O)C=N1 Chemical compound COC(C(OC)=C1)=CC2=C1N=CC1=C2N(CC(C2)CN2S(N)(=O)=O)C=N1 RZWFLIGXLSOSHF-UHFFFAOYSA-N 0.000 description 1
- MBIXAUYJVUGYLM-UHFFFAOYSA-N COC(C(OC)=C1)=CC2=C1N=CC1=C2N(CC(C2)CN2S(N)(=O)=O)N=C1 Chemical compound COC(C(OC)=C1)=CC2=C1N=CC1=C2N(CC(C2)CN2S(N)(=O)=O)N=C1 MBIXAUYJVUGYLM-UHFFFAOYSA-N 0.000 description 1
- ZRZLFKQVNRCSSB-UHFFFAOYSA-N COC(C(OC)=C1)=CC2=C1N=CC1=C2N(CC(C=C2)=CC=C2S(N)(=O)=O)N=C1 Chemical compound COC(C(OC)=C1)=CC2=C1N=CC1=C2N(CC(C=C2)=CC=C2S(N)(=O)=O)N=C1 ZRZLFKQVNRCSSB-UHFFFAOYSA-N 0.000 description 1
- ZTPYJTIBPGKDOM-UHFFFAOYSA-N COC(C(OC)=C1)=CC2=C1N=CC1=C2N(CC(C=C2)=CN=C2S(N)(=O)=O)N=C1 Chemical compound COC(C(OC)=C1)=CC2=C1N=CC1=C2N(CC(C=C2)=CN=C2S(N)(=O)=O)N=C1 ZTPYJTIBPGKDOM-UHFFFAOYSA-N 0.000 description 1
- JBUPGUABLNNUTI-UHFFFAOYSA-N COC(C(OC)=C1)=CC2=C1N=CC1=C2N(CC(C=C2)=CN=C2S(N)(=O)=O)N=N1 Chemical compound COC(C(OC)=C1)=CC2=C1N=CC1=C2N(CC(C=C2)=CN=C2S(N)(=O)=O)N=N1 JBUPGUABLNNUTI-UHFFFAOYSA-N 0.000 description 1
- ZJEUYYVAJDHSCL-UHFFFAOYSA-N COC(C(OC)=C1)=CC2=C1N=CC1=C2N(CC(N=C2)=CC=C2S(N)(=O)=O)N=C1 Chemical compound COC(C(OC)=C1)=CC2=C1N=CC1=C2N(CC(N=C2)=CC=C2S(N)(=O)=O)N=C1 ZJEUYYVAJDHSCL-UHFFFAOYSA-N 0.000 description 1
- DWDWJKODPCCCFQ-UHFFFAOYSA-N COC(C(OC)=C1)=CC2=C1N=CC1=C2N(CC(N=C2)=CC=C2S(N)(=O)=O)N=N1 Chemical compound COC(C(OC)=C1)=CC2=C1N=CC1=C2N(CC(N=C2)=CC=C2S(N)(=O)=O)N=N1 DWDWJKODPCCCFQ-UHFFFAOYSA-N 0.000 description 1
- OTLPHINYKHTSKU-UHFFFAOYSA-N COC(C=C1)=CC2=C1C(N(CC(C=C1)=CN=C1S(N)(=O)=O)C=N1)=C1N=N2 Chemical compound COC(C=C1)=CC2=C1C(N(CC(C=C1)=CN=C1S(N)(=O)=O)C=N1)=C1N=N2 OTLPHINYKHTSKU-UHFFFAOYSA-N 0.000 description 1
- XLHYMKSGRWQWAA-UHFFFAOYSA-N COC(C=C1C(C#CC2=CN=CC(S(N)(=O)=O)=C2)=NC=NC1=C1)=C1OC Chemical compound COC(C=C1C(C#CC2=CN=CC(S(N)(=O)=O)=C2)=NC=NC1=C1)=C1OC XLHYMKSGRWQWAA-UHFFFAOYSA-N 0.000 description 1
- ZCVRJKAKYWZGPX-UHFFFAOYSA-N COC(C=C1C(C2=CC=C(C(CCC3)N3S(N)(=O)=O)C=C2)=NC=NC1=C1)=C1OC Chemical compound COC(C=C1C(C2=CC=C(C(CCC3)N3S(N)(=O)=O)C=C2)=NC=NC1=C1)=C1OC ZCVRJKAKYWZGPX-UHFFFAOYSA-N 0.000 description 1
- PAENVVZVBJNWSD-UHFFFAOYSA-N COC1=C(C=C2C(=C1)C3=C(C=N2)OC(=O)N3CC4CCN(CC4)S(=O)(=O)N)OC Chemical compound COC1=C(C=C2C(=C1)C3=C(C=N2)OC(=O)N3CC4CCN(CC4)S(=O)(=O)N)OC PAENVVZVBJNWSD-UHFFFAOYSA-N 0.000 description 1
- JZCNTYWCKQIQMZ-UHFFFAOYSA-N COC1=C(C=C2C(=C1)C3=C(NC(=O)N3CC4=CC=C(C=C4)S(=O)(=O)N)N=N2)OC Chemical compound COC1=C(C=C2C(=C1)C3=C(NC(=O)N3CC4=CC=C(C=C4)S(=O)(=O)N)N=N2)OC JZCNTYWCKQIQMZ-UHFFFAOYSA-N 0.000 description 1
- MZJSABRVWDSKEL-UHFFFAOYSA-N COC1=CC2=C(C=C1)C3=C(NC(=O)N3CC4=C(C=C(C=C4)S(=O)(=O)N)F)N=N2 Chemical compound COC1=CC2=C(C=C1)C3=C(NC(=O)N3CC4=C(C=C(C=C4)S(=O)(=O)N)F)N=N2 MZJSABRVWDSKEL-UHFFFAOYSA-N 0.000 description 1
- AGXAPRLVLYRFEV-UHFFFAOYSA-N COC1=CC=C2C(=C(C=NC2=N1)C(=O)OCC)NCC1=CC=C(C=C1)CS(N)(=O)=O Chemical compound COC1=CC=C2C(=C(C=NC2=N1)C(=O)OCC)NCC1=CC=C(C=C1)CS(N)(=O)=O AGXAPRLVLYRFEV-UHFFFAOYSA-N 0.000 description 1
- JJEIXMUZGQEMDI-UHFFFAOYSA-N COC1=CC=C2C(=C(C=NC2=N1)C(=O)OCC)NCC1=CC=C(C=C1)S(N)(=O)=O Chemical compound COC1=CC=C2C(=C(C=NC2=N1)C(=O)OCC)NCC1=CC=C(C=C1)S(N)(=O)=O JJEIXMUZGQEMDI-UHFFFAOYSA-N 0.000 description 1
- ITLBMTFOPSEKQO-UHFFFAOYSA-N COC1=CC=CC(=N1)N=CC1C(OC(OC1=O)(C)C)=O Chemical compound COC1=CC=CC(=N1)N=CC1C(OC(OC1=O)(C)C)=O ITLBMTFOPSEKQO-UHFFFAOYSA-N 0.000 description 1
- MIXFUTFTGCYVKO-UHFFFAOYSA-N COC1=CC=CC(=N1)NC=C(C(=O)OCC)C(=O)OCC Chemical compound COC1=CC=CC(=N1)NC=C(C(=O)OCC)C(=O)OCC MIXFUTFTGCYVKO-UHFFFAOYSA-N 0.000 description 1
- KVPOKSVIYOLRJJ-UHFFFAOYSA-N COC1=NC2=NC=C(C(=C2C=C1)Cl)C=O Chemical compound COC1=NC2=NC=C(C(=C2C=C1)Cl)C=O KVPOKSVIYOLRJJ-UHFFFAOYSA-N 0.000 description 1
- OYHAWYCOYKZBBC-UHFFFAOYSA-N COC1=NC2=NC=CC(=C2C=C1)NC(=O)O Chemical compound COC1=NC2=NC=CC(=C2C=C1)NC(=O)O OYHAWYCOYKZBBC-UHFFFAOYSA-N 0.000 description 1
- AACJVQJSDDSTGA-UHFFFAOYSA-N COC=1C=C2N=CC=3N(C2=CC=1OC)C(=NN=3)C1=CC=C(CNC(OC(C)(C)C)=O)C=C1 Chemical compound COC=1C=C2N=CC=3N(C2=CC=1OC)C(=NN=3)C1=CC=C(CNC(OC(C)(C)C)=O)C=C1 AACJVQJSDDSTGA-UHFFFAOYSA-N 0.000 description 1
- ICMFCJWAPDUTTF-UHFFFAOYSA-N COC=1C=C2N=CC=3N(C2=CC=1OC)C(=NN=3)C1=CC=C(CNS(=O)(=O)NC(OC(C)(C)C)=O)C=C1 Chemical compound COC=1C=C2N=CC=3N(C2=CC=1OC)C(=NN=3)C1=CC=C(CNS(=O)(=O)NC(OC(C)(C)C)=O)C=C1 ICMFCJWAPDUTTF-UHFFFAOYSA-N 0.000 description 1
- FTFFXNMFKVQFID-UHFFFAOYSA-N COC=1C=CC=2C3=C(N=NC=2C=1)C=NN3 Chemical compound COC=1C=CC=2C3=C(N=NC=2C=1)C=NN3 FTFFXNMFKVQFID-UHFFFAOYSA-N 0.000 description 1
- CQXQQOQWLUGKIK-UHFFFAOYSA-N COC=1C=CC=2C=3C(C=NC=2N=1)=CN(N=3)CC1=CC=C(C=N1)S(=O)(=O)N Chemical compound COC=1C=CC=2C=3C(C=NC=2N=1)=CN(N=3)CC1=CC=C(C=N1)S(=O)(=O)N CQXQQOQWLUGKIK-UHFFFAOYSA-N 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- HPZBRPBKKAORRH-LBPRGKRZSA-N C[C@@H](C(C=C1)=CC=C1S(N)(=O)=O)N1N=CC2=C1C(C=C(C(OC)=C1)OC)=C1N=C2 Chemical compound C[C@@H](C(C=C1)=CC=C1S(N)(=O)=O)N1N=CC2=C1C(C=C(C(OC)=C1)OC)=C1N=C2 HPZBRPBKKAORRH-LBPRGKRZSA-N 0.000 description 1
- CFBVICOLHLGOLU-NSHDSACASA-N C[C@@H](C(C=C1)=CC=C1S(N)(=O)=O)N1N=NC2=C1C(C=C(C(OC)=C1)OC)=C1N=C2 Chemical compound C[C@@H](C(C=C1)=CC=C1S(N)(=O)=O)N1N=NC2=C1C(C=C(C(OC)=C1)OC)=C1N=C2 CFBVICOLHLGOLU-NSHDSACASA-N 0.000 description 1
- HPZBRPBKKAORRH-GFCCVEGCSA-N C[C@H](C(C=C1)=CC=C1S(N)(=O)=O)N1N=CC2=C1C(C=C(C(OC)=C1)OC)=C1N=C2 Chemical compound C[C@H](C(C=C1)=CC=C1S(N)(=O)=O)N1N=CC2=C1C(C=C(C(OC)=C1)OC)=C1N=C2 HPZBRPBKKAORRH-GFCCVEGCSA-N 0.000 description 1
- CFBVICOLHLGOLU-LLVKDONJSA-N C[C@H](C(C=C1)=CC=C1S(N)(=O)=O)N1N=NC2=C1C(C=C(C(OC)=C1)OC)=C1N=C2 Chemical compound C[C@H](C(C=C1)=CC=C1S(N)(=O)=O)N1N=NC2=C1C(C=C(C(OC)=C1)OC)=C1N=C2 CFBVICOLHLGOLU-LLVKDONJSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- UCRFFBSLXFUDOI-UHFFFAOYSA-N ClC1=C(C=NC2=CC(=C(C=C12)C#N)OC)C(=O)OCC Chemical compound ClC1=C(C=NC2=CC(=C(C=C12)C#N)OC)C(=O)OCC UCRFFBSLXFUDOI-UHFFFAOYSA-N 0.000 description 1
- USGHGIYIIKFFND-UHFFFAOYSA-N ClC1=C(C=NC2=NC(=CC=C12)OC)CO Chemical compound ClC1=C(C=NC2=NC(=CC=C12)OC)CO USGHGIYIIKFFND-UHFFFAOYSA-N 0.000 description 1
- QCYVLLRKBRTYHU-UHFFFAOYSA-N ClC1=C(N=NC2=CC(=CC=C12)OC)C=O Chemical compound ClC1=C(N=NC2=CC(=CC=C12)OC)C=O QCYVLLRKBRTYHU-UHFFFAOYSA-N 0.000 description 1
- CRVOEHDCZREYIV-UHFFFAOYSA-N ClC1=C2C=CC(=NC2=NC=C1[N+](=O)[O-])OC Chemical compound ClC1=C2C=CC(=NC2=NC=C1[N+](=O)[O-])OC CRVOEHDCZREYIV-UHFFFAOYSA-N 0.000 description 1
- 241000694440 Colpidium aqueous Species 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101150017770 ENPP1 gene Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- KHOQRSTXHYGICT-UHFFFAOYSA-N FC1=C(C(=CC(=C1)B1OC(C(O1)(C)C)(C)C)F)CN1C(N(C=2C=NC=3N=C(C=CC=3C=21)OC)C(=O)OC(C)(C)C)=O Chemical compound FC1=C(C(=CC(=C1)B1OC(C(O1)(C)C)(C)C)F)CN1C(N(C=2C=NC=3N=C(C=CC=3C=21)OC)C(=O)OC(C)(C)C)=O KHOQRSTXHYGICT-UHFFFAOYSA-N 0.000 description 1
- FWUNPZHUBONHJU-UHFFFAOYSA-N FC1=C(C=C(C(=C1)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)C)F)S(=O)(=O)N Chemical compound FC1=C(C=C(C(=C1)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)C)F)S(=O)(=O)N FWUNPZHUBONHJU-UHFFFAOYSA-N 0.000 description 1
- QKYCSEVYOHHZAA-UHFFFAOYSA-N FC1=C(C=CC(=C1)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)COC)S(=O)(=O)N Chemical compound FC1=C(C=CC(=C1)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)COC)S(=O)(=O)N QKYCSEVYOHHZAA-UHFFFAOYSA-N 0.000 description 1
- LLTNJFODIICRHM-UHFFFAOYSA-N FC=1C=C(C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)S(=O)(=O)NC(C)=O Chemical compound FC=1C=C(C=C(C=1CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O)F)S(=O)(=O)NC(C)=O LLTNJFODIICRHM-UHFFFAOYSA-N 0.000 description 1
- SYUZPFRAHVJYJE-UHFFFAOYSA-N FC=1C=C(C=CC=1S(N)(=O)=O)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)C1CN(C1)C(=O)OC(C)(C)C Chemical compound FC=1C=C(C=CC=1S(N)(=O)=O)CN1C(=NC=2C=NC=3N=C(C=CC=3C=21)OC)C1CN(C1)C(=O)OC(C)(C)C SYUZPFRAHVJYJE-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101000892398 Homo sapiens Tryptophan 2,3-dioxygenase Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- WTWZEGYNPLSFFL-UHFFFAOYSA-N N-[2-(4-bromophenyl)ethylideneamino]-6,7-dimethoxyquinoxalin-2-amine Chemical compound COC(C=C1N=CC(NN=CCC(C=C2)=CC=C2Br)=NC1=C1)=C1OC WTWZEGYNPLSFFL-UHFFFAOYSA-N 0.000 description 1
- XLSHOGODCWHNGW-UHFFFAOYSA-N NCC1=C(C(=C(C=C1)S(=O)(=O)N)F)F Chemical compound NCC1=C(C(=C(C=C1)S(=O)(=O)N)F)F XLSHOGODCWHNGW-UHFFFAOYSA-N 0.000 description 1
- CMNCXUDHRRDOIE-UHFFFAOYSA-N NCC1=C(C=C(C=C1)S(=O)(=O)N)C(F)(F)F Chemical compound NCC1=C(C=C(C=C1)S(=O)(=O)N)C(F)(F)F CMNCXUDHRRDOIE-UHFFFAOYSA-N 0.000 description 1
- JHFSKSDSLUNXQD-UHFFFAOYSA-N NCC1=CC(=C(C=C1)S(=O)(=O)N)C(F)(F)F Chemical compound NCC1=CC(=C(C=C1)S(=O)(=O)N)C(F)(F)F JHFSKSDSLUNXQD-UHFFFAOYSA-N 0.000 description 1
- GZVKNZNYYIHVLW-UHFFFAOYSA-N NCC1=CC(=C(C=C1)S(=O)(=O)N)OC(F)(F)F Chemical compound NCC1=CC(=C(C=C1)S(=O)(=O)N)OC(F)(F)F GZVKNZNYYIHVLW-UHFFFAOYSA-N 0.000 description 1
- AXVANAAJBOLCQU-UHFFFAOYSA-N NCC1=CC(=C(C=C1F)S(=O)(=O)N)F Chemical compound NCC1=CC(=C(C=C1F)S(=O)(=O)N)F AXVANAAJBOLCQU-UHFFFAOYSA-N 0.000 description 1
- PSJFYNUZMOOKFP-UHFFFAOYSA-N NCC1=CC=C(C=N1)S(N)(=O)=O Chemical compound NCC1=CC=C(C=N1)S(N)(=O)=O PSJFYNUZMOOKFP-UHFFFAOYSA-N 0.000 description 1
- XVQKMLBAGWOEFF-UHFFFAOYSA-N NCC1CCN(C1)S(N)(=O)=O Chemical compound NCC1CCN(C1)S(N)(=O)=O XVQKMLBAGWOEFF-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- KTMWVQHVKISFBF-RXMQYKEDSA-N N[C@H](C)C1=CC=C(C=N1)S(=O)(=O)N Chemical compound N[C@H](C)C1=CC=C(C=N1)S(=O)(=O)N KTMWVQHVKISFBF-RXMQYKEDSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- HBJDRLLSZFIITD-UHFFFAOYSA-N O=S(=O)(CC1=CC=C(CN2C(=O)NC3=C2C2=CC=C(OC)N=C2N=C3)C=C1)N Chemical compound O=S(=O)(CC1=CC=C(CN2C(=O)NC3=C2C2=CC=C(OC)N=C2N=C3)C=C1)N HBJDRLLSZFIITD-UHFFFAOYSA-N 0.000 description 1
- FTIBLQPGARMIGY-UHFFFAOYSA-N OC1=C2C=CC(OC)=NC2=NC(=C1)C Chemical compound OC1=C2C=CC(OC)=NC2=NC(=C1)C FTIBLQPGARMIGY-UHFFFAOYSA-N 0.000 description 1
- GYKCCHXWFPTAKO-UHFFFAOYSA-N OC1=C2C=CC(OC)=NC2=NC(=C1N(=O)=O)C Chemical compound OC1=C2C=CC(OC)=NC2=NC(=C1N(=O)=O)C GYKCCHXWFPTAKO-UHFFFAOYSA-N 0.000 description 1
- YIPKVMLXBWHPGX-UHFFFAOYSA-N OC1CC(C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O Chemical compound OC1CC(C1)CN1C(NC=2C=NC=3N=C(C=CC=3C=21)OC)=O YIPKVMLXBWHPGX-UHFFFAOYSA-N 0.000 description 1
- 229910020667 PBr3 Inorganic materials 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 229940044665 STING agonist Drugs 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101150037787 Sting gene Proteins 0.000 description 1
- 101150060741 Sting1 gene Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- HDYANYHVCAPMJV-LXQIFKJMSA-N UDP-alpha-D-glucuronic acid Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O HDYANYHVCAPMJV-LXQIFKJMSA-N 0.000 description 1
- HDYANYHVCAPMJV-UHFFFAOYSA-N Uridine diphospho-D-glucuronic acid Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OC(C(O)=O)C(O)C(O)C1O HDYANYHVCAPMJV-UHFFFAOYSA-N 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- NBYQWCMTKNOMBS-UHFFFAOYSA-N [4-(aminomethyl)phenyl]methanesulfonamide Chemical compound NCC1=CC=C(CS(N)(=O)=O)C=C1 NBYQWCMTKNOMBS-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960002648 alanylglutamine Drugs 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940044684 anti-microtubule agent Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000024055 brain glioblastoma Diseases 0.000 description 1
- 201000011609 brain glioblastoma multiforme Diseases 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical class CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- IMIKCSIRWPDLEI-UHFFFAOYSA-N ethyl 4-chloro-7-methoxy-1,6-naphthyridine-3-carboxylate Chemical compound ClC1=C(C=NC2=CC(=NC=C12)OC)C(=O)OCC IMIKCSIRWPDLEI-UHFFFAOYSA-N 0.000 description 1
- QOTDQRIITYIVKU-UHFFFAOYSA-N ethyl 4-chloro-7-methoxycinnoline-3-carboxylate Chemical compound CCOC(=O)c1nnc2cc(OC)ccc2c1Cl QOTDQRIITYIVKU-UHFFFAOYSA-N 0.000 description 1
- DUMZLRVMOQQKMY-UHFFFAOYSA-N ethyl 7-methoxy-4-oxo-1H-cinnoline-3-carboxylate Chemical compound CCOC(=O)c1n[nH]c2cc(OC)ccc2c1=O DUMZLRVMOQQKMY-UHFFFAOYSA-N 0.000 description 1
- FRCQNDNOFWAADS-UHFFFAOYSA-N ethyl 7-methoxy-4-oxo-1h-1,8-naphthyridine-3-carboxylate Chemical compound COC1=CC=C2C(=O)C(C(=O)OCC)=CNC2=N1 FRCQNDNOFWAADS-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000009459 flexible packaging Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- KEQQONPVAQQBHG-UHFFFAOYSA-N n-[4-(dimethylamino)pyridin-1-ium-1-yl]sulfonyl-1-[(2-methylpropan-2-yl)oxy]methanimidate Chemical compound C[N+](C)=C1C=CN(S(=O)(=O)[N-]C(=O)OC(C)(C)C)C=C1 KEQQONPVAQQBHG-UHFFFAOYSA-N 0.000 description 1
- VMFMUJZRXZXYAH-UHFFFAOYSA-N n-[5-[[5-chloro-4-[2-[2-(dimethylamino)-2-oxoacetyl]anilino]pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound C=CC(=O)NC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)C(=O)C(=O)N(C)C)C(Cl)=CN=2)C(OC)=CC=1N1CCN(C)CC1 VMFMUJZRXZXYAH-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 150000005054 naphthyridines Chemical class 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HRJJBEIFHFVBRT-UHFFFAOYSA-N tert-butyl n-[(4-formylphenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(C=O)C=C1 HRJJBEIFHFVBRT-UHFFFAOYSA-N 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CWLNAJYDRSIKJS-UHFFFAOYSA-N triethoxymethoxyethane Chemical compound CCOC(OCC)(OCC)OCC CWLNAJYDRSIKJS-UHFFFAOYSA-N 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Definitions
- This disclosure relates generally to compounds and compositions that may be useful as phosphodiesterase inhibitors.
- ENPP The Ectonucleotide Pyrophophatase/Phosphodiesterase (ENPP) family consists of seven members, ENNP1-7, which are either membrane-bound glycoproteins or ectoenzymes with an active site or as soluble proteins in body fluids.
- ENPP1 Pasma cell membrane glycoprotein, also known as PC-1
- ENPP1 may use nucleotides and nucleotide derivatives as substrates and hydrolyze them with the formation of nucleoside-5′ monophosphates.
- ATP is an identified substrate of ENPP1, which is hydrolyzed to AMP and PPi.
- Another known subtract 2′3′-cyclic guanosine monophosphate-adenosine monophosphate (2′3′-cGAMP) is an intracellular secondary messenger produced in response to cytosolic dsDNA.
- artificial phosphoric acid esters p-nitrophenyl 5′-thymidine monophosphate (TMP-pNP) and p-nitrophenyl 5′-adenosine monophosphate (AMP-pNP) are also taken by ENPP1 as substrates.
- ENPP1 is type II transmembrane glycoprotein originally identified as a negative regulator of bone mineralization, it expressed on the extracellular membrane of osteoblasts and chondrocytes and hydrolyzes extracellular ATP to produce AMP and diphosphate, an inhibitor of bone mineralization (Terkeltaub, R et, al. Purinergic Signaling 2006, 2, 371-377; Vaingankar, S. M. et, al. Cell Physiol. 2004, 286, C1177-C1187). ENPP1 is involved in many different biological processes.
- ENPP1 hydrolysis produces AMP, which subsequently is metabolized by ecto-5′-nucleotidase CD73 into the immunosuppressive adenosine (Ferretti, E., Immunol. Lett. 2018, 3, 307).
- ENPP1 inhibits insulin receptor tyrosine kinase activity in peripheral tissues, which are major targets of insulin action (Abate, N. et, al. Nature Clin. Pract. Endocrinol. Metab. 2006, 2, 694-701).
- Aberrant ENPP1 expression has also been reported in breast cancers, Hodgkin's lymphoma, hepatocellular carcinoma follicular lymphoma, glioblastoma and in other malignant tumor tissues.
- ENPP1 was found to play an important role in cancer immunity. Li et al reported ENPP1 is the dominant 2′3′-cGAMP hydrolase, breaking it down to 5′-AMP and 5′-GMP. 2′3′-cGAMP is the most potent natural agonist to the Stimulator of Interferon Genes (STING) pathway, a central pathway in anti-viral and anti-cancer innate immunity. 2′3′-cyclic guanosine monophosphate-adenosine monophosphate (2′3′-cGAMP) functions as an endogenous second messenger in response of cytosolic double-strand DNA.
- STING Stimulator of Interferon Genes
- ENPP1 inhibitors block 2′3′-cGAMP hydrolysis, subsequently enhance the cGAMP-induced STING pathway activation and stimulate anti-tumor immune response.
- FIG. 1 A , FIG. 1 B , FIG. 1 C , FIG. 1 D and FIG. 1 E show the % increase measured for IFN- ⁇ in cells treated with representative compounds of 12, 48, 89, 103 and 121 relative to that of untreated cells.
- a compound of formula (A), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, is of formulae (I)-(VI) as detailed herein.
- a method of treating or preventing a disorder of uncontrolled cellular proliferation related to ENPP1, skeletal and soft tissue mineralization related disorders, disorders related to ENPP1 genetic changes, viral infections, and/or cancers is provided.
- a method of treating a disorder or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (A), including a compound of formulae (I)-(VI), or pharmaceutically acceptable salt, stereoisomer or solvate thereof.
- compositions comprising: (A) a compound detailed herein, such as a compound of formula (A), including a compound of formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof; and (B) a pharmaceutically acceptable carrier or excipient.
- Kits comprising a compound detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof and optionally instructions for use are also provided.
- Compounds as detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof are provided for use as a medicament.
- Compounds as detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof are also provided for the manufacture of a medicament for the treatment or prevention of a disorder of uncontrolled cellular proliferation related to ENPP1, for example, a cancer.
- references to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X”.
- Alkyl refers to and includes, unless otherwise stated, a saturated linear (i.e., unbranched) or branched univalent hydrocarbon chain or combination thereof, having the number of carbon atoms designated (i.e., C 1 -C 10 means one to ten carbon atoms).
- Particular alkyl groups are those having 1 to 20 carbon atoms (a “C 1 -C 20 alkyl”), having 1 to 10 carbon atoms (a “C 1 -C 10 alkyl”), having 6 to 10 carbon atoms (a “C 6 -C 10 alkyl”), having 1 to 6 carbon atoms (a “C 1 -C 6 alkyl”), having 2 to 6 carbon atoms (a “C 2 -C 6 alkyl”), or having 1 to 4 carbon atoms (a “C 1 -C 4 alkyl”).
- alkyl groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.
- Cycloalkyl refers to and includes, unless otherwise stated, saturated cyclic univalent hydrocarbon structures, having the number of carbon atoms designated (i.e., C 3 -C 10 means three to ten carbon atoms). Cycloalkyl can consist of one ring, such as cyclohexyl, or multiple rings, such as adamantyl. A cycloalkyl comprising more than one ring may be fused, spiro or bridged, or combinations thereof. Particular cycloalkyl groups are those having from 3 to 12 annular carbon atoms.
- a preferred cycloalkyl is a cyclic hydrocarbon having from 3 to 8 annular carbon atoms (a “C 3 -C 8 cycloalkyl”), having 3 to 6 carbon atoms (a “C 3 -C 6 cycloalkyl”), or having from 3 to 4 annular carbon atoms (a “C 3 -C 4 cycloalkyl”).
- Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like.
- Heteroaryl refers to an unsaturated aromatic cyclic group having from 1 to 14 annular carbon atoms and at least one annular heteroatom, including but not limited to heteroatoms such as nitrogen, oxygen and sulfur.
- a heteroaryl group may have a single ring (e.g., pyridyl, furyl) or multiple condensed rings (e.g., indolizinyl, benzothienyl) which condensed rings may or may not be aromatic.
- Particular heteroaryl groups are 5 to 14-membered rings having 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 5 to 10-membered rings having 1 to 8 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, or 5, 6 or 7-membered rings having 1 to 5 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur.
- particular heteroaryl groups are monocyclic aromatic 5-, 6- or 7-membered rings having from 1 to 6 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur.
- particular heteroaryl groups are polycyclic aromatic rings having from 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur.
- a heteroaryl group having more than one ring where at least one ring is non-aromatic may be connected to the parent structure at either an aromatic ring position or at a non-aromatic ring position.
- a heteroaryl group having more than one ring where at least one ring is non-aromatic is connected to the parent structure at an aromatic ring position.
- a heteroaryl group may be connected to the parent structure at a ring carbon atom or a ring heteroatom.
- Heterocycle refers to a saturated or an unsaturated non-aromatic cyclic group having a single ring or multiple condensed rings, and having from 1 to 14 annular carbon atoms and from 1 to 6 annular heteroatoms, such as nitrogen, sulfur or oxygen, and the like.
- a heterocycle comprising more than one ring may be fused, bridged or spiro, or any combination thereof, but excludes heteroaryl groups.
- the heterocyclyl group may be optionally substituted independently with one or more substituents described herein.
- Particular heterocyclyl groups are 3 to 14-membered rings having 1 to 13 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 12-membered rings having 1 to 11 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 10-membered rings having 1 to 9 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 8-membered rings having 1 to 7 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, or 3 to 6-membered rings having 1 to 5 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur.
- heterocyclyl includes monocyclic 3-, 4-, 5-, 6- or 7-membered rings having from 1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6 annular carbon atoms and 1 to 2, 1 to 3, or 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur.
- heterocyclyl includes polycyclic non-aromatic rings having from 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur.
- Halo or “halogen” refers to elements of the Group 17 series having atomic number 9 to 85.
- Preferred halo groups include the radicals of fluorine, chlorine, bromine and iodine. Where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached, e.g., dihaloaryl, dihaloalkyl, trihaloaryl etc. refer to aryl and alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be but are not necessarily the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl.
- An alkyl group in which each hydrogen is replaced with a halo group is referred to as a “perhaloalkyl.”
- a preferred perhaloalkyl group is trifluoromethyl (—CF 3 ).
- Oxo refers to the moiety ⁇ O.
- Optionally substituted unless otherwise specified means that a group may be unsubstituted or substituted by one or more (e.g., 1, 2, 3, 4 or 5) of the substituents listed for that group in which the substituents may be the same of different.
- an optionally substituted group has one substituent.
- an optionally substituted group has two substituents.
- an optionally substituted group has three substituents.
- an optionally substituted group has four substituents.
- an optionally substituted group has 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, or 2 to 5 substituents.
- an optionally substituted group is unsubstituted.
- “Pharmaceutically acceptable salts” are those salts which retain at least some of the biological activity of the free (non-salt) compound and which can be administered as drugs or pharmaceuticals to an individual.
- Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, oxalic acid, propionic acid, succinic acid, maleic acid, tartaric acid and the like; (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base.
- a metal ion e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion
- coordinates with an organic base e.
- Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine and the like.
- Acceptable inorganic bases which can be used to prepared salts include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
- Pharmaceutically acceptable salts can be prepared in situ in the manufacturing process, or by separately reacting a purified compound of the invention in its free acid or base form with a suitable organic or inorganic base or acid, respectively, and isolating the salt thus formed during subsequent purification.
- a “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject.
- a pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
- excipient means an inert or inactive substance that may be used in the production of a drug or pharmaceutical, such as a tablet containing a compound of the invention as an active ingredient.
- a drug or pharmaceutical such as a tablet containing a compound of the invention as an active ingredient.
- Various substances may be embraced by the term excipient, including without limitation any substance used as a binder, disintegrant, coating, compression/encapsulation aid, cream or lotion, lubricant, solutions for parenteral administration, materials for chewable tablets, sweetener or flavoring, suspending/gelling agent, or wet granulation agent.
- treatment is an approach for obtaining beneficial or desired results including clinical results.
- beneficial or desired results include, but are not limited to, one or more of the following: decreasing symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, delaying the progression of the disease, and/or prolonging survival of an individual.
- “treatment” of a disorder does not include prevention of the disorder, and “prevention” is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or severity of a disorder or biological manifestation thereof, or to delay the onset of such disorder or biological manifestation thereof.
- an “effective dosage” or “effective amount” of compound or salt thereof or pharmaceutical composition is an amount sufficient to effect beneficial or desired results.
- beneficial or desired results include results such as eliminating or reducing the risk, lessening the severity of, or delaying the onset of the disease, including biochemical, histological and/or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presenting during development of the disease.
- beneficial or desired results include ameliorating, palliating, lessening, delaying or decreasing one or more symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, enhancing effect of another medication such as via targeting, delaying the progression of the disease, and/or prolonging survival.
- an effective amount is an amount sufficient to delay development. In some embodiments, an effective amount is an amount sufficient to prevent or delay recurrence.
- An effective dosage can be administered in one or more administrations.
- an effective dosage of compound or a salt thereof, or pharmaceutical composition is an amount sufficient to accomplish prophylactic or therapeutic treatment either directly or indirectly. It is intended and understood that an effective dosage of a compound or salt thereof, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition. Thus, an “effective dosage” may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.
- the term “subject” is a mammal, including humans.
- a subject includes, but is not limited to, human, bovine, horse, feline, canine, rodent, or primate. In some embodiments, the subject is human (including adults and children).
- substantially pure intends a composition that contains no more than 10% impurity, such as a composition comprising less than about 9%, 7%, 5%, 3%, 1%, 0.5% impurity.
- the invention provides a compound of Formula (A):
- L 1 is a bond, O, CR 1 R 2 , NR 3 , or *CR 1 R 2 NR 3 , wherein * denotes the point of attachment to ring A;
- L 2 is a bond, CR 1 R 2 , or C( ⁇ O);
- Q 1 , Q 2 , Q 3 , Q 4 , and Q 5 are independently N, C or C-E, A 2 , A 3 , A 4 and A 5 are independently N or CR 4 ;
- X is S, O, CR 1 R 2 , C-E, N or NR 3 ;
- Z is SO 2 NHR 5 , SO 2 R 5 , C(O)OH, C(O)NHR 5 , C(O)NHOR 5 , P(O)(OR 5 ) 2 , or B(OH) 2 ;
- E is, independently at each occurrence, selected from the group consisting of hydrogen, deuterium, halogen,
- a compound of Formula (A) wherein Q 2 is C, Q 3 is C-E, wherein E is oxo, Q 4 is N, and Q 5 is C, such that the compound of Formula (A) is a compound of Formula (I):
- L 1 is a bond, O, CR 1 R 2 , NR 3 , or *CR 1 R 2 NR 3 , wherein * denotes the point of attachment to ring A;
- L 2 is a bond, CR 1 R 2 , or C( ⁇ O);
- Q 1 is N or C-E
- a 2 , A 3 , A 4 and A 5 are independently N or CR 4 ;
- X is S, O, CR 1 R 2 or NR 3 ;
- Z is SO 2 NHR 5 , SO 2 R 5 , C(O)OH, C(O)NHR 5 , C(O)NHOR 5 , P(O)(OR 5 ) 2 , or B(OH) 2 ;
- E is selected from the group consisting of hydrogen, deuterium, halogen, oxo, —CN, —OR 3 , —NO 2 , —NR 3 R 3 ′, —C(O)R 3 , —C(O)OR 3 , —C(O)NR 3 R 3 ′, —SO 2 R 3 , —SO 2 NR 3 R 3 ′, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 4 alkoxy, C 3 -
- L 1 is a bond, O, CR 1 R 2 , NR 3 , or *CR 1 R 2 NR 3 , wherein * denotes the point of attachment to ring A;
- L 2 is a bond, CR 1 R 2 , or C( ⁇ O);
- Q 1 is N or C-E
- a 2 , A 3 , A 4 and A 5 are independently N or CR 4 ;
- Z is SO 2 NHR 5 , SO 2 R 5 , C(O)OH, C(O)NHR 5 , C(O)NHOR 5 , P(O)(OR 5 ) 2 , or B(OH) 2 ;
- E is, independently at each occurrence, selected from the group consisting of hydrogen, deuterium, halogen, oxo, —CN, —OR 3 , —NO 2 , —NR 3 R 3 ′, —C(O)R 3 , —C(O)OR 3 , —C(O)NR 3 R 3 ′, —SO 2 R 3 , —SO 2 NR 3 R 3 ′, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 4 alkoxy, C 3 -C 8 cycloalkyl, and 3-8 member
- L 1 is a bond, O, CR 1 R 2 , NR 3 , or *CR 1 R 2 NR 3 , wherein * denotes the point of attachment to ring A;
- L 2 is a bond, CR 1 R 2 , or C( ⁇ O);
- Q 1 is N or C-E
- Q 3 is N or C-E
- a 2 , A 3 , A 4 and A 5 are independently N or CR 4 ;
- Z is SO 2 NHR 5 , SO 2 R 5 , C(O)OH, C(O)NHR 5 , C(O)NHOR 5 , P(P)(OR 5 ) 2 , or B(OH) 2 ;
- E is, independently at each occurrence, selected from the group consisting of hydrogen, deuterium, halogen, oxo, —CN, —OR 3 , —NO 2 , —NR 3 R 3 ′, —C(O)R 3 , —C(O)OR 3 , —C(O)NR 3 R 3 ′, —SO 2 R 3 , —SO 2 NR 3 R 3 ′, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 4 alkoxy, C 3 -C 8 cycloalkyl, and 3-8 member
- L 1 is a bond, O, CR 1 R 2 , NR 3 , or *CR 1 R 2 NR 3 , wherein * denotes the point of attachment to ring A;
- L 2 is a bond, CR 1 R 2 , or C( ⁇ O);
- Q 1 is N or C-E
- a 2 , A 3 , A 4 and A 5 are independently N or CR 4 ;
- Z is SO 2 NHR 5 , SO 2 R 5 , C(O)OH, C(O)NHR 5 , C(O)NHOR 5 , P(O)(OR 5 ) 2 , or B(OH) 2 ;
- E is selected from the group consisting of hydrogen, deuterium, halogen, oxo, —CN, —OR 3 , —NO 2 , —NR 3 R 3 ′, —C(O)R 3 , —C(O)OR 3 , —C(O)NR 3 R 3 ′, —SO 2 R 3 , —SO 2 NR 3 R 3 ′, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 4 alkoxy, C 3 -C 8 cycloalkyl, and 3-8 membered heterocyclyl,
- R 4 is selected from the group consisting of hydrogen, deuterium, halogen, —CN, —OR 3 , —NO 2 , —NR 3 R 3 ′, —C(O)R 3 , —C(O)OR 3 , —C(O)NR 3 R 3 ′, —SO 2 R 3 , —SO 2 NR 3 R 3 ′, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3
- R 5 is, independently at each occurrence, selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, 3-8 membered heterocyclyl, and —C( ⁇ O)—C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, and 3-8 membered heterocyclyl are independently optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, phenyl, C 1 -C 4 alkoxy, C 1 -C 3 haloalkyl, and C 1 -C 3 haloalkoxy; and ring A is C 3 -C 8 cycloalkyl, 3- to 12-membered heterocyclyl, C 6 -C 14 ary
- L 1 is a bond, O, CR 1 R 2 , NR 3 , or *CR 1 R 2 NR 3 , wherein * denotes the point of attachment to ring A;
- L 2 is a bond, CR 1 R 2 , or C( ⁇ O);
- Q 1 and X are independently N or C-E;
- a 2 , A 3 , A 4 and A 5 are independently N or CR 4 ;
- Z is SO 2 NHR5, SO 2 R 5 , C(O)OH, C(O)NHR5, C(O)NHOR 5 , P(O)(OR 5 ) 2 , or B(OH) 2 ;
- E is selected from the group consisting of hydrogen, deuterium, halogen, oxo, —CN, —OR 3 , —NO 2 , —NR 3 R 3 ′, —C(O)R 3 , —C(O)OR 3 , —C
- L 1 is a bond, O, CR 1 R 2 , NR 3 , or *CR 1 R 2 NR 3 , wherein * denotes the point of attachment to ring A;
- L 2 is a bond, CR 1 R 2 , or C( ⁇ O);
- Q 1 , Q 3 and X are independently N or C-E;
- a 2 , A 3 , A 4 and A 5 are independently N or CR 4 ;
- Z is SO 2 NHR 5 , SO 2 R 5 , C(O)OH, C(O)NHR 5 , C(O)NHOR 5 , P(O)(OR 5 ) 2 , or B(OH) 2 ;
- E is, independently at each occurrence, selected from the group consisting of hydrogen, deuterium, halogen, oxo, —CN, —OR 3 , —NO 2 , —NR 3 R 3 ′, —C(O)R 3
- ring B is partially unsaturated.
- ring B is a 5-membered aryl or 5-membered heteroaryl.
- ring B is a 5-membered heterocyclyl or 5-membered cycloalkyl.
- a 2 , A 3 , A 4 and A 5 are each independently CR 4 , wherein R 4 is, independently of each other and independently at each occurrence, H, C 1 -C 4 alkoxy, or CN.
- a 2 is CH, A 3 is C—C 1 -C 4 alkoxy, A 4 is C—C 1 -C 4 alkoxy, and A 5 is CH.
- a 2 is CH, A 3 is C—OMe, A 4 is C—OMe, and A 5 is CH.
- a 2 is CH, A 3 is C—C 1 -C 4 alkoxy, A 4 is CH, and A 5 is CH.
- a 2 is CH, A 3 is C—OMe, A 4 is CH, and A 5 is CH. In some embodiments, A 2 is CH, A 3 is CH, A 4 is C—C 1 -C 4 alkoxy, and A 5 is CH. In some embodiments, A 2 is CH, A 3 is CH, A 4 is C—OMe, and A 5 is CH. In some embodiments, A 2 is CH, A 3 is C—C 1 -C 4 alkoxy, A 4 is CN, and A 5 is CH. In some embodiments, A 2 is CH, A 3 is C—OMe, A 4 is CN, and A 5 is CH.
- a 2 is CH, A 3 is C—C 1 -C 4 alkoxy, A 4 is N, and A 5 is CH. In some embodiments, A 2 is CH, A 3 is C—OMe, A 4 is N, and A 5 is CH. In some embodiments, A 2 is N, A 3 is C—C 1 -C 4 alkoxy, A 4 is CH, and A 5 is CH. In some embodiments, A 2 is N, A 3 is C—OMe, A 4 is CH, and A 5 is CH. In some embodiments, A 5 is CH, A 3 is C—C 1 -C 4 alkoxy, A 4 is CH, and A 5 is N.
- a 2 is CH, A 3 is C—OMe, A 4 is CH, and A 5 is N. In some embodiments, A 2 is CH, A 3 is C—C 1 -C 4 alkoxy, A 4 is N, and A 5 is CH. In some embodiments, A 2 is CH, A 3 is C—OMe, A 4 is N, and A 5 is CH. In some embodiments, A 2 is N, A 3 is C—C 1 -C 4 alkoxy, A 4 is C-halogen, and A 5 is CH. In some embodiments, A 2 is N, A 3 is C—OMe, A 4 is C—Cl, and A 5 is CH.
- provided herein is a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein A 2 is CH, A 3 is C—C 1 -C 4 alkoxy, A 4 is C—C 1 -C 4 alkoxy, and A 5 is CH.
- a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof wherein A 2 is CH, A 3 is C—OMe, A 4 is C—OMe, and A 5 is CH.
- provided herein is a compound of formula (II), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein A 2 is CH, A 3 is C—C 1 -C 4 alkoxy, A 4 is C—C 1 -C 4 alkoxy, and A 5 is CH.
- a compound of formula (II), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof wherein A 2 is, A 3 is C—OMe, A 4 is C—OMe, and A 5 is CH.
- provided herein is a compound of formula (II), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein A 2 is N, A 3 is C—C 1 -C 4 alkoxy, A 4 is CH, and A 5 is CH.
- a compound of formula (II), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof wherein A 2 is N, A 3 is C—OMe, A 4 is CH, and A 5 is CH.
- a compound of formula (A) such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein ring A is C 3 -C 8 cycloalkyl, 3- to 12-membered heterocyclyl, C 6 -C 14 aryl, or 5- to 10-membered heteroaryl, wherein the C 3 -C 8 cycloalkyl, 3- to 12-membered heterocyclyl, C 6 -C 14 aryl, and 5- to 10-membered heteroaryl of ring A are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- ring A is cyclobutyl.
- a compound of formula (A) such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein ring A is 3- to 12-membered heterocyclyl, wherein the 3- to 12-membered heterocyclyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- ring A is a 4- to 8-membered heterocyclyl. In some embodiments, ring A is a 5- or 6-membered heterocyclyl. In some embodiments, ring A is piperazinyl. In some embodiments, ring A is azetidinyl. In certain embodiments, ring A is piperidinyl. In other embodiments, ring A is pyrrolidinyl.
- a compound of formula (A) such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein ring A is C 6 -C 14 aryl, wherein the C 6 -C 14 aryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- ring A is C 6 -C 10 aryl. In some embodiments, ring A is phenyl. In some embodiments, ring A is phenyl, wherein the phenyl of ring A is optionally substituted with one or more halogen, CN, C 1 -C 3 alkyl, or C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen. In some embodiments, the halogen is F.
- a compound of formula (A) such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein ring A is 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- ring A is 5- or 6-membered heteroaryl. In some embodiments, ring A is 6-membered heteroaryl. In some embodiments, ring A is pyridinyl. In other embodiments, ring A is pyrimidinyl. In some embodiments, ring A is pyridinyl or pyrimidinyl, wherein the pyridinyl or pyrimidinyl of ring A is optionally substituted with one or more halogen, CN, C 1 -C 3 alkyl, or C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen. In some embodiments, the halogen is F. In some embodiments, ring A is dihydroisoquinolinyl.
- L 1 is a bond.
- L 1 is O, CR 1 R 2 , NR 3 , or *CR 1 R 2 NR 3 , wherein * denotes the point of attachment to ring A.
- L 1 is O.
- L 1 is CR 1 R 2 .
- L 1 is CR 1 R 2 , wherein R 1 and R 2 are independently selected from H and C 1 -C 6 alkyl. In some embodiments, L 1 is CR 1 R 2 , wherein R 1 and R 2 are independently selected from H and methyl. In some embodiments, L 1 is CR 1 R 2 , wherein R 1 and R 2 are both H. In some embodiments, L 1 is CR 1 R 2 , wherein one of R 1 and R 2 is H and the other of R 1 and R 2 is C 1 -C 6 alkyl. In some embodiments, L 1 is CR 1 R 2 , wherein one of R 1 and R 2 is H and the other of R 1 and R 2 is methyl.
- L 1 is NR 3 . In some embodiments, L 1 is NR 3 , wherein R 3 is H or C 1 -C 6 alkyl. In some embodiments, L 1 is NR 3 , wherein R 3 is H. In other embodiments, L 1 is NR 3 , wherein R 3 is methyl. In some embodiments, L 1 is *CR 1 R 2 NR 3 , wherein * denotes the point of attachment to ring A. In certain embodiments, L 1 is *CR 1 R 2 NR 3 , wherein * denotes the point of attachment to ring A, wherein R 1 and R 2 are both H.
- a compound of formula (A) such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein L 1 is a bond, 0, CR 1 R 2 , NR 3 , or *CR 1 R 2 NR 3 , wherein * denotes the point of attachment to ring A, and ring A is C 6 -C 14 aryl, wherein the C 6 -C 14 aryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- L 1 is a bond and ring A is C 6 -C 14 aryl, wherein the C 6 -C 14 aryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- L 1 is a bond and ring A is phenyl, wherein the phenyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- L 1 is CR 1 R 2 , wherein R 1 and R 2 are independently selected from H and C 1 -C 6 alkyl, and ring A is C 6 -C 14 aryl, wherein the C 6 -C 14 aryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- L 1 is CR 1 R 2 , wherein R 1 and R 2 are independently selected from H and C 1 -C 6 alkyl, and ring A is phenyl, wherein the phenyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- L 1 is *CR 1 R 2 NR 3 , wherein * denotes the point of attachment to ring A, wherein R 1 , R 2 and R 3 are each H, and ring A is phenyl, wherein the phenyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- L 1 is a bond and ring A is 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- L 1 is a bond and ring A is 6-membered heteroaryl, wherein the 6-membered heteroaryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- L 1 is a bond and ring A is pyridinyl or pyrimidinyl, wherein the pyridinyl or pyrimidinyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- L 1 is CR 1 R 2 , wherein R 1 and R 2 are independently selected from H and C 1 -C 6 alkyl, and ring A is 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- L 1 is CR 1 R 2 , wherein R 1 and R 2 are independently selected from H and C 1 -C 6 alkyl, and ring A is 6-membered heteroaryl, wherein the 6-membered heteroaryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- L 1 is CR 1 R 2 , wherein R 1 and R 2 are independently selected from H and C 1 -C 6 alkyl, and ring A is pyridinyl or pyrimidinyl, wherein the pyridinyl or pyrimidinyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- L 1 is *CR 1 R 2 NR 3 , wherein * denotes the point of attachment to ring A, wherein R 1 , R 2 and R 3 are each H, and ring A is pyridinyl or pyrimidinyl, wherein the pyridinyl or pyrimidinyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1 -C 3 alkyl, and C 1 -C 4 alkoxy, wherein the C 1 -C 3 alkyl and C 1 -C 4 alkoxy are independently optionally substituted with one or more halogen.
- X is O, CR 1 R 2 , C-E, N or NR 3 .
- X is O.
- X is N.
- X is NR 3 .
- X is NR 3 , wherein R 3 is H or C 1 -C 6 alkyl.
- X is C-E.
- X is C-E, wherein E is H or C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl of E is optionally substituted with one or more OH, halogen, C 1 -C 4 alkoxy, or 3-8 membered heterocyclyl. In some embodiments, X is N or C-E.
- a compound of formula (A) such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein Z is SO 2 NHR 5 , SO 2 R 5 , C(O)OH, C(O)NHR 5 , C(O)NHOR 5 , P(O)(OR 5 ) 2 , or B(OH) 2 .
- Z is SO 2 NHR5, wherein R 5 is H, C 1 -C 6 alkyl, or —C(O)—C 1 -C 6 alkyl.
- Z is SO 2 NHR 5 , wherein R 5 is H.
- Z is SO 2 R 5 . In certain embodiments, Z is C(O)OH, C(O)NHR 5 , or C(O)NHOR 5 . In certain embodiments, Z is C(O)OH. In some embodiments, Z is C(O)NHOR 5 , wherein R 5 is H. In some embodiments, Z is C(O)NHR 5 , wherein R 5 is H. In some embodiments, Z is B(OH) 2 . In some embodiments, Z is P(O)(OR 5 ) 2 , wherein each R 5 is independently H or C 1 -C 6 alkyl. In some embodiments, Z is P(O)(OR 5 ) 2 , wherein each R 5 is independently H.
- a compound of formula (A) such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein L 1 is a bond and Z is SO 2 NHR 5 , wherein R 5 is H, C 1 -C 6 alkyl, or —C(O)—C 1 -C 6 alkyl.
- L 1 is a bond and Z is SO 2 NHR 5 , wherein R 5 is H.
- L 1 is a bond and Z is SO 2 NHR 5 , wherein R 5 is C 1 -C 6 alkyl.
- L 1 is NR 3 , wherein R 3 is H, and Z is SO 2 NHR 5 , wherein R 5 is H, C 1 -C 6 alkyl, or —C(O)—C 1 -C 6 alkyl.
- L 1 is NR 3 , wherein R 3 is H, and Z is SO 2 NHR 5 , wherein R 5 is H.
- L 1 is CR 1 R 2 , wherein R 1 and R 2 are independently selected from H and C 1 -C 6 alkyl, and Z is SO 2 NHR 5 , wherein R 5 is H, C 1 -C 6 alkyl, or —C(O)—C 1 -C 6 alkyl.
- L 1 is CR 1 R 2 , wherein R 1 and R 2 are independently selected from H and C 1 -C 6 alkyl, and Z is SO 2 NHR 5 , wherein R 5 is H.
- L 1 is a bond and Z is P(O)(OR 5 ) 2 , wherein each R 5 is independently H or C 1 -C 6 alkyl.
- L 1 is a bond and Z is B(OH) 2 .
- L 1 is a bond and Z is C(O)OH, C(O)NHR 5 , or C(O)NHOR 5 .
- L 1 is a bond and Z is C(O)OH, C(O)NHR 5 , or C(O)NHOR 5 , wherein each R 5 is independently H.
- compounds of formula (A), or compounds of formula (I)-(VI) are not the following analogs:
- compounds of formula (A), or compounds of formula (I)-(VI) are not the following analogs:
- provided herein is a compound described in Table 1 or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof.
- the compounds described herein exist as their pharmaceutically acceptable salts.
- the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts.
- the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
- the compounds described herein possess acidic or basic groups and therefor react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
- these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
- Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds described herein with a mineral, organic acid, or inorganic base, such salts including acetate, acrylate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, bisulfite, bromide, butyrate, butyn-1,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, fiimarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-1,6-dioate, hydroxy
- the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methane sulfonic acid, ethanesulfonic acid, 1,2-ethane
- those compounds described herein which comprise a free acid group react with a suitable base, such as the hydroxide, carbonate, bicarbonate, sulfate, of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine.
- a suitable base such as the hydroxide, carbonate, bicarbonate, sulfate, of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine.
- Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like.
- bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N + (C 1-4 alkyl) 4 , and the like.
- Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. It should be understood that the compounds described herein also include the quatemization of any basic nitrogen-containing groups they contain. In some embodiments, water or oil-soluble or dispersible products are obtained by such quatemization.
- the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti,
- Z isomers as well as the corresponding mixtures thereof. In some situations, the compounds described herein possess one or more chiral centers and each center exists in the R configuration, or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof.
- mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein.
- the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers.
- dissociable complexes are preferred.
- the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities.
- the diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in solubility.
- the optically pure enantiomer is then recovered, along with the resolving agent.
- the compounds described herein exist as solvates.
- the invention provides for methods of treating diseases by administering such solvates.
- the invention further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions.
- Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and, in some embodiments, are formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein can be conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents including, but not limited to, dioxane, tetrahydrofuran, or methanol. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
- prodrugs of the compounds described herein can be converted to a compound of formula (A), or formulae (I)-(VI), when administered to a subject, e.g., upon metabolic processing of the prodrug.
- prodrugs are examples using compound 40 for illustration purposes. In some embodiments, similar analogs can be made using sulfonamide as a handle.
- compositions of any of the compounds detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof are embraced by this disclosure.
- the present disclosure includes pharmaceutical compositions comprising a compound as detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier or excipient.
- the pharmaceutically acceptable salt is an acid addition salt, such as a salt formed with an inorganic or organic acid.
- Pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and topical administration, etc.
- pharmaceutical compositions may take a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration or a form suitable for administration by inhalation.
- a compound as detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof may in one aspect be in a purified form and compositions comprising a compound in purified forms are detailed herein.
- Compositions comprising a compound as detailed herein or a salt thereof are provided, such as compositions of substantially pure compounds.
- a composition containing a compound as detailed herein or a salt thereof is in substantially pure form.
- the compounds herein are synthetic compounds prepared for administration to an individual.
- compositions are provided containing a compound in substantially pure form.
- the present disclosure embraces pharmaceutical compositions comprising a compound detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.
- methods of administering a compound are provided. The purified forms, pharmaceutical compositions and methods of administering the compounds are suitable for any compound or form thereof detailed herein.
- a compound detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, may be formulated for any available delivery route, including an oral, mucosal (e.g., nasal, sublingual, vaginal, buccal or rectal), parenteral (e.g., intramuscular, subcutaneous or intravenous), topical or transdermal delivery form.
- oral, mucosal e.g., nasal, sublingual, vaginal, buccal or rectal
- parenteral e.g., intramuscular, subcutaneous or intravenous
- topical or transdermal delivery form e.g., topical or transdermal delivery form.
- a compound or salt thereof may be formulated with suitable carriers to provide delivery forms that include, but are not limited to, tablets, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), cachets, troches, lozenges, gums, dispersions, suppositories, ointments, cataplasms (poultices), pastes, powders, dressings, creams, solutions, patches, aerosols (e.g., nasal spray or inhalers), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions or water-in-oil liquid emulsions), solutions and elixirs.
- suitable carriers include, but are not limited to, tablets, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), cachets, troches, lozenges, gums, dispersions, suppositories, ointments, cataplasms (poultic
- One or several compounds described herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, can be used in the preparation of a formulation, such as a pharmaceutical formulation, by combining the compound or compounds, or a salt thereof, as an active ingredient with a pharmaceutically acceptable carrier, such as those mentioned above.
- a pharmaceutically acceptable carrier such as those mentioned above.
- the carrier may be in various forms.
- pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, re-wetting agents, emulgators, sweeteners, dyes, adjusters, and salts for the adjustment of osmotic pressure, buffers, coating agents or antioxidants.
- Formulations comprising the compound may also contain other substances which have valuable therapeutic properties.
- Pharmaceutical formulations may be prepared by known pharmaceutical methods. Suitable formulations can be found, e.g., in Remington's Pharmaceutical Sciences , Mack Publishing Company, Philadelphia, Pa., 20 th ed. (2000), which is incorporated herein by reference.
- compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and can be prepared in the form of tablets, pills, powders, suspensions, emulsions, solutions, syrups, and capsules.
- Oral composition may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- the tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example, peanut oil, liquid paraffin or olive oil.
- compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.
- compositions for transdermal application include an effective amount of a compound of the invention with a suitable carrier.
- Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host.
- transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
- compositions for topical application include aqueous solutions, suspensions, ointments, creams, gels or spray formulations, e. g., for delivery by aerosol or the like.
- Such topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like.
- a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurized container, pump, spray, atomizer or nebulizer, with or without the use of a suitable propellant.
- a dry powder either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids
- compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will decompose.
- agents which are referred to herein as “stabilizers,” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
- the invention includes methods of using the same as further described herein.
- the compounds of formula (A), or formulae (I)-(VI), or pharmaceutically acceptable salt, prodrug, or solvate thereof may be used for treating STING pathway mediated diseases or disorders.
- a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof have desired physicochemical properties, for example, solubility in water.
- ENPP Ectonucleotide Pyrophophatase/Phosphodiesterase
- ENPP1 is also expressed on the extracellular membrane of osteoblasts and chondrocytes, and it has a great effect on bone mineralization. (Terkeltaub, R et, al. Purinergic Signalling 2006, 2, 371-377; Vaingankar, S. M et, al. Cell Physiol. 2004, 286, C1177-C1187).
- ENPP1 was shown to play an important role in cancer immunotherapy and autoimmune diseases.
- ENPP1 hydrolyzes 2′3′-cyclic guanosine monophosphate-adenosine monophosphate (2′3′-cGAMP), breaking it down into 5′-AMP and 5′-GMP.
- cGAMP activates the Stimulator of Interferon Genes (STING) pathway, leading to production of type I interferon (IFN) and other cytokines that trigger the immune response.
- STING Interferon Genes
- IFN type I interferon
- ENPP1 inhibitors which block the hydrolysis of cGAMP and induce sting activity can be potentially utilized to increase immune response. Similar to checkpoint inhibitors such as anti PD-1 or PD-L1 which are promising immune-therapeutics for various cancers, activation of STING pathway by these inhibitors become more critical for tumor control in cancer immunotherapies.
- the invention provides a method of treating a disorder mediated by inappropriate ENPP1 activity comprising administering a safe and effective dose of a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof.
- ENPP1 mediated diseases or disorders are selected from the group consisting of diseases related to skeletal and soft tissue mineralization, T2D, cardiovascular diseases, cancers, autoimmune diseases and osteoarthritis.
- ENPP1 mediated diseases or disorders are autoimmune diseases such as asthma, type I diabetes, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease (COPD), and lupus.
- autoimmune diseases such as asthma, type I diabetes, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease (COPD), and lupus.
- COPD chronic obstructive pulmonary disease
- the compounds described herein may be used to treat cancers that are mediated by inappropriate ENPP1 activity.
- the disease is a hematologic malignancy.
- the disease is a solid tumor.
- the indication is to treat solid tumor with abnormal ENPP1 expression, such as astrocytic brain tumors, and glioblastoma stem-like cells and metastasis of breast cancer.
- potencies of compounds as inhibitors of an enzyme activity can be established by determining the concentrations at which each compound inhibits the activity to a predefined extent and then comparing the results.
- concentrations at which each compound inhibits the activity can be determined by the concentration that inhibits 50% or 90% of the activity in a biochemical assay, which can be accomplished using conventional techniques known in the art, including the techniques describes in the Examples below.
- inhibition of ENPP1 activity refers to a decrease in ENPP1 activity as a direct or indirect response to the presence of a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, relative to the activity of ENPP1 in the absence of the compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof.
- a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof may be used in combination with one or more additional therapeutic agents to treat cancers or inflammatory disorders.
- the one or more additional therapeutic agents may be a chemotherapeutic agent, a radiotherapy, a targeted therapy, an immunotherapeutic agent or any current best of care treatment, either as a small molecule or a biologic nature.
- Chemotherapeutic agents may be categorized by their mechanism of action into: alkylating agents, antimetabolites, anti-microtubule agents, topoisomerase inhibitors and cytotoxic agents.
- a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof may be used in combination with chemotherapeutics to sensitize and improve the efficacy of certain chemotherapeutic agents to treat blood or solid tumors.
- Immunotherapeutic agents that may be suitable to be used in combination with a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof include but are not limited to therapeutic antibodies, small molecules and vaccines suitable for treating patients; such as IDOL and TDO2 inhibitors, A2A receptor inhibitors, arginase inhibitors, toll-like receptor agonists, chemokine regulators (including CCR and CXCR families), STING agonists, check point blockage antibodies such as antibodies that regulate PD-1, PD-L1, CTLA-4, OX40-OX40 ligand, LAGS, TIM3, or any combination thereof.
- IDOL and TDO2 inhibitors such as IDOL and TDO2 inhibitors, A2A receptor inhibitors, arginase inhibitors, toll-like receptor agonists, chemokine regulators (including CCR and CXCR families), STING agonists, check point blockage antibodies such as antibodies that regulate PD-1
- Radiotherapy is part of cancer treatment to control or kill malignant cells and commonly applied to the cancerous tumor because of its ability to control cell growth.
- a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof may be used in combination with radiotherapy, to improve the efficacy of radiotherapy to treat blood or solid tumors, or with surgery, chemotherapy, immunotherapy and combination of the four.
- Targeted therapies that may be suitable to be used in combination therapies include but are not limit to an inhibitor to PI3Ks, cyclin-dependent kinase (CDK) such as CDK1, CDK2, CDK4/6, CDK7, and CDK9, Janus kinase (JAK) such as JAK1, JAK2 and/or JAK3, spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), mitogen-activated protein kinase (MEK) such as MEK 1 and MEK2, bromodomain containing protein inhibitors (BRD) such as BRD4, isocitrate dehydrogenase (IDH) such as IDH1, histone deacetylase (HDAC), or any combination thereof.
- CDK cyclin-dependent kinase
- JAK1 Janus kinase
- JAK2 and/or JAK3 Janus kinase
- a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof may be used in combination with one or more additional therapeutic agents to treat patients who are substantially refractory to at least one chemotherapy treatment, or in relapse after treatment with chemotherapy.
- a dose of a pharmaceutical composition or combination is dependent on the body weight, age and individual condition, the disorder or disease or the severity thereof being treated.
- the effective dose is determined by a physician or clinician to prevent, treat or inhibit the progress of the disorder or disease.
- a safe and effective dose is an amount sufficient to treat the patient's condition but low enough to avoid serious side effects.
- a safe and effective dose may vary with the particular compound chosen (e.g. consider the potency, efficacy, and half-life of the compound); the route of administration chosen; the disorder being treated; the severity of the disorder being treated; the age, size, weight, and physical condition of the patient being treated; the medical history of the patient to be treated; the duration of the treatment; the nature of concurrent therapy; the desired therapeutic effect; and like factors.
- a therapeutically effective amount of any one of the compounds of this invention or a combination of any of the compounds of this invention or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, is administered via any of the usual and acceptable methods known in the art, either singly or in combination.
- the compounds or compositions can thus be administered orally (e.g., buccal cavity), sublingually, parenterally (e.g., intramuscularly, intravenously, or subcutaneously), rectally (e.g., by suppositories or washings), transdermally (e.g., skin electroporation) or by inhalation (e.g., by aerosol), and in the form of solid, liquid or gaseous dosages, including tablets and suspensions.
- the administration can be conducted in a single unit dosage form with continuous therapy or in a single dose therapy ad libitum.
- the therapeutic composition can also be in the form of an oil emulsion or dispersion in conjunction with a lipophilic salt such as pamoic acid, or in the form of a biodegradable sustained-release composition for subcutaneous or intramuscular administration.
- compositions may be administered in either single or multiple doses.
- a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof can be formulated so as to provide the desired release schedule of the active ingredient based on the therapeutic treatment purpose.
- the pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient in the form of tablets, pills, powders, suspensions, emulsions, solutions, syrups, and capsules.
- these may contain an amount of active ingredient from about 0.1 to 1000 mg, preferably from about 0.1 to 500 mg.
- a suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods.
- the daily dose can be administered in one to four doses per day.
- the active compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration drops suitable for administration to the eye, ear, or nose.
- a suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg administered one to four, preferably one or two times daily.
- the active ingredient may comprise from 0.001% to 10% w/w, e.g. from 1% to 2% by weight of the formulation, preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation.
- a compound or composition of the invention may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer, which in some variations may be for the duration of the individual's life.
- the compound is administered on a daily or intermittent schedule.
- the compound can be administered to an individual continuously (for example, at least once daily) over a period of time.
- the dosing frequency can also be less than once daily, e.g., about a once weekly dosing.
- the dosing frequency can be more than once daily, e.g., twice or three times daily.
- the dosing frequency can also be intermittent, including a ‘drug holiday’ (e.g., once daily dosing for 7 days followed by no doses for 7 days, repeated for any 14 day time period, such as about 2 months, about 4 months, about 6 months or more). Any of the dosing frequencies can employ any of the compounds described herein together with any of the dosages described herein.
- a drug holiday e.g., once daily dosing for 7 days followed by no doses for 7 days, repeated for any 14 day time period, such as about 2 months, about 4 months, about 6 months or more.
- the method comprises administering to the subject an initial daily dose of about 0.1 to 500 mg of a compound of formula (A), or formulae (I)-(VI) and increasing the dose by increments until clinical efficacy is achieved. Increments of about 5, 10, 25, 50, or 100 mg can be used to increase the dose. The dosage can be increased daily, every other day, twice per week, or once per week.
- the present disclosure further provides articles of manufacture comprising a compound of the disclosure or a salt thereof, composition, and unit dosages described herein in suitable packaging.
- the article of manufacture is for use in any of the methods described herein.
- suitable packaging is known in the art and includes, for example, vials, vessels, ampules, bottles, jars, flexible packaging and the like.
- An article of manufacture may further be sterilized and/or sealed.
- kits for carrying out the methods of the disclosure which comprises one or more compounds described herein or a composition comprising a compound described herein.
- the kits may employ any of the compounds disclosed herein.
- the kit employs a compound described herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof.
- the kits may be used for any one or more of the uses described herein, and, accordingly, may contain instructions for the treatment of disease described herein.
- Kits generally comprise suitable packaging.
- the kits may comprise one or more containers comprising any compound described herein.
- Each component if there is more than one component
- kits may be in unit dosage forms, bulk packages (e.g., multi-dose packages) or sub-unit doses.
- kits may be provided that contain sufficient dosages of a compound as disclosed herein and/or a second pharmaceutically active compound useful for a disease detailed herein (e.g., hypertension) to provide effective treatment of an individual for an extended period, such as any of a week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months, or more.
- Kits may also include multiple unit doses of the compounds and instructions for use and be packaged in quantities sufficient for storage and use in pharmacies (e.g., hospital pharmacies and compounding pharmacies).
- kits may optionally include a set of instructions, generally written instructions, although electronic storage media (e.g., magnetic diskette or optical disk) containing instructions are also acceptable, relating to the use of component(s) of the methods of the present invention.
- the instructions included with the kit generally include information as to the components and their administration to an individual.
- solvent refers to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), ethyl acetate (EA or EtOAc), dichloromethane (DCM), diethyl ether, methanol, pyridine and the like.
- the solvents used in the reactions of the present invention are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen and argon.
- the compounds of formula (I)-(VI) may be prepared using the methods disclosed herein and routine modifications thereof, which will be apparent given the disclosure herein and methods are well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein. The synthesis of representative compounds described herein may be accomplished as described in the following examples. If available, reagents may be purchased commercially, e.g., from Sigma Aldrich or other chemical suppliers.
- Step 3 Synthesis of 6,7-dimethoxy-4-(((4-sulfamoylphenyl)methyl)amino)quinoline-3-carboxylic acid
- Step 4 Synthesis of 4-((7,8-dimethoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzene-sulfonamide
- 6-((7,8-dimethoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)methyl)pyridine-3-sulfonamide is prepared according to General procedure 2 from a known compound 6-(aminomethyl)pyridine-3-sulfonamide (J. Bakonyi, et al, U.S. Pat. Appl. Publ., 20150291607).
- Step 1 Boc diamines (0.8 mmol, 1 eq) were dissolved in DCM (4.4 mL, 0.2 M) followed by the addition of (tert-butoxycarbonyl)((4-(dimethyliminio)pyridin-1(4H)-yl)sulfonyl)amide (262 mg, 1 eq). The mixture was stirred at room temperature for 18 hrs. Upon completion, the mixture was concentrated in vacuo. The crude was purified through FCC using Hex/THF (100%/0% to 60%/40%) yielding the product.
- Step 2 The above product (1 eq) was dissolved in DCM (5 mL, 0.1 M) then cooled to 0° C. TFA (5 mL, 0.1 M) was added to the mixture then the cooling bath was removed. The mixture was stirred at room temperature for 2 hrs. Upon completion, the mixture was concentrated in vacuo and neutralized by NaHCO 3 and extracted with DCM. The crude was used in the next step without further purification.
- Step 1 6-Methoxypyridin-2-amine (9.8 g, 78.9 mmol, 1.1 eq) was dissolved in ethyoxymethylene diethylmalonate (15.5 g, 71.8 mmol, 1 eq). The mixture was heated to 95° C. for 1 hr under vacuum. After completion, the mixture was cooled to 45° C. and hexanes was added. The mixture was further cooled by dry ice to induce precipitation. The resulting precipitate was filtered and dried (14.8 g, 70%). The crude product was used without further purification.
- Step 2 Diethyl 2-(((6-methoxypyridin-2-yl)amino)methylene)malonate (14.8 g, 50.3 mmol) was added to a solution of diphenyl ether (125 mL, 0.4 M) at 260° C. After addition, the mixture was heated at reflux for another 45 mins. After completion, the mixture was cooled to 85° C. and hexanes was added. Once cooled to room temperature, the solid was filtered and purified through FCC yielding the product.
- Step 3 Ethyl 4-hydroxy-7-methoxy-1,8-naphthyridine-3-carboxylate (130 mg, 0.52 mmol, 1 eq) was dissolved in DCM (2.6 mL, 0.2 M) followed by the addition of oxylyl chloride (53 ⁇ L, 0.63 mmol, 1.2 eq) and DMF (1 drop). The mixture was heated to reflux for 5 mins. Upon completion, the mixture was cooled to room temperature and concentrated in vacuo. The crude was used without further purification.
- Step 4 Ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (0.26 mmol, 1 eq) and 4-(aminomethyl)benzenesulfonamide HCl (75 mg, 0.34 mmol, 1.3 eq) were dissolved in DMF (2.6 mL, 0.1 M) followed by the addition of DIEA (226 ⁇ L, 1.3 mmol, 5 eq). The mixture was heated to 60° C. Upon completion, the mixture was cooled to room temperature then added to water. The resulting precipitate was filtered and dried (21 mg, 19%).
- Step 5 Ethyl 7-methoxy-4-((4-sulfamoylbenzyl)amino)-1,8-naphthyridine-3-carboxylate (21 mg, 0.05 mmol, 1 eq) was dissolved in THF/MeOH (1 mL/0.3 mL) then cooled to 0° C. Aqueous LiOH (1 M, 0.5 mmol, 10 eq) was added to the mixture. The resulting mixture was heated to 50° C. Upon completion, the mixture was cooled to room temperature and diluted with water. The aqueous layer was washed with EtOAc then the aqueous layer was acidified to pH 4 with 2 N HCl. The resulting precipitate was filtered and dried (14 mg, 74%).
- Step 6 7-Methoxy-4-((4-sulfamoylbenzyl)amino)-1,8-naphthyridine-3-carboxylic acid (14 mg, 0.04 mmol, 1 eq) was dissolved in DMF (2 mL) followed by the addition of DPPA (9.3 ⁇ L, 0.043 mmol, 1.2 eq). The resulting mixture was heated to 110° C. Upon completion, the mixture was cooled to room temperature and concentrated in vacuo. The crude was purified through FCC yielding the product (8.8 mg, 44%).
- Step 1 A mixture of Meldrum's acid (13.36 g, 92.6 mmol) and triethyl orthoformate (35.8 g, 3.0 eq) was heated at 92° C. for 90 min before addition of 6-methoxypyridin-2-amine (10 g, 80.6 mmol) portionwise at 70° C. over 5 min. Then the reaction mixture was stirred for 20 min, cooled and filtered to give 5-(((6-methoxypyridin-2-yl)imino)methyl)-2,2-dimethyl-1,3-dioxane-4,6-dione as a grey solid (19.27 g, 75%).
- Step 2 The above solid (19.2 g, 69 mmol) was added to heated diphenyl ether (30 mL) at 260° C. portionwise then the resulted mixture was stirred at 260° C. for 40 min before being cooled to rt. Hexane (100 mL) was added and the solid was filtered, washed with hexane and dried (11.25 g, 93%).
- Step 3 The above solid (1.0 g, 5.7 mmol) in CH 3 CH 2 CO 2 H (35 mL) was treated with fuming HNO 3 (0.59 mL) dropwise and then stirred for 2 h. The resulted solid was filtered, washed and dried (725 mg, 58%).
- Step 4 The above solid (725 mg, 3.3 mmol) in DCM (20 mL) was treated with SOCl 2 (0.60 mL) followed with 2 drops of DMF. After 6 h, the reaction mixture was concentrated and purified by combiflash (DCM/EtOAc) to give a white solid (578 mg, 74%).
- Step 3 The above solid (49 mg, 0.17 mmol) was added to a mixture of DMF (1.1 mL) and triethyl orthoformate (2.2 mL) and then heated to 120° C. for 8 h. After cool to rt, the reaction mixture was concentrated and purified by combiflash (DCM/MeOH) to give a yellow solid (41 mg, 65%).
- 6-((7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridine-3-sulfonamide was prepared in the similar manner as Compound 39 from intermediate B and 6-(aminomethyl)pyridine-3-sulfonamide HCl salt.
- Ethyl 8,9-dimethoxypyrazolo[1,5-c]quinazoline-1-carboxylate (prepared according to a known procedure by Feng, H. , RSC Adv., 2016, 6, 95774) is converted to the corresponding alcohol by reducing reagents such as LiBH 4 .
- Bromo analog is prepared by treatment of the alcohol with PBr 3 .
- Coupling with (4-sulfamoylphenyl)boronic acid under palladium catalyst provides 4-((8,9-dimethoxypyrazolo[1,5-c]quinazolin-1-yl)methyl)benzenesulfonamide (42).
- Step 1 2-chloro-6,7-dimethoxyquinoxaline (0.28 g, 1.24 mmol, 1 eq) was dissolved in reagent alcohol (6.2 mL, 0.2 M) followed by the addition of hydrazine monohydrate (6.2 mL, 0.2 M). The mixture was heated to 80° C. for 2 hrs. Upon completion, the mixture was cooled to room temperature then added to water. The resulting precipitate was filtered and dried (206 mg, 75%).
- Step 4 1-(4-bromobenzyl)-7,8-dimethoxy-2 ⁇ 2 , 10 ⁇ 4 -[1,2,4]triazolo[4,3-a]quinoxaline (0.22 mmol, 1 eq), Pd(dba) 2 (13 mg, 0.022 mmol, 0.1 eq), and XantPhos (13 mg, 0.022 mmol, 0.1 eq) were dissolved in dioxane followed by the addition of DIEA (153 ⁇ L, 0.44 mmol, 2 eq). The mixture was purged with nitrogen for 1 min followed by the addition of benzyl mercaptan (28 ⁇ L, 0.24 mmol, 1.1 eq).
- the mixture was heated to 100° C. for 4 hrs. Upon completion, the mixture was cooled to room temperature and added to water. The aqueous layer was extracted with EtOAc (3 ⁇ 2 mL). The combined organic layers was dried and concentrated in vacuo. The crude was purified through FCC yielding the product (97 mg, 99%).
- Step 5 1-(4-(benzylthio)benzyl)-7,8-dimethoxy-2 ⁇ 2 , 10 ⁇ 4 -[1,2,4]triazolo[4,3-a]quinoxaline (97 mg, 0.22 mmol, 1 eq) was dissolved in MeCN (2.27 mL, 0.1 M) followed by the addition of AcOH (86 ⁇ L, 2.57 M) and water (56 ⁇ L, 3.9 M). The mixture was cooled to 0° C. followed by the addition of 1,3-dichloro-5,5-dimethylhydantoin (52 mg, 0.264 mmol, 1.2 eq). The mixture was stirred at 0° C.
- 2-(4-Bromophenyl)acetonitrile is converted to 2-(4-bromobenzyl)-1H-imidazole by the treatment of ethylenediamine.
- This material is reacted with 1-fluoro-4-methoxy-2-nitrobenzene and then the resulted product is cyclized to give 1-(4-bromobenzyl)-7-methoxy-2 ⁇ 2 ,10 ⁇ 4 -imidazo[3,4-a]quinoxaline.
- a similar transformation as 44 is used to convert bromo to sulfonamide.
- Step 1 2-hydrazineyl-6,7-dimethoxyquinoxaline (50 mg, 0.22 mmol, 1 eq) and tert-butyl (4-formylbenzyl)carbamate (57 mg, 0.24 mmol, 1.1 eq) were dissolved in reagent alcohol (2.2 mL, 0.1 M). The mixture was heated to reflux for 1 hr. Upon completion, the mixture was cooled to room temperature then added to water. The resulting precipitate was filtered and dried (96 mg, 99%).
- Step 2 tert-Butyl-(4-((2-(6,7-dimethoxyquinoxalin-2-yl)hydrazineylidene)methyl)-benzyl)-carbamate (96 mg, 0.22 mmol, 1 eq) was dissolved in DCM (4.4 mL, 0.05 M) followed by the addition of iodobenzene diacetate (78 mg, 0.24 mmol, 1.1 eq). The mixture was stirred at room temperature for 3 hrs. Upon completion, the mixture was concentrated in vacuo. The resulting oil was triturated with hexanes then used without further purification.
- Step 3 tert-Butyl (4-(7,8-dimethoxy-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)benzyl)carbamate (96 mg, 0.22 mmol, 1 eq) dissolved in DCM (0.55 mL, 0.4 M) then cooled to 0° C. TFA (0.55 mL, 0.4 M) was added to the mixture. The mixture was warmed to room temperature and stirred for 1 hr. Upon completion, the mixture was concentrated in vacuo.
- the crude was dissolved in DCM/DMF (1:1, 8 mL) followed by the addition of Et 3 N (276 ⁇ L, 1.98 mmol, 9 eq) and sulfamoylating reagent (73 mg, 0.242 mmol, 1.1 eq). The mixture was heated to 60° C. for 1 hr. Upon completion, the mixture was concentrated in vacuo. The crude was pushed through a silica plug then used without further purification.
- Step 4 tert-butyl (N-(4-(7,8-dimethoxy-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)benzyl)sulfamoyl)-carbamate (0.22 mmol, 1 eq) was dissolved in DCM (1 mL) then cooled to 0° C. TFA (1 mL) was added to the mixture. The mixture was warmed to room temperature and stirred for 0.5 hr. Upon completion, the mixture was concentrated in vacuo. The crude was purified through FCC yielding the product (11 mg, 10%).
- 1-(4-bromobenzyl)-7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridine was prepared in the similar manner as Compound 39 from intermediate B and 4-bromobenzylamine.
- 1-(4-bromobenzyl)-7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridine (10 mg, 0.027 mmol) in a mixture of dioxane/DMF (0.5/0.5 mL) was treated with bis(pinacolato)diboron (10 mg, 1.5 eq), Pd(dppf) 2 Cl 2 (2.2 mg, 10%) and KOAc (8 mg, 3.0 eq) and the reaction mixture was purged with N2 for 2 min and then heated to 100° C.
- Ethyl 8,9-dimethoxypyrazolo[1,5-c]quinazoline-1-carboxylate (prepared according to a known procedure by Feng, H. , RSC Adv., 2016, 6, 95774) is converted to the corresponding acid by saponification with LiOH solution in THF. Coupling with piperazine-1-sulfonamide with HATU provides 4-(8,9-dimethoxypyrazolo[1,5-c]quinazoline-1-carbonyl)piperazine-1-sulfonamide (58).
- Step 1 To a flask containing water (45 mL, 2.3 M) at 0° C., thionyl chloride (7.5 mL, 103.2 mmol, 4.3 eq) was added dropwise. The resulting mixture was stirred at 22° C. for 18 hr. 4-Bromo-2,6-difluoroaniline (5 g, 24 mmol, 1 eq) at 0° C. was added conc HCl (24 mL, 1 M) and the resulting mixture was heated to 50° C. for 1 hr then cooled to ⁇ 5° C. (internal temperature).
- Step 2 4-bromo-2,6-difluorobenzenesulfonamide (2 g, 7.35 mmol, 1 eq), Zn(CN) 2 (518 mg, 4.41 mmol, 0.6 eq), and Pd(PPh 3 ) 4 (424 mg, 0.37 mmol, 0.05 eq) were suspended in DMF (37 mL, 0.2 M). The mixture was purged with nitrogen for 1 min and heated to 100° C. for 5 hr. Upon completion, the mixture was cooled to 22° C. and poured into water. The resulting ligand precipitate was filtered. The filtrate was acidified to pH 2 with 2 M HCl and extracted with EtOAc (3 ⁇ 100 mL).
- Step 1 To a mixture of 4-bromo-2,6-difluoro-benzaldehyde (2.5 g, 11.31 mmol, 1 eq) in ethanol (40 mL) was added hydroxylamine hydrochloride (1.10 g, 15.84 mmol, 1.40 eq) and potassium acetate (1.30 g, 13.24 mmol, 1.17 eq) in one portion at 22° C. for 1 h. Upon completion, water (40 mL) was added into the reaction mixture at 0° C. and stirred for 1 hr. The resulting precipitate filtered and washed by cold 1:1 EtOH/Water yielding the product (2.5 g, 94%).
- Step 2 (E)-4-bromo-2,6-difluoro-benzaldehyde oxime (2.5 g, 10.59 mmol, 1 eq) was dissolved in AcOH (60 mL). Zn (5.54 g, 84.74 mmol, 8 eq) was added in one portion at 65° C. The mixture was stirred at 65° C. for 2 hr. Upon completion, the reaction mixture was filtered and the filtrate was concentrated. The residual was dissolved in water (50 ml) and washed with diethyl ether (3 ⁇ 50 mL).
- Step 1 6-cyanopyridine-3-sulfonamide (1.4 g, 7.65 mmol, 1 eq) dissolved in THF (60 mL) then cooled to 0° C. MeMgCl (3.0 M, 7.6 mL, 22.95 mmol, 3 eq) was added to the reaction mixture. After addition, the mixture was stirred at 22° C. for 2 hr. Upon completion, the mixture was quenched with sat. NH 4 C 1 . Layer separated and the aqueous extracted with EtOAc (2 ⁇ 50 mL). The combined organic layers dried over Na 2 SO 4 and concentrated. The crude was purified by FCC yielding the product (1.14 g, 76%).
- Step 1 To a mixture of cyclopropanecarboxylic acid (6.21 mg, 72.14 mol, 5.70 ⁇ L, 1.3 eq) in DMF (0.3 mL) was added HATU (27.43 mg, 72.14 umol, 1.3 eq) and DIEA (27.97 mg, 216.43 umol, 37.70 ⁇ L, 3.9 eq) in one portion at 22° C. The mixture was stirred at 22° C. for 1 hr.
- Step 1 4-(((3-amino-7-methoxy-1,8-naphthyridin-4-yl)amino)methyl)-2-fluorobenzenesulfonamide (70 mg, 0.185 mmol, 1 eq) was dissolved in DMF (1.85 mL, 0.1 M) followed by the addition of chloroacetic anhydride (35 mg, 0.204 mmol, 1.1 eq). The mixture was stirred at 22° C. for 4 days. Upon completion, the mixture was partitioned between water and EtOAc. Layer was separated and the aqueous layer was extracted with EtOAc (3 ⁇ 3 mL).
- Step 2 4-((2-(Chloromethyl)-7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-2-fluorobenzenesulfonamide (17 mg, 0.039 mmol, 1 eq) was dissolved in MeOH (0.4 mL, 0.1 M) followed by the addition of 25 wt % NaOMe (286 ⁇ L). The mixture was stirred at 22° C. for 1 hr. Upon completion. The mixture was quenched with sat. NH 4 C 1 and concentrated. The crude was purified by Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the product (10 mg, 59%).
- Step 1 4-((2-(Chloromethyl)-7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-2-fluorobenzenesulfonamide (17.7 mg, 0.041 mmol, 1 eq) was dissolved in EtOH (0.82 mL, 0.05 M) followed by the addition of NaSMe (9 mg, 0.123 mmol, 3 eq). The mixture stirred at 22° C. for 3 hr. Upon completion, the mixture was concentrated yielding the product. The crude product was used in the next step without further purification.
- Methyl 2-(1-(3-fluoro-4-sulfamoylbenzyl)-7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-2-yl)acetate (10 mg, 0.022 mmol, 1 eq) was dissolved in 2 N ammonia in MeOH (0.21 mL) The mixture was heated to 65° C. for 2 hr. Additional 2 N ammonia in MeOH (0.42 mL) was added and heated to 65° C. for 3 hr. Upon completion, the mixture was concentrated. The crude was purified by Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the product (3.8 mg, 39%).
- tert-butyl 3-(1-((3-fluoro-4-sulfamoyl-phenyl)methyl)-7-methoxy-imidazo[4,5-c][1,8]naphthyridin-2-yl)azetidine-1-carboxylate obtained from following the procedure for the synthesis of compound 74 (43 mg, 79.25 mol, 1 eq) dissolved in DCM (1 mL) then cooled to 0° C. followed by the addition of TFA (308.00 mg, 2.70 mmol, 0.2 mL, 34.08 eq). The cooling bath removed and the mixture stirred at 22° C. for 1 hr.
- Step 1 6-methoxy-2-amino-pyridine (5 g, 40.3 mmol, 1 eq) and methyl acetoacetate (43 mL, 400.3 mmol, 10 eq) was added PPA (13 g). The mixture was heated to 190° C. for 3 hr. Upon completion, the mixture cooled to 22° C. diluted with water then washed with EtOAc (2 ⁇ 50 mL) to remove excess ethyl acetoacetate. The aqueous layer added EtOAc (100 mL) and with stirring pH adjusted to 8 with 2 M NaOH. The resulting ppt was filtered and dried yielding the product (2.7 g, 35%).
- Step 2 7-methoxy-2-methyl-1,8-naphthyridin-4-ol (1 g, 5.26 mmol, 1 eq) dissolved in sulfuric acid (50 mL) then cooled to 0° C.
- Fuming nitric acid (3.70 g, 58.72 mmol, 2.5 mL, 11.17 eq) was added slowly dropwise to the mixture at 0° C.
- the mixture was stirred at 0° C. for 0.5 hr.
- the cooling bath removed and the mixture stirred at 22° C. for 18 hr.
- the mixture heated to 60° C. for 5 hr.
- the mixture cooled to 22° C. then poured into stirring ice water.
- the resulting ppt was filtered and dried yielding the product (432 mg, 34%).
- Step 3 7-methoxy-2-methyl-3-nitro-1,8-naphthyridin-4-ol (423 mg, 1.80 mmol, 1 eq) suspended in POCl 3 (5.94 g, 38.74 mmol, 3.6 mL, 21.54 eq) and heated to 80° C. for 1.5 hr. Upon completion, the mixture was concentrated and dissolved in DCM. The organic layer was washed with sat. NaHCO 3 (3 ⁇ 10 mL). The organic layer was dried over Na 2 SO 4 and concentrated yielding the product (447 mg, 98%).
- Step 1 4-chloro-7-methoxy-2-methyl-3-nitro-1,8-naphthyridine (200 mg, 788.51 ⁇ mol, 1 eq) dissolved in NH 3 in MeOH (2 M, 8 mL, 20.29 eq) and stirred at 22° C. for 3 days. Upon completion, mixture concentrated and the resulting precipitate triturated with water. The resulting precipitate filtered and dried yielding the product (184 mg, 99%).
- Step 2 7-methoxy-2-methyl-3-nitro-1,8-naphthyridin-4-amine (184 mg, 785.62 mol, 1 eq) suspended in MeOH (8 mL) followed by the addition of 10% palladium on carbon (184 mg, 172.84 mol, 0.22 eq) and HCl (12 M, 65.47 ⁇ L, 1 eq). The mixture purged with hydrogen (3 cycles) and stirred under hydrogen balloon at 22° C. for 3 hr. Upon completion, mixture filtered through a pad of celite. The cake was washed with MeOH/Et 3 N (90%/10%) and the filtrate concentrated yielding the product (160 mg, 99%).
- Step 3 7-methoxy-2-methyl-1,8-naphthyridine-3,4-diamine (157 mg, 768.75 mol, 1 eq) dissolved in DMF (8 mL) followed by the addition of triethyl orthoacetate (3.47 g, 21.41 mmol, 3.92 mL, 27.85 eq) and acetic acid (55.40 mg, 922.50 mol, 52.76 ⁇ L, 1.2 eq). Vial sealed and heated to 80° C. for 8 hr. Upon completion, the mixture was concentrated. The resulting residual triturated with sat. NaHCO 3 and the brown precipitate filtered. The aqueous layer was allowed to sit at 22° C. for 2 hr and light yellow solid began to form. The light yellow precipitate was filtered and dried yielding the product (48 mg, 27%).
- Step 4 7-methoxy-2,4-dimethyl-1H-imidazo[4,5-c][1,8]naphthyridine (44 mg, 192.77 mol, 1 eq) and 5-bromo-2-(bromomethyl)pyrimidine (58.27 mg, 231.33 mol, 1.2 eq) were dissolved in DMF (1 mL). The vial sealed and heated to 50° C. for 4 hr. Additional 5-bromo-2-(bromomethyl)pyrimidine (58.27 mg, 231.33 umol, 1.2 eq) was added and heated to 50° C. for 2 hr.
- Step 5 1-((5-bromopyrimidin-2-yl)methyl)-7-methoxy-2,4-dimethyl-imidazo[4,5-c][1,8]naphthyridine (33 mg, 82.66 mol, 1 eq), Pd(dba) 2 (4.75 mg, 8.27 mol, 0.1 eq), Xantphos (4.78 mg, 8.27 mol, 0.1 eq), and DIEA (32.05 mg, 247.97 mol, 43.19 ⁇ L, 3 eq) were dissolved in dioxane (0.8 mL). The mixture purged with nitrogen for 20 sec and sealed. Heated to 80° C. for 30 sec then cooled to 22° C.
- Step 6 1-((5-benzylsulfanylpyrimidin-2-yl)methyl)-7-methoxy-2,4-dimethyl-imidazo[4,5-c][1,8]naphthyridine (21.3 mg, 48.13 mol, 1 eq) dissolved in MeCN (0.5 mL) followed by the addition of H 2 O (12.14 mg, 673.85 mol, 12.14 ⁇ L, 14 eq) and AcOH (20.23 mg, 336.92 mol, 19.27 ⁇ L, 7 eq) then cooled to 0° C.
- 1,3-dichloro-5,5-dimethyl-imidazolidine-2,4-dione 13.28 mg, 67.38 mol, 1.4 eq was added and stirred at 0° C. for 1 hr. Additional 1,3-dichloro-5,5-dimethyl-imidazolidine-2,4-dione (13.28 mg, 67.38 mol, 1.4 eq) added and stirred at 0° C. for 10 min. The mixture was added to NH 4 OH (0.5 mL) at 0° C. and stirred for 10 min. The resulting mixture pH was adjusted to 8 using 2 M HCl. The mixture was concentrated.
- Step 1 4-[[(3-amino-7-methoxy-2-methyl-1,8-naphthyridin-4-yl)amino]methyl]-2,5-difluoro-benzenesulfonamide (25 mg, 61.06 mol, 1 eq) dissolved in DMF (0.6 mL) then cooled to 0° C. followed by the addition of (2-chloro-2-oxo-ethyl) acetate (8.34 mg, 61.06 mol, 6.56 ⁇ L, 1 eq). Mixture stirred at 0° C. for 1 hr. Upon completion, mixture quenched with water at 0° C. and sat. NaHCO 3 added. The aqueous layer extracted with EtOAc (3 ⁇ 2 mL). The combined organic layer dried over Na 2 SO 4 and concentrated yielding the product. The crude product was used in the next step without further purification.
- Step 2 (2-((4-((2,5-difluoro-4-sulfamoyl-phenyl)methylamino)-7-methoxy-2-methyl-1,8-naphthyridin-3-yl)amino)-2-oxo-ethyl) acetate (31 mg, 60.85 ⁇ mol, 1 eq) dissolved in EtOH (1.2 mL) followed by the addition of NaOH (2 M, 45.63 ⁇ L, 1.5 eq). Vial sealed and heated to 60° C. for 1.5 hr. Upon completion, the mixture cooled to 22° C. and neutralized with 2 M HCl (46 ⁇ L). The mixture concentrated.
- Step 1 3,5-difluoro-4-((7-methoxy-2-oxo-3H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (50 mg, 118.66 ⁇ mol, 1 eq) dissolved in DMF (0.6 mL) followed by the addition of Et 3 N (30.02 mg, 296.65 ⁇ mol, 41.29 ⁇ L, 2.5 eq), DMAP (1.45 mg, 11.87 ⁇ mol, 0.1 eq), and acetic anhydride (30.28 mg, 296.65 ⁇ mol, 27.78 ⁇ L, 2.5 eq). The mixture stirred at 22° C. for 1 hr.
- Step 2 N-(3,5-difluoro-4-((7-methoxy-2-oxo-3H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)phenyl)sulfonylacetamide (30 mg, 64.74 ⁇ mol, 1 eq) suspended in MeOH (1 mL) followed by the addition of NaOH (0.2 M, 323.68 ⁇ L, 1 eq). The mixture became homogenous and stirred at 22° C. for 5 min. Upon completion, the mixture was concentrated yielding the product (30.6 mg, 97%).
- Step 2 To a mixture of methyl 3,5-difluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzoate (62 mg, 155 mol, 1 eq) in THF/MeOH (2 mL) was added LiOH (1 M, 1.62 mL, 10 eq) in one portion at 22° C. The mixture was stirred at 55° C. for 1 hour. Upon completion, the mixture was concentrated. The crude was purified through FCC using Biotage C18 Duo 12 g column using water/MeCN (0.1% TFA) gradient yielding the compound 108 (2.4 mg, 4%).
- Methyl 3,5-difluoro-4-((7-methoxy-2-oxo-3H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzoate (50 mg, 124.90 mol, 1 eq) dissolved in NH 3 in MeOH (2 M, 2.50 mL, 40 eq). Vial sealed and heated to 65° C. for 2 hr. Additional NH 3 in MeOH (2 M, 2.50 mL, 40 eq) was added and heated to 65° C. for 18 hr. Upon completion, the mixture was concentrated. The resulting precipitate was triturated with sat. NaHCO 3 . The precipitate was filtered.
- Methyl 3,5-difluoro-4-((7-methoxy-2-oxo-3H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzoate (50 mg, 124.90 ⁇ mol, 1 eq) dissolved in MeOH (2.5 mL) followed by the addition of hydroxylamine hydrochloride (86.79 mg, 1.25 mmol, 10 eq). The mixture was sonicated until hydroxylamine dissolved then cooled to 0° C. NaOMe (4.4 M, 369.01 ⁇ L, 13 eq) was added to the mixture in one portion. The mixture was allowed to stir at 22° for 2 hr.
- Step 1 1-((4-bromo-2,6-difluoro-phenyl)methyl)-7-methoxy-3H-imidazo[4,5-c][1,8]naphthyridin-2-one (400 mg, 949.68 ⁇ mol, 1 eq) dissolved in DMF (2.5 mL) followed by the addition of Boc 2 O (298.46 mg, 1.37 mmol, 314.17 ⁇ L, 1.44 eq) and Cs 2 CO 3 (464.13 mg, 1.42 mmol, 1.5 eq). The mixture stirred at 22° C. for 2 hr. Upon completion, the mixture was added to water and the resulting precipitate was filtered and dried yielding the product (463 mg, 94%).
- Step 2 tert-butyl 1-((4-bromo-2,6-difluoro-phenyl)methyl)-7-methoxy-2-oxo-imidazo[4,5-c][1,8]naphthyridine-3-carboxylate (260 mg, 498.74 ⁇ mol, 1 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (151.98 mg, 598.49 ⁇ mol, 1.2 eq), KOAc (146.84 mg, 1.50 mmol, 3 eq), and Pd(dppf)Cl 2 DCM complex (40.73 mg, 49.87 ⁇ mol, 0.1 eq) were suspended in dioxane (2.5 mL).
- Step 3 tert-butyl 1-((2,6-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methyl)-7-methoxy-2-oxo-imidazo[4,5-c][1,8]naphthyridine-3-carboxylate (50 mg, 87.97 ⁇ mol, 1 eq) dissolved in acetone (1.35 mL) and H 2 O (0.9 mL) followed by the addition of NaIO 4 (56.45 mg, 263.91 ⁇ mol, 14.62 ⁇ L, 3 eq) and NH 4 OAc (20.34 mg, 263.91 ⁇ mol, 3 eq).
- Step 1 To a mixture of 1-((4-bromo-2,6-difluoro-phenyl)methyl)-7-methoxy-3H-imidazo[4,5-c][1,8]naphthyridin-2-one (110 mg, 261.16 ⁇ mol, 1 eq) in DMF (2.5 mL) was added MeI (44.48 mg, 313.39 ⁇ mol, 19.51 ⁇ L, 1.2 eq), and NaH (12.54 mg, 313.39 ⁇ mol, 60% purity, 1.2 eq) in one portion at 0° C. The mixture was stirred at 0° C. for 1 hr. Upon completion, water (10 mL) was added into reaction mixture.
- Step 2 To a mixture of 1-((4-bromo-2,6-difluoro-phenyl)methyl)-7-methoxy-3-methyl-imidazo[4,5-c][1,8]naphthyridin-2-one (70 mg, 160.84 ⁇ mol, 1 eq) in DMF (2 mL) was added DIEA (74.83 mg, 579.02 ⁇ mol, 100.85 ⁇ L, 3.6 eq), XantPhos (9.31 mg, 16.08 ⁇ mol, 0.1 eq), and Pd(dba) 2 (9.25 mg, 16.08 ⁇ mol, 0.1 eq) in one portion at 22° C. under N 2 . The mixture was stirred at 80° C.
- Step 3 To a mixture of 1-((4-benzylsulfanyl-2,6-difluoro-phenyl)methyl)-7-methoxy-3-methyl-imidazo[4,5-c][1,8]naphthyridin-2-one (30 mg, 62.69 ⁇ mol, 1 eq) in THF (2 mL) and MeCN (1 mL) was added AcOH (26.35 mg, 438.86 ⁇ mol, 25.10 ⁇ L, 7 eq), and H 2 O (15.82 mg, 877.72 ⁇ mol, 15.82 ⁇ L, 14 eq) in one portion at 0° C.
- 1,3-Dichloro-5,5-dimethylhydantoin (17.29 mg, 87.77 ⁇ mol, 1.4 eq) was then added into reaction mixture at 0° C. The mixture was stirred at 0° C. for 2 hr.
- NH 4 OH (659.15 mg, 18.81 mmol, 724.34 ⁇ L, 300 eq) was cooled down to 0° C.
- Step 1 Ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (276 mg, 1.03 mmol, 1 eq) was dissolved in DCM (10 mL, 0.1 M) then cooled to ⁇ 78° C. 1 M DIBAL in cyclohexane (2.4 mL, 2.4 mmol, 2.4 eq) was added to the mixture. Upon completion, the mixture was warmed to 0° C. and quenched with sat. NH 4 C 1 . The aqueous layer was extracted with EtOAc (3 ⁇ 20 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated. The product was used in the next step without further purification.
- Step 2 (4-Chloro-7-methoxy-1,8-naphthyridin-3-yl)methanol from the previous step was dissolved in DCM (10 mL) followed by the addition of MnO2 (870 mg, 10 mmol, 10 eq). The mixture was stirred at 22° C. for 2 hr. Upon completion, the mixture was filtered over a pad of celite and the filtrate concentrated yielding the product (132 mg, 59% over 2 steps).
- Step 3 4-Chloro-7-methoxy-1,8-naphthyridine-3-carbaldehyde (122 mg, 0.55 mmol, 1 eq) was dissolved in MeOH (11 mL, 0.05 M) followed by the addition of hydrazine monohydrate (32 ⁇ L, 0.66 mmol, 1.2 eq). The vial was sealed and heated to 90° C. for 24 hr. Upon completion, the mixture was cooled to 22° C. and concentrated. The crude was dissolved in EtOAc and washed with sat. NaHCO 3 . The aqueous layer was back extracted with EtOAc (2 ⁇ 20 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated yielding the product (100 mg, 91%).
- Step 4 7-Methoxy-1H-pyrazolo[4,3-c][1,8]naphthyridine (20 mg, 0.1 mmol, 1 eq) was dissolved in DMF (1 mL, 0.1 M) followed by the addition of 60% NaH (5 mg, 0.12 mmol. 1.2 eq) and 4-(bromomethyl)benzenesulfonamide (30 mg, 0.12 mmol, 1.2 eq). The mixture was stirred at 22° C. for 3 hr then at 40° C. for 1 hr. The mixture was purified through Prep HPLC using water/MeCN (0.1% TFA) yielding the product (7.3 mg, 20%).
- Step 1 5-chloro-2-methoxy-1,8-naphthyridine (527 mg, 2.7 mmol, 1 eq), tert-butyl carbamate (380 mg, 3.25 mmol, 1.2 eq), Pd(dba) 2 (78 mg, 0.135 mmol, 0.05 eq), XPhos (129 mg, 0.27 mmol, 0.1 eq), and Cs 2 CO 3 (1.76 g, 5.4 mmol. 2 eq) were suspended in dioxane (14 mL, 0.2 M). The mixture was purged with nitrogen for 1 min then heated to 100° C. for 5 hr under nitrogen atmosphere. Upon completion, the mixture was cooled to 22° C. and poured into water. The resulting precipitate was filtered and dried. The crude product was used in the next step without further purification.
- Step 2 (7-methoxy-1,8-naphthyridin-4-yl)carbamate from previous step was suspending in DCM (5.4 mL, 0.5M) then cooled to 0° C. followed by the addition of 4 M HCl in dioxane (2.7 mL). The mixture was stirred at 22° C. until all starting material was consumed. Upon completion, the mixture was concentrated yielding the product. The product was used in the next step without further purification.
- Step 3 7-Methoxy-1,8-naphthyridin-4-amine HCl was dissolved in AcOH (14 mL, 0.2 M) then cooled to 0° C. Bromine (153 ⁇ L, 2.97 mmol, 1.1 eq) was added to the mixture. The mixture was stirred at 22° C. until no more starting material was observed on LCMS. Upon completion, the mixture was poured into water. The resulting precipitate was filtered and dried yielding the product (459 mg, 67% over 3 steps).
- Step 6 7-Methoxy-1H-pyrrolo[3,2-c][1,8]naphthyridine HCl (50 mg, 0.212 mmol, 1 eq) was dissolved in DMF (3 mL) followed by the addition of 4-(bromomethyl)benzenesulfonamide (64 mg, 0.255 mmol, 1.2 eq) and K 2 CO 3 (88 mg, 0.64 mmol, 3 eq). The mixture was heated to 60° C. Upon completion, the mixture was cooled to 22° C. and concentrated. The crude was purified through Prep HPLC using water/MeCN (0.1% TFA) yielding the product (22.7 mg, 22%).
- Step 1 To a mixture of ethyl 4-chloro-7-methoxy-cinnoline-3-carboxylate (300 mg, 1.12 mmol, 1 eq) in THF (10 mL) was added DIBAL (1 M, 3.37 mL, 3 eq) dropwise at ⁇ 78° C. The mixture was stirred at ⁇ 78° C. for 3 hours. Upon completion, sat. NaHCO 3 , potassium sodium tartrate, EtOAc were added into reaction mixture at ⁇ 78° C. and stirred at 22° C. for 18 hr. The aqueous layer was extracted by EtOAc (3 ⁇ 20 mL). The organic layer was combined and dried over Na 2 SO 4 and concentrated.
- Step 2 To a mixture of 4-chloro-7-methoxy-cinnoline-3-carbaldehyde (156 mg, 700.72 ⁇ mol, 1 eq) in MeOH (15 mL) was added hydrazine (40.42 mg, 1.26 mmol, 45.63 ⁇ L, 1.8 eq) in one portion at 22° C. The mixture was stirred at 65° C. for 18 hr. Upon completion, the mixture was concentrated. The crude was purified by FCC yielding the product (87 mg, 62%).
- Step 3 To a mixture of 7-methoxy-1H-pyrazolo[4,3-c]cinnoline (35 mg, 174.83 ⁇ mol, 1 eq) in DMF (1 mL) was added NaH (8.39 mg, 209.79 ⁇ mol, 60% purity, 1.2 eq) in one portion at 22° C. The mixture was stirred at 22° C. for 5 mins. 4-(bromomethyl)-2-fluoro-benzenesulfonamide (56.25 ⁇ g, 0.21 ⁇ mol, 1.20e-3 eq) was added into reaction mixture, and stirred for 2 hours. Upon completion, the reaction was quenched by 1N HCl (2 mL). Solid crashed out from solution. The precipitate filtered.
- NaNO 2 (4.82 mg, 69.92 ⁇ mol, 1.2 eq) was dissolved in water (0.1 mL).
- Step 1 To a mixture of 1-ethoxyphosphonoyloxyethane (82.20 mg, 595.23 umol, 76.82 ⁇ L, 6 eq) and 1-((4-bromo-3-fluoro-phenyl)methyl)-7-methoxy-3H-imidazo[4,5-c][1,8]naphthyridin-2-one (40 mg, 99.21 ⁇ mol, 1 eq) in DMF (1.2 mL) was added Et 3 N (30.12 mg, 297.62 ⁇ mol, 41.42 ⁇ L, 3 eq) and Pd(dppf)Cl 2 (7.26 mg, 9.92 ⁇ mol, 0.1 eq) in one portion at 22° C.
- Step 2 To a mixture of 1-((4-diethoxyphosphoryl-3-fluoro-phenyl)methyl)-7-methoxy-3H-imidazo[4,5-c][1,8]naphthyridin-2-one (96 mg, 208.52 ⁇ mol, 1 eq) in DCM (10 mL) was added 2,6-lutidine (379.82 mg, 3.54 mmol, 412.85 ⁇ L, 17 eq) in one portion at 22° C. The mixture was cooled to 0° C., TMSBr (1.60 g, 10.43 mmol, 1.35 mL, 50 eq) was added into reaction mixture dropwise. The reaction mixture was then stirred at 22° C. for 5 hr.
- Methyl hydrogen (2-fluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)phenyl)phosphonate (127) was prepared in 8.1 mg following the procedure for the synthesis of compound 121.
- LCMS [M+H] + 419.
- Step 1 To a mixture of ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (77 mg, 288.74 mol, 1 eq) and (4-(aminomethyl)phenyl)methanesulfonamide (109.36 mg, 461.98 mol, 1.6 eq, HCl) in MeCN (5 mL) was added DIEA (373.16 mg, 2.89 mmol, 502.91 ⁇ L, 10 eq) in one portion at 22° C. The mixture was stirred at 65° C. for 1 hour. Upon completion, the mixture was concentrated. The resulting residual was triturated with EtOAc yielding the product (112 mg, 90%).
- Step 3 To a mixture of this crude product in DMF (3 mL) was added DPPA (171.84 mg, 624.42 ⁇ mol, 135.31 ⁇ L, 2.4 eq), Et 3 N (263.27 mg, 2.60 mmol, 362.13 ⁇ L, 10 eq) in one portion at 22° C. The mixture was stirred at 80° C. for 3 hr. Upon completion, the mixture was concentrated. The crude was purified by DCM/MeOH yielding the product (17 mg, 16%).
- Step 1 1-((4-bromo-2,6-difluoro-phenyl)methyl)-7-methoxy-3H-imidazo[4,5-c][1,8]naphthyridin-2-one (400 mg, 949.68 ⁇ mol, 1 eq) dissolved in DMF (2.5 mL) followed by the addition of Boc 2 O (298.46 mg, 1.37 mmol, 314.17 ⁇ L, 1.44 eq) and Cs 2 CO 3 (464.13 mg, 1.42 mmol, 1.5 eq). The mixture stirred at 22° C. for 2 hr. Upon completion, the mixture was added to water and the resulting precipitate was filtered and dried yielding the product (463 mg, 94%).
- Step 2 tert-butyl 1-((4-bromo-2,6-difluoro-phenyl)methyl)-7-methoxy-2-oxo-imidazo[4,5-c][1,8]naphthyridine-3-carboxylate (60 mg, 115.09 ⁇ mol, 1 eq), Pd(OAc) 2 (1.29 mg, 5.75 ⁇ mol, 0.05 eq), Xantphos (3.33 mg, 5.75 ⁇ mol, 0.05 eq), Cs 2 CO 3 (112.50 mg, 345.28 ⁇ mol, 3 eq), and tert-butyl carbamate (26.97 mg, 230.19 ⁇ mol, 2 eq) were dissolved in dioxane (0.8 mL).
- Step 3 tert-butyl 1-((4-(tert-butoxycarbonylamino)-2,6-difluoro-phenyl)methyl)-7-methoxy-2-oxo-imidazo[4,5-c][1,8]naphthyridine-3-carboxylate (108 mg, 193.71 ⁇ mol, 1 eq) dissolved in DCM (0.5 mL) followed by the addition of TFA (770.00 mg, 6.75 mmol, 0.5 mL, 34.86 eq). The mixture stirred at 22° C. for 1.5 hr. Upon completion, the mixture was concentrated then dissolved in DCM. The crude was free based using sat.
- Example B1 ENPP1 Activity Assay Using p-Nitrophenyl-5′-TMP as a Substrate
- ENPP1 is a transmembrane glycoprotein that hydrolyzes nucleotides and nucleotide derivatives with the formation of nucleotide-5′-monophosphates.
- ENPP1 hydrolyzes artificial phosphoric acid ester thymidine 5′monophosphate p-nitrophenyl ester (TMP-pNP) to nucleotide-5′-monophosphate and p-nitrophenol, which is a chromogenic product.
- TMP-pNP artificial phosphoric acid ester thymidine 5′monophosphate p-nitrophenyl ester
- the amount of p-nitrophenol product formed is measured using its absorbance at 405 nm, which is directly proportional to enzyme activity.
- IC 50 values 8 point of different concentrations of each inhibitor were prepared with the final assay concentrations starting at 1000 nM with 50 mM Tris buffer (pH 9.5) containing 250 mM NaCl. Load into a well with 20 ng of human soluble ENPP1 in 50 ⁇ L and incubate at room temperature with 25 ⁇ L inhibitor solution (4 ⁇ Final Concentration) for 30 mins. Then, add 25 ⁇ L 2 mM TMP solution (2 ⁇ Final Concentration) into the well, Incubate at RT for 1 hour. The amounts of released p-nitrophenolate were measured by reading OD value at 405 nm.
- IC 50 values for percent inhibition versus compound concentration were determined by fitting the inhibition curves using a four-parameter variable slope model in GraphPad Prism® 8. The IC 50 values determined were listed in Table 2.
- Example B2 ENPP1 Activity Assay Using p-Nitrophenyl-5′-AMP as a Substrate
- an inhibitor of ENPP-1 is able to selectively blocking the hydrolysis of 2′3′-cGAMP while only minimally inhibiting the hydrolysis of ATP. Therefore, the ATP analog p-Nitrophenyl 5′-Adenosine Monophosphate (AMP-pNP) has been demonstrated to accurately reflect hydrolysis of native ATP by different classes of ENPP1 inhibitors.
- AMP-pNP can be used as substrate of ENPP-1. Its hydrolysis products were nucleotide-5′-monophosphate and p-nitrophenol, which is also a chromogenic product. The amount of p-nitrophenol product formed is measured using its absorbance at 405 nm, which is directly proportional to enzyme activity.
- IC 50 values 12 point of different concentrations of each inhibitor were prepared with the final assay concentrations starting at 9000 nM, 3 ⁇ series dilution with 50 mM Tris buffer (pH 9.5) containing 250 mM NaCl. Load into a well with 35 ng of human soluble ENPP1 in 50 ⁇ L and incubate at room temperature with 25 ⁇ L inhibitor solution (4 ⁇ Final Concentration) for 30 mins prior adding 25 ⁇ L 3 mM AMP solution (2 ⁇ Final Concentration) into the well, Incubate at RT for 1 hour. The amounts of released p-nitrophenolate were measured by reading OD value at 405 nm.
- IC 50 values for percent inhibition versus compound concentration are determined by fitting the inhibition curves using a four-parameter variable slope model in GraphPad Prism® 8. The IC 50 values determined are listed in Table 2.
- the hydrolysis products of 5′-GMP and 5′-AMP were generated when ENPP-1 use 2′3′-cGAMP as substrate.
- ENPP1 activity with 2′3′-cGAMP substrate is measured using the AMP-GloTM Assay kit (Promega Corporation) to quantitate the production of 5′-AMP.
- the AMP-GloTM Assay Kit contains two reagents that are added sequentially. Reagent I converts the 5′-AMP produced in the reaction to 5′ADP. Reagent II converts the 5′-ADP to 5′ATP and reacts the 5′-ATP with the luciferase/luciferin pair to produce the luminescence signal.
- the ENPP1 assay with 2′3′-cGAMP substrate is conducted in 50 mM Tris buffer (pH 9.5) containing 250 mM NaCl. 12 point of different concentrations of each inhibitor were prepared with the final assay concentrations starting at 9000 nM, 3 ⁇ series dilution. Duplicate wells are run at each inhibitor concentration. The final assay volume is 18 ⁇ L per well in 384 white assay plate containing 9 ⁇ L inhibitor solution, 4.5 ⁇ L human recombinant ENPP-1 protein (20 ng/well) and 4.5 ⁇ L, 2′,3′-cGAMP with final concentration of 20 ⁇ M.
- the assay is initiated by the addition of substrate and incubate at room temperature for 2 hours prior to taking 5 ⁇ L out to mix with 5 ⁇ L Reagent I to stop the reaction. 10 ⁇ L of Reagent II is then added and the wells are again incubated for another 60 minutes at room temperature. The luminescence signal is then measured using a plate reader with luminometer.
- Example B4 Cellular Enzymatic Assay of ENPP-1 Inhibitors Using TMP-pNP as Substrate
- ENPP-1 were mainly expressed on the surface of cell membrane where it hydrolytes 2′3′-cGAMP to generate 5′-GMP and 5′-AMP.
- ENPP-1 also has the ability to hydrolyzes artificial phosphoric acid ester TMP-pNP to nucleotide-5′-monophosphate and p-nitrophenol there, which is a chromogenic product. Therefore, in cultured MDA-MB-231, HEK293 and/or Saos-2 cells, TMP-pNP was used as substrate to reflect the enzymatic activity of ENPP1.
- the amount of p-nitrophenol product formed in the culture medium is measured using its absorbance at 405 nm, which is directly proportional to activity of ENPP1.
- IC 50 values for percent inhibition versus compound concentration are determined by fitting the inhibition curves using a four-parameter variable slope model in GraphPad Prism® 8.
- Example B5 ENPP1 Inhibitors Screening on cGAMP Activated THP-1 Cells
- THP-1 cells from bulk cultures were counted and suspended in RPMI 1640, 20% FBS, 2.5 mM L-alanyl-L-glutamine at a concentration of 5.5 ⁇ 10 6 cells/mL.
- the THP-1 cells were subsequently seeded into 96 well round bottom plates 180 ⁇ L/well (1 ⁇ 10 6 cells per well), incubated for 1 hour at 37° C., 5% CO 2 .
- Test compounds were screened in triplicate on THP-1 cells at a final concentration of 10 ⁇ M. A working solutions at 0.2 mM. Each well contains 180 ⁇ L of THP-1 cell suspension, 10 ⁇ L (30 ⁇ M, 40 ⁇ M or 50 ⁇ M) 2′3′-cGAMP (InvivoGen, catalog # tlrl-nacga23) solution (600 ⁇ M, 800 ⁇ M or 1000 ⁇ M) and 10 ⁇ L test compound working solution. Incubate for 1 hour.
- Vehicle control wells contain 2′3′-cGAMP at concentrations of 30 ⁇ M and 50 ⁇ M without any test compound. Positive control, 2′3′-cGAMP or 2′,3′-cGAM(PS)2 (Rp/Sp) (InvivoGen, cat # tlrl-nacga2srs) at 40 ⁇ M and 80 ⁇ M (final concentration).
- the supernatants were harvested at 200 ⁇ g for 10 minutes. Cell culture supernatants were then transferred to a clean plate and stored at ⁇ 80° C. until ready to analyze for IFN- ⁇ levels.
- the IFN- ⁇ levels in cell culture supernatants were determined by ELISA kits (PBL Assay Science, catalog #41410) according to the manufacturer's instructions.
- the test compounds potently increased the IFN- ⁇ levels at very low concentrations.
- Liver microsome assay was used to evaluate the metabolic stability of I-VI.
- the test article at the concentration of 1 ⁇ M was incubated with 0.5 mg/mL liver microsome in the presence of NADPH and UDPGA as the co-factors for 0, 15, 30, 45 and 60 minutes. The incubation was carried out at 37° C. with 5% CO 2 and saturating humidity. Disappearance of the test article was monitored by LC/MS/MS. the disappearance half-life (t 1/2 ), intrinsic clearance and hepatic extraction ratio were determined.
- test sample was prepared at 1.0 mg/mL in 5% DMSO/40% PEG400/55% water and administered to male CD-1 mice (4-6 weeks old, 20-30 grams, 3 animals each group) via intravenous (IV) bolus at 1 mg/kg and by oral gavage (PO) at 5 mg/kg.
- IV intravenous
- PO oral gavage
- Blood samples ( ⁇ 0.03 mL each time point) were collected via the jugular vein into tubes containing sodium heparin as the anticoagulant at 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose for IV administration and 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose for PO administration.
- PK pharmacokinetic
Abstract
Description
- This application claims prior benefit of U.S. Provisional Patent Application No. 62/904,501, filed Sep. 23, 2019, and of U.S. Provisional Patent Application No. 62/968,755, filed Jan. 31, 2020, the disclosures of each of which are hereby incorporated herein by reference in their entirety.
- This disclosure relates generally to compounds and compositions that may be useful as phosphodiesterase inhibitors.
- The Ectonucleotide Pyrophophatase/Phosphodiesterase (ENPP) family consists of seven members, ENNP1-7, which are either membrane-bound glycoproteins or ectoenzymes with an active site or as soluble proteins in body fluids. Among them, ENPP1 (Plasma cell membrane glycoprotein, also known as PC-1), is involved in a number of physiological processes, such as development, formation and trafficking, as well as in pathophysiological conditions. ENPP1 may use nucleotides and nucleotide derivatives as substrates and hydrolyze them with the formation of nucleoside-5′ monophosphates. ATP is an identified substrate of ENPP1, which is hydrolyzed to AMP and PPi. Another known subtract 2′3′-cyclic guanosine monophosphate-adenosine monophosphate (2′3′-cGAMP) is an intracellular secondary messenger produced in response to cytosolic dsDNA. Moreover, artificial phosphoric acid esters p-nitrophenyl 5′-thymidine monophosphate (TMP-pNP) and p-nitrophenyl 5′-adenosine monophosphate (AMP-pNP) are also taken by ENPP1 as substrates.
- ENPP1 is type II transmembrane glycoprotein originally identified as a negative regulator of bone mineralization, it expressed on the extracellular membrane of osteoblasts and chondrocytes and hydrolyzes extracellular ATP to produce AMP and diphosphate, an inhibitor of bone mineralization (Terkeltaub, R et, al. Purinergic Signaling 2006, 2, 371-377; Vaingankar, S. M. et, al. Cell Physiol. 2004, 286, C1177-C1187). ENPP1 is involved in many different biological processes. In lymphoid organs, ENPP1 hydrolysis produces AMP, which subsequently is metabolized by ecto-5′-nucleotidase CD73 into the immunosuppressive adenosine (Ferretti, E., Immunol. Lett. 2018, 3, 307). In animal model, ENPP1 inhibits insulin receptor tyrosine kinase activity in peripheral tissues, which are major targets of insulin action (Abate, N. et, al. Nature Clin. Pract. Endocrinol. Metab. 2006, 2, 694-701). Aberrant ENPP1 expression has also been reported in breast cancers, Hodgkin's lymphoma, hepatocellular carcinoma follicular lymphoma, glioblastoma and in other malignant tumor tissues.
- In recent years, ENPP1 was found to play an important role in cancer immunity. Li et al reported ENPP1 is the dominant 2′3′-cGAMP hydrolase, breaking it down to 5′-AMP and 5′-GMP. 2′3′-cGAMP is the most potent natural agonist to the Stimulator of Interferon Genes (STING) pathway, a central pathway in anti-viral and anti-cancer innate immunity. 2′3′-cyclic guanosine monophosphate-adenosine monophosphate (2′3′-cGAMP) functions as an endogenous second messenger in response of cytosolic double-strand DNA. It binds and activates STING to stimulate production of type I interferon (IFN) and other cytokines that subsequently trigger the anti-viral and anti-tumor immune response (Manas Sharma, et, al. Int J cell Sci & Mol Biol., 2018, 5, 555655). Therefore, ENPP1 inhibitors block 2′3′-cGAMP hydrolysis, subsequently enhance the cGAMP-induced STING pathway activation and stimulate anti-tumor immune response.
- Therefore, there is a need to develop ENPP inhibitors for therapeutics.
-
FIG. 1A ,FIG. 1B ,FIG. 1C ,FIG. 1D andFIG. 1E show the % increase measured for IFN-β in cells treated with representative compounds of 12, 48, 89, 103 and 121 relative to that of untreated cells. - In one aspect, provided is a compound of Formula (A):
- or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein each variable is as detailed herein.
- Also disclosed herein is a compound of Formula (I)-(VI):
- or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein each variable is as detailed herein.
- In some embodiments, a compound of formula (A), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, is of formulae (I)-(VI) as detailed herein.
- In another aspect, provided is a method of treating or preventing a disorder of uncontrolled cellular proliferation related to ENPP1, skeletal and soft tissue mineralization related disorders, disorders related to ENPP1 genetic changes, viral infections, and/or cancers.
- In some embodiments, provided is a method of treating a disorder or disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (A), including a compound of formulae (I)-(VI), or pharmaceutically acceptable salt, stereoisomer or solvate thereof.
- Also provided are pharmaceutical compositions comprising: (A) a compound detailed herein, such as a compound of formula (A), including a compound of formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof; and (B) a pharmaceutically acceptable carrier or excipient. Kits comprising a compound detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof and optionally instructions for use are also provided.
- Compounds as detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof are provided for use as a medicament. Compounds as detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof are also provided for the manufacture of a medicament for the treatment or prevention of a disorder of uncontrolled cellular proliferation related to ENPP1, for example, a cancer.
- For use herein, unless clearly indicated otherwise, use of the terms “a”, “an” and the like refers to one or more.
- Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X”.
- “Alkyl” as used herein refers to and includes, unless otherwise stated, a saturated linear (i.e., unbranched) or branched univalent hydrocarbon chain or combination thereof, having the number of carbon atoms designated (i.e., C1-C10 means one to ten carbon atoms). Particular alkyl groups are those having 1 to 20 carbon atoms (a “C1-C20 alkyl”), having 1 to 10 carbon atoms (a “C1-C10 alkyl”), having 6 to 10 carbon atoms (a “C6-C10 alkyl”), having 1 to 6 carbon atoms (a “C1-C6 alkyl”), having 2 to 6 carbon atoms (a “C2-C6 alkyl”), or having 1 to 4 carbon atoms (a “C1-C4 alkyl”). Examples of alkyl groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.
- “Cycloalkyl” as used herein refers to and includes, unless otherwise stated, saturated cyclic univalent hydrocarbon structures, having the number of carbon atoms designated (i.e., C3-C10 means three to ten carbon atoms). Cycloalkyl can consist of one ring, such as cyclohexyl, or multiple rings, such as adamantyl. A cycloalkyl comprising more than one ring may be fused, spiro or bridged, or combinations thereof. Particular cycloalkyl groups are those having from 3 to 12 annular carbon atoms. A preferred cycloalkyl is a cyclic hydrocarbon having from 3 to 8 annular carbon atoms (a “C3-C8 cycloalkyl”), having 3 to 6 carbon atoms (a “C3-C6 cycloalkyl”), or having from 3 to 4 annular carbon atoms (a “C3-C4 cycloalkyl”). Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like.
- “Heteroaryl” as used herein refers to an unsaturated aromatic cyclic group having from 1 to 14 annular carbon atoms and at least one annular heteroatom, including but not limited to heteroatoms such as nitrogen, oxygen and sulfur. A heteroaryl group may have a single ring (e.g., pyridyl, furyl) or multiple condensed rings (e.g., indolizinyl, benzothienyl) which condensed rings may or may not be aromatic. Particular heteroaryl groups are 5 to 14-membered rings having 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 5 to 10-membered rings having 1 to 8 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, or 5, 6 or 7-membered rings having 1 to 5 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In one variation, particular heteroaryl groups are monocyclic aromatic 5-, 6- or 7-membered rings having from 1 to 6 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In another variation, particular heteroaryl groups are polycyclic aromatic rings having from 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. A heteroaryl group having more than one ring where at least one ring is non-aromatic may be connected to the parent structure at either an aromatic ring position or at a non-aromatic ring position. In one variation, a heteroaryl group having more than one ring where at least one ring is non-aromatic is connected to the parent structure at an aromatic ring position. A heteroaryl group may be connected to the parent structure at a ring carbon atom or a ring heteroatom.
- “Heterocycle”, “heterocyclic”, or “heterocyclyl” as used herein refers to a saturated or an unsaturated non-aromatic cyclic group having a single ring or multiple condensed rings, and having from 1 to 14 annular carbon atoms and from 1 to 6 annular heteroatoms, such as nitrogen, sulfur or oxygen, and the like. A heterocycle comprising more than one ring may be fused, bridged or spiro, or any combination thereof, but excludes heteroaryl groups. The heterocyclyl group may be optionally substituted independently with one or more substituents described herein. Particular heterocyclyl groups are 3 to 14-membered rings having 1 to 13 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 12-membered rings having 1 to 11 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 10-membered rings having 1 to 9 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 8-membered rings having 1 to 7 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, or 3 to 6-membered rings having 1 to 5 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In one variation, heterocyclyl includes monocyclic 3-, 4-, 5-, 6- or 7-membered rings having from 1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6 annular carbon atoms and 1 to 2, 1 to 3, or 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In another variation, heterocyclyl includes polycyclic non-aromatic rings having from 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur.
- “Halo” or “halogen” refers to elements of the Group 17 series having atomic number 9 to 85. Preferred halo groups include the radicals of fluorine, chlorine, bromine and iodine. Where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached, e.g., dihaloaryl, dihaloalkyl, trihaloaryl etc. refer to aryl and alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be but are not necessarily the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl. An alkyl group in which each hydrogen is replaced with a halo group is referred to as a “perhaloalkyl.” A preferred perhaloalkyl group is trifluoromethyl (—CF3).
- “Oxo” refers to the moiety ═O.
- “Optionally substituted” unless otherwise specified means that a group may be unsubstituted or substituted by one or more (e.g., 1, 2, 3, 4 or 5) of the substituents listed for that group in which the substituents may be the same of different. In one embodiment, an optionally substituted group has one substituent. In another embodiment, an optionally substituted group has two substituents. In another embodiment, an optionally substituted group has three substituents. In another embodiment, an optionally substituted group has four substituents. In some embodiments, an optionally substituted group has 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, or 2 to 5 substituents. In one embodiment, an optionally substituted group is unsubstituted.
- “Pharmaceutically acceptable salts” are those salts which retain at least some of the biological activity of the free (non-salt) compound and which can be administered as drugs or pharmaceuticals to an individual. Such salts, for example, include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, oxalic acid, propionic acid, succinic acid, maleic acid, tartaric acid and the like; (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine and the like. Acceptable inorganic bases which can be used to prepared salts include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like. Pharmaceutically acceptable salts can be prepared in situ in the manufacturing process, or by separately reacting a purified compound of the invention in its free acid or base form with a suitable organic or inorganic base or acid, respectively, and isolating the salt thus formed during subsequent purification.
- A “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
- The term “excipient” as used herein means an inert or inactive substance that may be used in the production of a drug or pharmaceutical, such as a tablet containing a compound of the invention as an active ingredient. Various substances may be embraced by the term excipient, including without limitation any substance used as a binder, disintegrant, coating, compression/encapsulation aid, cream or lotion, lubricant, solutions for parenteral administration, materials for chewable tablets, sweetener or flavoring, suspending/gelling agent, or wet granulation agent. Binders include, e.g., carbomers, povidone, xanthan gum, etc.; coatings include, e.g., cellulose acetate phthalate, ethylcellulose, gellan gum, maltodextrin, enteric coatings, etc.; compression/encapsulation aids include, e.g., calcium carbonate, dextrose, fructose dc (dc=“directly compressible”), honey dc, lactose (anhydrate or monohydrate; optionally in combination with aspartame, cellulose, or microcrystalline cellulose), starch dc, sucrose, etc.; disintegrants include, e.g., croscarmellose sodium, gellan gum, sodium starch glycolate, etc.; creams or lotions include, e.g., maltodextrin, carrageenans, etc.; lubricants include, e.g., magnesium stearate, stearic acid, sodium stearyl fumarate, etc.; materials for chewable tablets include, e.g., dextrose, fructose dc, lactose (monohydrate, optionally in combination with aspartame or cellulose), etc.; suspending/gelling agents include, e.g., carrageenan, sodium starch glycolate, xanthan gum, etc.; sweeteners include, e.g., aspartame, dextrose, fructose dc, sorbitol, sucrose dc, etc.; and wet granulation agents include, e.g., calcium carbonate, maltodextrin, microcrystalline cellulose, etc.
- As used herein, “treatment” or “treating” is an approach for obtaining beneficial or desired results including clinical results. For example, beneficial or desired results include, but are not limited to, one or more of the following: decreasing symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, delaying the progression of the disease, and/or prolonging survival of an individual. In some embodiments, “treatment” of a disorder does not include prevention of the disorder, and “prevention” is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or severity of a disorder or biological manifestation thereof, or to delay the onset of such disorder or biological manifestation thereof.
- As used herein, an “effective dosage” or “effective amount” of compound or salt thereof or pharmaceutical composition is an amount sufficient to effect beneficial or desired results. For prophylactic use, beneficial or desired results include results such as eliminating or reducing the risk, lessening the severity of, or delaying the onset of the disease, including biochemical, histological and/or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presenting during development of the disease. For therapeutic use, beneficial or desired results include ameliorating, palliating, lessening, delaying or decreasing one or more symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, enhancing effect of another medication such as via targeting, delaying the progression of the disease, and/or prolonging survival. In some embodiments, an effective amount is an amount sufficient to delay development. In some embodiments, an effective amount is an amount sufficient to prevent or delay recurrence. An effective dosage can be administered in one or more administrations. For purposes of this disclosure, an effective dosage of compound or a salt thereof, or pharmaceutical composition is an amount sufficient to accomplish prophylactic or therapeutic treatment either directly or indirectly. It is intended and understood that an effective dosage of a compound or salt thereof, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition. Thus, an “effective dosage” may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.
- As used herein, the term “subject” is a mammal, including humans. A subject includes, but is not limited to, human, bovine, horse, feline, canine, rodent, or primate. In some embodiments, the subject is human (including adults and children).
- Unless otherwise stated, “substantially pure” intends a composition that contains no more than 10% impurity, such as a composition comprising less than about 9%, 7%, 5%, 3%, 1%, 0.5% impurity.
- It is understood that aspects and variations described herein also include “consisting” and/or “consisting essentially of” aspects and variations.
- All references throughout, such as publications, patents, patent applications and published patent applications, are incorporated herein by reference in their entireties.
- In one aspect, the invention provides a compound of Formula (A):
- or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein:
L1 is a bond, O, CR1R2, NR3, or *CR1R2NR3, wherein * denotes the point of attachment to ring A;
L2 is a bond, CR1R2, or C(═O);
Q1, Q2, Q3, Q4, and Q5 are independently N, C or C-E,
A2, A3, A4 and A5 are independently N or CR4;
X is S, O, CR1R2, C-E, N or NR3;
Z is SO2NHR5, SO2R5, C(O)OH, C(O)NHR5, C(O)NHOR5, P(O)(OR5)2, or B(OH)2;
E is, independently at each occurrence, selected from the group consisting of hydrogen, deuterium, halogen, oxo, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkoxy, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, N(C1-C6 alkyl)2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, 3-8 membered heterocyclyl, —C(O)—C1-C4 alkoxy, —C(O)—NH2, and —S(O)2—C1-C6 alkyl;
R1 and R2 are independently selected from the group consisting of hydrogen, deuterium, halogen, C1-C6 alkyl, and C3-C8 cycloalkyl, wherein the C1-C6 alkyl, and C3-C8 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy, or R1 and R2 together form a C3-C6 cycloalkyl;
R3 and R3′ are independently selected from the group consisting of hydrogen, C1-C6 alkyl, 3-6 membered cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, and C3-C6 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy;
R4 is selected from the group consisting of hydrogen, deuterium, halogen, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy;
R5 is, independently at each occurrence, selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8 membered heterocyclyl, and —C(═O)—C1-C6 alkyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are independently optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy; and
ring A is C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, or 5- to 10-membered heteroaryl, wherein the C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, and 5- to 10-membered heteroaryl of ring A are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen; and - indicates that ring B is fully unsaturated, or partially unsaturated.
- In some embodiments, provided herein is a compound of Formula (A), wherein Q2 is C, Q3 is C-E, wherein E is oxo, Q4 is N, and Q5 is C, such that the compound of Formula (A) is a compound of Formula (I):
- or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein:
L1 is a bond, O, CR1R2, NR3, or *CR1R2NR3, wherein * denotes the point of attachment to ring A;
L2 is a bond, CR1R2, or C(═O); - A2, A3, A4 and A5 are independently N or CR4;
X is S, O, CR1R2 or NR3;
Z is SO2NHR5, SO2R5, C(O)OH, C(O)NHR5, C(O)NHOR5, P(O)(OR5)2, or B(OH)2;
E is selected from the group consisting of hydrogen, deuterium, halogen, oxo, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkoxy, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, N(C1-C6 alkyl)2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, 3-8 membered heterocyclyl, —C(O)—C1-C4 alkoxy, —C(O)—NH2, and —S(O)2—C1-C6 alkyl;
R1 and R2 are independently selected from the group consisting of hydrogen, deuterium, halogen, C1-C6 alkyl, and C3-C8 cycloalkyl, wherein the C1-C6 alkyl, and C3-C8 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy, or R1 and R2 together form a C3-C6 cycloalkyl;
R3 and R3′ are independently selected from the group consisting of hydrogen, C1-C6 alkyl, 3-6 membered cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, and C3-C6 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy;
R4 is selected from the group consisting of hydrogen, deuterium, halogen, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy;
R5 is, independently at each occurrence, selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8 membered heterocyclyl, and —C(═O)—C1-C6 alkyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are independently optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy; and
ring A is C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, or 5- to 10-membered heteroaryl, wherein the C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, and 5- to 10-membered heteroaryl of ring A are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. - In some embodiments, provided herein is a compound of Formula (A), wherein Q2 is C, Q3 is C-E, Q4 is N, Q5 is C, and X is N, such that the compound of Formula (A) is a compound of Formula (II):
- or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein:
L1 is a bond, O, CR1R2, NR3, or *CR1R2NR3, wherein * denotes the point of attachment to ring A;
L2 is a bond, CR1R2, or C(═O); - A2, A3, A4 and A5 are independently N or CR4;
Z is SO2NHR5, SO2R5, C(O)OH, C(O)NHR5, C(O)NHOR5, P(O)(OR5)2, or B(OH)2;
E is, independently at each occurrence, selected from the group consisting of hydrogen, deuterium, halogen, oxo, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkoxy, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, N(C1-C6 alkyl)2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, 3-8 membered heterocyclyl, —C(O)—C1-C4 alkoxy, —C(O)—NH2, and —S(O)2—C1-C6 alkyl;
R1 and R2 are independently selected from the group consisting of hydrogen, deuterium, halogen, C1-C6 alkyl, and C3-C8 cycloalkyl, wherein the C1-C6 alkyl, and C3-C8 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy, or R1 and R2 together form a C3-C6 cycloalkyl;
R3 and R3′ are independently selected from the group consisting of hydrogen, C1-C6 alkyl, 3-6 membered cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, and C3-C6 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy;
R4 is selected from the group consisting of hydrogen, deuterium, halogen, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy;
R5 is, independently at each occurrence, selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8 membered heterocyclyl, and —C(═O)—C1-C6 alkyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are independently optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy; and
ring A is C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, or 5- to 10-membered heteroaryl, wherein the C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, and 5- to 10-membered heteroaryl of ring A are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. - In some embodiments, provided is a compound of Formula (A), wherein Q2 is C, Q4 is N, Q5 is C, and X is C-E, such that the compound of Formula (A) is a compound of Formula (III):
- or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein:
L1 is a bond, O, CR1R2, NR3, or *CR1R2NR3, wherein * denotes the point of attachment to ring A;
L2 is a bond, CR1R2, or C(═O); - A2, A3, A4 and A5 are independently N or CR4;
Z is SO2NHR5, SO2R5, C(O)OH, C(O)NHR5, C(O)NHOR5, P(P)(OR5)2, or B(OH)2;
E is, independently at each occurrence, selected from the group consisting of hydrogen, deuterium, halogen, oxo, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkoxy, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, N(C1-C6 alkyl)2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, 3-8 membered heterocyclyl, —C(O)—C1-C4 alkoxy, —C(O)—NH2, and —S(O)2—C1-C6 alkyl;
R1 and R2 are independently selected from the group consisting of hydrogen, deuterium, halogen, C1-C6 alkyl, and C3-C8 cycloalkyl, wherein the C1-C6 alkyl, and C3-C8 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy, or R1 and R2 together form a C3-C6 cycloalkyl;
R3 and R3′ are independently selected from the group consisting of hydrogen, C1-C6 alkyl, 3-6 membered cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, and C3-C6 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy;
R4 is selected from the group consisting of hydrogen, deuterium, halogen, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy;
R5 is, independently at each occurrence, selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8 membered heterocyclyl, and —C(═O)—C1-C6 alkyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are independently optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy; and
ring A is C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, or 5- to 10-membered heteroaryl, wherein the C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, and 5- to 10-membered heteroaryl of ring A are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. - In some embodiments, provided is a compound of Formula (A), wherein Q2 is C, Q3 is N, Q4 is N, Q5 is C, and X is N, such that the compound of Formula (A) is a compound of Formula (IV):
- or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein:
L1 is a bond, O, CR1R2, NR3, or *CR1R2NR3, wherein * denotes the point of attachment to ring A; - L2 is a bond, CR1R2, or C(═O);
- A2, A3, A4 and A5 are independently N or CR4;
Z is SO2NHR5, SO2R5, C(O)OH, C(O)NHR5, C(O)NHOR5, P(O)(OR5)2, or B(OH)2;
E is selected from the group consisting of hydrogen, deuterium, halogen, oxo, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkoxy, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, N(C1-C6 alkyl)2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, 3-8 membered heterocyclyl, —C(O)—C1-C4 alkoxy, —C(O)—NH2, and —S(O)2—C1-C6 alkyl;
R1 and R2 are independently selected from the group consisting of hydrogen, deuterium, halogen, C1-C6 alkyl, and C3-C8 cycloalkyl, wherein the C1-C6 alkyl, and C3-C8 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy, or R1 and R2 together form a C3-C6 cycloalkyl;
R3 and R3′ are independently selected from the group consisting of hydrogen, C1-C6 alkyl, 3-6 membered cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, and C3-C6 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy; - R4 is selected from the group consisting of hydrogen, deuterium, halogen, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy;
- R5 is, independently at each occurrence, selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8 membered heterocyclyl, and —C(═O)—C1-C6 alkyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are independently optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy; and
ring A is C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, or 5- to 10-membered heteroaryl, wherein the C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, and 5- to 10-membered heteroaryl of ring A are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. - In some embodiments, provided is a compound of Formula (A), wherein Q2 is C, Q3 is N, Q4 is C, and Q5 is N, such that the compound of Formula (A) is a compound of Formula (V):
- or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein:
L1 is a bond, O, CR1R2, NR3, or *CR1R2NR3, wherein * denotes the point of attachment to ring A;
L2 is a bond, CR1R2, or C(═O);
Q1 and X are independently N or C-E;
A2, A3, A4 and A5 are independently N or CR4;
Z is SO2NHR5, SO2R5, C(O)OH, C(O)NHR5, C(O)NHOR5, P(O)(OR5)2, or B(OH)2;
E is selected from the group consisting of hydrogen, deuterium, halogen, oxo, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkoxy, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, N(C1-C6 alkyl)2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, 3-8 membered heterocyclyl, —C(O)—C1-C4 alkoxy, —C(O)—NH2, and —S(O)2—C1-C6 alkyl;
R1 and R2 are independently selected from the group consisting of hydrogen, deuterium, halogen, C1-C6 alkyl, and C3-C8 cycloalkyl, wherein the C1-C6 alkyl, and C3-C8 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy, or R1 and R2 together form a C3-C6 cycloalkyl;
R3 and R3′ are independently selected from the group consisting of hydrogen, C1-C6 alkyl, 3-6 membered cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, and C3-C6 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy;
R4 is selected from the group consisting of hydrogen, deuterium, halogen, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy;
R5 is, independently at each occurrence, selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8 membered heterocyclyl, and —C(═O)—C1-C6 alkyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are independently optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy; and
ring A is C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, or 5- to 10-membered heteroaryl, wherein the C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, and 5- to 10-membered heteroaryl of ring A are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. - In some embodiments, provided is a compound of Formula (A), wherein Q2 is N, Q4 is C, and Q5 is C, such that the compound of Formula (A) is a compound of Formula (VI):
- or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein:
L1 is a bond, O, CR1R2, NR3, or *CR1R2NR3, wherein * denotes the point of attachment to ring A;
L2 is a bond, CR1R2, or C(═O);
Q1, Q3 and X are independently N or C-E;
A2, A3, A4 and A5 are independently N or CR4;
Z is SO2NHR5, SO2R5, C(O)OH, C(O)NHR5, C(O)NHOR5, P(O)(OR5)2, or B(OH)2;
E is, independently at each occurrence, selected from the group consisting of hydrogen, deuterium, halogen, oxo, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkoxy, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, N(C1-C6 alkyl)2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, 3-8 membered heterocyclyl, —C(O)—C1-C4 alkoxy, —C(O)—NH2, and —S(O)2—C1-C6 alkyl;
R1 and R2 are independently selected from the group consisting of hydrogen, deuterium, halogen, C1-C6 alkyl, and C3-C8 cycloalkyl, wherein the C1-C6 alkyl, and C3-C8 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy, or R1 and R2 together form a C3-C6 cycloalkyl;
R3 and R3′ are independently selected from the group consisting of hydrogen, C1-C6 alkyl, 3-6 membered cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, and C3-C6 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy;
R4 is selected from the group consisting of hydrogen, deuterium, halogen, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy;
R5 is, independently at each occurrence, selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8 membered heterocyclyl, and —C(═O)—C1-C6 alkyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are independently optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy; and
ring A is C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, or 5- to 10-membered heteroaryl, wherein the C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, and 5- to 10-membered heteroaryl of ring A are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. - In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein ring is fully unsaturated. In other embodiments, ring B is partially unsaturated. In some embodiments, ring B is a 5-membered aryl or 5-membered heteroaryl. In other embodiments, ring B is a 5-membered heterocyclyl or 5-membered cycloalkyl.
- In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein A2, A3, A4 and A5 are each independently N or CR4, wherein R4 is, independently at each occurrence, selected from the group consisting of hydrogen, deuterium, halogen, —CN, —OR3, —NO2, —NR3R3′, —C(O)R3, —C(O)OR3, —C(O)NR3R3′, —SO2R3, —SO2NR3R3′, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, and 3-8 membered heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy. In some embodiments, A2, A3, A4 and A5 are each independently CR4, wherein R4 is, independently of each other and independently at each occurrence, H, C1-C4 alkoxy, or CN. In some embodiments, A2 is CH, A3 is C—C1-C4 alkoxy, A4 is C—C1-C4 alkoxy, and A5 is CH. In some embodiments, A2 is CH, A3 is C—OMe, A4 is C—OMe, and A5 is CH. In some embodiments, A2 is CH, A3 is C—C1-C4 alkoxy, A4 is CH, and A5 is CH. In some embodiments, A2 is CH, A3 is C—OMe, A4 is CH, and A5 is CH. In some embodiments, A2 is CH, A3 is CH, A4 is C—C1-C4 alkoxy, and A5 is CH. In some embodiments, A2 is CH, A3 is CH, A4 is C—OMe, and A5 is CH. In some embodiments, A2 is CH, A3 is C—C1-C4 alkoxy, A4 is CN, and A5 is CH. In some embodiments, A2 is CH, A3 is C—OMe, A4 is CN, and A5 is CH. In some embodiments, A2 is CH, A3 is C—C1-C4 alkoxy, A4 is N, and A5 is CH. In some embodiments, A2 is CH, A3 is C—OMe, A4 is N, and A5 is CH. In some embodiments, A2 is N, A3 is C—C1-C4 alkoxy, A4 is CH, and A5 is CH. In some embodiments, A2 is N, A3 is C—OMe, A4 is CH, and A5 is CH. In some embodiments, A5 is CH, A3 is C—C1-C4 alkoxy, A4 is CH, and A5 is N. In some embodiments, A2 is CH, A3 is C—OMe, A4 is CH, and A5 is N. In some embodiments, A2 is CH, A3 is C—C1-C4 alkoxy, A4 is N, and A5 is CH. In some embodiments, A2 is CH, A3 is C—OMe, A4 is N, and A5 is CH. In some embodiments, A2 is N, A3 is C—C1-C4 alkoxy, A4 is C-halogen, and A5 is CH. In some embodiments, A2 is N, A3 is C—OMe, A4 is C—Cl, and A5 is CH.
- In some embodiments, provided herein is a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein A2 is CH, A3 is C—C1-C4 alkoxy, A4 is C—C1-C4 alkoxy, and A5 is CH. In some embodiments, provided herein is a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein A2 is CH, A3 is C—OMe, A4 is C—OMe, and A5 is CH. In some embodiments, provided herein is a compound of formula (II), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein A2 is CH, A3 is C—C1-C4 alkoxy, A4 is C—C1-C4 alkoxy, and A5 is CH. In some embodiments, provided herein is a compound of formula (II), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein A2 is, A3 is C—OMe, A4 is C—OMe, and A5 is CH. In some embodiments, provided herein is a compound of formula (II), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein A2 is N, A3 is C—C1-C4 alkoxy, A4 is CH, and A5 is CH. In some embodiments, provided herein is a compound of formula (II), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein A2 is N, A3 is C—OMe, A4 is CH, and A5 is CH.
- In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein ring A is C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, or 5- to 10-membered heteroaryl, wherein the C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, C6-C14 aryl, and 5- to 10-membered heteroaryl of ring A are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen.
- In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein ring A is C3-C8 cycloalkyl, wherein the C3-C8 cycloalkyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. In some embodiments, ring A is cyclobutyl.
- In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein ring A is 3- to 12-membered heterocyclyl, wherein the 3- to 12-membered heterocyclyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. In some embodiments, ring A is a 4- to 8-membered heterocyclyl. In some embodiments, ring A is a 5- or 6-membered heterocyclyl. In some embodiments, ring A is piperazinyl. In some embodiments, ring A is azetidinyl. In certain embodiments, ring A is piperidinyl. In other embodiments, ring A is pyrrolidinyl.
- In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein ring A is C6-C14 aryl, wherein the C6-C14 aryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. In some embodiments, ring A is C6-C10 aryl. In some embodiments, ring A is phenyl. In some embodiments, ring A is phenyl, wherein the phenyl of ring A is optionally substituted with one or more halogen, CN, C1-C3 alkyl, or C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. In some embodiments, the halogen is F.
- In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein ring A is 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. In some embodiments, ring A is 5- or 6-membered heteroaryl. In some embodiments, ring A is 6-membered heteroaryl. In some embodiments, ring A is pyridinyl. In other embodiments, ring A is pyrimidinyl. In some embodiments, ring A is pyridinyl or pyrimidinyl, wherein the pyridinyl or pyrimidinyl of ring A is optionally substituted with one or more halogen, CN, C1-C3 alkyl, or C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. In some embodiments, the halogen is F. In some embodiments, ring A is dihydroisoquinolinyl.
- In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein L1 is a bond, O, CR1R2, NR3, or *CR1R2NR3, wherein * denotes the point of attachment to ring A. In some embodiments, L1 is a bond. In other embodiments, L1 is O, CR1R2, NR3, or *CR1R2NR3, wherein * denotes the point of attachment to ring A. In some embodiments, L1 is O. In certain embodiments, L1 is CR1R2. In some embodiments, L1 is CR1R2, wherein R1 and R2 are independently selected from H and C1-C6 alkyl. In some embodiments, L1 is CR1R2, wherein R1 and R2 are independently selected from H and methyl. In some embodiments, L1 is CR1R2, wherein R1 and R2 are both H. In some embodiments, L1 is CR1R2, wherein one of R1 and R2 is H and the other of R1 and R2 is C1-C6 alkyl. In some embodiments, L1 is CR1R2, wherein one of R1 and R2 is H and the other of R1 and R2 is methyl. In other embodiments, L1 is NR3. In some embodiments, L1 is NR3, wherein R3 is H or C1-C6 alkyl. In some embodiments, L1 is NR3, wherein R3 is H. In other embodiments, L1 is NR3, wherein R3 is methyl. In some embodiments, L1 is *CR1R2NR3, wherein * denotes the point of attachment to ring A. In certain embodiments, L1 is *CR1R2NR3, wherein * denotes the point of attachment to ring A, wherein R1 and R2 are both H.
- In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein L1 is a bond, 0, CR1R2, NR3, or *CR1R2NR3, wherein * denotes the point of attachment to ring A, and ring A is C6-C14 aryl, wherein the C6-C14 aryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen.
- In some embodiments, L1 is a bond and ring A is C6-C14 aryl, wherein the C6-C14 aryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. In some embodiments, L1 is a bond and ring A is phenyl, wherein the phenyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen.
- In some embodiments, L1 is CR1R2, wherein R1 and R2 are independently selected from H and C1-C6 alkyl, and ring A is C6-C14 aryl, wherein the C6-C14 aryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. In some embodiments, L1 is CR1R2, wherein R1 and R2 are independently selected from H and C1-C6 alkyl, and ring A is phenyl, wherein the phenyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. In certain embodiments, L1 is *CR1R2NR3, wherein * denotes the point of attachment to ring A, wherein R1, R2 and R3 are each H, and ring A is phenyl, wherein the phenyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen.
- In some embodiments, L1 is a bond and ring A is 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. In some embodiments, L1 is a bond and ring A is 6-membered heteroaryl, wherein the 6-membered heteroaryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. In some embodiments, L1 is a bond and ring A is pyridinyl or pyrimidinyl, wherein the pyridinyl or pyrimidinyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen.
- In some embodiments, L1 is CR1R2, wherein R1 and R2 are independently selected from H and C1-C6 alkyl, and ring A is 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. L1 is CR1R2, wherein R1 and R2 are independently selected from H and C1-C6 alkyl, and ring A is 6-membered heteroaryl, wherein the 6-membered heteroaryl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. In some embodiments, L1 is CR1R2, wherein R1 and R2 are independently selected from H and C1-C6 alkyl, and ring A is pyridinyl or pyrimidinyl, wherein the pyridinyl or pyrimidinyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. In certain embodiments, L1 is *CR1R2NR3, wherein * denotes the point of attachment to ring A, wherein R1, R2 and R3 are each H, and ring A is pyridinyl or pyrimidinyl, wherein the pyridinyl or pyrimidinyl of ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, CN, OH, NH2, C1-C3 alkyl, and C1-C4 alkoxy, wherein the C1-C3 alkyl and C1-C4 alkoxy are independently optionally substituted with one or more halogen. In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein L2 is a bond, CR1R2, or C(═O). In some embodiments, L2 is a bond. In some embodiments, L2 is O. In certain embodiments, L2 is CR1R2. In some embodiments, L2 is CR1R2, wherein R1 and R2 are independently selected from H and C1-C6 alkyl. In some embodiments, L2 is CR1R2, wherein R1 and R2 are independently selected from H and methyl. In some embodiments, L2 is CR1R2, wherein R1 and R2 are both H. In some embodiments, L2 is CR1R2, wherein one of R1 and R2 is H and the other of R1 and R2 is C1-C6 alkyl. In some embodiments, L2 is CR1R2, wherein one of R1 and R2 is H and the other of R1 and R2 is methyl. In some embodiments, L2 is Q=0).
- In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I)-(VI), as applicable, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein X is S, O, CR1R2, C-E, N or NR3. In some embodiments, X is O, CR1R2, C-E, N or NR3. In some embodiments, X is O. In certain embodiments, X is N. In some embodiments, X is NR3. In other embodiments, X is NR3, wherein R3 is H or C1-C6 alkyl. In some embodiments, X is C-E. In some embodiments, X is C-E, wherein E is H or C1-C6 alkyl, wherein the C1-C6 alkyl of E is optionally substituted with one or more OH, halogen, C1-C4 alkoxy, or 3-8 membered heterocyclyl. In some embodiments, X is N or C-E.
- In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein Z is SO2NHR5, SO2R5, C(O)OH, C(O)NHR5, C(O)NHOR5, P(O)(OR5)2, or B(OH)2. In some embodiments, Z is SO2NHR5, wherein R5 is H, C1-C6 alkyl, or —C(O)—C1-C6 alkyl. In some embodiments, Z is SO2NHR5, wherein R5 is H. In some embodiments, Z is SO2R5. In certain embodiments, Z is C(O)OH, C(O)NHR5, or C(O)NHOR5. In certain embodiments, Z is C(O)OH. In some embodiments, Z is C(O)NHOR5, wherein R5 is H. In some embodiments, Z is C(O)NHR5, wherein R5 is H. In some embodiments, Z is B(OH)2. In some embodiments, Z is P(O)(OR5)2, wherein each R5 is independently H or C1-C6 alkyl. In some embodiments, Z is P(O)(OR5)2, wherein each R5 is independently H.
- Representative compounds are listed in Table 1. In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein L1 is a bond and Z is SO2NHR5, wherein R5 is H, C1-C6 alkyl, or —C(O)—C1-C6 alkyl. In some embodiments, L1 is a bond and Z is SO2NHR5, wherein R5 is H. In other embodiments, L1 is a bond and Z is SO2NHR5, wherein R5 is C1-C6 alkyl. L1 is NR3, wherein R3 is H, and Z is SO2NHR5, wherein R5 is H, C1-C6 alkyl, or —C(O)—C1-C6 alkyl. In some embodiments, L1 is NR3, wherein R3 is H, and Z is SO2NHR5, wherein R5 is H. In some embodiments, L1 is CR1R2, wherein R1 and R2 are independently selected from H and C1-C6 alkyl, and Z is SO2NHR5, wherein R5 is H, C1-C6 alkyl, or —C(O)—C1-C6 alkyl. In some embodiments, L1 is CR1R2, wherein R1 and R2 are independently selected from H and C1-C6 alkyl, and Z is SO2NHR5, wherein R5 is H. In some embodiments, L1 is a bond and Z is P(O)(OR5)2, wherein each R5 is independently H or C1-C6 alkyl. In some embodiments, L1 is a bond and Z is B(OH)2. In some embodiments, L1 is a bond and Z is C(O)OH, C(O)NHR5, or C(O)NHOR5. In some embodiments, L1 is a bond and Z is C(O)OH, C(O)NHR5, or C(O)NHOR5, wherein each R5 is independently H.
- Representative compounds are listed in Table 1.
-
TABLE 1 # Structure Name 1 4-((7,8-dimethoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c]quinolin-1- yl)methyl)benzenesulfonamide 2 4-((7,8-dimethoxy-3-methyl-2-oxo-2,3- dihydro-1H-imidazo[4,5-c]quinolin-1- yl)methyl)benzenesulfonamide 3a (R)-4-(1-(7,8-dimethoxy-2-oxo-2,3-dihydro- 1H-imidazo[4,5-c]quinolin-1- yl)ethyl)benzenesulfonamide 3b (S)-4-(1-(7,8-dimethoxy-2-oxo-2,3-dihydro- 1H-imidazo[4,5-c]quinolin-1- yl)ethyl)benzenesulfonamide 4 4-((7,8-dimethoxy-2-oxooxazolo[5,4- c]quinolin-1(2H)- yl)methyl)benzenesulfonamide 5 6-((7,8-dimethoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c]quinolin-1-yl)methyl)pyridine- 3-sulfonamide 6 5-((6,7-dimethoxyquinazolin-4- yl)ethynyl)pyridine-3-sulfonamide 7 3-((7,8-dimethoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c]quinolin-1- yl)methyl)benzenesulfonamide 8 (R)-4-(1-(7-methoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c]quinolin-1- yl)ethyl)benzenesulfonamide 9 4-((7,8-dimethoxy-2-methyl-1H- imidazo[4,5-c]quinolin-1- yl)methyl)benzenesulfonamide 10 5-((7,8-dimethoxy-1H-imidazo[4,5- c]quinolin-1-yl)methyl)pyridine-2- sulfonamide 11a (R)-4-(1-(7,8-dimethoxy-1H-imidazo[4,5- c]quinolin-1-yl)ethyl)benzenesulfonamide 11b (S)-4-(1-(7,8-dimethoxy-1H-imidazo[4,5- c]quinolin-1-yl)ethyl) benzenesulfonamide 12 6-((7,8-dimethoxy-1H-imidazo[4,5- c]quinolin-1-yl)methyl)pyridine-3- sulfonamide 13 4-((7,8-dimethoxy-1H-[1,2,3]triazolo[4,5- c]quinolin-1-yl)methyl)benzenesulfonamide 14a (R)-4-(1-(7,8-dimethoxy-1H- [1,2,3]triazolo[4,5-c]quinolin-1- yl)ethyl)benzenesulfonamide 14b (S)-4-(1-(7,8-dimethoxy-1H- [1,2,3]triazolo[4,5-c]quinolin-1- yl)ethyl)benzenesulfonamide 15 5-((7,8-dimethoxy-1H-[1,2,3]triazolo[4,5- c]quinolin-1-yl)methyl)pyridine-2- sulfonamide 16 6-((7,8-dimethoxy-1H-[1,2,3]triazolo[4,5- c]quinolin-1-yl)methyl)pyridine-3- sulfonamide 17 4-((7,8-dimethoxy-1H-pyrazolo[4,3- c]quinolin-1-yl)methyl)benzenesulfonamide 18 4-((7,8-dimethoxy-3-methyl-1H- pyrazolo[4,3-c]quinolin-1- yl)methyl)benzenesulfonamide 19a (R)-4-(1-(7,8-dimethoxy-1H-pyrazolo[4,3- c]quinolin-1-yl)ethyl)benzenesulfonamide 19b (S)-4-(1-(7,8-dimethoxy-1H-pyrazolo[4,3- c]quinolin-1-yl)ethyl) benzenesulfonamide 20 5-((7,8-dimethoxy-1H-pyrazolo[4,3- c]quinolin-1-yl)methyl)pyridine-2- sulfonamide 21 6-((7,8-dimethoxy-1H-pyrazolo[4,3- c]quinolin-1-yl)methyl)pyridine-3- sulfonamide 22 4-((7,8-dimethoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c]quinolin-1-yl)methyl)-2- fluorobenzenesulfonamide 23 2-(4-(6,7-dimethoxyquinazolin-4- yl)phenyl)pyrrolidine-1-sulfonamide 24 3-((7,8-dimethoxy-3-methyl-2-oxo-2,3- dihydro-1H-imidazo[4,5-c]quinolin-1- yl)methyl)azetidine-1-sulfonamide 25 3-((7,8-dimethoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c]quinolin-1- yl)methyl)pyrrolidine-1-sulfonamide 26 4-((7,8-dimethoxy-3-methyl-2-oxo-2,3- dihydro-1H-imidazo[4,5-c]quinolin-1- yl)methyl)piperidine-1-sulfonamide 27 3-((7,8-dimethoxy-1H-imidazo[4,5- c]quinolin-1-yl)methyl)azetidine-1- sulfonamide 28 3-((7,8-dimethoxy-1H-pyrazolo[4,3- c]quinolin-1-yl)methyl)azetidine-1- sulfonamide 29 3-((7,8-dimethoxy-2-methyl-1H- imidazo[4,5-c]quinolin-1- yl)methyl)pyrrolidine-1-sulfonamide 30 3-((7,8-dimethoxy-1H-[1,2,3]triazolo[4,5- c]quinolin-1-yl)methyl)pyrrolidine-1- sulfonamide 31 4-((7,8-dimethoxy-2-oxooxazolo[5,4- c]quinolin-1(2H)-yl)methyl)piperidine-1- sulfonamide 32 4-((7,8-dimethoxy-1H-imidazo[4,5- c]quinolin-1-yl)methyl)piperidine-1- sulfonamide 33 4-((7-methoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c][1,6]naphthyridin-1- yl)methyl)benzenesulfonamide 34 4-((8-cyano-7-methoxy-2-oxo-2,3-dihydro- 1H-imidazo[4,5-c]quinolin-1- yl)methyl)benzenesulfonamide 35 4-((7-methoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c]quinolin-1- yl)methyl)benzenesulfonamide 36 4-((8-methoxy-1H-imidazo[4,5-c]quinolin-1- yl)methyl)benzenesulfonamide 37 3-((7,8-dimethoxy-1H-imidazo[4,5- c]quinolin-1-yl)methyl)benzenesulfonamide 38 4-((7-methoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 39 4-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 40 6-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)methyl)pyridine-3- sulfonamide 41 5-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)methyl)pyridine-2- sulfonamide 42 4-((8,9-dimethoxypyrazolo[1,5-c]quinazolin- 1-yl)methyl)benzenesulfonamide 43 (R)-6-(1-(7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)ethyl)pyridine-3- sulfonamide 44 4-((7,8-dimethoxy-2λ2,10λ4- [1,2,4]triazolo[4,3-a]quinoxalin-1- yl)methyl)benzenesulfonamide 45 4-((7-methoxy-2λ2,10λ4-imidazo[3,4- a]quinoxalin-1- yl)methyl)benzenesulfonamide 46 4-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)methyl)phenyl sulfamide 47 4-((7-methoxy-2-(trifluoromethyl)-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl) benzenesulfonamide 48 4-((7-methoxy-2-methyl-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 49 4-((7-methoxy-1H-imidazo[4,5- c][1,5]naphthyridin-1- yl)methyl)benzenesulfonamide 50 4-((7-methoxy-1H-imidazo[4,5- c][1,6]naphthyridin-1- yl)methyl)benzenesulfonamide 51 4-(7,8-dimethoxy-[1,2,4]triazolo[4,3- a]quinoxalin-1-yl)benzylsulfamide 52 3-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)methyl)azetidine-1- sulfonamide 53 7-(7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)-3,4- dihydroisoquinoline-2(1H)-sulfonamide 54 (R)-4-(1-(7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)ethyl)benzenesulfonamide 55 (4-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)phenyl)boronic acid 56 4-((7,8-dimethoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c]cinnolin-1- yl)methyl)benzenesulfonamide 57 5-((7-methoxy-1H-imidazo[4,5-c]cinnolin-1- yl)methyl)pyridine-2-sulfonamide 58 4-(8,9-dimethoxypyrazolo[l,5-c]quinazoline- 1-carbonyl)piperazine-1-sulfonamide 59 4-(7-methoxy-1H-imidazo[4,5- c][1,6]naphthyridin-1-yl)benzyl sulfamide 60 (R)-6-(1-(7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)ethyl)pyridine-3- sulfonamide 61 2-fluoro-4-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 62 3-fluoro-4-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 63 2-cyano-6-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)methyl)pyridine-3- sulfonamide 64 2-methoxy-4-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 65 4-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)methyl)-2- (trifluoromethyl)benzenesulfonamide 66 4-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)methyl)-2- (trifluoromethoxy)benzenesulfonamide 67 4-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)methyl)-3- (trifluoromethyl)benzenesulfonamide 68 3-bromo-4-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 69 3-cyano-4-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 70 2,5-difluoro-4-((7-methoxy-2-methyl-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 71 2-fluoro-4-((7-methoxy-2-methyl-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 72 6-((7-methoxy-2-methyl-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)methyl)pyridine-3- sulfonamide 73 5-((7-methoxy-2-methyl-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)methyl)pyridine-2- sulfonamide 74 6-((2-cyclopropyl-7-methoxy-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)pyridine-3-sulfonamide 75 6-((7-methoxy-2-(tetrahydro-2H-pyran-4-yl)- 1H-imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)pyridine-3-sulfonamide 76 N-((2-fluoro-4-((7-methoxy-2-methyl-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)phenyl)sulfonyl)acetamide 77 N-((6-((7-methoxy-2-methyl-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)pyridin-3-yl)sulfonyl)acetamide 78 4-((2,7-dimethoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)methyl)-2- fluorobenzenesulfonamide 79 2-fluoro-4-((7-methoxy-2-(methoxymethyl)- 1H-imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 80 2-fluoro-4-((7-methoxy-2- (morpholinomethyl)-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 81 2-fluoro-4-((7-methoxy-2- ((methylsulfonyl)methyl)-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 82 4-((2-(cyanomethyl)-7-methoxy-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)-2-fluorobenzenesulfonamide 83 methyl 2-(1-(3-fluoro-4-sulfamoylbenzyl)-7- methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-2-yl)acetate 84 2-(1-(3-fluoro-4-sulfamoylbenzyl)-7- methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-2-yl)acetamide 85 4-((2-(azetidin-3-yl)-7-methoxy-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)-2-fluorobenzenesulfonamide 86 2-fluoro-4-((7-methoxy-2-(1- (methylsulfonyl)azetidin-3-yl)-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 87 6-((7-methoxy-4-methyl-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)methyl)pyridine-3- sulfonamide 88 2-fluoro-4-((7-methoxy-4-methyl-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl) benzenesulfonamide 89 6-((7-methoxy-2,4-dimethyl-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)pyridine-3-sulfonamide 90 2,5-difluoro-4-((7-methoxy-2,4-dimethyl- 1H-imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 91a 2-((7-methoxy-2,4-dimethyl-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)pyrimidine-5-sulfonamide 91b 2-((6-chloro-7-methoxy-2,4-dimethyl-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)pyrimidine-5-sulfonamide 92 4-((2-((dimethylamino)methyl)-7-methoxy- 4-methyl-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)methyl)-2,5- difluorobenzenesulfonamide 93 2,5-difluoro-4-((7-methoxy-2-(2- methoxyethyl)-4-methyl-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 94 2,5-difluoro-4-((2-(hydroxymethyl)-7- methoxy-4-methyl-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 95 2,3-difluoro-4-((7-methoxy-2-oxo-2,3- dihydro-1H-imidazo[4,5-c][1,8]naphthyridin- 1-yl)methyl)benzenesulfonamide 96 5-((7-methoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)pyridine-2-sulfonamide 97 3-((7-methoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)cyclobutyl sulfamate 98 2-fluoro-4-((7-methoxy-2-oxo-2,3-dihydro- 1H-imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 99 6-((7-methoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)pyridine-3-sulfonamide 100 2,6-difluoro-4-((7-methoxy-2-oxo-2,3- dihydro-1H-imidazo[4,5-c][1,8]naphthyridin- 1-yl)methyl)benzenesulfonamide 101 (R)-4-(1-(7-methoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)ethyl)benzenesulfonamide 102 3-fluoro-4-((7-methoxy-2-oxo-2,3-dihydro- 1H-imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl) benzenesulfonamide 103 3,5-difluoro-4-((7-methoxy-2-oxo-2,3- dihydro-1H-imidazo[4,5-c][1,8]naphthyridin- 1-yl)methyl)benzenesulfonamide 104 sodium acetyl((3,5-difluoro-4-((7-methoxy- 2-oxo-2,3-dihydro-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)phenyl)sulfonyl)amide 105 sodium ((3,5-difluoro-4-((7-methoxy-2-oxo- 2,3-dihydro-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)phenyl)sulfonyl)(propionyl)amide 106 sodium butyryl((3,5-difluoro-4-((7-methoxy- 2-oxo-2,3-dihydro-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)phenyl)sulfonyl)amide 107 3,5-difluoro-4-((7-methoxy-2-oxo-2,3- dihydro-1H-imidazo[4,5-c][1,8]naphthyridin- 1-yl)methyl)-N-methylbenzenesulfonamide 108 3,5-difluoro-4-((7-methoxy-2-oxo-2,3- dihydro-1H-imidazo[4,5-c][1,8]naphthyridin- 1-yl)methyl)benzoic acid 109 3,5-difluoro-4-((7-methoxy-2-oxo-2,3- dihydro-1H-imidazo[4,5-c][1,8]naphthyridin- 1-yl)methyl)benzamide 110 3,5-difluoro-N-hydroxy-4-((7-methoxy-2- oxo-2,3-dihydro-1H-imidazo[4,5- c][1,8]naphthyridin-1-yl)methyl)benzamide 111 (3,5-difluoro-4-((7-methoxy-2-oxo-2,3- dihydro-1H-imidazo[4,5-c][1,8]naphthyridin- 1-yl)methyl)phenyl)boronic acid 112 2,3,5-trifluoro-4-((7-methoxy-2-oxo-2,3- dihydro-1H-imidazo[4,5-c][1,8]naphthyridin- 1-yl)methyl)benzenesulfonamide 113 3,5-difluoro-4-((7-methoxy-4-methyl-2-oxo- 2,3-dihydro-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 114 3,5-difluoro-4-((7-methoxy-3-methyl-2-oxo- 2,3-dihydro-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 115 3,5-difluoro-4-((3-(2-hydroxyethyl)-7- methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 116 4-((7-methoxy-1H-pyrazolo[4,3- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 117 4-((7-methoxy-1H-pyrrolo[3,2- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 118 2-fluoro-4-((7-methoxy-1H-pyrazolo[4,3- c]cinnolin-1-yl)methyl)benzenesulfonamide 119 6-((7-methoxy-1H-[1,2,3]triazolo[4,5- c][1,8]naphthyridin-1-yl)methyl)pyridine-3- sulfonamide 120 2-fluoro-4-((7-methoxy-1H- [1,2,3]triazolo[4,5-c][1,8]naphthyridin-1- yl)methyl) benzenesulfonamide 121 (2-fluoro-4-((7-methoxy-2-oxo-2,3-dihydro- 1H-imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)phenyl)phosphonic acid 122a 2-fluoro-4-((7-methoxy-1H-pyrazolo[4,3- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 122b 2-fluoro-4-((7-methoxy-2H-pyrazolo[4,3- c][1,8]naphthyridin-2- yl)methyl)benzenesulfonamide 123 3-fluoro-4-((7-methoxy-2-oxo-2,3-dihydro- 1H-imidazo[4,5-c]cinnolin-1- yl)methyl)benzenesulfonamide 124 (3,5-difluoro-4-((7-methoxy-2-oxo-2,3- dihydro-1H-imidazo[4,5-c][1,8]naphthyridin- 1-yl)methyl)phenyl)phosphonic acid 125 (2,5-difluoro-4-((7-methoxy-2-methyl-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)phenyl)phosphonic acid 126 (6-((7-methoxy-2,4-dimethyl-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)pyridin-3-yl)phosphonic acid 127 methyl hydrogen(2-fluoro-4-((7-methoxy-2- oxo-2,3-dihydro-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)phenyl)phosphonate 128 (4-((7-Methoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)phenyl)-methanesulfonamide 129 3,5-difluoro-4-((7-methoxy-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 130 3,5-difluoro-4-((7-methoxy-2-methyl-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 131 3,5-difluoro-4-((7-methoxy-2-oxo-3-(2,2,2- trifluoroethyl)-2,3-dihydro-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 132 3,5-difluoro-4-((7-methoxy-3-(2- methoxyethyl)-2-oxo-2,3-dihydro-1H- imidazo[4,5-c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 133 3,5-difluoro-4-((3-(3-hydroxypropyl)-7- methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide 134 3-chloro-5-fluoro-4-((7-methoxy-2-oxo-2,3- dihydro-1H-imidazo[4,5-c][1,8]naphthyridin- 1-yl)methyl)benzenesulfonamide 135a 6-((7-methoxy-1H-pyrazolo[4,3- c][1,8]naphthyridin-1-yl)methyl)pyridine-3- sulfonamide 135b 6-((7-methoxy-2H-pyrazolo[4,3- c][1,8]naphthyridin-2-yl)methyl)pyridine-3- sulfonamide 136 6-((7-methoxy-4-methyl-1H- [1,2,3]triazolo[4,5-c][1,8]naphthyridin-1- yl)methyl)pyridine-3-sulfonamide 137 4-((7-methoxy-2-oxo-2,3-dihydro-1H- imidazo[4,5-c]cinnolin-1- yl)methyl)benzenesulfonamide 138 3,5-difluoro-4-(7-methoxy-2-oxo-2,3- dihydro-1H-imidazo[4,5-c][1,8]naphthyridin- 1-yl)methyl)benzenesulfamide 139 3,5-difluoro-4-((7-methoxy-3-(oxetan-3-yl)- 2-oxo-2,3-dihydro-1H-imidazo[4,5- c][1,8]naphthyridin-1- yl)methyl)benzenesulfonamide - In some embodiments, compounds of formula (A), or compounds of formula (I)-(VI) are not the following analogs:
- or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof.
- In some embodiments, compounds of formula (A), or compounds of formula (I)-(VI) are not the following analogs:
- or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof.
- In some embodiments, provided herein is a compound described in Table 1 or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof.
- In some embodiments, the compounds described herein exist as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
- In some embodiments, the compounds described herein possess acidic or basic groups and therefor react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
- Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds described herein with a mineral, organic acid, or inorganic base, such salts including acetate, acrylate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, bisulfite, bromide, butyrate, butyn-1,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, fiimarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-1,6-dioate, hydroxybenzoate, g-hydroxybutyrate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogenphosphate, 1-napthalene sulfonate, 2-napthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, tosylateundeconate, and xylenesulfonate.
- Further, the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methane sulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethane sulfonic acid, benzene sulfonic acid, 2-naphthalene sulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4′-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid.
- In some embodiments, those compounds described herein which comprise a free acid group react with a suitable base, such as the hydroxide, carbonate, bicarbonate, sulfate, of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine. Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N+(C1-4 alkyl)4, and the like.
- Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. It should be understood that the compounds described herein also include the quatemization of any basic nitrogen-containing groups they contain. In some embodiments, water or oil-soluble or dispersible products are obtained by such quatemization.
- In some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the corresponding mixtures thereof. In some situations, the compounds described herein possess one or more chiral centers and each center exists in the R configuration, or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof. In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. In some embodiments, dissociable complexes are preferred. In some embodiments, the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In some embodiments, the diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in solubility. In some embodiments, the optically pure enantiomer is then recovered, along with the resolving agent.
- In some embodiments, the compounds described herein exist as solvates. The invention provides for methods of treating diseases by administering such solvates. The invention further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions.
- Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and, in some embodiments, are formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein can be conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents including, but not limited to, dioxane, tetrahydrofuran, or methanol. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
- Also provided are prodrugs of the compounds described herein. In some embodiments, the prodrug can be converted to a compound of formula (A), or formulae (I)-(VI), when administered to a subject, e.g., upon metabolic processing of the prodrug.
- The following prodrugs are examples using compound 40 for illustration purposes. In some embodiments, similar analogs can be made using sulfonamide as a handle.
- Pharmaceutical compositions of any of the compounds detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, are embraced by this disclosure. Thus, the present disclosure includes pharmaceutical compositions comprising a compound as detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier or excipient. In one aspect, the pharmaceutically acceptable salt is an acid addition salt, such as a salt formed with an inorganic or organic acid. Pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and topical administration, etc. In some embodiments, pharmaceutical compositions may take a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration or a form suitable for administration by inhalation.
- A compound as detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, may in one aspect be in a purified form and compositions comprising a compound in purified forms are detailed herein. Compositions comprising a compound as detailed herein or a salt thereof are provided, such as compositions of substantially pure compounds. In some embodiments, a composition containing a compound as detailed herein or a salt thereof is in substantially pure form.
- In one variation, the compounds herein are synthetic compounds prepared for administration to an individual. In another variation, compositions are provided containing a compound in substantially pure form. In another variation, the present disclosure embraces pharmaceutical compositions comprising a compound detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier. In another variation, methods of administering a compound are provided. The purified forms, pharmaceutical compositions and methods of administering the compounds are suitable for any compound or form thereof detailed herein.
- A compound detailed herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, may be formulated for any available delivery route, including an oral, mucosal (e.g., nasal, sublingual, vaginal, buccal or rectal), parenteral (e.g., intramuscular, subcutaneous or intravenous), topical or transdermal delivery form. A compound or salt thereof may be formulated with suitable carriers to provide delivery forms that include, but are not limited to, tablets, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), cachets, troches, lozenges, gums, dispersions, suppositories, ointments, cataplasms (poultices), pastes, powders, dressings, creams, solutions, patches, aerosols (e.g., nasal spray or inhalers), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions or water-in-oil liquid emulsions), solutions and elixirs.
- One or several compounds described herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, can be used in the preparation of a formulation, such as a pharmaceutical formulation, by combining the compound or compounds, or a salt thereof, as an active ingredient with a pharmaceutically acceptable carrier, such as those mentioned above. Depending on the therapeutic form of the system (e.g., transdermal patch vs. oral tablet), the carrier may be in various forms. In addition, pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, re-wetting agents, emulgators, sweeteners, dyes, adjusters, and salts for the adjustment of osmotic pressure, buffers, coating agents or antioxidants. Formulations comprising the compound may also contain other substances which have valuable therapeutic properties. Pharmaceutical formulations may be prepared by known pharmaceutical methods. Suitable formulations can be found, e.g., in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 20th ed. (2000), which is incorporated herein by reference.
- Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and can be prepared in the form of tablets, pills, powders, suspensions, emulsions, solutions, syrups, and capsules. Oral composition may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. The tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
- Certain injectable compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.
- Suitable compositions for transdermal application include an effective amount of a compound of the invention with a suitable carrier. Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
- Suitable compositions for topical application, e.g., to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or spray formulations, e. g., for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like.
- As used herein a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurized container, pump, spray, atomizer or nebulizer, with or without the use of a suitable propellant.
- The invention further provides pharmaceutical compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will decompose. Such agents, which are referred to herein as “stabilizers,” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
- In addition to the compounds as disclosed herein, their pharmaceutically acceptable salts, stereoisomers, solvates, and compositions and combinations comprising these compounds, the invention includes methods of using the same as further described herein.
- The compounds of formula (A), or formulae (I)-(VI), or pharmaceutically acceptable salt, prodrug, or solvate thereof may be used for treating STING pathway mediated diseases or disorders. Provided herein, in some embodiments, are methods for inhibiting ENPP1 activity using a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof. In some embodiments, a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, have desired physicochemical properties, for example, solubility in water.
- The Ectonucleotide Pyrophophatase/Phosphodiesterase (ENPP) family consists of seven members, ENNP1-7, which are membrane-bound glycoproteins or ectoenzymes with an active site or as soluble proteins in body fluids. ENPP1 has been involved in many different biological processes. In animal model, it was reported that overexpressed ENPP1 inhibits insulin receptor tyrosine kinase activity in peripheral tissues, which are major targets of insulin action. (Abate, N. et, al. Nature Clin. Pract. Endocrinol. Metab. 2006, 2, 694-701). ENPP1 is also expressed on the extracellular membrane of osteoblasts and chondrocytes, and it has a great effect on bone mineralization. (Terkeltaub, R et, al. Purinergic Signalling 2006, 2, 371-377; Vaingankar, S. M et, al. Cell Physiol. 2004, 286, C1177-C1187).
- Recently, ENPP1 was shown to play an important role in cancer immunotherapy and autoimmune diseases. ENPP1 hydrolyzes 2′3′-cyclic guanosine monophosphate-adenosine monophosphate (2′3′-cGAMP), breaking it down into 5′-AMP and 5′-GMP. cGAMP activates the Stimulator of Interferon Genes (STING) pathway, leading to production of type I interferon (IFN) and other cytokines that trigger the immune response. (Manas Sharma, et, al. Int J cell Sci & Mol Biol., 2018, 5, 555655). Therefore, ENPP1 inhibitors which block the hydrolysis of cGAMP and induce sting activity can be potentially utilized to increase immune response. Similar to checkpoint inhibitors such as anti PD-1 or PD-L1 which are promising immune-therapeutics for various cancers, activation of STING pathway by these inhibitors become more critical for tumor control in cancer immunotherapies.
- Additionally, Lau W M and Kominsky S L [2013, PLoS ONE 8(7)] found that expression of “Enpp1 was elevated in human breast cancer cell lines known to produce bone metastasis in animal models compared to non-metastatic and normal mammary epithelial cell lines.” They further demonstrated that levels of ENPP1 were significantly elevated in human primary breast tumors relative to normal mammary epithelium, in clinical specimens, with highest levels observed in breast-bone metastasis.
- In one aspect, the invention provides a method of treating a disorder mediated by inappropriate ENPP1 activity comprising administering a safe and effective dose of a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof.
- In some embodiments, ENPP1 mediated diseases or disorders are selected from the group consisting of diseases related to skeletal and soft tissue mineralization, T2D, cardiovascular diseases, cancers, autoimmune diseases and osteoarthritis.
- In some embodiments, ENPP1 mediated diseases or disorders are autoimmune diseases such as asthma, type I diabetes, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease (COPD), and lupus.
- In some embodiments, the compounds described herein may be used to treat cancers that are mediated by inappropriate ENPP1 activity. In certain embodiments, the disease is a hematologic malignancy. In some embodiments, the disease is a solid tumor. In some embodiments, the indication is to treat solid tumor with abnormal ENPP1 expression, such as astrocytic brain tumors, and glioblastoma stem-like cells and metastasis of breast cancer.
- The potencies of compounds as inhibitors of an enzyme activity (or other biological activity) can be established by determining the concentrations at which each compound inhibits the activity to a predefined extent and then comparing the results. “IC50” or “IC90” of an inhibitor can be determined by the concentration that inhibits 50% or 90% of the activity in a biochemical assay, which can be accomplished using conventional techniques known in the art, including the techniques describes in the Examples below. As used herein, “inhibition of ENPP1 activity” or variants refer to a decrease in ENPP1 activity as a direct or indirect response to the presence of a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, relative to the activity of ENPP1 in the absence of the compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof.
- In some embodiments, a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof may be used in combination with one or more additional therapeutic agents to treat cancers or inflammatory disorders. The one or more additional therapeutic agents may be a chemotherapeutic agent, a radiotherapy, a targeted therapy, an immunotherapeutic agent or any current best of care treatment, either as a small molecule or a biologic nature.
- Chemotherapeutic agents may be categorized by their mechanism of action into: alkylating agents, antimetabolites, anti-microtubule agents, topoisomerase inhibitors and cytotoxic agents. A compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof may be used in combination with chemotherapeutics to sensitize and improve the efficacy of certain chemotherapeutic agents to treat blood or solid tumors.
- Immunotherapeutic agents that may be suitable to be used in combination with a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof include but are not limited to therapeutic antibodies, small molecules and vaccines suitable for treating patients; such as IDOL and TDO2 inhibitors, A2A receptor inhibitors, arginase inhibitors, toll-like receptor agonists, chemokine regulators (including CCR and CXCR families), STING agonists, check point blockage antibodies such as antibodies that regulate PD-1, PD-L1, CTLA-4, OX40-OX40 ligand, LAGS, TIM3, or any combination thereof.
- Radiotherapy is part of cancer treatment to control or kill malignant cells and commonly applied to the cancerous tumor because of its ability to control cell growth. A compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof may be used in combination with radiotherapy, to improve the efficacy of radiotherapy to treat blood or solid tumors, or with surgery, chemotherapy, immunotherapy and combination of the four.
- Targeted therapies that may be suitable to be used in combination therapies include but are not limit to an inhibitor to PI3Ks, cyclin-dependent kinase (CDK) such as CDK1, CDK2, CDK4/6, CDK7, and CDK9, Janus kinase (JAK) such as JAK1, JAK2 and/or JAK3, spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), mitogen-activated protein kinase (MEK) such as
MEK 1 and MEK2, bromodomain containing protein inhibitors (BRD) such as BRD4, isocitrate dehydrogenase (IDH) such as IDH1, histone deacetylase (HDAC), or any combination thereof. - In some embodiments, a compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof may be used in combination with one or more additional therapeutic agents to treat patients who are substantially refractory to at least one chemotherapy treatment, or in relapse after treatment with chemotherapy.
- A dose of a pharmaceutical composition or combination is dependent on the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. The effective dose is determined by a physician or clinician to prevent, treat or inhibit the progress of the disorder or disease. In some embodiments, a safe and effective dose is an amount sufficient to treat the patient's condition but low enough to avoid serious side effects. A safe and effective dose may vary with the particular compound chosen (e.g. consider the potency, efficacy, and half-life of the compound); the route of administration chosen; the disorder being treated; the severity of the disorder being treated; the age, size, weight, and physical condition of the patient being treated; the medical history of the patient to be treated; the duration of the treatment; the nature of concurrent therapy; the desired therapeutic effect; and like factors.
- In the practice of the method of the present invention, a therapeutically effective amount of any one of the compounds of this invention or a combination of any of the compounds of this invention or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, is administered via any of the usual and acceptable methods known in the art, either singly or in combination. The compounds or compositions can thus be administered orally (e.g., buccal cavity), sublingually, parenterally (e.g., intramuscularly, intravenously, or subcutaneously), rectally (e.g., by suppositories or washings), transdermally (e.g., skin electroporation) or by inhalation (e.g., by aerosol), and in the form of solid, liquid or gaseous dosages, including tablets and suspensions. The administration can be conducted in a single unit dosage form with continuous therapy or in a single dose therapy ad libitum. The therapeutic composition can also be in the form of an oil emulsion or dispersion in conjunction with a lipophilic salt such as pamoic acid, or in the form of a biodegradable sustained-release composition for subcutaneous or intramuscular administration.
- The pharmaceutical compositions may be administered in either single or multiple doses. A compound of formula (A), or formulae (I)-(VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof can be formulated so as to provide the desired release schedule of the active ingredient based on the therapeutic treatment purpose.
- The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient in the form of tablets, pills, powders, suspensions, emulsions, solutions, syrups, and capsules. For example, these may contain an amount of active ingredient from about 0.1 to 1000 mg, preferably from about 0.1 to 500 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods. The daily dose can be administered in one to four doses per day. For therapeutic purposes, the active compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration drops suitable for administration to the eye, ear, or nose. A suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg administered one to four, preferably one or two times daily. For topical administration, the active ingredient may comprise from 0.001% to 10% w/w, e.g. from 1% to 2% by weight of the formulation, preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation.
- A compound or composition of the invention may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer, which in some variations may be for the duration of the individual's life. In one variation, the compound is administered on a daily or intermittent schedule. The compound can be administered to an individual continuously (for example, at least once daily) over a period of time. The dosing frequency can also be less than once daily, e.g., about a once weekly dosing. The dosing frequency can be more than once daily, e.g., twice or three times daily. The dosing frequency can also be intermittent, including a ‘drug holiday’ (e.g., once daily dosing for 7 days followed by no doses for 7 days, repeated for any 14 day time period, such as about 2 months, about 4 months, about 6 months or more). Any of the dosing frequencies can employ any of the compounds described herein together with any of the dosages described herein.
- In certain embodiment, the method comprises administering to the subject an initial daily dose of about 0.1 to 500 mg of a compound of formula (A), or formulae (I)-(VI) and increasing the dose by increments until clinical efficacy is achieved. Increments of about 5, 10, 25, 50, or 100 mg can be used to increase the dose. The dosage can be increased daily, every other day, twice per week, or once per week.
- The present disclosure further provides articles of manufacture comprising a compound of the disclosure or a salt thereof, composition, and unit dosages described herein in suitable packaging. In certain embodiments, the article of manufacture is for use in any of the methods described herein. Suitable packaging is known in the art and includes, for example, vials, vessels, ampules, bottles, jars, flexible packaging and the like. An article of manufacture may further be sterilized and/or sealed.
- The present disclosure further provides kits for carrying out the methods of the disclosure, which comprises one or more compounds described herein or a composition comprising a compound described herein. The kits may employ any of the compounds disclosed herein. In one variation, the kit employs a compound described herein or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof. The kits may be used for any one or more of the uses described herein, and, accordingly, may contain instructions for the treatment of disease described herein.
- Kits generally comprise suitable packaging. The kits may comprise one or more containers comprising any compound described herein. Each component (if there is more than one component) can be packaged in separate containers or some components can be combined in one container where cross-reactivity and shelf life permit.
- The kits may be in unit dosage forms, bulk packages (e.g., multi-dose packages) or sub-unit doses. For example, kits may be provided that contain sufficient dosages of a compound as disclosed herein and/or a second pharmaceutically active compound useful for a disease detailed herein (e.g., hypertension) to provide effective treatment of an individual for an extended period, such as any of a week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months, or more. Kits may also include multiple unit doses of the compounds and instructions for use and be packaged in quantities sufficient for storage and use in pharmacies (e.g., hospital pharmacies and compounding pharmacies).
- The kits may optionally include a set of instructions, generally written instructions, although electronic storage media (e.g., magnetic diskette or optical disk) containing instructions are also acceptable, relating to the use of component(s) of the methods of the present invention. The instructions included with the kit generally include information as to the components and their administration to an individual.
- The invention can be further understood by reference to the following examples, which are provided by way of illustration and are not meant to be limiting.
- Reagents and solvents used below can be obtained from commercial sources. 1H-NMR spectra were recorded on a Bruker 400 and 600 MHz NMR spectrometer. Significant peaks are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet), coupling constant(s) in Hertz (Hz) and number of protons. Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion (in parentheses). Electrospray ionization (ESI) mass spectrometry analysis was conducted on an Agilent 1100 LC/MSD electrospray mass spectrometer.
- The terms “solvent”, “inert organic solvent”, or “inert solvent” refer to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), ethyl acetate (EA or EtOAc), dichloromethane (DCM), diethyl ether, methanol, pyridine and the like. Unless specified to the contrary, the solvents used in the reactions of the present invention are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen and argon.
- The compounds of formula (I)-(VI) may be prepared using the methods disclosed herein and routine modifications thereof, which will be apparent given the disclosure herein and methods are well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein. The synthesis of representative compounds described herein may be accomplished as described in the following examples. If available, reagents may be purchased commercially, e.g., from Sigma Aldrich or other chemical suppliers.
-
- A stirred mixture of 4-hydroxy-6,7-dimethoxyquinoline-3-carbonitrile (550 mg, 2.39 mmol) and 10 mL of POCl3 was heated at reflux for 3 h. Volatile materials were removed under vacuum at about 70° C. The residue was stirred at 0° C. with methylene chloride and H2O, solid K2CO3 was carefully added until the pH was 8-9. After stirring for 30 min at 25° C. the organic layer was separated, washed with H2O, dried, filtered through Celite, and concentrated to give crude product. The residue was purified by flash column chromatography (0˜30% EA in PE) to give the product of 4-chloro-6,7-dimethoxyquinoline-3-carbonitrile 2 as a light yellow solid (600 mg, 95% yield). LCMS(ESI) [M+H]+=249.
- To a solution of 4-chloro-6,7-dimethoxyquinoline-3-carbonitrile (550 mg, 2.21 mmol), 4-(Aminomethyl)benzenesulfonamide hydrochloride (591 mg, 2.65 mmol) and potassium carbonate (1.528 g, 11.06 mmol) in DMF (15 ml). The reaction mixture was stirred at 70° C. for 16 h, monitored by LCMS. After filtrated, the organic layer was concentrated in vacuum, the residue was purified by recrystallization from DCM/MeOH (10:1) to give the product of 4-(((3-cyano-6,7-dimethoxyquinolin-4-yl)amino)methyl)benzenesulfonamide as a yellow solid (800 mg, 72.6% yield). LCMS(ESI) [M+H]+=399.
- To a solution of 4-(((3-cyano-6,7-dimethoxyquinolin-4-yl)amino)methyl)benzenesulfonamide (500 mg, 1.255 mmol) in EtOH (5 ml) was added KOH (1734 mg, 12.55 mmol, dissolved in 5 ml water). The reaction mixture was heated to reflux for 16 h. The solution was concentrated in vacuum, the crude product was purified by prep-HPLC to give the product of 6,7-dimethoxy-4-(((4-sulfamoylphenyl)methyl)amino)quinoline-3-carboxylic acid as a white solid (90 mg, 16% yield). LCMS (ESI) [M+H]+=418.
- To a solution of 6,7-dimethoxy-4-(((4-sulfamoylphenyl)methyl)amino)quinoline-3-carboxylic acid (20 mg, 0.048 mmol) in t-BuOH (2 ml) was added triethylamine (5.8 mg, 0.057 mmol) and DPPA (15.8 mg, 0.057 mmol). The reaction mixture was stirred at 100° C. for 16 h under nitrogen. The solution was concentrated to dryness, purified by prep-HPLC to give the product of 4-((7,8-dimethoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzene-sulfonamide (1) as a white solid (5 mg, 21% yield). LCMS(ESI) [M+H]+=415; 1H NMR (400 MHz, DMSO) δ 11.58 (br, 1H), 8.51 (s, 1H), 8.17 (s, 1H), 7.79 (d, J=8.3 Hz, 2H), 7.45 (d, J=8.3 Hz, 2H), 7.31 (s, 2H), 6.95 (s, 1H), 5.63 (s, 2H), 3.84 (s, 3H), 3.59 (s, 3H).
-
- A similar synthetic method (W, Huang et el, Eur. J. Org. Chem. 2018, 1572-1580) was adapted to provide the titled analogs from a known starting material (4-chloro-6,7-dimethoxyquinolin-3-amine, made according to a literature procedure, Fuchss, Thomas et al, PCT Int. Appl., 2012028233).
-
-
-
- Similar synthetic methods (A. Boullilot, WO 2011/054846 A1) were adapted to provide the titled analogs (General procedures 2, 3, and 4) from a known starting material (4-chloro-3-nitro-6,7-dimethoxyquinoline, made according to a literature procedure, Fuchss, Thomas et al, PCT Int. Appl., 2012028233).
-
- A similar synthetic method (A Gopalsamy et al, Journal of Medicinal Chemistry 2007, 50, 5547-5549) was adapted to provide the titled analogs from 4-chloro-6,7-dimethoxyquinoline-3-carbaldehyde.
-
- A similar synthetic method (By A. Jeffrey S. et al, PCT Int. Appl., 2014152029) was adapted to provide the titled analogs from 3,4-dimethoxyaniline.
-
- A similar synthetic method (W, Huang et el, Eur. J. Org. Chem. 2018, 1572-1580) was adapted to provide the titled analogs 2 from a known starting material (4-chloro-6,7-dimethoxyquinolin-3-amine, made according to a literature procedure, Fuchss, Thomas et al, PCT Int. Appl., 2012028233). LCMS (ESI) [M+H]+=428; 1H NMR (400 MHz, DMSO) δ LCMS [M+H]+=429; 1H NMR (600 MHz, DMSO-d6) δ ppm 3.62 (d, J=4.03 Hz, 6H) 3.86-3.93 (m, 3H) 5.76 (s, 2H) 7.04 (s, 1H) 7.33 (s, 2H) 7.41 (s, 1H) 7.50 (d, J=8.44 Hz, 2H) 7.78-7.81 (m, 2H) 8.95 (br s, 1H).
- (R)-4-(1-(7,8-dimethoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)ethyl)benzenesulfonamide (3a) and (S)-4-(1-(7,8-dimethoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)ethyl)benzenesulfonamide (3b) are prepared according to General procedure 2 from known compound (R)-4-(1-aminoethyl)benzenesulfonamide and (S)-4-(1-aminoethyl)benzenesulfonamide (Canales et al, PCT Int. Appl., 2010002998).
- 4-((7,8-dimethoxy-2-oxooxazolo[5,4-c]quinolin-1(2H)-yl)methyl)benzenesulfonamide is prepared according to General procedure 6.
- 6-((7,8-dimethoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)methyl)pyridine-3-sulfonamide is prepared according to General procedure 2 from a known compound 6-(aminomethyl)pyridine-3-sulfonamide (J. Bakonyi, et al, U.S. Pat. Appl. Publ., 20150291607).
- 5-((7,8-dimethoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)methyl)pyridine-2-sulfonamide is prepared according to General procedure 2 from a known compound 5-(aminomethyl)pyridine-2-sulfonamide (A. Macleod, et al, PCT Int. Appl., 2009024585).
- 3-((7,8-dimethoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1 yl)methyl)-benzenesulfonamide is prepared according to General procedure 2 from 3-(aminomethyl)benzenesulfonamide.
- (R)-4-(1-(7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)ethyl)benzene-sulfonamide is prepared in a similar manner as
compound 1. LCMS (ESI) [M+H]+=399; 1H NMR (600 MHz, DMSO-d6) δ ppm 1.98 (br d, J=6.97 Hz, 4H) 3.85 (s, 3H) 6.28 (q, J=7.21 Hz, 1H) 7.01 (br s, 1H) 7.33-7.39 (m, 3H) 7.54 (d, J=8.07 Hz, 2H) 7.78-7.83 (m, 2H) 8.66 (s, 1H) 11.62 (br s, 1H). - 4-((7,8-dimethoxy-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzenesulfonamide is prepared according to General procedure 3 using triethyl orthoacetate.
- 5-((7,8-dimethoxy-1H-imidazo[4,5-c]quinolin-1-yl)methyl)pyridine-2-sulfonamide was prepared according to General procedure 3. LCMS (ESI) [M+H]+=400; 1H NMR (600 MHz, DMSO-d6) δ ppm 3.70-3.76 (m, 4H) 3.94 (s, 3H) 6.31 (s, 2H) 7.25 (s, 1H) 7.47 (s, 2H) 7.61 (s, 1H) 7.72 (dd, J=8.44, 2.20 Hz, 1H) 7.87 (d, J=8.07 Hz, 1H) 8.71 (d, J=1.83 Hz, 1H) 8.84 (s, 1H) 9.53 (br s, 1H).
- (R)-4-(1-(7,8-dimethoxy-1H-imidazo[4,5-c]quinolin-1-yl)ethyl)benzenesulfonamide (11a) and (S)-4-(1-(7,8-dimethoxy-1H-imidazo[4,5-c]quinolin-1-yl)ethyl)benzenesulfonamide (11b) were prepared according to General procedure 3. 11a: LCMS (ESI) [M+H]+=413; 1H NMR (600 MHz, DMSO-d6) δ ppm 2.15 (d, J=6.60 Hz, 3H) 3.77-3.84 (m, 4H) 3.90-3.97 (m, 4H) 6.73-6.81 (m, 1H) 7.34 (s, 2H) 7.40 (br d, J=8.44 Hz, 3H) 7.64 (br s, 1H) 7.79 (d, J=8.80 Hz, 2H) 9.16 (br s, 1H) 9.67 (br s, 1H). 11b: LCMS (ESI) [M+H]+=413.
- 6-((7,8-dimethoxy-1H-imidazo[4,5-c]quinolin-1-yl)methyl)pyridine-3-sulfonamide (12) was prepared according to General procedure 3. LCMS [M+H]+=400; 1H NMR (600 MHz, DMSO-d6) δ ppm 1.16 (s, 1H) 2.09 (s, 1H) 3.77 (s, 3H) 3.94 (s, 3H) 6.33 (s, 2H) 7.39 (s, 1H) 7.58 (s, 3H) 8.21 (dd, J=8.44, 2.20 Hz, 1H) 8.80 (br s, 1H) 8.84 (d, J=1.83 Hz, 1H).
- Compound 13 was prepared according to General procedure 4. LCMS [M+H]+=400; 1H NMR (600 MHz, DMSO-d6) δ ppm 3.78 (s, 3H) 3.93 (s, 3H) 6.56 (s, 2H) 7.33 (d, J=12.10 Hz, 3H) 7.37 (d, J=8.80 Hz, 2H) 7.64 (s, 1H) 7.80 (d, J=8.44 Hz, 2H) 9.43 (s, 1H) 11.69 (s, 1H).
- Compounds 14a, 14b, 15 and 16 are prepared according to General procedure 4.
-
Compound 17, 18, 19a, 19b, 20 and 21 are prepared according to General procedure 5. - 4-((7,8-dimethoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)methyl)-2-fluorobenzenesulfonamide (22) is prepared according to General procedure 2 from 4-(aminomethyl)-2-fluorobenzenesulfonamide (prepared according to S. Yamamoto et al, PCT Int. Appl., 2018030550).
-
-
Step 1. Boc diamines (0.8 mmol, 1 eq) were dissolved in DCM (4.4 mL, 0.2 M) followed by the addition of (tert-butoxycarbonyl)((4-(dimethyliminio)pyridin-1(4H)-yl)sulfonyl)amide (262 mg, 1 eq). The mixture was stirred at room temperature for 18 hrs. Upon completion, the mixture was concentrated in vacuo. The crude was purified through FCC using Hex/THF (100%/0% to 60%/40%) yielding the product. - Step 2. The above product (1 eq) was dissolved in DCM (5 mL, 0.1 M) then cooled to 0° C. TFA (5 mL, 0.1 M) was added to the mixture then the cooling bath was removed. The mixture was stirred at room temperature for 2 hrs. Upon completion, the mixture was concentrated in vacuo and neutralized by NaHCO3 and extracted with DCM. The crude was used in the next step without further purification.
- 4-((7,8-dimethoxy-1H-imidazo[4,5-c]quinolin-1-yl)methyl)piperidine-1-sulfonamide was prepared according to general procedure 3 from intermediate 4-(aminomethyl)piperidine-1-sulfonamide. LCMS (ESI) [M+H]+=406; 1H NMR (600 MHz, DMSO-d6) δ ppm 1.22-1.28 (m, 2H) 1.41-1.50 (m, 2H) 1.65 (br d, J=11.37 Hz, 2H) 2.01-2.10 (m, 1H) 2.41-2.48 (m, 2H) 3.40-3.52 (m, 6H) 3.99 (s, 3H) 4.01-4.07 (m, 3H) 4.72 (br d, J=6.97 Hz, 2H) 6.63-6.69 (m, 2H) 7.60 (s, 1H) 7.66 (s, 1H) 8.53 (br s, 1H).
- Compounds 23-31 are prepared from the above intermediates according to General procedure 2-6.
-
- 4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,6]naphthyridin-1-yl)methyl)benzenesulfonamide is prepared in a similar manner as the preparation of
compound 1 from ethyl 4-chloro-7-methoxy-1,6-naphthyridine-3-carboxylate. - 4-((8-cyano-7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzenesulfonamide is prepared in a similar manner as the preparation of
compound 1 from ethyl 4-chloro-6-cyano-7-methoxyquinoline-3-carboxylate. - 4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)methyl)-benzenesulfonamide was prepared according to General procedure 2. LCMS (ESI) [M+H]+=385; 1H NMR (600 MHz, DMSO-d6) δ ppm 3.85 (s, 3H) 5.59 (s, 2H) 7.10 (dd, J=9.35, 2.75 Hz, 1H) 7.31 (s, 2H) 7.37 (d, J=2.57 Hz, 1H) 7.42 (d, J=8.80 Hz, 2H) 7.77 (d, J=7.91 Hz, 2H) 7.82 (d, J=9.54 Hz, 1H) 8.66 (s, 1H) 11.63 (s, 1H).
- 4-((8-methoxy-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzenesulfonamide was prepared according to General procedure 3. LCMS (ESI) [M+H]+=369; 1H NMR (600 MHz, DMSO-d6) δ ppm 3.71 (s, 4H) 6.20 (s, 2H) 7.28 (d, J=2.57 Hz, 1H) 7.32-7.38 (m, 5H) 7.79 (d, J=7.76 Hz, 2H) 8.08 (d, J=9.17 Hz, 1H) 8.75 (s, 1H) 9.33 (br s, 1H).
- 3-((7,8-dimethoxy-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzenesulfonamide was prepared according to General procedure 3. LCMS (ESI) [M+H]+=399; 1H NMR (600 MHz, DMSO-d6) δ ppm 0.83-0.90 (m, 3H) 0.99-1.09 (m, 2H) 1.15 (d, J=5.87 Hz, 3H) 1.18-1.23 (m, 5H) 1.23-1.36 (m, 4H) 1.39-1.50 (m, 2H) 1.79 (dd, J=13.94, 2.93 Hz, 1H) 3.38-3.44 (m, 19H) 3.44-3.56 (m, 7H) 3.69-3.74 (m, 3H) 3.89-3.94 (m, 3H) 6.20 (s, 2H) 7.28 (s, 1H) 7.35 (d, J=8.07 Hz, 1H) 7.38 (s, 2H) 7.54-7.59 (m, 2H) 7.74 (s, 1H) 7.77 (d, J=7.70 Hz, 1H).
-
-
Step 1. 6-Methoxypyridin-2-amine (9.8 g, 78.9 mmol, 1.1 eq) was dissolved in ethyoxymethylene diethylmalonate (15.5 g, 71.8 mmol, 1 eq). The mixture was heated to 95° C. for 1 hr under vacuum. After completion, the mixture was cooled to 45° C. and hexanes was added. The mixture was further cooled by dry ice to induce precipitation. The resulting precipitate was filtered and dried (14.8 g, 70%). The crude product was used without further purification. - Step 2. Diethyl 2-(((6-methoxypyridin-2-yl)amino)methylene)malonate (14.8 g, 50.3 mmol) was added to a solution of diphenyl ether (125 mL, 0.4 M) at 260° C. After addition, the mixture was heated at reflux for another 45 mins. After completion, the mixture was cooled to 85° C. and hexanes was added. Once cooled to room temperature, the solid was filtered and purified through FCC yielding the product.
- Step 3. Ethyl 4-hydroxy-7-methoxy-1,8-naphthyridine-3-carboxylate (130 mg, 0.52 mmol, 1 eq) was dissolved in DCM (2.6 mL, 0.2 M) followed by the addition of oxylyl chloride (53 μL, 0.63 mmol, 1.2 eq) and DMF (1 drop). The mixture was heated to reflux for 5 mins. Upon completion, the mixture was cooled to room temperature and concentrated in vacuo. The crude was used without further purification.
- Step 4. Ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (0.26 mmol, 1 eq) and 4-(aminomethyl)benzenesulfonamide HCl (75 mg, 0.34 mmol, 1.3 eq) were dissolved in DMF (2.6 mL, 0.1 M) followed by the addition of DIEA (226 μL, 1.3 mmol, 5 eq). The mixture was heated to 60° C. Upon completion, the mixture was cooled to room temperature then added to water. The resulting precipitate was filtered and dried (21 mg, 19%).
- Step 5. Ethyl 7-methoxy-4-((4-sulfamoylbenzyl)amino)-1,8-naphthyridine-3-carboxylate (21 mg, 0.05 mmol, 1 eq) was dissolved in THF/MeOH (1 mL/0.3 mL) then cooled to 0° C. Aqueous LiOH (1 M, 0.5 mmol, 10 eq) was added to the mixture. The resulting mixture was heated to 50° C. Upon completion, the mixture was cooled to room temperature and diluted with water. The aqueous layer was washed with EtOAc then the aqueous layer was acidified to pH 4 with 2 N HCl. The resulting precipitate was filtered and dried (14 mg, 74%).
- Step 6. 7-Methoxy-4-((4-sulfamoylbenzyl)amino)-1,8-naphthyridine-3-carboxylic acid (14 mg, 0.04 mmol, 1 eq) was dissolved in DMF (2 mL) followed by the addition of DPPA (9.3 μL, 0.043 mmol, 1.2 eq). The resulting mixture was heated to 110° C. Upon completion, the mixture was cooled to room temperature and concentrated in vacuo. The crude was purified through FCC yielding the product (8.8 mg, 44%). LCMS [M+H]+=386; 1H NMR (600 MHz, DMSO-d6) δ ppm 4.00 (s, 3H) 5.63 (s, 2H) 7.00-7.06 (m, 1H) 7.06-7.11 (m, 1H) 7.13-7.18 (m, 1H) 7.25-7.31 (m, 1H) 7.34 (s, 2H) 7.43 (d, J=8.44 Hz, 2H) 7.77 (d, J=8.44 Hz, 2H) 8.29 (br d, J=9.35 Hz, 1H) 8.74 (s, 1H).
-
-
Step 1. A mixture of Meldrum's acid (13.36 g, 92.6 mmol) and triethyl orthoformate (35.8 g, 3.0 eq) was heated at 92° C. for 90 min before addition of 6-methoxypyridin-2-amine (10 g, 80.6 mmol) portionwise at 70° C. over 5 min. Then the reaction mixture was stirred for 20 min, cooled and filtered to give 5-(((6-methoxypyridin-2-yl)imino)methyl)-2,2-dimethyl-1,3-dioxane-4,6-dione as a grey solid (19.27 g, 75%). - Step 2. The above solid (19.2 g, 69 mmol) was added to heated diphenyl ether (30 mL) at 260° C. portionwise then the resulted mixture was stirred at 260° C. for 40 min before being cooled to rt. Hexane (100 mL) was added and the solid was filtered, washed with hexane and dried (11.25 g, 93%).
- Step 3. The above solid (1.0 g, 5.7 mmol) in CH3CH2CO2H (35 mL) was treated with fuming HNO3 (0.59 mL) dropwise and then stirred for 2 h. The resulted solid was filtered, washed and dried (725 mg, 58%).
- Step 4. The above solid (725 mg, 3.3 mmol) in DCM (20 mL) was treated with SOCl2 (0.60 mL) followed with 2 drops of DMF. After 6 h, the reaction mixture was concentrated and purified by combiflash (DCM/EtOAc) to give a white solid (578 mg, 74%).
-
-
Step 1. A mixture of intermediate B (90 mg, 0.38 mmol), 4-(aminomethyl)benzenesulfonamide HCl salt (100 mg, 1.2 eq), hunig's base (0.33 mL, 5.0 eq) and MeCN (4 mL) was heated to 80° C. for 4 h. After cool to rt, the reaction mixture was concentrated and treated with water (5 mL). The resulted solid was filtered, wash with water and dried (107 mg, 73%). LCMS [M+H]+=390. - Step 2. The above solid (107 mg, 0.28 mmol) in MeOH (5 mL) and EtOAc (5 mL) was heated to 65° C. and then Pd/C (10%, 10 mg) was added. The reaction mixture was stirred under H2 balloon overnight. After cool to rt, the reaction mixture was filtered, concentrated and purified by combiflash (DCM/MeOH) to give a yellow solid (49 mg, 49%). LCMS [M+H]+=360.
- Step 3. The above solid (49 mg, 0.17 mmol) was added to a mixture of DMF (1.1 mL) and triethyl orthoformate (2.2 mL) and then heated to 120° C. for 8 h. After cool to rt, the reaction mixture was concentrated and purified by combiflash (DCM/MeOH) to give a yellow solid (41 mg, 65%). LCMS [M+H]+=370; 1H NMR (500 MHz, DMSO-d6) δ ppm 3.98 (s, 3H) 6.08 (s, 2H) 7.18 (d, J=9.00 Hz, 1H) 7.24 (d, J=8.39 Hz, 2H) 7.28 (s, 2H) 7.69 (d, J=8.39 Hz, 2H) 8.44 (d, J=9.16 Hz, 1H) 8.76 (s, 1H) 9.51 (s, 1H).
- 6-((7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridine-3-sulfonamide was prepared in the similar manner as Compound 39 from intermediate B and 6-(aminomethyl)pyridine-3-sulfonamide HCl salt. LCMS [M+H]+=371; 1H NMR (500 MHz, DMSO-d6) δ ppm 4.02-4.09 (m, 3H) 6.27 (s, 2H) 7.26 (m, J=9.16 Hz, 1H) 7.59 (s, 2H) 7.64 (d, J=8.24 Hz, 1H) 8.20 (dd, J=8.32, 2.36 Hz, 1H) 8.58 (m, J=9.00 Hz, 1H) 8.75 (d, J=2.14 Hz, 1H) 8.81 (s, 1H) 9.57 (s, 1H).
- 5-((7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridine-2-sulfonamide was prepared in the similar manner as Compound 39 from intermediate B and 5-(aminomethyl)pyridine-2-sulfonamide HCl salt. LCMS [M+H]+=371; 1H NMR (500 MHz, DMSO-d6) δ ppm 3.99 (s, 4H) 6.15 (s, 2H) 7.21 (d, J=9.16 Hz, 1H) 7.40 (s, 2H) 7.60 (dd, J=8.16, 2.21 Hz, 1H) 7.76 (d, J=8.09 Hz, 1H) 8.54 (d, J=9.16 Hz, 1H) 8.61 (d, J=1.83 Hz, 1H) 8.77 (s, 1H) 9.52 (s, 1H).
-
- Ethyl 8,9-dimethoxypyrazolo[1,5-c]quinazoline-1-carboxylate (prepared according to a known procedure by Feng, H. , RSC Adv., 2016, 6, 95774) is converted to the corresponding alcohol by reducing reagents such as LiBH4. Bromo analog is prepared by treatment of the alcohol with PBr3. Coupling with (4-sulfamoylphenyl)boronic acid under palladium catalyst provides 4-((8,9-dimethoxypyrazolo[1,5-c]quinazolin-1-yl)methyl)benzenesulfonamide (42).
- (R)-6-(1-(7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)ethyl)pyridine-3-sulfonamide was prepared in the similar manner as Compound 39 from intermediate B and (R)-6-(1-(-aminoethyl)pyridine-3-sulfonamide HCl salt. LCMS [M+H]+=385; 1H NMR (600 MHz, DMSO-d6) δ ppm: 2.08 (d, J=6.97 Hz, 3H) 3.99 (s, 4H) 6.67 (q, J=6.91 Hz, 1H) 7.24 (d, J=9.17 Hz, 1H) 7.51 (s, 2H) 7.68 (d, J=8.25 Hz, 1H) 8.13 (dd, J=8.25, 2.38 Hz, 1H) 8.68 (br d, J=8.80 Hz, 1H) 8.74 (d, J=2.38 Hz, 1H) 9.02 (s, 1H) 9.55 (s, 1H).
-
-
Step 1. 2-chloro-6,7-dimethoxyquinoxaline (0.28 g, 1.24 mmol, 1 eq) was dissolved in reagent alcohol (6.2 mL, 0.2 M) followed by the addition of hydrazine monohydrate (6.2 mL, 0.2 M). The mixture was heated to 80° C. for 2 hrs. Upon completion, the mixture was cooled to room temperature then added to water. The resulting precipitate was filtered and dried (206 mg, 75%). - Step 2. 2-hydrazineyl-6,7-dimethoxyquinoxaline (50 mg, 0.22 mmol, 1 eq) and 2-(4-bromophenyl)acetaldehyde (53 mg, 0.264 mmol, 1.2 eq) were dissolved in reagent alcohol (2.2 mL, 0.1 M). The mixture was heated to reflux for 1 hr. Upon completion, the mixture was cooled to room temperature then added to water. The resulting precipitate was filtered and dried (88 mg, 99%).
- Step 3. 2-(2-(2-(4-bromophenyl)ethylidene)hydrazineyl)-6,7-dimethoxyquinoxaline (88 mg, 0.22 mmol, 1 eq) was dissolved in DCM (4.4 mL, 0.05 M) followed by the addition of iodobenzene diacetate (78 mg, 0.24 mmol, 1.1 eq). The mixture was stirred at room temperature for 3 hrs. Upon completion, the mixture was concentrated in vacuo. The resulting oil was triturated with hexanes then used without further purification.
- Step 4. 1-(4-bromobenzyl)-7,8-dimethoxy-2λ2, 10λ4-[1,2,4]triazolo[4,3-a]quinoxaline (0.22 mmol, 1 eq), Pd(dba)2 (13 mg, 0.022 mmol, 0.1 eq), and XantPhos (13 mg, 0.022 mmol, 0.1 eq) were dissolved in dioxane followed by the addition of DIEA (153 μL, 0.44 mmol, 2 eq). The mixture was purged with nitrogen for 1 min followed by the addition of benzyl mercaptan (28 μL, 0.24 mmol, 1.1 eq). The mixture was heated to 100° C. for 4 hrs. Upon completion, the mixture was cooled to room temperature and added to water. The aqueous layer was extracted with EtOAc (3×2 mL). The combined organic layers was dried and concentrated in vacuo. The crude was purified through FCC yielding the product (97 mg, 99%).
- Step 5. 1-(4-(benzylthio)benzyl)-7,8-dimethoxy-2λ2, 10λ4-[1,2,4]triazolo[4,3-a]quinoxaline (97 mg, 0.22 mmol, 1 eq) was dissolved in MeCN (2.27 mL, 0.1 M) followed by the addition of AcOH (86 μL, 2.57 M) and water (56 μL, 3.9 M). The mixture was cooled to 0° C. followed by the addition of 1,3-dichloro-5,5-dimethylhydantoin (52 mg, 0.264 mmol, 1.2 eq). The mixture was stirred at 0° C. Upon completion, the mixture was diluted with EtOAc and basified with sat. NaHCO3. The aqueous layer was extracted with EtOAc (2×2 mL). The combined organic layers was cooled to 0° C. followed by the addition of NH4OH (2 mL). The mixture was stirred at 0° C. for 1 hr. Upon completion, the mixture was acidified with 2 N HCl to pH 2. Layers separated and the aqueous extracted with EtOAc. The combined organic layers was dried and concentrated in vacuo. The crude was triturated with Et2O to yield the product 44 (18 mg, 20%). LCMS [M+H]+=400; 1H NMR (600 MHz, DMSO-d6) δ ppm 3.70 (s, 3H) 3.90 (s, 3H) 5.17 (s, 2H) 7.32 (d, J=7.15 Hz, 3H) 7.39 (d, J=8.44 Hz, 2H) 7.59 (s, 1H) 7.76-7.79 (m, 2H) 9.25 (s, 1H).
-
- 2-(4-Bromophenyl)acetonitrile is converted to 2-(4-bromobenzyl)-1H-imidazole by the treatment of ethylenediamine. This material is reacted with 1-fluoro-4-methoxy-2-nitrobenzene and then the resulted product is cyclized to give 1-(4-bromobenzyl)-7-methoxy-2λ2,10λ4-imidazo[3,4-a]quinoxaline. A similar transformation as 44 is used to convert bromo to sulfonamide.
-
- 4-((7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)aniline was prepared in the similar manner as Compound 39 from intermediate B and 4-(aminomethyl)aniline HCl salt. 4-((7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)aniline (41 mg, 0.13 mmol) was dissolved in MeCN (2 mL) and then treated with 4-nitrophenyl sulfamate (44 mg, 1.5 eq) followed with hunig's base (0.046 mL, 2.0 eq). After overnight at rt, the reaction mixture was worked up and purified by reverse HPLC (MeCN/H2O/0.1% TFA) to give a white solid (1.5 mg). LCMS [M+H]+=385.
-
- 4-(((3-amino-7-methoxy-1,8-naphthyridin-4-yl)amino)methyl)benzenesulfonamide (18 mg, 0.05 mmol) in tol (1 mL) and pyridine (1 mL) was treated with trifluoroacetic anhydride (0.0081 mL, 1.15 eq) and then heated to 140° C. overnight. The reaction mixture was concentrated and purified by reverse HPLC (MeCN/H2O/0.1% TFA) to give a white solid (5.5 mg). LCMS [M+H]+=438; 1H NMR (500 MHz, DMSO-d6) δ ppm 3.99-4.05 (m, 3H) 4.46 (d, J=5.80 Hz, 1H) 6.18 (s, 2H) 7.13 (d, J=9.00 Hz, 1H) 7.27 (d, J=8.39 Hz, 2H) 7.32-7.36 (m, 3H) 7.76 (d, J=8.39 Hz, 2H) 8.36 (d, J=9.16 Hz, 1H) 9.50 (s, 1H).
-
- 4-((7-methoxy-2-methyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzene-sulfonamide was prepared in the similar manner as Compound 39 from 4-(((3-amino-7-methoxy-1,8-naphthyridin-4-yl)amino)methyl)benzenesulfonamide and triethyl orthoacetate. LCMS [M+H]+=384; 1H NMR (500 MHz, DMSO-d6) δ ppm 2.66-2.72 (m, 3H) 4.06 (s, 3H) 6.10 (s, 2H) 7.26 (br d, J=8.24 Hz, 3H) 7.36 (s, 2H) 7.77 (br d, J=7.42 Hz, 2H) 8.55 (br d, J=8.70 Hz, 1H) 9.50 (br s, 1H).
-
- 4-chloro-7-methoxy-3-nitro-1,5-naphthyridine was prepared in the similar manner as Intermediate B from 5-methoxypyridin-3-amine; 4-((7-methoxy-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl)benzenesulfonamide (49) was then prepared in the similar manner as Compound 39 from 4-chloro-7-methoxy-3-nitro-1,5-naphthyridine and 4-(aminomethyl)benzenesulfonamide. LCMS [M+H]+=371; 1H NMR (600 MHz, DMSO-d6) δ ppm 3.97-4.00 (m, 3H) 6.19 (s, 2H) 7.28 (s, 2H) 7.49 (m, J=8.25 Hz, 2H) 7.74 (m, J=8.25 Hz, 2H) 7.97 (d, J=2.75 Hz, 1H) 8.65 (s, 1H) 8.75 (d, J=2.75 Hz, 1H) 9.29 (s, 1H).
-
- 4-((7-methoxy-1H-imidazo[4,5-c][1,6]naphthyridin-1-yl)methyl)benzenesulfonamide was prepared in the similar manner as Compound 39 from a known compound 8-bromo-7-methoxy-1,6-naphthyridin-4-ol (Morgentin, Remy et al, Tetrahedron, 2008, 64, 2772-2782). LCMS [M+H]+=371; 1H NMR (500 MHz, DMSO-d6) δ ppm 3.94 (s, 3H) 6.16 (s, 2H) 7.30-7.37 (m, 5H) 7.79 (d, J=8.39 Hz, 2H) 8.66 (s, 1H) 9.10-9.17 (m, 1H) 9.43 (s, 1H).
-
-
Step 1. 2-hydrazineyl-6,7-dimethoxyquinoxaline (50 mg, 0.22 mmol, 1 eq) and tert-butyl (4-formylbenzyl)carbamate (57 mg, 0.24 mmol, 1.1 eq) were dissolved in reagent alcohol (2.2 mL, 0.1 M). The mixture was heated to reflux for 1 hr. Upon completion, the mixture was cooled to room temperature then added to water. The resulting precipitate was filtered and dried (96 mg, 99%). - Step 2. tert-Butyl-(4-((2-(6,7-dimethoxyquinoxalin-2-yl)hydrazineylidene)methyl)-benzyl)-carbamate (96 mg, 0.22 mmol, 1 eq) was dissolved in DCM (4.4 mL, 0.05 M) followed by the addition of iodobenzene diacetate (78 mg, 0.24 mmol, 1.1 eq). The mixture was stirred at room temperature for 3 hrs. Upon completion, the mixture was concentrated in vacuo. The resulting oil was triturated with hexanes then used without further purification.
- Step 3. tert-Butyl (4-(7,8-dimethoxy-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)benzyl)carbamate (96 mg, 0.22 mmol, 1 eq) dissolved in DCM (0.55 mL, 0.4 M) then cooled to 0° C. TFA (0.55 mL, 0.4 M) was added to the mixture. The mixture was warmed to room temperature and stirred for 1 hr. Upon completion, the mixture was concentrated in vacuo. The crude was dissolved in DCM/DMF (1:1, 8 mL) followed by the addition of Et3N (276 μL, 1.98 mmol, 9 eq) and sulfamoylating reagent (73 mg, 0.242 mmol, 1.1 eq). The mixture was heated to 60° C. for 1 hr. Upon completion, the mixture was concentrated in vacuo. The crude was pushed through a silica plug then used without further purification.
- Step 4. tert-butyl (N-(4-(7,8-dimethoxy-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)benzyl)sulfamoyl)-carbamate (0.22 mmol, 1 eq) was dissolved in DCM (1 mL) then cooled to 0° C. TFA (1 mL) was added to the mixture. The mixture was warmed to room temperature and stirred for 0.5 hr. Upon completion, the mixture was concentrated in vacuo. The crude was purified through FCC yielding the product (11 mg, 10%). LCMS [M+H]+=415; 1H NMR (600 MHz, DMSO-d6) δ ppm 3.38-3.40 (m, 3H) 3.91 (s, 3H) 4.25 (d, J=6.24 Hz, 2H) 6.71 (s, 2H) 6.86 (s, 1H) 7.28 (br t, J=6.42 Hz, 1H) 7.61 (s, 1H) 7.68 (m, J=8.07 Hz, 2H) 7.77 (m, J=8.07 Hz, 2H) 9.31 (s, 1H).
- 3-((7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)azetidine-1-sulfonamide was prepared in the similar manner as Compound 39 from intermediate B and 3-(aminomethyl)azetidine-1-sulfonamide. LCMS [M+H]+=349; 1H NMR (600 MHz, DMSO-d6) δ ppm 3.08-3.17 (m, 2H) 3.59 (br dd, J=8.34, 5.59 Hz, 8H) 3.78-3.84 (m, 3H) 4.12 (s, 3H) 4.97 (d, J=7.34 Hz, 2H) 6.90 (s, 2H) 7.43 (d, J=8.99 Hz, 1H) 8.83 (s, 1H) 8.95 (d, J=9.17 Hz, 1H) 9.60 (s, 1H).
- 7-(7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide was prepared in the similar manner as Compound 39 from intermediate B and 7-amino-3,4-dihydroisoquinoline-2(1H)-sulfonamide. LCMS [M+H]+=411; 1H NMR (600 MHz, DMSO-d6) δ ppm 3.10 (br s, 2H) 4.06 (s, 3H) 4.31 (br s, 2H) 7.01 (s, 2H) 7.19 (d, J=8.99 Hz, 1H) 7.51-7.56 (m, 1H) 7.56-7.59 (m, 1H) 7.65 (s, 1H) 7.78 (d, J=9.17 Hz, 1H) 8.72 (s, 1H) 9.58 (s, 1H).
- (R)-4-(1-(7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)ethyl)benzenesulfonamide was prepared in the similar manner as Compound 39 from intermediate B and (R)-4-(1-aminoethyl)benzenesulfonamide. LCMS [M+H]+=384; 1H NMR (600 MHz, DMSO-d6) δ ppm 2.12 (d, J=6.97 Hz, 3H) 4.05 (s, 3H) 6.64 (q, J=6.91 Hz, 1H) 7.28 (d, J=9.17 Hz, 1H) 7.34 (s, 2H) 7.40 (d, J=8.44 Hz, 2H) 7.75-7.79 (m, 2H) 8.65 (d, J=9.17 Hz, 1H) 9.07 (s, 1H) 9.62 (s, 1H).
-
- 1-(4-bromobenzyl)-7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridine was prepared in the similar manner as Compound 39 from intermediate B and 4-bromobenzylamine. 1-(4-bromobenzyl)-7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridine (10 mg, 0.027 mmol) in a mixture of dioxane/DMF (0.5/0.5 mL) was treated with bis(pinacolato)diboron (10 mg, 1.5 eq), Pd(dppf)2Cl2 (2.2 mg, 10%) and KOAc (8 mg, 3.0 eq) and the reaction mixture was purged with N2 for 2 min and then heated to 100° C. for 2 h. After cool to rt, the reaction mixture was treated with NaIO4 (17 mg, 3.0 eq), NH4OAc (6 mg, 3.0 eq) and water (1 mL) for 1 h. Work up and the residue was purified by reverse phase HPLC (MeCN/H2O/0.1% TFA) to give a white solid as (4-((7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)phenyl)boronic acid. LCMS [M+H]+=335.
-
- Ethyl 8,9-dimethoxypyrazolo[1,5-c]quinazoline-1-carboxylate (prepared according to a known procedure by Feng, H. , RSC Adv., 2016, 6, 95774) is converted to the corresponding acid by saponification with LiOH solution in THF. Coupling with piperazine-1-sulfonamide with HATU provides 4-(8,9-dimethoxypyrazolo[1,5-c]quinazoline-1-carbonyl)piperazine-1-sulfonamide (58).
- 4-(7-methoxy-1H-imidazo[4,5-c][1,6]naphthyridin-1-yl)benzyl sulfamide (59) is made in a similar manner as the preparation of compound 43.
-
- 4-bromo-2-(trifluoromethyl)benzenesulfonyl chloride (2.5 g, 7.73 mmol, 1 eq) was dissolved in THF (40 mL, 0.2 M) and added dropwise to a stirring solution of NH4OH at −20° C. keeping the internal temperature below −10° C. during addition. After addition, the reaction mixture was stirred at −10° C. for additional 10 min. Upon completion, the mixture was poured into 2 M HCl (250 mL) and EtOAc (100 mL) at 0° C. Layer separated and the aqueous layer extracted with EtOAc (2×100 mL). The combined organic layers dried over Na2SO4 and concentrated yielding the product (2.3 g, 98%).
- The following intermediates were made in the same manner as 4-bromo-2 (trifluoromethyl)-benzenesulfonamide:
- 4-Bromo-2,3-difluorobenzenesulfonamide
- 4-Bromo-3,5-difluorobenzenesulfonamide
- 4-Bromo-2-(trifluoromethoxy)benzenesulfonamide
- 4-Bromo-3-(trifluoromethyl)benzenesulfonamide
- 4-(aminomethyl)-2,6-difluorobenzenesulfonamide HCl
-
Step 1. To a flask containing water (45 mL, 2.3 M) at 0° C., thionyl chloride (7.5 mL, 103.2 mmol, 4.3 eq) was added dropwise. The resulting mixture was stirred at 22° C. for 18 hr. 4-Bromo-2,6-difluoroaniline (5 g, 24 mmol, 1 eq) at 0° C. was added conc HCl (24 mL, 1 M) and the resulting mixture was heated to 50° C. for 1 hr then cooled to −5° C. (internal temperature). A solution of NaNO2 (1.77 g, 25.7 mmol, 1.07 eq) dissolved in water (7 mL) was added to the reaction mixture. During addition, the internal temperature was kept below 0° C. After addition the mixture was stirred for additional 10 min at −5° C. The aqueous thionyl chloride mixture was cooled to −5° C. (internal temperature) and CuCl (24 mg, 0.24 mmol, 0.01 eq) was added. The freshly formed diazonium mixture was added slowly to the aqueous thionyl chloride mixture while keeping the internal temperature below 0° C. After addition, the mixture was stirred at −5° C. for additional 20 min. The resulting precipitate was filtered and dissolved in THF (100 mL). The sulfonyl chloride in THF was added slowly to a stirring mixture of NH4OH (82 mL) at −10° C. (internal temperature). During the addition, the internal temperature was kept below −5° C. After the addition, the mixture was poured into 2 M HCl (600 mL). At pH 2, the aqueous layer was extracted with EtOAc (3×100 mL). The combined organic layer was dried over Na2SO4 and concentrated yielding the product (5.34 g, 82%). - Step 2. 4-bromo-2,6-difluorobenzenesulfonamide (2 g, 7.35 mmol, 1 eq), Zn(CN)2 (518 mg, 4.41 mmol, 0.6 eq), and Pd(PPh3)4 (424 mg, 0.37 mmol, 0.05 eq) were suspended in DMF (37 mL, 0.2 M). The mixture was purged with nitrogen for 1 min and heated to 100° C. for 5 hr. Upon completion, the mixture was cooled to 22° C. and poured into water. The resulting ligand precipitate was filtered. The filtrate was acidified to pH 2 with 2 M HCl and extracted with EtOAc (3×100 mL). The combined organic layer dried over Na2SO4 and concentrated yielding the product (1.4 g, 88%) Step 3. 4-cyano-2,6-difluorobenzenesulfonamide (844 mg, 3.87 mmol, 1 eq) was dissolved in MeOH (39 mL, 0.1 M) then added to a flask containing 10% Pd/C (844 mg) under nitrogen atmosphere. Conc HCl (355 μL, 4.3 mmol, 1.1 eq) was added and the mixture purged with hydrogen (3 cycles). The resulting mixture was stirred at 22° C. for 1 hr. Upon completion, the mixture was filtered over a pad of celite. The filtrate was concentrated. The residual was triturated with EtOAc several times yielding the product (903 mg, 90%). LCMS [M+H]+=223.
- The following intermediates were made in the same manner as 4-(aminomethyl)-2,6-difluorobenzenesulfonamide HCl:
- 4-(Aminomethyl)-2,5-difluorobenzenesulfonamide HCl
- 4-(Aminomethyl)-2,3-difluorobenzenesulfonamide HCl
- 4-(Aminomethyl)-3,5-difluorobenzenesulfonamide HCl
- 4-(Aminomethyl)-2-(trifluoromethyl)benzenesulfonamide HCl
- 4-(Aminomethyl)-2-(trifluoromethoxy)benzenesulfonamide HCl
- 4-(Aminomethyl)-3-(trifluoromethyl)benzenesulfonamide HCl
-
-
Step 1. To a mixture of 4-bromo-2,6-difluoro-benzaldehyde (2.5 g, 11.31 mmol, 1 eq) in ethanol (40 mL) was added hydroxylamine hydrochloride (1.10 g, 15.84 mmol, 1.40 eq) and potassium acetate (1.30 g, 13.24 mmol, 1.17 eq) in one portion at 22° C. for 1 h. Upon completion, water (40 mL) was added into the reaction mixture at 0° C. and stirred for 1 hr. The resulting precipitate filtered and washed by cold 1:1 EtOH/Water yielding the product (2.5 g, 94%). - Step 2. (E)-4-bromo-2,6-difluoro-benzaldehyde oxime (2.5 g, 10.59 mmol, 1 eq) was dissolved in AcOH (60 mL). Zn (5.54 g, 84.74 mmol, 8 eq) was added in one portion at 65° C. The mixture was stirred at 65° C. for 2 hr. Upon completion, the reaction mixture was filtered and the filtrate was concentrated. The residual was dissolved in water (50 ml) and washed with diethyl ether (3×50 mL). The combined organic layers was back extracted with water (2×50 mL, with AcOH 2 drops), the two aqueous layers were combined, neutralized by NaHCO3. The basic aqueous layer extracted EtOAc (3×50 mL). The EtOAc layers combined and dried over Na2SO4. After concentration, the product was obtained without further purification (1.46 g, 62%). LCMS [M+H]+=222.
- Step 3. Product was prepared following the procedure for the (4-bromo-2,6-difluorophenyl)-methanamine. LCMS [M+H]+=240.
-
-
Step 1. 6-cyanopyridine-3-sulfonamide (1.4 g, 7.65 mmol, 1 eq) dissolved in THF (60 mL) then cooled to 0° C. MeMgCl (3.0 M, 7.6 mL, 22.95 mmol, 3 eq) was added to the reaction mixture. After addition, the mixture was stirred at 22° C. for 2 hr. Upon completion, the mixture was quenched with sat. NH4C1. Layer separated and the aqueous extracted with EtOAc (2×50 mL). The combined organic layers dried over Na2SO4 and concentrated. The crude was purified by FCC yielding the product (1.14 g, 76%). - Step 2. 6-acetylpyridine-3-sulfonamide (1.14 g, 5.69 mmol, 1 eq) dissolved in THF (14 mL, 0.4M) followed by the addition of (R)-2-Methylpropane-2-sulfinamide (828 mg, 6.83 mmol, 1.2 eq). Ti(OEt)4 (1.72 mL, 11.38 mmol, 2 eq) was added to the mixture and the mixture was heated to reflux for 18 hr. Upon completion, the mixture was cooled to 0° C. and quenched with water. EtOAc was added and the layers separated. The aqueous layer was extracted with EtOAc (2×50 mL). The combined organic layers dried over Na2SO4 and concentrated. The crude was purified by FCC using DCM/THF gradient yielding the product (0.97 g, 56%).
- Step 3. (E)-6-(1-((tert-butylsulfinyl)imino)ethyl)pyridine-3-sulfonamide (0.97 g, 3.2 mmol, 1 eq) was dissolved in THF (11 mL, 0.3 M) then cooled to 0° C. 9-BBN (0.5 M, 8.3 mL, 4.2 mmol, 1.3 eq) was added to the mixture. The mixture was stirred at 0° C. for 2 hr. Upon completion, the mixture was quenched with MeOH (11 mL) and HCl in EtOH (1.25M, 11 mL) was added. The mixture was stirred at 0° C. for additional 30 min then concentrated. The resulting residual was triturated with EtOAc several times yielding the product (613 mg, 81%). LCMS [M+H]+=202.
- Compounds 60-69 and 129 were prepared from the amine intermediates in a similar manner as the preparation of compound 39.
- (R)-6-(1-(7-Methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)ethyl)pyridine-3-sulfonamide (60) was prepared in 16 mg. LCMS [M+H]+=385; 1H NMR (600 MHz, DMSO-d6) δ ppm 2.08 (d, J=6.97 Hz, 3H) 3.99 (s, 4H) 6.67 (q, J=6.91 Hz, 1H) 7.24 (d, J=9.17 Hz, 1H) 7.51 (s, 2H) 7.68 (d, J=8.25 Hz, 1H) 8.13 (dd, J=8.25, 2.38 Hz, 1H) 8.68 (br d, J=8.80 Hz, 1H) 8.74 (d, J=2.38 Hz, 1H) 9.02 (s, 1H) 9.55 (s, 1H).
- 2-Fluoro-4-((7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzene-sulfonamide (61) was prepared in 15 mg. LCMS [M+H]+=388.
- 3-Fluoro-4-((7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzene-sulfonamide (62) was prepared in 24.2 mg. LCMS [M+H]+=388.
- 2-Cyano-6-((7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridine-3-sulfonamide (63) was prepared in 0.5 mg. LCMS [M+H]+=396; 1H NMR (600 MHz, DMSO-d6) δ ppm 1.08 (s, 6H) 2.02 (s, 1H) 3.98 (s, 3H) 6.22 (s, 2H) 7.16 (br d, J=9.17 Hz, 1H) 7.60-7.75 (m, 1H) 8.44 (d, J=8.07 Hz, 1H) 8.54 (br d, J=8.99 Hz, 2H) 8.73 (br s, 1H) 9.04 (br s, 1H) 9.39-9.51 (m, 1H).
- 2-Methoxy-4-((7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzene-sulfonamide (64) was prepared in 4.1 mg. LCMS [M+H]+=400; 1H NMR (600 MHz, DMSO-d6) δ ppm 3.93 (s, 3H) 5.68 (s, 1H) 6.19 (s, 2H) 7.17 (dd, J=3.30, 1.65 Hz, 1H) 7.28 (s, 2H) 7.45 (d, J=8.99 Hz, 1H) 7.52 (d, J=8.62 Hz, 2H) 7.68-7.74 (m, 2H) 7.97 (dd, J=3.30, 2.20 Hz, 1H) 8.94 (d, J=8.99 Hz, 1H) 9.93 (s, 1H) 13.70 (br s, 1H).
- 4-((7-Methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-2-(trifluoromethyl)benzenesulfonamide (65) was prepared in 7.6 mg. LCMS [M+H]+=438; 1H NMR (600 MHz, DMSO-d6) δ ppm 4.06 (s, 3H) 6.23 (s, 2H) 7.25 (d, J=9.17 Hz, 1H) 7.39 (d, J=8.44 Hz, 1H) 7.70 (s, 2H) 7.94 (s, 1H) 8.03 (d, J=8.25 Hz, 1H) 8.56 (d, J=9.17 Hz, 1H) 8.81 (s, 1H) 9.58 (s, 1H).
- 4-((7-Methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-2-(trifluoromethoxy)-benzene-sulfonamide (66) was prepared in 3.7 mg. LCMS [M+H]+=454.
- 4-((7-Methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-3-(trifluoromethyl)-benzenesulfonamide (67) was prepared in 3.1 mg. LCMS [M+H]+=438.
- 3-Bromo-4-((7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzene-sulfonamide (68) was prepared in 214 mg. LCMS [M+H]+=449; 1H NMR (300 MHz, DMSO-d6) δ ppm 4.03 (s, 3H) 6.08 (s, 2H) 6.61-6.68 (m, 1H) 7.15-7.24 (m, 1H) 7.48 (s, 2H) 7.56-7.60 (m, 1H) 8.15 (s, 1H) 8.18 (d, J=8.79 Hz, 1H) 8.64 (s, 1H) 9.47-9.54 (m, 1H).
- 3-Cyano-4-((7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzene-sulfonamide (69) was prepared in 6.7 mg. LCMS [M+H]+=395; 1H NMR (300 MHz, DMSO-d6) δ ppm 4.05 (s, 3H) 6.36 (s, 2H) 6.90 (d, J=8.21 Hz, 1H) 7.20 (d, J=9.38 Hz, 1H) 7.58 (s, 2H) 7.85 (dd, J=8.21, 2.34 Hz, 1H) 8.32 (d, J=1.76 Hz, 1H) 8.44 (d, J=8.79 Hz, 1H) 8.71 (s, 1H) 9.58 (s, 1H).
- 3,5-difluoro-4-((7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (129) was prepared in 29.4 mg. LCMS [M+H]+=406; 1H NMR (400 MHz, DMSO-d6) δ ppm 4.04 (s, 3H) 6.16 (s, 2H) 7.34 (d, J=9.00 Hz, 1H) 7.52 (s, 1H) 7.54 (s, 1H) 7.65 (s, 2H) 8.64 (s, 1H) 8.83 (d, J=9.00 Hz, 1H) 9.47 (s, 1H).
- Compounds 70-73 and 130 were prepared from the amine intermediates in a similar manner as the preparation of compound 39, using triethyl orthoacetate in the place of triethyl orthoformate in the last step.
- 2,5-Difluoro-4-((7-methoxy-2-methyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-y1)methyl)benzenesulfonamide (70) was prepared in 3.7 mg. LCMS [M+H]+=420.
- 2-Fluoro-4-((7-methoxy-2-methyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfon-amide (71) was prepared in 2.3 mg. LCMS [M+H]+=402; 1H NMR (300 MHz, DMSO-d6) δ ppm 2.69 (s, 3H) 4.06 (s, 3H) 6.09 (s, 2H) 6.98 (d, J=7.62 Hz, 1H) 7.17-7.34 (m, 2H) 7.64-7.76 (m, 3H) 8.54 (d, J=9.38 Hz, 1H) 9.54 (s, 1H).
- 6-((7-Methoxy-2-methyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridine-3-sulfonamide (72) was prepared in 3.4 mg. LCMS [M+H]+=385; 1H NMR (300 MHz, DMSO-d6) δ ppm 2.69 (s, 3H) 4.04 (s, 3H) 6.15-6.21 (m, 2H) 7.16-7.30 (m, 1H) 7.55 (s, 2H) 7.70 (d, J=8.79 Hz, 1H) 8.17-8.24 (m, 1H) 8.57-8.67 (m, 1H) 8.71-8.74 (m, 1H) 9.40-9.42 (m, 1H).
- 5-((7-Methoxy-2-methyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridine-2-sulfonamide (73) was prepared in 6 mg. LCMS [M+H]+=385.
- 3,5-difluoro-4-((7-methoxy-2-methyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (130) was prepared in 14 mg. LCMS [M+H]+=420.
-
-
Step 1. To a mixture of cyclopropanecarboxylic acid (6.21 mg, 72.14 mol, 5.70 μL, 1.3 eq) in DMF (0.3 mL) was added HATU (27.43 mg, 72.14 umol, 1.3 eq) and DIEA (27.97 mg, 216.43 umol, 37.70 μL, 3.9 eq) in one portion at 22° C. The mixture was stirred at 22° C. for 1 hr. 6-(((3-amino-7-methoxy-1,8-naphthyridin-4-yl)amino)methyl)pyridine-3-sulfonamide (20 mg, 55.50 mol, 1 eq) was then added into reaction mixture and then stirred at 22° C. for 18 hr. Upon completion, water was added into reaction mixture and extracted by EtOAc. The organic layer was dried over Na2SO4 and concentrated. The crude product was used in the next step without further purification. - Step 2. 6-((2-cyclopropyl-7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridine-3-sulfonamide in EtOH/Water=4:1 (1 mL) was added K2CO3 (23.01 mg, 166.49 mol, 3 eq) at 22° C. The reaction was stirred at 65° C. for 18 hr. Upon completion, the mixture was concentrated. The crude was purified by Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the product (2.5 mg, 9%). LCMS [M+H]+=411.
- 6-((7-methoxy-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridine-3-sulfonamide (75) was prepared in 1.0 mg in a similar manner as the preparation of compound 74. LCMS [M+H]+=455.
- N-((2-fluoro-4-((7-methoxy-2-methyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-phenyl)sulfonyl)acetamide (76) was isolated as a byproduct in the last step of preparation of compound 71. LCMS [M+H]+=444; 1H NMR (300 MHz, DMSO-d6) δ ppm 1.92 (s, 3H) 2.70 (s, 3H) 4.08 (s, 3H) 6.10-6.17 (m, 2H) 7.10 (d, J=8.21 Hz, 1H) 7.25 (d, J=11.14 Hz, 1H) 7.33 (d, J=8.79 Hz, 1H) 7.83 (t, J=7.91 Hz, 1H) 8.55-8.61 (m, 1H) 9.59-9.62 (m, 1H).
- N-((6-((7-methoxy-2-methyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridin-3-yl)-sulfonyl)acetamide (77) was isolated as a byproduct in the last step of preparation of compound 72. LCMS [M+H]+=427; 1H NMR (300 MHz, DMSO-d6) δ ppm 1.89 (s, 3H) 2.71 (s, 3H) 4.07 (s, 3H) 6.25 (s, 2H) 7.27 (br d, J=4.10 Hz, 1H) 7.85 (s, 1H) 8.30-8.40 (m, 1H) 8.69 (d, J=9.38 Hz, 1H) 8.77 (d, J=2.34 Hz, 1H) 9.53 (s, 1H).
- 4-((2,7-Dimethoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-2-fluorobenzenesulfonamide (78) was prepared in 9.7 mg using tetraethyl orthocarbonate in the last step following a similar manner as the preparation of compound 39. LCMS [M+H]+=418; 1H NMR (300 MHz, DMSO-d6) δ ppm 4.06 (s, 3H) 4.27 (s, 3H) 5.88 (s, 2H) 7.11 (d, J=8.21 Hz, 1H) 7.30-7.35 (m, 1H) 7.64 (s, 2H) 7.71 (br t, J=7.62 Hz, 2H) 8.50 (d, J=8.79 Hz, 1H) 9.39 (s, 1H).
-
-
Step 1. 4-(((3-amino-7-methoxy-1,8-naphthyridin-4-yl)amino)methyl)-2-fluorobenzenesulfonamide (70 mg, 0.185 mmol, 1 eq) was dissolved in DMF (1.85 mL, 0.1 M) followed by the addition of chloroacetic anhydride (35 mg, 0.204 mmol, 1.1 eq). The mixture was stirred at 22° C. for 4 days. Upon completion, the mixture was partitioned between water and EtOAc. Layer was separated and the aqueous layer was extracted with EtOAc (3×3 mL). The combined organic layer was dried over Na2SO4 and concentrated yielding 4-((2-(Chloromethyl)-7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-2-fluorobenzenesulfonamide (47.4 mg, 59%) without further purification. - Step 2. 4-((2-(Chloromethyl)-7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-2-fluorobenzenesulfonamide (17 mg, 0.039 mmol, 1 eq) was dissolved in MeOH (0.4 mL, 0.1 M) followed by the addition of 25 wt % NaOMe (286 μL). The mixture was stirred at 22° C. for 1 hr. Upon completion. The mixture was quenched with sat. NH4C1 and concentrated. The crude was purified by Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the product (10 mg, 59%). LCMS [M+H]+=432; 1H NMR (300 MHz, DMSO-d6) δ ppm 4.03 (s, 3H) 4.84 (s, 2H) 6.09 (s, 2H) 6.88-6.99 (m, 1H) 7.15-7.23 (m, 2H) 7.61 (s, 2H) 7.67 (t, J=7.62 Hz, 1H) 8.34-8.45 (m, 1H) 9.47-9.56 (m, 1H).
-
- 4-((2-(Chloromethyl)-7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-2-fluorobenzenesulfonamide (10 mg, 0.023 mmol, 1 eq) was dissolved in DMF (0.46 mL, 0.05 M) followed by the addition of morpholine (10 μL, 0.115 mmol, 5 eq). The mixture was stirred at 22° C. for 1 hr. Upon completion, the mixture was purified by Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the product (4 mg). LCMS [M+H]+=487; 1H NMR (300 MHz, DMSO-d6) δ ppm 2.58-2.74 (m, 4H) 3.78 (br s, 2H) 4.04 (s, 3H) 4.13-4.24 (m, 2H) 6.14 (s, 2H) 6.92 (s, 1H) 7.13-7.21 (m, 1H) 7.24 (d, J=8.79 Hz, 1H) 7.65 (s, 2H) 7.68-7.71 (m, 1H) 8.43 (d, J=9.38 Hz, 1H) 9.53 (s, 1H).
-
-
Step 1. 4-((2-(Chloromethyl)-7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-2-fluorobenzenesulfonamide (17.7 mg, 0.041 mmol, 1 eq) was dissolved in EtOH (0.82 mL, 0.05 M) followed by the addition of NaSMe (9 mg, 0.123 mmol, 3 eq). The mixture stirred at 22° C. for 3 hr. Upon completion, the mixture was concentrated yielding the product. The crude product was used in the next step without further purification. - Step 2. 2-Fluoro-4-((7-methoxy-2-((methylthio)methyl)-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide was dissolved in THF (0.18 mL) then added to a solution of oxone (11 mg, 0.018 mmol, 1 eq) in water (0.18 mL). The mixture was stirred at 22° C. for 3 hr. Upon completion, the mixture was purified by Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the product (5.3 mg, 31%). LCMS [M+H]+=480; 1H NMR (300 MHz, DMSO-d6) δ ppm 3.26 (s, 3H) 4.02 (s, 3H) 5.26 (s, 2H) 6.21 (s, 2H) 6.93 (d, J=7.86 Hz, 1H) 7.10 (d, J=11.14 Hz, 1H) 7.18 (d, J=8.79 Hz, 1H) 7.61 (s, 2H) 7.67 (t, J=7.91 Hz, 1H) 8.37 (d, J=9.38 Hz, 1H) 9.53 (s, 1H).
-
- 4-((2-(Chloromethyl)-7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-2-fluorobenzenesulfonamide (11.3 mg, 0.026 mmol, 1 eq) was dissolved in DMSO (0.26 mL, 0.1 M) followed by the addition of NaCN (2.5 mg, 0.052 mmol, 2 eq). The mixture was heated to 80° C. for 10 min. Upon completion, the mixture was purified by Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the product (2.6 mg, 24%). LCMS [M+H]+=427.
-
- 4-(((3-amino-7-methoxy-1,8-naphthyridin-4-yl)amino)methyl)-2-fluorobenzenesulfonamide (80 mg, 0.212 mmol, 1 eq) was dissolved in DMF (4.24 mL, 0.05 M) followed by the addition of Et3N (35 μL, 0.254 mmol, 1.2 eq). The mixture was cooled to 0° C. and methyl malonyl chloride (24 μL, 0.223 mmol, 1.05 eq) was added. The mixture stirred at 0° C. for 1 hr then heated to 100° C. for 3 hr. Upon completion, the mixture was partitioned between water and EtOAc. The layers separated and the aqueous extracted with EtOAc (3×5 mL). The combined organic layers dried over Na2SO4 and concentrated. The crude was purified by FCC using DCM/THF yielding the product (26 mg, 27%). LCMS [M+H]+=460.
-
- Methyl 2-(1-(3-fluoro-4-sulfamoylbenzyl)-7-methoxy-1H-imidazo[4,5-c][1,8]naphthyridin-2-yl)acetate (10 mg, 0.022 mmol, 1 eq) was dissolved in 2 N ammonia in MeOH (0.21 mL) The mixture was heated to 65° C. for 2 hr. Additional 2 N ammonia in MeOH (0.42 mL) was added and heated to 65° C. for 3 hr. Upon completion, the mixture was concentrated. The crude was purified by Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the product (3.8 mg, 39%). LCMS [M+H]+=445; 1H NMR (300 MHz, DMSO-d6) δ ppm 4.03 (s, 3H) 6.11 (s, 2H) 7.01 (s, 1H) 7.11-7.18 (m, 1H) 7.18-7.24 (m, 2H) 7.60 (s, 2H) 7.65-7.70 (m, 1H) 7.75 (br s, 1H) 8.38-8.43 (m, 1H) 9.48 (s, 1H).
-
- tert-butyl 3-(1-((3-fluoro-4-sulfamoyl-phenyl)methyl)-7-methoxy-imidazo[4,5-c][1,8]naphthyridin-2-yl)azetidine-1-carboxylate obtained from following the procedure for the synthesis of compound 74 (43 mg, 79.25 mol, 1 eq) dissolved in DCM (1 mL) then cooled to 0° C. followed by the addition of TFA (308.00 mg, 2.70 mmol, 0.2 mL, 34.08 eq). The cooling bath removed and the mixture stirred at 22° C. for 1 hr. Upon completion, the mixture was concentrated yielding the product TFA salt (44 mg, 99%). LCMS [M+H]+=443; 1H NMR (300 MHz, DMSO-d6) δ ppm 4.02 (s, 3H) 4.29-4.43 (m, 4H) 4.45-4.57 (m, 1H) 5.95 (s, 2H) 6.95 (d, J=8.21 Hz, 1H) 7.15-7.22 (m, 2H) 7.64 (s, 2H) 7.70 (t, J=7.91 Hz, 1H) 8.42 (d, J=8.79 Hz, 1H) 8.98-9.15 (m, 1H) 9.51 (s, 1H).
-
- 4-[[2-(azetidin-3-yl)-7-methoxy-imidazo[4,5-c][1,8]naphthyridin-1-yl]methyl]-2-fluoro-benzenesulfonamide (19.1 mg, 34.32 mol, 1 eq, TFA) dissolved in DMF (0.34 mL) then cooled to 0° C. Et3N (2 M, 17.16 μL, 1 eq) added to the mixture followed by MsCl (2 M, 17.16 μL, 1 eq). The mixture stirred at 0° C. for 0.5 hr. Mixture warmed to 22° C. and stirred for 1.5 hr. Cooled to 0° C., Additional Et3N (2 M, 17.16 μL, 1 eq) and MsCl (2 M, 17.16 μL, 1 eq) were added and stirred at 0° C. for 30 min. The mixture was stirred to 22° C. over 18 hours. Upon completion, the mixture was concentrated. The crude was purified by Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the product (1.7 mg, 10%). LCMS [M+H]+=521.
-
-
Step 1. 6-methoxy-2-amino-pyridine (5 g, 40.3 mmol, 1 eq) and methyl acetoacetate (43 mL, 400.3 mmol, 10 eq) was added PPA (13 g). The mixture was heated to 190° C. for 3 hr. Upon completion, the mixture cooled to 22° C. diluted with water then washed with EtOAc (2×50 mL) to remove excess ethyl acetoacetate. The aqueous layer added EtOAc (100 mL) and with stirring pH adjusted to 8 with 2 M NaOH. The resulting ppt was filtered and dried yielding the product (2.7 g, 35%). - Step 2. 7-methoxy-2-methyl-1,8-naphthyridin-4-ol (1 g, 5.26 mmol, 1 eq) dissolved in sulfuric acid (50 mL) then cooled to 0° C. Fuming nitric acid (3.70 g, 58.72 mmol, 2.5 mL, 11.17 eq) was added slowly dropwise to the mixture at 0° C. The mixture was stirred at 0° C. for 0.5 hr. The cooling bath removed and the mixture stirred at 22° C. for 18 hr. The mixture heated to 60° C. for 5 hr. Upon completion, the mixture cooled to 22° C. then poured into stirring ice water. The resulting ppt was filtered and dried yielding the product (432 mg, 34%).
- Step 3. 7-methoxy-2-methyl-3-nitro-1,8-naphthyridin-4-ol (423 mg, 1.80 mmol, 1 eq) suspended in POCl3 (5.94 g, 38.74 mmol, 3.6 mL, 21.54 eq) and heated to 80° C. for 1.5 hr. Upon completion, the mixture was concentrated and dissolved in DCM. The organic layer was washed with sat. NaHCO3 (3×10 mL). The organic layer was dried over Na2SO4 and concentrated yielding the product (447 mg, 98%).
- Compounds 87 and 88 were made in a similar manner as the preparation of compound 39 from intermediate 4-chloro-7-methoxy-2-methyl-3-nitro-1,8-naphthyridine.
- 6-((7-Methoxy-4-methyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridine-3-sulfonamide (87) was prepared in 11.9 mg. LCMS [M+H]+=385; 1H NMR (300 MHz, DMSO-d6) δ ppm 2.86 (s, 3H) 3.94 (s, 3H) 6.14 (s, 2H) 6.94 (d, J=8.79 Hz, 1H) 7.43 (d, J=8.21 Hz, 1H) 7.48-7.60 (m, 2H) 8.10-8.15 (m, 1H) 8.31 (d, J=8.79 Hz, 1H) 8.50 (s, 1H) 8.79 (d, J=2.34 Hz, 1H).
- 2-fluoro-4-((7-methoxy-4-methyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (88) was prepared in 7 mg. LCMS [M+H]+=370; 1H NMR (500 MHz, DMSO-d6) δ ppm 3.94 (s, 3H) 6.16 (s, 2H) 7.30-7.37 (m, 5H) 7.79 (d, J=8.39 Hz, 2H) 8.66 (s, 1H) 9.10-9.17 (m, 1H).
-
Compounds 89 and 90 were made in a similar manner as the preparation of compound 39 using triethyl orthoacetate from intermediate 4-chloro-7-methoxy-2-methyl-3-nitro-1,8-naphthyridine. - 6-((7-Methoxy-2,4-dimethyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridine-3-sulfonamide (89) was prepared in 1.4 mg. LCMS [M+H]+=399; 1H NMR (300 MHz, DMSO-d6) δ ppm 2.69 (s, 3H) 4.06 (s, 3H) 6.19 (s, 2H) 7.17-7.29 (m, 1H) 7.57 (s, 2H) 7.68-7.78 (m, 1H) 8.17-8.26 (m, 1H) 8.58-8.67 (m, 1H) 8.70 (d, J=2.34 Hz, 1H).
- 2,5-Difluoro-4-((7-methoxy-2,4-dimethyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-benzenesulfonamide (90) was prepared in 12.1 mg. LCMS [M+H]+=434; 1H NMR (300 MHz, DMSO-d6) δ ppm 2.68 (s, 3H) 3.04 (s, 3H) 4.08 (s, 3H) 6.08 (s, 2H) 6.85-6.95 (m, 1H) 7.28 (d, J=8.79 Hz, 1H) 7.66 (dd, J=9.08, 5.57 Hz, 1H) 7.80 (s, 2H) 8.56 (d, J=8.79 Hz, 1H).
-
-
Step 1. 4-chloro-7-methoxy-2-methyl-3-nitro-1,8-naphthyridine (200 mg, 788.51 μmol, 1 eq) dissolved in NH3 in MeOH (2 M, 8 mL, 20.29 eq) and stirred at 22° C. for 3 days. Upon completion, mixture concentrated and the resulting precipitate triturated with water. The resulting precipitate filtered and dried yielding the product (184 mg, 99%). - Step 2. 7-methoxy-2-methyl-3-nitro-1,8-naphthyridin-4-amine (184 mg, 785.62 mol, 1 eq) suspended in MeOH (8 mL) followed by the addition of 10% palladium on carbon (184 mg, 172.84 mol, 0.22 eq) and HCl (12 M, 65.47 μL, 1 eq). The mixture purged with hydrogen (3 cycles) and stirred under hydrogen balloon at 22° C. for 3 hr. Upon completion, mixture filtered through a pad of celite. The cake was washed with MeOH/Et3N (90%/10%) and the filtrate concentrated yielding the product (160 mg, 99%).
- Step 3. 7-methoxy-2-methyl-1,8-naphthyridine-3,4-diamine (157 mg, 768.75 mol, 1 eq) dissolved in DMF (8 mL) followed by the addition of triethyl orthoacetate (3.47 g, 21.41 mmol, 3.92 mL, 27.85 eq) and acetic acid (55.40 mg, 922.50 mol, 52.76 μL, 1.2 eq). Vial sealed and heated to 80° C. for 8 hr. Upon completion, the mixture was concentrated. The resulting residual triturated with sat. NaHCO3 and the brown precipitate filtered. The aqueous layer was allowed to sit at 22° C. for 2 hr and light yellow solid began to form. The light yellow precipitate was filtered and dried yielding the product (48 mg, 27%).
- Step 4. 7-methoxy-2,4-dimethyl-1H-imidazo[4,5-c][1,8]naphthyridine (44 mg, 192.77 mol, 1 eq) and 5-bromo-2-(bromomethyl)pyrimidine (58.27 mg, 231.33 mol, 1.2 eq) were dissolved in DMF (1 mL). The vial sealed and heated to 50° C. for 4 hr. Additional 5-bromo-2-(bromomethyl)pyrimidine (58.27 mg, 231.33 umol, 1.2 eq) was added and heated to 50° C. for 2 hr. Additional 5-bromo-2-(bromomethyl)pyrimidine (58.27 mg, 231.33 μmol, 1.2 eq) was added and stirred at 50° C. for 2 hr. Upon completion, the mixture added 3 drops of TFA. The mixture was purified by Biotage C18 Duo 12 g column using water/MeCN (0.1% TFA) gradient. The product fractions combined and basified with sat. NaHCO3. The aqueous layer extracted with EtOAc (3×5 mL). The combined organic layer dried over Na2SO4 and concentrated yielding the product (33 mg, 43%).
- Step 5. 1-((5-bromopyrimidin-2-yl)methyl)-7-methoxy-2,4-dimethyl-imidazo[4,5-c][1,8]naphthyridine (33 mg, 82.66 mol, 1 eq), Pd(dba)2 (4.75 mg, 8.27 mol, 0.1 eq), Xantphos (4.78 mg, 8.27 mol, 0.1 eq), and DIEA (32.05 mg, 247.97 mol, 43.19 μL, 3 eq) were dissolved in dioxane (0.8 mL). The mixture purged with nitrogen for 20 sec and sealed. Heated to 80° C. for 30 sec then cooled to 22° C. Benzyl mercaptan (11.29 mg, 90.92 mol, 10.65 μL, 1.1 eq) added to the mixture and mixture purged with nitrogen for 20 sec. The vial sealed and heated to 80° C. for 1 hr. Upon completion, the mixture was diluted with water and extracted with EtOAc (3×5 mL). The combined organic layer dried over Na2SO4 and concentrated. The crude was purified through FCC using Biotage Sfar 5 g silica column using DCM/MeOH (100%/0% to 80%/20%) gradient yielding the product (21.3 mg, 58%).
- Step 6. 1-((5-benzylsulfanylpyrimidin-2-yl)methyl)-7-methoxy-2,4-dimethyl-imidazo[4,5-c][1,8]naphthyridine (21.3 mg, 48.13 mol, 1 eq) dissolved in MeCN (0.5 mL) followed by the addition of H2O (12.14 mg, 673.85 mol, 12.14 μL, 14 eq) and AcOH (20.23 mg, 336.92 mol, 19.27 μL, 7 eq) then cooled to 0° C. 1,3-dichloro-5,5-dimethyl-imidazolidine-2,4-dione (13.28 mg, 67.38 mol, 1.4 eq) was added and stirred at 0° C. for 1 hr. Additional 1,3-dichloro-5,5-dimethyl-imidazolidine-2,4-dione (13.28 mg, 67.38 mol, 1.4 eq) added and stirred at 0° C. for 10 min. The mixture was added to NH4OH (0.5 mL) at 0° C. and stirred for 10 min. The resulting mixture pH was adjusted to 8 using 2 M HCl. The mixture was concentrated. The crude was purified through Prep HPLC using water/MeCN (0.1% TFA) gradient yielding 91a (3.3 mg, 13%). LCMS [M+H]+=400; 91b, LCMS [M+H]+=434; 1H NMR (400 MHz, DMSO-d6) δ ppm 2.78 (s, 3H) 3.39 (br s, 3H) 3.70 (s, 3H) 5.77 (s, 2H) 6.59 (br s, 2H) 7.53 (d, J=9.00 Hz, 1H) 7.78 (s, 2H).
- Compounds 92-93 were prepared in a similar manner as the preparation of compound 94.
- 4-((2-((Dimethylamino)methyl)-7-methoxy-4-methyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-2,5-difluorobenzenesulfonamide (92) was prepared in 23.1 mg. LCMS [M+H]+=477; 1H NMR (300 MHz, DMSO-d6) δ ppm 2.93 (br s, 6H) 3.03-3.05 (m, 3H) 4.04 (s, 3H) 4.81 (br s, 2H) 6.10 (s, 2H) 6.85 (dd, J=9.67, 5.57 Hz, 1H) 7.20 (d, J=9.38 Hz, 1H) 7.67 (dd, J=9.38, 5.86 Hz, 1H) 7.82 (s, 2H) 8.39 (d, J=9.38 Hz, 1H).
- 2,5-Difluoro-4-((7-methoxy-2-(2-methoxyethyl)-4-methyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (93) was prepared in 18.8 mg. LCMS [M+H]+=478; 1H NMR (300 MHz, DMSO-d6) δ ppm 3.06 (s, 3H) 3.14 (s, 3H) 3.76-3.80 (m, 2H) 4.08 (s, 3H) 6.13 (s, 2H) 6.72-6.84 (m, 1H) 7.28 (d, J=9.38 Hz, 1H) 7.62-7.72 (m, 1H) 7.80 (s, 2H) 8.51 (d, J=8.79 Hz, 1H).
-
-
Step 1. 4-[[(3-amino-7-methoxy-2-methyl-1,8-naphthyridin-4-yl)amino]methyl]-2,5-difluoro-benzenesulfonamide (25 mg, 61.06 mol, 1 eq) dissolved in DMF (0.6 mL) then cooled to 0° C. followed by the addition of (2-chloro-2-oxo-ethyl) acetate (8.34 mg, 61.06 mol, 6.56 μL, 1 eq). Mixture stirred at 0° C. for 1 hr. Upon completion, mixture quenched with water at 0° C. and sat. NaHCO3 added. The aqueous layer extracted with EtOAc (3×2 mL). The combined organic layer dried over Na2SO4 and concentrated yielding the product. The crude product was used in the next step without further purification. - Step 2. (2-((4-((2,5-difluoro-4-sulfamoyl-phenyl)methylamino)-7-methoxy-2-methyl-1,8-naphthyridin-3-yl)amino)-2-oxo-ethyl) acetate (31 mg, 60.85 μmol, 1 eq) dissolved in EtOH (1.2 mL) followed by the addition of NaOH (2 M, 45.63 μL, 1.5 eq). Vial sealed and heated to 60° C. for 1.5 hr. Upon completion, the mixture cooled to 22° C. and neutralized with 2 M HCl (46 μL). The mixture concentrated. The crude was purified by Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the product (19.5 mg, 57%). LCMS [M+H]+=450; 1H NMR (300 MHz, DMSO-d6) δ ppm 3.06-3.07 (m, 3H) 4.08 (s, 3H) 4.88 (s, 2H) 6.16 (s, 2H) 6.69 (dd, J=9.96, 5.86 Hz, 1H) 7.28 (d, J=8.79 Hz, 1H) 7.66 (dd, J=9.08, 5.57 Hz, 1H) 7.79 (s, 2H) 8.44 (d, J=9.38 Hz, 1H).
- The following compounds were prepared according to the synthesis of compound 38.
- 2,3-Difluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-benzenesulfonamide (95) was prepared in 16.1 mg. LCMS [M+H]+=422.
- 5-((7-Methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridine-2-sulfonamide (96) was prepared in 0.8 mg. LCMS [M+H]+=387. 1H NMR (400 MHz, DMSO-d6) δ ppm 3.93 (s, 3H) 5.54 (s, 2H) 6.99 (d, J=9.00 Hz, 1H) 7.11-7.21 (m, 2H) 7.60 (dd, J=9.39, 5.48 Hz, 1H) 7.78 (s, 2H) 8.19 (d, J=9.00 Hz, 1H) 8.63 (s, 1H) 11.72 (s, 1H).
- 2-Fluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-benzenesulfonamide (98) was prepared in 34.5 mg. LCMS [M+H]+=404. 1H NMR (400 MHz, DMSO-d6) δ ppm 3.88-3.94 (m, 3H) 5.54 (s, 2H) 6.95 (d, J=9.00 Hz, 1H) 7.08 (dd, J=8.02, 1.37 Hz, 1H) 7.34 (d, J=11.04 Hz, 1H) 7.61 (s, 2H) 7.68 (t, J=8.02 Hz, 1H) 8.14 (d, J=9.39 Hz, 1H) 8.63 (s, 1H) 11.73 (br s, 1H).
- 6-((7-Methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridine-3-sulfonamide (99) was prepared in 26 mg. LCMS [M+H]+=387. 1H NMR (400 MHz, DMSO-d6) δ ppm 3.95 (s, 3H) 5.69 (s, 2H) 7.02 (d, J=9.39 Hz, 1H) 7.55 (s, 2H) 7.62 (d, J=8.22 Hz, 1H) 8.14 (dd, J=8.41, 2.15 Hz, 1H) 8.32 (d, J=9.00 Hz, 1H) 8.67 (s, 1H) 8.74 (d, J=2.35 Hz, 1H) 11.95 (br s, 1H).
- 2,6-Difluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-benzenesulfonamide (100) was prepared in 37.3 mg. LCMS [M+H]+=422; 1H NMR (400 MHz, DMSO-d6) δ ppm 3.92 (s, 3H) 5.51 (s, 2H) 6.99 (d, J=9.00 Hz, 1H) 7.16-7.21 (m, 2H) 7.95 (s, 2H) 8.13 (d, J=9.00 Hz, 1H) 8.64 (s, 1H).
- (R)-4-(1-(7-Methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)ethyl)benzene-sulfonamide (101) was prepared in 58 mg. LCMS [M+H]+=400; 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.84-1.87 (m, 3H) 3.87-3.88 (m, 3H) 6.19-6.25 (m, 1H) 6.56-6.69 (m, 1H) 7.07-7.15 (m, 1H) 7.16-7.23 (m, 1H) 7.43-7.45 (m, 2H) 7.74-7.77 (m, 2H) 8.43-8.51 (m, 1H).
-
- Formic acid (4.90 mg, 106.56 μmol, 4.02 μL, 2 eq) was added into chlorosulfonyl isocyanate (15.08 mg, 106.56 μmol, 9.25 μL, 2 eq) dropwise at 0° C. The resulting mixture was stirred for 18 hr to generate sulfamoyl chloride. To a mixture of 1-((3-hydroxycyclobutyl)methyl)-7-methoxy-1,3-dihydro-2H-imidazo[4,5-c][1,8]-naphthyridin-2-one (16 mg, 0.053 mmol, 1 eq, obtained from following the preparation of compound 38) in DMA (0.5 mL) was added sulfamoyl chloride dropwise at 0° C. The reaction mixture was slowly warmed to 22° C. and stirred for 3 hr. Upon completion, the solution was subjected to Prep HPLC using water/MeCN (0.1% TFA) yielding the product (1.9 mg, 9%). LCMS [M+H]+=380.
- 3-Fluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-benzenesulfonamide (102) was prepared in 32.7 mg. LCMS [M+H]+=404.
- 3,5-Difluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (103) was prepared in 8.4 mg. LCMS [M+H]+=422; 1H NMR (400 MHz, DMSO-d6) δ ppm 3.93 (s, 3H) 5.58 (s, 2H) 6.99 (d, J=9.00 Hz, 1H) 7.43 (d, J=6.95 Hz, 2H) 8.54-8.57 (m, 2H).
- 2,3,5-Trifluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-benzenesulfonamide (112) was prepared in 21.9 mg. LCMS [M+H]+=440; 1H NMR (300 MHz, DMSO-d6) δ ppm 4.06 (s, 3H) 5.70 (s, 2H) 7.23-7.31 (m, 1H) 7.39-7.50 (m, 1H) 8.01 (s, 2H) 8.67-8.77 (m, 1H) 8.82-8.87 (m, 1H).
- 3,5-Difluoro-4-((7-methoxy-4-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (113) was prepared in 12.4 mg. LCMS [M+H]+=436; 1H NMR (300 MHz, DMSO-d6) δ ppm 2.61 (s, 3H) 3.91-3.98 (m, 3H) 5.56-5.68 (m, 2H) 6.92-7.08 (m, 1H) 7.43-7.56 (m, 2H) 7.56-7.64 (m, 2H) 8.47-8.62 (m, 1H).
-
-
Step 1. 3,5-difluoro-4-((7-methoxy-2-oxo-3H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (50 mg, 118.66 μmol, 1 eq) dissolved in DMF (0.6 mL) followed by the addition of Et3N (30.02 mg, 296.65 μmol, 41.29 μL, 2.5 eq), DMAP (1.45 mg, 11.87 μmol, 0.1 eq), and acetic anhydride (30.28 mg, 296.65 μmol, 27.78 μL, 2.5 eq). The mixture stirred at 22° C. for 1 hr. The mixture was concentrated and dissolved in MeOH. 2 M NaOH (5 eq) was added and stirred for 5 min. The pH of the mixture adjusted to 4 using 2 M HCl. The resulting precipitate was filtered. The crude was purified through Prep HPLC using water/MeCN (0.1% TFA) gradient. The product fractions combined and pH adjusted to 4 then extracted with EtOH/CHCl3 (3:1). The combined organic layers concentrated yielding the product (31 mg, 56%). - Step 2. N-(3,5-difluoro-4-((7-methoxy-2-oxo-3H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)phenyl)sulfonylacetamide (30 mg, 64.74 μmol, 1 eq) suspended in MeOH (1 mL) followed by the addition of NaOH (0.2 M, 323.68 μL, 1 eq). The mixture became homogenous and stirred at 22° C. for 5 min. Upon completion, the mixture was concentrated yielding the product (30.6 mg, 97%). LCMS [M+H]+=464; LCMS [M+H]+=422; 1H NMR (300 MHz, DMSO-d6) δ ppm 1.62-1.67 (m, 3H) 3.96 (s, 3H) 5.56 (s, 2H) 6.97-7.09 (m, 1H) 7.32 (d, J=8.21 Hz, 2H) 8.56-8.62 (m, 2H) 11.51-11.62 (m, 1H).
- Sodium ((3,5-difluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)phenyl)sulfonyl)(propionyl)amide (105) was prepared in 16.6 mg following the procedure for the synthesis of compound 104. LCMS [M+H]+=478; 1H NMR (300 MHz, DMSO-d6) δ ppm 0.80 (t, J=7.62 Hz, 3H) 1.88 (q, J=7.62 Hz, 2H) 3.95 (s, 3H) 5.54 (s, 2H) 6.95-7.07 (m, 1H) 7.28 (d, J=8.21 Hz, 2H) 8.53-8.60 (m, 2H).
- Sodium butyryl((3,5-difluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)phenyl)sulfonyl)amide (106) was prepared in 25.6 mg following the procedure for the synthesis of compound 104. LCMS [M+H]+=492; 1H NMR (300 MHz, DMSO-d6) δ ppm 0.70 (t, J=7.33 Hz, 3H) 1.25-1.39 (m, 2H) 1.81-1.87 (m, 2H) 3.94 (s, 3H) 5.53 (s, 2H) 6.92-7.02 (m, 1H) 7.25-7.30 (m, 2H) 8.49-8.56 (m, 2H).
- 3,5-Difluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-N-methylbenzenesulfonamide (107) was prepared in 2 mg following the preparation of compound 38. LCMS [M+H]+=436; 1H NMR (300 MHz, DMSO-d6) δ ppm 2.76 (s, 3H) 3.75-3.81 (m, 3H) 6.48-6.58 (m, 2H) 7.43-7.50 (m, 1H) 7.72-7.81 (m, 2H) 8.77-8.86 (m, 1H) 9.02-9.09 (m, 2H).
-
-
Step 1. To a mixture of 1-(4-bromo-2,6-difluorobenzyl)-7-methoxy-1,3-dihydro-2H-imidazo[4,5-c][1,8]naphthyridin-2-one (84 mg, 198 mol, 1 eq) in MeOH (1 mL) was added Et3N (60.23 mg, 595.23 mol, 82.85 μL, 3 eq), and Pd(dppf)Cl2 (14.52 mg, 19.84 mol, 0.1 eq) in one portion at 22° C. The mixture was degassed by CO balloon and stirred at 65° C. for 1 hour. Upon completion, the mixture was concentrated. The crude was purified through FCC using Biotage C18 Duo 12 g column using water/MeCN (0.1% TFA) gradient yielding the product (62 mg, 78%). LCMS [M+H]+=401. - Step 2. To a mixture of methyl 3,5-difluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzoate (62 mg, 155 mol, 1 eq) in THF/MeOH (2 mL) was added LiOH (1 M, 1.62 mL, 10 eq) in one portion at 22° C. The mixture was stirred at 55° C. for 1 hour. Upon completion, the mixture was concentrated. The crude was purified through FCC using Biotage C18 Duo 12 g column using water/MeCN (0.1% TFA) gradient yielding the compound 108 (2.4 mg, 4%). LCMS [M+H]+=387. 1H NMR (300 MHz, DMSO-d6) δ ppm 4.04 (s, 3H) 5.69 (s, 2H) 7.24 (d, J=9.38 Hz, 1H) 7.51-7.58 (m, 2H) 8.71 (s, 1H) 8.77 (d, J=9.38 Hz, 1H) 12.15 (br s, 1H).
-
- Methyl 3,5-difluoro-4-((7-methoxy-2-oxo-3H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzoate (50 mg, 124.90 mol, 1 eq) dissolved in NH3 in MeOH (2 M, 2.50 mL, 40 eq). Vial sealed and heated to 65° C. for 2 hr. Additional NH3 in MeOH (2 M, 2.50 mL, 40 eq) was added and heated to 65° C. for 18 hr. Upon completion, the mixture was concentrated. The resulting precipitate was triturated with sat. NaHCO3. The precipitate was filtered. The crude was purified through Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the compound 109 (9.3 mg, 15%). LCMS [M+H]+=386; 1H NMR (300 MHz, DMSO-d6) δ ppm 4.05 (s, 3H) 5.68 (s, 2H) 7.27 (d, J=9.38 Hz, 1H) 7.54 (d, J=8.79 Hz, 2H) 7.63 (br s, 1H) 8.07 (br s, 1H) 8.72 (s, 1H) 8.80 (d, J=9.38 Hz, 1H) 12.23 (br s, 1H).
-
- Methyl 3,5-difluoro-4-((7-methoxy-2-oxo-3H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzoate (50 mg, 124.90 μmol, 1 eq) dissolved in MeOH (2.5 mL) followed by the addition of hydroxylamine hydrochloride (86.79 mg, 1.25 mmol, 10 eq). The mixture was sonicated until hydroxylamine dissolved then cooled to 0° C. NaOMe (4.4 M, 369.01 μL, 13 eq) was added to the mixture in one portion. The mixture was allowed to stir at 22° for 2 hr. Upon completion, the mixture was stored at −20° C. for 18 hr. The mixture was filtered over a pad of celite and the filtrate concentrated. The crude was triturated with sat. NaHCO3 and the resulting precipitate was filtered. The crude was purified through Prep HPLC using water/MeCN (0.1% TFA) gradient yielding compound 110 (29.4 mg, 46%). LCMS [M+H]+=402; 1H NMR (300 MHz, DMSO-d6) δ ppm 4.04 (s, 3H) 5.66 (s, 2H) 7.22-7.26 (m, 1H) 7.43 (d, J=8.79 Hz, 2H) 8.71 (s, 1H) 8.77 (br d, J=8.79 Hz, 1H) 11.24-11.50 (m, 1H) 12.02-12.28 (m, 1H). LCMS [M+H]+=387.
- (3,5-difluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)phenyl)boronic acid (111)
-
Step 1. 1-((4-bromo-2,6-difluoro-phenyl)methyl)-7-methoxy-3H-imidazo[4,5-c][1,8]naphthyridin-2-one (400 mg, 949.68 μmol, 1 eq) dissolved in DMF (2.5 mL) followed by the addition of Boc2O (298.46 mg, 1.37 mmol, 314.17 μL, 1.44 eq) and Cs2CO3 (464.13 mg, 1.42 mmol, 1.5 eq). The mixture stirred at 22° C. for 2 hr. Upon completion, the mixture was added to water and the resulting precipitate was filtered and dried yielding the product (463 mg, 94%). - Step 2. tert-butyl 1-((4-bromo-2,6-difluoro-phenyl)methyl)-7-methoxy-2-oxo-imidazo[4,5-c][1,8]naphthyridine-3-carboxylate (260 mg, 498.74 μmol, 1 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (151.98 mg, 598.49 μmol, 1.2 eq), KOAc (146.84 mg, 1.50 mmol, 3 eq), and Pd(dppf)Cl2 DCM complex (40.73 mg, 49.87 μmol, 0.1 eq) were suspended in dioxane (2.5 mL). The mixture purged with nitrogen for 30 sec and sealed. The mixture heated to 80° C. for 2 hr. Upon completion, the mixture cooled to 22° C. and diluted with water. The mixture was extracted with EtOAc (3×5 mL). The combined organic layer dried over Na2SO4 and concentrated. The crude was purified through FCC using Biotage Sfar 5 g silica column using DCM/MeOH (100%/0% to 80%/20%) gradient yielding the product (198 mg, 70%).
- Step 3. tert-butyl 1-((2,6-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methyl)-7-methoxy-2-oxo-imidazo[4,5-c][1,8]naphthyridine-3-carboxylate (50 mg, 87.97 μmol, 1 eq) dissolved in acetone (1.35 mL) and H2O (0.9 mL) followed by the addition of NaIO4 (56.45 mg, 263.91 μmol, 14.62 μL, 3 eq) and NH4OAc (20.34 mg, 263.91 μmol, 3 eq). The mixture stirred at 22° C. for 4 hr. Upon completion, the mixture was filtered through a pad of celite and concentrated. The residual was suspended in 1:1 DCM: TFA (2 mL) and stirred at 22° C. for 10 min. The mixture was concentrated. The crude was purified through Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the compound 111 (23.6 mg, 54%). LCMS [M+H]+=387; 1H NMR (300 MHz, DMSO-d6) δ ppm 4.04 (s, 3H) 5.65 (s, 2H) 7.25 (d, J=8.79 Hz, 1H) 7.35 (d, J=8.79 Hz, 2H) 8.41 (br s, 1H) 8.71-8.76 (m, 2H) 12.21 (br s, 1H).
-
-
Step 1. To a mixture of 1-((4-bromo-2,6-difluoro-phenyl)methyl)-7-methoxy-3H-imidazo[4,5-c][1,8]naphthyridin-2-one (110 mg, 261.16 μmol, 1 eq) in DMF (2.5 mL) was added MeI (44.48 mg, 313.39 μmol, 19.51 μL, 1.2 eq), and NaH (12.54 mg, 313.39 μmol, 60% purity, 1.2 eq) in one portion at 0° C. The mixture was stirred at 0° C. for 1 hr. Upon completion, water (10 mL) was added into reaction mixture. The aqueous layer was extracted by EtOH/CHCl3=1:3. The organic layer was dried over Na2SO4, and concentrated. The crude was purified by Biotage Sfar 10 g silica column using DCM/EtOAc yielding the product (28 mg, 25%). - Step 2. To a mixture of 1-((4-bromo-2,6-difluoro-phenyl)methyl)-7-methoxy-3-methyl-imidazo[4,5-c][1,8]naphthyridin-2-one (70 mg, 160.84 μmol, 1 eq) in DMF (2 mL) was added DIEA (74.83 mg, 579.02 μmol, 100.85 μL, 3.6 eq), XantPhos (9.31 mg, 16.08 μmol, 0.1 eq), and Pd(dba)2 (9.25 mg, 16.08 μmol, 0.1 eq) in one portion at 22° C. under N2. The mixture was stirred at 80° C. for 10 min. Benzyl mercaptan (23.97 mg, 193.01 μmol, 22.61 μL, 1.2 eq) was added into reaction and then heated to 80° C. for 2 hr. Upon completion, the mixture was concentrated. The crude was purified by Biotage Sfar 5 g silica column using DCM/MeOH yielding the product (60 mg, 78%).
- Step 3. To a mixture of 1-((4-benzylsulfanyl-2,6-difluoro-phenyl)methyl)-7-methoxy-3-methyl-imidazo[4,5-c][1,8]naphthyridin-2-one (30 mg, 62.69 μmol, 1 eq) in THF (2 mL) and MeCN (1 mL) was added AcOH (26.35 mg, 438.86 μmol, 25.10 μL, 7 eq), and H2O (15.82 mg, 877.72 μmol, 15.82 μL, 14 eq) in one portion at 0° C. 1,3-Dichloro-5,5-dimethylhydantoin (17.29 mg, 87.77 μmol, 1.4 eq) was then added into reaction mixture at 0° C. The mixture was stirred at 0° C. for 2 hr. NH4OH (659.15 mg, 18.81 mmol, 724.34 μL, 300 eq) was cooled down to 0° C. The reaction mixture was added into NH4OH (659.15 mg, 18.81 mmol, 724.34 μL, 300 eq) dropwise and stirred at 0° C. for 1 hr. Upon completion, the mixture was acidified to pH=1 and concentrated. The crude was purified by Biotage C18 Duo 12 g column using water/MeCN (0.1% TFA) yielding the product (28.6 mg, 83%). LCMS [M+H]+=436; 1H NMR (300 MHz, DMSO-d6) δ ppm 3.51 (br s, 3H) 4.08 (s, 3H) 5.72 (s, 2H) 7.31 (d, J=9.38 Hz, 1H) 7.45-7.54 (m, 2H) 7.63 (s, 2H) 8.93 (d, J=9.38 Hz, 1H) 9.05 (s, 1H).
- The following compounds were prepared according to the preparation of compound 114.
- 3,5-Difluoro-4-((3-(2-hydroxyethyl)-7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (115) was prepared in 9.9 mg following the procedure for the synthesis of compound 114. LCMS [M+H]+=466.
- 3,5-Difluoro-4-((7-methoxy-2-oxo-3-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (131) was prepared in 29.5 mg following the procedure for the synthesis of compound 114. LCMS [M+H]+=504; 1H NMR (400 MHz, DMSO-d6) δ ppm 3.99 (s, 3H) 5.00 (d, J=9.00 Hz, 2H) 5.71 (s, 2H) 7.17-7.20 (m, 1H) 7.46 (d, J=7.43 Hz, 2H) 7.61 (s, 2H) 8.74 (d, J=9.00 Hz, 1H) 9.04 (s, 1H).
- 3,5-Difluoro-4-((7-methoxy-3-(2-methoxyethyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (132) was prepared in 30 mg following the procedure for the synthesis of compound 114. LCMS [M+H]+=480; 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 3.21-3.22 (m, 3H) 3.63-3.67 (m, 2H) 4.02-4.10 (m, 3H) 4.18-4.24 (m, 2H) 5.69-5.77 (m, 2H) 7.23-7.33 (m, 1H) 7.46-7.53 (m, 2H) 7.61-7.68 (m, 2H) 8.82-8.90 (m, 1H) 8.99-9.05 (m, 1H).
- 3,5-Difluoro-4-((3-(3-hydroxypropyl)-7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (133) was prepared in 29.5 mg following the procedure for the synthesis of compound 114. LCMS [M+H]+=480; 1H NMR (400 MHz, DMSO-d6) δ ppm 1.82 (t, J=6.85 Hz, 2H) 3.41-3.42 (m, 2H) 4.02-4.07 (m, 5H) 5.69-5.73 (m, 2H) 7.20-7.28 (m, 1H) 7.47 (d, J=7.43 Hz, 2H) 7.62 (s, 2H) 8.76-8.85 (m, 1H) 9.01 (s, 1H).
- 3,5-difluoro-4-((7-methoxy-3-(oxetan-3-yl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (139) was prepared in 6.6 mg following the procedure for the synthesis of compound 114. LCMS [M+H]+=478.
-
-
Step 1. Ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (276 mg, 1.03 mmol, 1 eq) was dissolved in DCM (10 mL, 0.1 M) then cooled to −78° C. 1 M DIBAL in cyclohexane (2.4 mL, 2.4 mmol, 2.4 eq) was added to the mixture. Upon completion, the mixture was warmed to 0° C. and quenched with sat. NH4C1. The aqueous layer was extracted with EtOAc (3×20 mL). The combined organic layer was dried over Na2SO4 and concentrated. The product was used in the next step without further purification. - Step 2. (4-Chloro-7-methoxy-1,8-naphthyridin-3-yl)methanol from the previous step was dissolved in DCM (10 mL) followed by the addition of MnO2 (870 mg, 10 mmol, 10 eq). The mixture was stirred at 22° C. for 2 hr. Upon completion, the mixture was filtered over a pad of celite and the filtrate concentrated yielding the product (132 mg, 59% over 2 steps).
- Step 3. 4-Chloro-7-methoxy-1,8-naphthyridine-3-carbaldehyde (122 mg, 0.55 mmol, 1 eq) was dissolved in MeOH (11 mL, 0.05 M) followed by the addition of hydrazine monohydrate (32 μL, 0.66 mmol, 1.2 eq). The vial was sealed and heated to 90° C. for 24 hr. Upon completion, the mixture was cooled to 22° C. and concentrated. The crude was dissolved in EtOAc and washed with sat. NaHCO3. The aqueous layer was back extracted with EtOAc (2×20 mL). The combined organic layer was dried over Na2SO4 and concentrated yielding the product (100 mg, 91%).
- Step 4. 7-Methoxy-1H-pyrazolo[4,3-c][1,8]naphthyridine (20 mg, 0.1 mmol, 1 eq) was dissolved in DMF (1 mL, 0.1 M) followed by the addition of 60% NaH (5 mg, 0.12 mmol. 1.2 eq) and 4-(bromomethyl)benzenesulfonamide (30 mg, 0.12 mmol, 1.2 eq). The mixture was stirred at 22° C. for 3 hr then at 40° C. for 1 hr. The mixture was purified through Prep HPLC using water/MeCN (0.1% TFA) yielding the product (7.3 mg, 20%). LCMS [M+H]+=370; 1H NMR (300 MHz, DMSO-d6) δ ppm 3.98 (s, 3H) 6.26 (s, 2H) 7.34 (s, 2H) 7.61 (d, J=8.79 Hz, 3H) 7.75-7.79 (m, 3H) 7.99-8.11 (m, 1H) 8.90 (d, J=8.79 Hz, 1H) 10.29 (s, 1H).
- 2-Fluoro-4-((7-methoxy-1H-pyrazolo[4,3-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (122a) and 2-fluoro-4-((7-methoxy-2H-pyrazolo[4,3-c][1,8]naphthyridin-2-yl)methyl)benzenesulfonamide (122b): The two products were prepared in 66 mg and 10 mg respectively with 35% yield following the procedure for the synthesis of 4-((7-Methoxy-1H-pyrazolo[4,3-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide. 122a: LCMS [M+H]+=388; 1H NMR (300 MHz, DMSO-d6) δ ppm 4.06 (s, 3H) 5.93 (s, 2H) 7.29 (br d, J=8.79 Hz, 1H) 7.33 (br d, J=8.21 Hz, 1H) 7.43 (br d, J=11.14 Hz, 1H) 7.65 (s, 2H) 7.77-7.83 (m, 1H) 8.74 (d, J=8.79 Hz, 1H) 9.33 (s, 1H) 9.70 (s, 1H); 122b: LCMS [M+H]+=388; 1H NMR (300 MHz, DMSO-d6) δ ppm 3.95 (s, 3H) 6.25 (s, 2H) 7.58 (d, J=8.79 Hz, 1H) 7.75 (t, J=7.91 Hz, 1H) 7.84-7.93 (m, 1H) 7.93-7.98 (m, 2H) 8.07-8.13 (m, 1H) 8.67-8.72 (m, 1H) 8.91 (d, J=8.79 Hz, 1H) 10.26 (s, 1H).
- 6-((7-Methoxy-1H-pyrazolo[4,3-c][1,8]naphthyridin-1-yl)methyl)pyridine-3-sulfonamide (135a) and 6-((7-methoxy-211-pyrazolo[4,3-c][1,8]naphthyridin-2-y1)methyl)pyridine-3-sulfonamide (135b): Products were prepared in 4.8 mg and 2.6 mg respectively following the procedure for the synthesis of 4-((7-Methoxy-1H-pyrazolo[4,3-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide. 135a: LCMS [M+H]+=371; 135b: LCMS [M+H]+=371.
-
-
Step 1. 5-chloro-2-methoxy-1,8-naphthyridine (527 mg, 2.7 mmol, 1 eq), tert-butyl carbamate (380 mg, 3.25 mmol, 1.2 eq), Pd(dba)2 (78 mg, 0.135 mmol, 0.05 eq), XPhos (129 mg, 0.27 mmol, 0.1 eq), and Cs2CO3 (1.76 g, 5.4 mmol. 2 eq) were suspended in dioxane (14 mL, 0.2 M). The mixture was purged with nitrogen for 1 min then heated to 100° C. for 5 hr under nitrogen atmosphere. Upon completion, the mixture was cooled to 22° C. and poured into water. The resulting precipitate was filtered and dried. The crude product was used in the next step without further purification. - Step 2. (7-methoxy-1,8-naphthyridin-4-yl)carbamate from previous step was suspending in DCM (5.4 mL, 0.5M) then cooled to 0° C. followed by the addition of 4 M HCl in dioxane (2.7 mL). The mixture was stirred at 22° C. until all starting material was consumed. Upon completion, the mixture was concentrated yielding the product. The product was used in the next step without further purification.
- Step 3. 7-Methoxy-1,8-naphthyridin-4-amine HCl was dissolved in AcOH (14 mL, 0.2 M) then cooled to 0° C. Bromine (153 μL, 2.97 mmol, 1.1 eq) was added to the mixture. The mixture was stirred at 22° C. until no more starting material was observed on LCMS. Upon completion, the mixture was poured into water. The resulting precipitate was filtered and dried yielding the product (459 mg, 67% over 3 steps).
- Step 4. 3-Bromo-7-methoxy-1,8-naphthyridin-4-amine (455 mg, 1.79 mmol, 1 eq), (E)-2-(2-ethoxyvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (709 mg, 3.58 mmol, 2 eq), Pd(OAc)2 (12 mg, 0.05 mmol, 0.03 eq), SPhos (55 mg, 0.133, 0.075 eq), and K3PO4 (760 mg, 3.58 mmol, 2 eq) were dissolved in 4:1 MeCN/H2O (10 mL, 0.18 M). The mixture was purged with nitrogen for 1 min then heated to 110° C. Upon completion, the mixture was cooled to 22° C. and poured into sat. NH4C1. The aqueous layer was extracted with EtOAc (3×30 mL). The combined organic layer dried over Na2SO4 and concentrated. The crude was purified through FCC using DCM/MeOH yielding the product (280 mg, 64%).
- Step 5. (E)-3-(2-Ethoxyvinyl)-7-methoxy-1,8-naphthyridin-4-amine (280 mg, 1.14 mmol, 1 eq) was dissolved in 1.25 M HCl in EtOH (14 mL). The mixture was heated to 75° C. Upon completion, the mixture was cooled to 22° C. and concentrated yielding the product (259 mg, 97%).
- Step 6. 7-Methoxy-1H-pyrrolo[3,2-c][1,8]naphthyridine HCl (50 mg, 0.212 mmol, 1 eq) was dissolved in DMF (3 mL) followed by the addition of 4-(bromomethyl)benzenesulfonamide (64 mg, 0.255 mmol, 1.2 eq) and K2CO3 (88 mg, 0.64 mmol, 3 eq). The mixture was heated to 60° C. Upon completion, the mixture was cooled to 22° C. and concentrated. The crude was purified through Prep HPLC using water/MeCN (0.1% TFA) yielding the product (22.7 mg, 22%). LCMS [M+H]+=369; 1H NMR (600 MHz, DMSO-d6) δ ppm 3.99 (s, 3H) 6.08 (s, 2H) 6.93-6.97 (m, 1H) 7.21 (br d, J=9.35 Hz, 2H) 7.59 (s, 2H) 7.65 (t, J=7.89 Hz, 1H) 8.43 (d, J=9.17 Hz, 1H) 8.75 (s, 1H) 9.52 (s, 1H).
-
-
Step 1. To a mixture of ethyl 4-chloro-7-methoxy-cinnoline-3-carboxylate (300 mg, 1.12 mmol, 1 eq) in THF (10 mL) was added DIBAL (1 M, 3.37 mL, 3 eq) dropwise at −78° C. The mixture was stirred at −78° C. for 3 hours. Upon completion, sat. NaHCO3, potassium sodium tartrate, EtOAc were added into reaction mixture at −78° C. and stirred at 22° C. for 18 hr. The aqueous layer was extracted by EtOAc (3×20 mL). The organic layer was combined and dried over Na2SO4 and concentrated. The crude residual was dissolved in DCM (10 mL). MnO2 (978.03 mg, 11.25 mmol, 10 eq) was added into reaction mixture at 22° C. The reaction was stirred at 22° C. for 3 hours. Upon completion, the reaction was filtered through a pad of celite and concentrated. The crude was purified by FCC yielding the product (156 mg, 63%). - Step 2. To a mixture of 4-chloro-7-methoxy-cinnoline-3-carbaldehyde (156 mg, 700.72 μmol, 1 eq) in MeOH (15 mL) was added hydrazine (40.42 mg, 1.26 mmol, 45.63 μL, 1.8 eq) in one portion at 22° C. The mixture was stirred at 65° C. for 18 hr. Upon completion, the mixture was concentrated. The crude was purified by FCC yielding the product (87 mg, 62%).
- Step 3. To a mixture of 7-methoxy-1H-pyrazolo[4,3-c]cinnoline (35 mg, 174.83 μmol, 1 eq) in DMF (1 mL) was added NaH (8.39 mg, 209.79 μmol, 60% purity, 1.2 eq) in one portion at 22° C. The mixture was stirred at 22° C. for 5 mins. 4-(bromomethyl)-2-fluoro-benzenesulfonamide (56.25 μg, 0.21 μmol, 1.20e-3 eq) was added into reaction mixture, and stirred for 2 hours. Upon completion, the reaction was quenched by 1N HCl (2 mL). Solid crashed out from solution. The precipitate filtered. The filtrate was purified by Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the product (3.8 mg, 5.6%). LCMS [M+H]+=388; 1H NMR (300 MHz, DMSO-d6) δ ppm 3.96 (s, 3H) 6.25 (s, 2H) 7.41-7.53 (m, 2H) 7.58 (br d, J=7.62 Hz, 1H) 7.63 (s, 2H) 7.75 (br t, J=7.91 Hz, 1H) 7.93 (br s, 1H) 8.91 (d, J=8.79 Hz, 1H) 10.25 (s, 1H).
-
- NaNO2 (4.82 mg, 69.92 μmol, 1.2 eq) was dissolved in water (0.1 mL). To a mixture of 6-(((3-amino-7-methoxy-1,8-naphthyridin-4-yl)amino)methyl)pyridine-3-sulfonamide (21 mg, 58.27 μmol, 1 eq) in HCl (2 M, 291.35 μL, 10 eq) was added NaNO2 (4.82 mg, 69.92 mol, 1.2 eq) solution in one portion at 0° C. The mixture was stirred at 0° C. for 30 min. Upon completion, the solution was subjected to Prep HPLC using water/MeCN (0.1% TFA) yielding the product (6.2 mg, 29%). LCMS [M+H]+=372; 1H NMR (300 MHz, DMSO-d6) δ ppm 4.02 (s, 3H) 6.60 (s, 2H) 7.19 (d, J=8.79 Hz, 1H) 7.53 (s, 2H) 7.64 (d, J=8.21 Hz, 1H) 8.19 (dd, J=8.21, 2.34 Hz, 1H) 8.61 (d, J=8.79 Hz, 1H) 8.71 (d, J=2.34 Hz, 1H) 9.66 (s, 1H).
- 2-Fluoro-4-((7-methoxy-1H-[1,2,3]triazolo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (120) was prepared in 3.9 mg following the synthesis of compound 119. LCMS [M+H]+=389; 1H NMR (400 MHz, DMSO-d6) δ ppm 4.00 (s, 3H) 6.46 (s, 2H) 6.97 (dd, J=8.22, 1.57 Hz, 1H) 7.22 (d, J=8.61 Hz, 1H) 7.32 (d, J=10.62 Hz, 1H) 7.64 (s, 2H) 7.68 (t, J=8.02 Hz, 1H) 8.58 (d, J=9.00 Hz, 1H) 9.67 (s, 1H).
- 6-((7-Methoxy-4-methyl-1H-[1,2,3]triazolo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridine-3-sulfonamide (136) was prepared in 3.2 mg following the synthesis of compound 119. LCMS [M+H]+=386; 1H NMR (300 MHz, DMSO-d6) δ ppm 3.00 (s, 3H) 4.00 (s, 3H) 6.57 (s, 2H) 7.09 (d, J=8.79 Hz, 1H) 7.53 (s, 2H) 7.61 (d, J=8.21 Hz, 1H) 8.18 (d, J=8.21 Hz, 1H) 8.50-8.56 (m, 1H) 8.71-8.75 (m, 1H).
-
-
Step 1. To a mixture of 1-ethoxyphosphonoyloxyethane (82.20 mg, 595.23 umol, 76.82 μL, 6 eq) and 1-((4-bromo-3-fluoro-phenyl)methyl)-7-methoxy-3H-imidazo[4,5-c][1,8]naphthyridin-2-one (40 mg, 99.21 μmol, 1 eq) in DMF (1.2 mL) was added Et3N (30.12 mg, 297.62 μmol, 41.42 μL, 3 eq) and Pd(dppf)Cl2 (7.26 mg, 9.92 μmol, 0.1 eq) in one portion at 22° C. under N2. The mixture was stirred at 80° C. for 3 hour. Upon completion, the mixture was concentrated. The crude was purified by Biotage Sfar 5 g silica column using DCM/MeOH yielding the product (44 mg, 96%). - Step 2. To a mixture of 1-((4-diethoxyphosphoryl-3-fluoro-phenyl)methyl)-7-methoxy-3H-imidazo[4,5-c][1,8]naphthyridin-2-one (96 mg, 208.52 μmol, 1 eq) in DCM (10 mL) was added 2,6-lutidine (379.82 mg, 3.54 mmol, 412.85 μL, 17 eq) in one portion at 22° C. The mixture was cooled to 0° C., TMSBr (1.60 g, 10.43 mmol, 1.35 mL, 50 eq) was added into reaction mixture dropwise. The reaction mixture was then stirred at 22° C. for 5 hr. Upon completion, MeOH (20 mL) was added into reaction mixture and stirred for 30 min. The mixture was concentrated and the crude was purified by Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the product (30 mg, 36%). LCMS [M+H]+=405; 1H NMR (400 MHz, DMSO-d6) δ ppm 3.92 (s, 3H) 5.51 (s, 2H) 6.93-7.04 (m, 2H) 7.08-7.18 (m, 1H) 7.51-7.63 (m, 1H) 8.12-8.21 (m, 1H) 8.61-8.68 (m, 1H).
- Compounds 124-127 were prepared according to the preparation of
compound 121. - (3,5-Difluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)-phenyl)phosphonic acid (124) was prepared in 9.1 mg following the procedure for the synthesis of
compound 121. LCMS [M+H]+=423. - (2,5-difluoro-4-((7-methoxy-2-methyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)phenyl)phosphonic acid (125). LCMS [M+H]+=421.
- (6-((7-methoxy-2,4-dimethyl-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)pyridin-3-yl)phosphonic acid (126): LCMS [M+H]+=400.
- Methyl hydrogen (2-fluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)phenyl)phosphonate (127) was prepared in 8.1 mg following the procedure for the synthesis of
compound 121. LCMS [M+H]+=419. - 3-Fluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]cinnolin-1-yl)methyl)benzenesulfon-amide (123) was prepared in 14.6 mg following the preparation of compound 38. LCMS [M+H]+=404; 1H NMR (300 MHz, DMSO-d6) δ ppm 3.95-3.97 (m, 3H) 5.62 (s, 2H) 7.37 (d, J=1.76 Hz, 1H) 7.40 (d, J=2.34 Hz, 1H) 7.49 (s, 2H) 7.51 (br d, J=1.76 Hz, 2H) 7.67 (dd, J=9.96, 1.76 Hz, 1H) 7.96 (d, J=9.38 Hz, 1H).
-
-
Step 1. To a mixture of ethyl 4-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate (77 mg, 288.74 mol, 1 eq) and (4-(aminomethyl)phenyl)methanesulfonamide (109.36 mg, 461.98 mol, 1.6 eq, HCl) in MeCN (5 mL) was added DIEA (373.16 mg, 2.89 mmol, 502.91 μL, 10 eq) in one portion at 22° C. The mixture was stirred at 65° C. for 1 hour. Upon completion, the mixture was concentrated. The resulting residual was triturated with EtOAc yielding the product (112 mg, 90%). - Step 2. To a mixture of ethyl 7-methoxy-4-[[4-(sulfamoylmethyl)phenyl]methylamino]-1,8-naphthyridine-3-carboxylate (112 mg, 260.18 μmol, 1 eq) in EtOH/THF (2.6 mL) was added LiOH (1 M, 2.60 mL, 10 eq) in one portion at 22° C. The mixture was stirred at 50° C. for 1 hour. Upon completion, the organic solvent was removed under vacuum and then acidify to pH=4. The aqueous layer was extracted by EtOH/CHCl3=1:3. Both water and organic layer contain product. All the solvents were combined and then concentrated. The resulting white solid was extracted with EtOH and filtered. The filtrate was concentrated yielding the crude product. The product was used in the next step without further purification.
- Step 3. To a mixture of this crude product in DMF (3 mL) was added DPPA (171.84 mg, 624.42 μmol, 135.31 μL, 2.4 eq), Et3N (263.27 mg, 2.60 mmol, 362.13 μL, 10 eq) in one portion at 22° C. The mixture was stirred at 80° C. for 3 hr. Upon completion, the mixture was concentrated. The crude was purified by DCM/MeOH yielding the product (17 mg, 16%). LCMS [M+H]+=400; 1H NMR (400 MHz, DMSO-d6) δ ppm 4.01 (s, 3H) 4.19 (s, 2H) 5.56 (s, 2H) 6.79 (s, 2H) 7.17 (d, J=9.00 Hz, 1H) 7.22-7.25 (m, 2H) 7.27-7.30 (m, 2H) 8.40 (d, J=9.00 Hz, 1H) 8.76 (s, 1H) 12.16-12.50 (m, 1H).
- 3-chloro-5-fluoro-4-((7-methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c][1,8]naphthyridin-1-yl)methyl)benzenesulfonamide (134) was prepared in 16.8 mg following the preparation of compound 38. LCMS [M+H]+=438.
- 4-((7-Methoxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]cinnolin-1-yl)methyl)benzene-sulfonamide (137) was prepared in 11 mg from ethyl 4-hydroxy-7-methoxycinnoline-3-carboxylate following the preparation of compound 38. LCMS [M+H]+=386; 1H NMR (300 MHz, DMSO-d6) δ ppm 3.93-3.96 (m, 3H) 5.62 (s, 2H) 7.32 (s, 2H) 7.36 (dd, J=9.67, 2.64 Hz, 1H) 7.45 (d, J=2.34 Hz, 1H) 7.50 (d, J=8.21 Hz, 2H) 7.75 (d, J=8.21 Hz, 2H) 7.91 (d, J=9.38 Hz, 1H).
-
-
Step 1. 1-((4-bromo-2,6-difluoro-phenyl)methyl)-7-methoxy-3H-imidazo[4,5-c][1,8]naphthyridin-2-one (400 mg, 949.68 μmol, 1 eq) dissolved in DMF (2.5 mL) followed by the addition of Boc2O (298.46 mg, 1.37 mmol, 314.17 μL, 1.44 eq) and Cs2CO3 (464.13 mg, 1.42 mmol, 1.5 eq). The mixture stirred at 22° C. for 2 hr. Upon completion, the mixture was added to water and the resulting precipitate was filtered and dried yielding the product (463 mg, 94%). - Step 2. tert-butyl 1-((4-bromo-2,6-difluoro-phenyl)methyl)-7-methoxy-2-oxo-imidazo[4,5-c][1,8]naphthyridine-3-carboxylate (60 mg, 115.09 μmol, 1 eq), Pd(OAc)2 (1.29 mg, 5.75 μmol, 0.05 eq), Xantphos (3.33 mg, 5.75 μmol, 0.05 eq), Cs2CO3 (112.50 mg, 345.28 μmol, 3 eq), and tert-butyl carbamate (26.97 mg, 230.19 μmol, 2 eq) were dissolved in dioxane (0.8 mL). The mixture purged with nitrogen for 30 sec and sealed. The mixture heated to 100° C. for 1 hr. Upon completion, the mixture cooled to 22° C. and diluted with water. The resulting precipitate was filtered and dried yielding the product (55.5 mg, 60%).
- Step 3. tert-butyl 1-((4-(tert-butoxycarbonylamino)-2,6-difluoro-phenyl)methyl)-7-methoxy-2-oxo-imidazo[4,5-c][1,8]naphthyridine-3-carboxylate (108 mg, 193.71 μmol, 1 eq) dissolved in DCM (0.5 mL) followed by the addition of TFA (770.00 mg, 6.75 mmol, 0.5 mL, 34.86 eq). The mixture stirred at 22° C. for 1.5 hr. Upon completion, the mixture was concentrated then dissolved in DCM. The crude was free based using sat. NaHCO3 and extracted with EtOAc (3×10 mL). The combined organic dried over Na2SO4 and concentrated. The crude was purified by Biotage C18 Duo 12 g column using water/MeCN (0.1% TFA) gradient yielding the product (24 mg, 35%).
- Step 4. 1-((4-amino-2,6-difluoro-phenyl)methyl)-7-methoxy-3H-imidazo[4,5-c][1,8]naphthyridin-2-one (24 mg, 67.17 μmol, 1 eq) dissolved in DMA (0.7 mL) followed by the addition of sulfamoyl chloride (77.61 mg, 671.68 μmol, 10 eq). The mixture stirred at 22° C. for 2 hr. Et3N (135.93 mg, 1.34 mmol, 186.98 μL, 20 eq) added and stirred at 22° C. for 18 hr. Upon completion, the mixture was purified by Prep HPLC using water/MeCN (0.1% TFA) gradient yielding the product (28.1 mg, 76%). LCMS [M+H]+=437.
- ENPP1 is a transmembrane glycoprotein that hydrolyzes nucleotides and nucleotide derivatives with the formation of nucleotide-5′-monophosphates. ENPP1 hydrolyzes artificial phosphoric acid ester thymidine 5′monophosphate p-nitrophenyl ester (TMP-pNP) to nucleotide-5′-monophosphate and p-nitrophenol, which is a chromogenic product. The amount of p-nitrophenol product formed is measured using its absorbance at 405 nm, which is directly proportional to enzyme activity.
- For determination of IC50 values, 8 point of different concentrations of each inhibitor were prepared with the final assay concentrations starting at 1000 nM with 50 mM Tris buffer (pH 9.5) containing 250 mM NaCl. Load into a well with 20 ng of human soluble ENPP1 in 50 μL and incubate at room temperature with 25 μL inhibitor solution (4× Final Concentration) for 30 mins. Then, add 25 μL 2 mM TMP solution (2× Final Concentration) into the well, Incubate at RT for 1 hour. The amounts of released p-nitrophenolate were measured by reading OD value at 405 nm.
- The percent inhibition at each compound is calculated as follows: % inhibition=(ODMAX−ODCOMPOUND)/(ODMAX−ODMIN)*100. (MAX: absence of ENPP1 inhibitors control, MIN: blank control.)
- The IC50 values for percent inhibition versus compound concentration were determined by fitting the inhibition curves using a four-parameter variable slope model in GraphPad Prism® 8. The IC50 values determined were listed in Table 2.
- In some instances, an inhibitor of ENPP-1 is able to selectively blocking the hydrolysis of 2′3′-cGAMP while only minimally inhibiting the hydrolysis of ATP. Therefore, the ATP analog p-Nitrophenyl 5′-Adenosine Monophosphate (AMP-pNP) has been demonstrated to accurately reflect hydrolysis of native ATP by different classes of ENPP1 inhibitors. AMP-pNP can be used as substrate of ENPP-1. Its hydrolysis products were nucleotide-5′-monophosphate and p-nitrophenol, which is also a chromogenic product. The amount of p-nitrophenol product formed is measured using its absorbance at 405 nm, which is directly proportional to enzyme activity.
- For determination of IC50 values, 12 point of different concentrations of each inhibitor were prepared with the final assay concentrations starting at 9000 nM, 3× series dilution with 50 mM Tris buffer (pH 9.5) containing 250 mM NaCl. Load into a well with 35 ng of human soluble ENPP1 in 50 μL and incubate at room temperature with 25 μL inhibitor solution (4× Final Concentration) for 30 mins prior adding 25 μL 3 mM AMP solution (2× Final Concentration) into the well, Incubate at RT for 1 hour. The amounts of released p-nitrophenolate were measured by reading OD value at 405 nm.
- The percent inhibition at each compound is calculated as follows: % inhibition=(ODMAX−ODCOMPOUND)/(ODMAX−ODMIN)*100. (MAX: absence of ENPP1 inhibitors control, MIN: blank control.)
- The IC50 values for percent inhibition versus compound concentration are determined by fitting the inhibition curves using a four-parameter variable slope model in GraphPad Prism® 8. The IC50 values determined are listed in Table 2.
-
TABLE 2 Compound ID TMP-pNP (IC50, nM) AMP-pNP (IC50, nM) PF-QS1* 10 37 MV0000658** 6.2 237 1 1.7 5.9 2 10 — 8 0.30 — 10 1.1 27 11a 0.88 2.5 11b 196 — 12 1.2 3.9 13 4.3 33 17 — — 32 7.7 — 35 0.37 35 36 3.1 36 37 165 — 38 0.31 0.75 39 0.25 0.42 40 0.15 0.23 41 0.21 0.9 44 65 — 46 5.2 — 47 1.0 — 48 0.29 0.44 49 1.9 4.8 50 28 — 51 884 — 52 0.54 2.2 54 0.53 1.8 60 0.31 1.51 61 0.53 1.9 62 0.1 1.5 64 2.8 8.9 65 3.0 8.7 66 3.0 13 67 2.3 8.6 68 0.49 1.7 69 0.67 2.1 70 0.64 1.2 71 1.0 2.9 72 0.58 1.2 73 0.36 0.96 74 0.09 0.12 75 0.24 0.68 76 13 26 77 8.6 15 78 1.7 7.2 79 2.1 9.2 80 1.8 6.4 81 6.9 23 82 0.8 2.4 83 3.2 7.7 84 3.5 8.4 85 2.0 5.2 86 0.81 3.2 87 1.3 4.0 88 4.0 12 89 0.52 2.1 90 2.4 7.7 91a 83 323 91b 62 199 92 9.3 29 93 3.7 13 94 3.4 8.8 95 1.4 4.6 96 1.7 5.4 97 0.56 1.1 98 0.60 3.0 99 0.27 0.79 100 8.8 — 101 0.67 1.1 102 0.51 0.74 103 0.090 0.06 104 8.9 11 105 21 19 107 43 79 108 16 66 110 0.60 2.6 111 7.4 21 112 0.30 0.99 113 1.1 5.0 114 0.27 0.23 115 0.11 0.32 116 0.38 1.8 117 8.1 34 118 2.9 8.2 119 0.70 1.1 120 1.78 4.4 121 9.4 31 122a 1.6 4.3 123 0.61 2.4 124 19 56 125 7.2 21 129 0.10 0.19 130 0.16 0.16 131 0.040 0.19 132 0.33 0.74 135a 0.66 1.4 136 7.4 21 137 1.1 2.4 138 38 141 *PF-QS1 is compound 1 in Bioorganic & Medicinal Chemistry Letters 19 (2009) 3339-3343, Snahel D. Patel et al; **MV0000658 is a representative compound in WO2019/046778 Al, Gallatin, W. M et al. - The hydrolysis products of 5′-GMP and 5′-AMP were generated when ENPP-1 use 2′3′-cGAMP as substrate. In some instances, ENPP1 activity with 2′3′-cGAMP substrate is measured using the AMP-Glo™ Assay kit (Promega Corporation) to quantitate the production of 5′-AMP. The AMP-Glo™ Assay Kit contains two reagents that are added sequentially. Reagent I converts the 5′-AMP produced in the reaction to 5′ADP. Reagent II converts the 5′-ADP to 5′ATP and reacts the 5′-ATP with the luciferase/luciferin pair to produce the luminescence signal.
- The ENPP1 assay with 2′3′-cGAMP substrate is conducted in 50 mM Tris buffer (pH 9.5) containing 250 mM NaCl. 12 point of different concentrations of each inhibitor were prepared with the final assay concentrations starting at 9000 nM, 3× series dilution. Duplicate wells are run at each inhibitor concentration. The final assay volume is 18 μL per well in 384 white assay plate containing 9 μL inhibitor solution, 4.5 μL human recombinant ENPP-1 protein (20 ng/well) and 4.5 μL, 2′,3′-cGAMP with final concentration of 20 μM. The assay is initiated by the addition of substrate and incubate at room temperature for 2 hours prior to taking 5 μL out to mix with 5 μL Reagent I to stop the reaction. 10 μL of Reagent II is then added and the wells are again incubated for another 60 minutes at room temperature. The luminescence signal is then measured using a plate reader with luminometer.
- The percent inhibition at each compound is calculated as follows: % inhibition=(RLUMAX−RLUCOMPOUND)/(RLUMAX−RLUMIN)*100. (MAX: ABSENCE OF ENPP1 INHIBITORS control, MIN: blank control.)
- ENPP-1 were mainly expressed on the surface of cell membrane where it hydrolytes 2′3′-cGAMP to generate 5′-GMP and 5′-AMP. ENPP-1 also has the ability to hydrolyzes artificial phosphoric acid ester TMP-pNP to nucleotide-5′-monophosphate and p-nitrophenol there, which is a chromogenic product. Therefore, in cultured MDA-MB-231, HEK293 and/or Saos-2 cells, TMP-pNP was used as substrate to reflect the enzymatic activity of ENPP1. The amount of p-nitrophenol product formed in the culture medium is measured using its absorbance at 405 nm, which is directly proportional to activity of ENPP1. The lower OD value at 405, the higher potency of ENPP-1 inhibitor.
- 8 point of different concentrations of each inhibitor were prepared with the final assay concentrations starting at 20 μM. 3× series dilution by DMEM medium without FBS was applied. Prior to adding inhibitors, 75000 cells per well were incubated at 37° C., 5% CO2 in DMEM for 24 hours. After removing the supernatant medium, 50 μL inhibitor solution was added into each well with cultured cells and incubate at 37° C., 5% CO2 for 60 minutes. Then, 4 mM (2× Final Concentration) TMP-pNP solution was mixed with inhibitor in each well for 5 hours before reading OD value at 405 nm using a plate reader.
- The IC50 values for percent inhibition versus compound concentration are determined by fitting the inhibition curves using a four-parameter variable slope model in GraphPad Prism® 8.
-
TABLE 3-1 MDA-MB-231 Compound ID Relative IC50 (μM) % Inhibition (at 20 μM) PF-QS1 1.8 50 Mv0000658 — 57 1 2.9 50 12 0.55 79 11a 0.60 79 35 1.5 73 36 1.5 66 39 0.40 82 40 0.065 85 41 0.31 81 46 1.6 75 47 3.4 72 48 0.55 80 49 6.0 67 50 — — 52 1.3 79 54 0.9 82 60 0.49 83 61 0.78 80 62 0.045 89 64 4.7 68 65 1.6 75 66 3.4 71 67 1.3 80 68 0.61 86 69 0.51 79 70 0.29 85 71 1.1 76 72 0.34 81 73 0.27 81 74 0.085 81 75 0.31 81 76 6.9 51 77 4.8 65 79 1.9 74 80 1.8 75 81 4.9 63 82 0.56 82 83 1.2 83 84 2.5 76 85 0.90 79 86 0.62 80 87 0.36 85 88 2.2 81 89 0.41 78 90 0.98 74 91a >6.7 53 92 4.1 68 93 2.2 74 94 2.7 74 95 1.4 75 96 11 57 97 0.81 78 98 3.8 62 99 0.60 77 101 2.4 76 102 0.43 86 103 0.034 87 104 3.4 72 105 >6.7 67 106 >6.7 57 108 5.7 64 109 >20 11 110 0.15 86 111 0.00031 80 112 0.07 80 113 0.25 72 114 0.08 77 115 0.056 78 116 1.8 68 117 16 16 118 2.0 70 119 0.12 83 120 1.1 79 121 0.0082 91 122a 1.7 74 123 1.8 66 124 0.0096 86 125 0.0027 82 126 0.48 80 127 0.081 78 128 20 82 131 0.08 88 132 — 87 135a 0.08 88 136 0.00031 80 137 1.8 59 -
TABLE 3-2 HEK 293 Compound ID Relative IC50 (μM) % Inhibition (at 20 μM) PF-QS1 — 41 Mv0000658 — 29 1 — 19 11a 2.1 84 12 2.3 85 35 3.4 51 36 5.0 57 39 0.73 94 40 0.13 96 41 0.66 96 46 2.4 85 47 5.0 77 48 0.67 95 49 10 67 -
TABLE 3-3 Saos-2 Compound ID Relative IC50 (μM) % Inhibition (@20 μM) PF-QS1 — 50 Mv0000658 — 52 1 — 32 11a 1.2 87 12 1.0 87 35 5.6 76 36 2.0 48 - THP-1 cells from bulk cultures were counted and suspended in
RPMI 1640, 20% FBS, 2.5 mM L-alanyl-L-glutamine at a concentration of 5.5×106 cells/mL. The THP-1 cells were subsequently seeded into 96 well round bottom plates 180 μL/well (1×106 cells per well), incubated for 1 hour at 37° C., 5% CO2. - Test compounds were screened in triplicate on THP-1 cells at a final concentration of 10 μM. A working solutions at 0.2 mM. Each well contains 180 μL of THP-1 cell suspension, 10 μL (30 μM, 40 μM or 50 μM) 2′3′-cGAMP (InvivoGen, catalog # tlrl-nacga23) solution (600 μM, 800 μM or 1000 μM) and 10 μL test compound working solution. Incubate for 1 hour.
- Vehicle control wells contain 2′3′-cGAMP at concentrations of 30 μM and 50 μM without any test compound. Positive control, 2′3′-cGAMP or 2′,3′-cGAM(PS)2 (Rp/Sp) (InvivoGen, cat # tlrl-nacga2srs) at 40 μM and 80 μM (final concentration).
- The final assay volume were 200 μL/well contains: 1) THP-1 cells=180 μL, 2) test compounds=10 μL, 3) 2′3′-cGAMP or 2′3′-cGAM(PS)2 (Rp/Sp) or vehicle control=10 μL.
- After incubation for 24 hours at 37° C., 5% CO2, the supernatants were harvested at 200× g for 10 minutes. Cell culture supernatants were then transferred to a clean plate and stored at −80° C. until ready to analyze for IFN-β levels. The IFN-β levels in cell culture supernatants were determined by ELISA kits (PBL Assay Science, catalog #41410) according to the manufacturer's instructions.
- The % increase measured for IFN-β in cells treated by the test compounds 12, 48, 89, 103 and 121 relative to that of untreated cells were tested (as shown in
FIGS. 1A-1E ). The test compounds potently increased the IFN-β levels at very low concentrations. - Liver microsome assay was used to evaluate the metabolic stability of I-VI. The test article at the concentration of 1 μM was incubated with 0.5 mg/mL liver microsome in the presence of NADPH and UDPGA as the co-factors for 0, 15, 30, 45 and 60 minutes. The incubation was carried out at 37° C. with 5% CO2 and saturating humidity. Disappearance of the test article was monitored by LC/MS/MS. the disappearance half-life (t1/2), intrinsic clearance and hepatic extraction ratio were determined.
-
TABLE 4 Stability of selected compounds in liver microsomes Intrinsic Hepatic Half-life clearance Cl′int, extraction Compound t1/2 (min) (μL/min/mg protein) ratio Re Mouse liver microsome 1 ∞ 0 0 12 237 5.9 0.20 11a 11 131 0.85 35 ∞ 0 0 36 49 28 0.55 Human liver microsome 10 ∞ 0 0 12 496 2.8 0.14 35 ∞ 0 0 - A dosing solution of test sample was prepared at 1.0 mg/mL in 5% DMSO/40% PEG400/55% water and administered to male CD-1 mice (4-6 weeks old, 20-30 grams, 3 animals each group) via intravenous (IV) bolus at 1 mg/kg and by oral gavage (PO) at 5 mg/kg. Blood samples (˜0.03 mL each time point) were collected via the jugular vein into tubes containing sodium heparin as the anticoagulant at 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose for IV administration and 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose for PO administration. The blood samples were then centrifuged for 5 minutes in a centrifuge refrigerated at 4° C. The resultant plasma samples were analyzed using LC/MS/MS to determine concentrations of test sample. Non-compartmental model with WinNonlin (Phoenix™, version 8.0) software was used to calculate pharmacokinetic (PK) parameters. The PK results are listed in Table 5. In comparison with the quinoline analog of
compound 12, most of naphthyridine analogs showed significant improvement in terms of clearance, AUC, half-life and oral bioavailability. -
TABLE 5 Pharmacokinetic parameters in male CD-1 mice (1 mg/kg, iv) Cl AUC Vdss Compounds T1/2 (h) (ml/min/kg) (h*ng/mL) (L/kg) % F 12 0.25 180 93 2.9 0% 38 1.9 45 370 3.3 NT 39 0.33 115 115 3.1 NT 40 2.7 70 241 7.3 NT 41 1.2 74 227 4.0 NT 48 0.33 70 239 1.7 NT 52 0.35 103 179 1.1 NT 60 2.5 78 215 11 NT 61 1.4 62 271 4.5 NT 62 4.9 105 163 39 NT 65 0.72 92 185 3.1 NT 70 2.6 26 668 4.3 NT 71 0.74 60 288 2.8 NT 72 1.4 56 303 2.9 NT 73 0.60 63 267 1.6 NT 74 1.4 123 138 14 NT 80 0.13 107 158 1.0 NT 82 0.86 66 253 2.2 NT 89 0.54 26 656 0.80 NT 102 5.1 26 657 5.2 8.4% 114 3.9 37 454 12 33% 119 1.4 56 301 4.5 NT 120 2.0 65 260 8.9 NT 122a 0.33 100 170 2.0 NT 137 1.2 39 429 1.6 NT *NT: not tested - It is to be understood that the invention is not limited to the particular embodiments and aspects of the disclosure described above, as variations of the particular embodiments and aspects may be made and still fall within the scope of the appended claims. All documents cited to or relied upon herein are expressly incorporated by reference.
Claims (34)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/641,633 US20230014730A1 (en) | 2019-09-23 | 2020-09-23 | Phosphodiesterase inhibitors and use |
US17/702,704 US11673889B2 (en) | 2019-09-23 | 2022-03-23 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962904501P | 2019-09-23 | 2019-09-23 | |
US202062968755P | 2020-01-31 | 2020-01-31 | |
US17/641,633 US20230014730A1 (en) | 2019-09-23 | 2020-09-23 | Phosphodiesterase inhibitors and use |
PCT/US2020/052260 WO2021061803A1 (en) | 2019-09-23 | 2020-09-23 | Phosphodiesterase inhibitors and use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/052260 A-371-Of-International WO2021061803A1 (en) | 2019-09-23 | 2020-09-23 | Phosphodiesterase inhibitors and use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/702,704 Continuation US11673889B2 (en) | 2019-09-23 | 2022-03-23 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230014730A1 true US20230014730A1 (en) | 2023-01-19 |
Family
ID=82323583
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/641,633 Pending US20230014730A1 (en) | 2019-09-23 | 2020-09-23 | Phosphodiesterase inhibitors and use |
US17/702,704 Active US11673889B2 (en) | 2019-09-23 | 2022-03-23 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/702,704 Active US11673889B2 (en) | 2019-09-23 | 2022-03-23 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors |
Country Status (1)
Country | Link |
---|---|
US (2) | US20230014730A1 (en) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1180156A (en) * | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | 1-(substitutedaryl)alkyl-1h-imidazopyridin-4-amine derivative |
US8541438B2 (en) | 2004-06-18 | 2013-09-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
WO2006009826A1 (en) | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
WO2010002998A1 (en) | 2008-07-03 | 2010-01-07 | Gilead Sciences, Inc. | 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS |
JP2012528829A (en) | 2009-06-04 | 2012-11-15 | ノバルティス アーゲー | 1H-imidazo [4,5-c] quinolinone compound |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
DE102010035744A1 (en) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
EP2674170B1 (en) * | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
CA2904364A1 (en) | 2013-03-15 | 2014-09-25 | Epigenetix, Inc. | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors |
US9242989B2 (en) | 2014-04-14 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Compounds as modulators of RORγ |
WO2018030550A1 (en) | 2016-08-09 | 2018-02-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds with an ror(gamma)t modulating activity |
SG11202001664VA (en) | 2017-08-31 | 2020-03-30 | Abbvie Inc | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
-
2020
- 2020-09-23 US US17/641,633 patent/US20230014730A1/en active Pending
-
2022
- 2022-03-23 US US17/702,704 patent/US11673889B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20220220114A1 (en) | 2022-07-14 |
US11673889B2 (en) | 2023-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020353005A1 (en) | Phosphodiesterase inhibitors and use | |
US10358446B2 (en) | Bruton's tyrosine kinase inhibitors | |
US8178534B2 (en) | cMET inhibitors | |
US10059694B2 (en) | 2-aminopyrimidine compound and pharmaceutical composition and use thereof | |
US9546165B2 (en) | Heterocyclic compounds useful as PDK1 inhibitors | |
JP5363350B2 (en) | MAPK / ERK kinase inhibitor | |
US11542262B2 (en) | Phosphatidylinositol 3-kinase inhibitors | |
NZ533542A (en) | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | |
JP7287951B2 (en) | Quinoxaline derivatives as adenosine receptor antagonists | |
JP2011521979A (en) | HIV integrase inhibitor derived from pyridoxine | |
US20180002321A1 (en) | Substituted mono- and polyazanaphthalene derivatives and their use | |
US11446301B2 (en) | Quinoline analogs as phosphatidylinositol 3-kinase inhibitors | |
US20200071316A1 (en) | Activators of the retinoic acid inducible gene "rig-i" pathway and methods of use thereof | |
US20230227484A1 (en) | Pyrimidine compound as axl inhibitor | |
US20170002011A1 (en) | Benzene sulfonamides as ccr9 inhibitors | |
US11673889B2 (en) | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors | |
US9562033B2 (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses | |
US20230257364A1 (en) | Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof | |
US20230348423A1 (en) | Pyrimidinedione-based compounds as axl, c-met, and mer inhibitors and methods of use thereof | |
US20230174481A1 (en) | Kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HANGZHOU ZHENGXIANG PHARMACEUTICALS CO., LTD;REEL/FRAME:059230/0230 Effective date: 20211025 Owner name: HANGZHOU ZHENGXIANG PHARMACEUTICALS CO., LTD, CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HAO, XIAOLIN;REEL/FRAME:059230/0179 Effective date: 20211025 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |